"","X","nct_id","result_group_id","X.AE_probability","X.AE_Subjects","X.Total_Subjects","time_frame","AEdescription","Treatment","Treatment_description"
"9",9,"NCT00411671",479292,1,105,105,"Adverse events will be recorded for all patients from the time of consent until 30 days following the last dose of study treatment.","Collection period: December 18, 2006 to November 13, 2010.","Sorafenib 400 mg","Sorafenib 400 mg by mouth twice daily in continuous 28 day cycles."
"10",10,"NCT00352105",500559,1,60,60,"For 2 years of the study",NA,"5-FU, Cisplatin, Radiation and Iressa","Patients undergo hyperfractionated radiotherapy twice daily, 5 days a week, beginning on day 1 and continuing for 6 weeks. Patients also receive fluorouracil IN continuously over 96 hrs. and cisplatin IV continuously over 96 hrs. on days 1-3 and 22-25 and oral gefitinib beginning once daily on day 1 and continuing for up to 2 years in the absence of disease progression or unacceptable toxicity."
"11",11,"NCT00436956",469358,1,59,59,NA,NA,"All Participants - AZD2171 & Prednisone","This group combines participants who received 20 mg AZD2171 (Cediranib) orally daily (n=35), in addition to participants who received 20 mg AZD2171 (Cediranib) orally daily plus 10mg prednisone (n=23). One pt was not evaluable due to a cord compression on day 2 of therapy; was removed from the trial (n=1)."
"14",14,"NCT00465179",458638,1,57,57,"Adverse Events (AEs) and Serious Adverse Events (SAEs) were collected from administration of study drug on day 1 of course 1 and on day 1 of all subsequent courses, up to 5 years.","Overall collection period: March 2007 to February 2015.","Sunitinib Malate","Sunitinib Malate 50 mg by mouth daily for 4 weeks, then 2 weeks off. These 6 weeks are considered 1 cycle of study treatment."
"16",16,"NCT00004888",577415,1,48,48,"Information about toxicities was collected during treatment for all treated patients and the table shows toxicities experienced by patients. These are limited to toxicities reported on case report forms. The average time period was 5-6 months.","Please note that all of these toxicities are considered at least possibly treatment related by the study chair.","Arm II: Doxorubicin, Taxotere, and Herceptin","Patients received the weekly antibody therapy with trastuzumab in addition to the induction chemotherapy with PLD and docetaxel every 3 weeks as outlined for Arm I above for a total of 8 cycles. Trastuzumab was administered 4 mg/kg IV on Day 1, then 2 mg/kg IV weekly."
"33",43,"NCT00118157",556370,1,19,19,NA,NA,"Arm 1","Patients receive oral lapatinib and oral tamoxifen once daily on days 1-28.
lapatinib ditosylate: Given orally
tamoxifen citrate: Given orally"
"43",53,"NCT00524316",437833,1,16,16,NA,NA,"Treatment: Sunitinib and Chemoembolization","Treatment: Cycle (C)1-Sunitinib 37.5mg po d1-7 followed by TACE with doxorubicin in lipodiol on d8, continued sunitinib 37.5mg po qd d15-36 followed by 2 weeks off. C2 onwards- sunitinib 4 weeks on and 2 weeks off, with dose escalation to 50 mg in pts without any grade 3 toxicities in C1."
"47",58,"NCT00918385",291252,1,14,14,NA,NA,"Arm 1=High AR Nilutamide","High Androgen Receptor (AR) activity of >= 0.50
Nilutamide: Nilutamide 150mg orally each day for 28 days per cycle. After first progression, Nilutamide 150mg orally each day in combination with Dasatinib 100mg orally each day for 28 days per cycle."
"59",71,"NCT00245128",532779,1,10,10,NA,NA,"Imatinib Mesylate (Gleevec)","Once daily oral administration of Imatinib Mesylate at a dose of 600mg for 12 months."
"73",86,"NCT01256567",180334,1,7,7,NA,NA,"Ramucirumab and Docetaxel Combination","Docetaxel: Docetaxel administered by intravenous infusion at a dose of 75 milligrams per square meter (mg/m^2) every 3 weeks.
Ramucirumab: Ramucirumab administered as an intravenous infusion at a dose of 10 milligrams per kilogram (mg/kg) every 3 weeks."
"78",94,"NCT01251653",182100,1,6,6,"From first drug administration until 28 days after last drug administration, up to 717 days",NA,"Afatinib 50mg and Docetaxel 75mg","Afatinib (film-coated tablet) 50 mg qd (once daily) was administered orally in combination with Docetaxel 75 mg/m2 administered as intravenous infusion on Day 1 of each 3- week treatment course."
"83",100,"NCT00561795",421018,1,6,6,"Enrollment to End of Study (up to a year)",NA,"A5-1","Paclitaxel 175 milligrams (mg)/square meter (m^2) plus carboplatin area under the concentration-time curve (AUC) 5 intravenously (IV) on Day 1 of a 21-day cycle for 6 cycles plus pazopanib 800 mg/day orally starting on Day 1 for the duration of the study"
"87",104,"NCT00387894",488371,1,6,6,"30 days after the last study treatment, thereafter for survival","Only AEs Grade 3 or higher were required to be collected as AEs, per protocol","Oral Erlotinib Hydrochloride (Tarceva) Daily on Days 1-28","erlotinib hydrochloride (Tarceva) self-administered in an open-label, unblinded manner to all patients enrolled in the study."
"112",134,"NCT01004003",260207,1,4,4,"From first administration of the trial drug and until 28 days after the last administration of nintedanib or sorafenib, up to 1289 days",NA,"Phase I Group 1, 200mg Nintedanib Bid","Oral administration of Nintedanib (BIBF 1120) 200 mg soft gelatine capsules (two capsules of 100mg) twice daily (bid). Phase I: A standard 3+3 dose escalation part to determine the MTD. Group 1 patients had a baseline Child-Pugh score of 5 or 6, and AST and ALT ≤2 times the upper limit of normal (ULN)."
"116",140,"NCT00539617",431194,1,4,4,"Adverse events were collected from first dose to 30 days after last dose for all patients. For the 4 patients who started treatment, this period was over 1 year and 2 months.",NA,"FOLFOX and Erlotinib","Single arm study of FOLFOX6 plus Erlotinib"
"120",146,"NCT00195260",539809,1,4,4,NA,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.","Bosutinib 50 mg","Bosutinib 50 milligram (mg) capsule orally once daily continuously in 21-day cycles until disease progression, unacceptable toxicity, or consent withdrawal."
"130",163,"NCT01264081",177190,1,3,3,NA,"Three study participants were affected by the adverse events: 2 - who completed the study and 1 who did not complete cycle 1 due to death of progressive disease. The participant who withdrew from study didn't take Lapatinib and experience any adverse events.","Group A","Lapatinib: 500 mg PO (orally) twice a day for 28 days (1 cycle). Up to 27 cycles allowed if response seen."
"132",165,"NCT01099358",230308,1,3,3,NA,"All participants who received at least one dose of study drug.","Cisplatin on Cetuximab (A)","Cisplatin on Cetuximab (A)
Cycle 1:
100 mg/m² cisplatin admin I.V on week 1, day 1. 5- FU admin as a 96-hour C.I. of 1000 mg/m²/d admin starting on week 1, day 1-4.
400 mg/m² cetuximab admin I.V on week 2, day 1. 250 mg/m² cetuximab admin I.V on week 3, day 1.
Cycle 2 +:
100 mg/m² cisplatin admin I.V on week 1, day 1. 5- FU admin as a 96-hour C.I. of 1000 mg/m²/d admin starting on week 1, day 1-4.
250 mg/m² cetuximab admin I.V on weeks 1-3, day 1.
After 7 cycles, participants may then receive weekly Cetuximab monotherapy until progression of disease, unacceptable toxicity, or another withdrawal criterion is met.
Due to protocol amendment in September 2011, any newly enrolled participants were placed into cetuximab and cisplatin (C) arm only. After protocol amendment February 2014, any newly enrolled participants will be placed into cetuximab and cisplatin (D) arm only."
"137",174,"NCT01004003",260206,1,3,3,"From first administration of the trial drug and until 28 days after the last administration of nintedanib or sorafenib, up to 1289 days",NA,"Phase I Group 2, 50mg Nintedanib Bid","Oral administration of Nintedanib (BIBF 1120) 50 mg soft gelatine capsules twice daily (bid). Phase I: A standard 3+3 dose escalation part to determine the MTD. Group 2 patients had a baseline Child-Pugh score of 7, or AST or ALT >2 to ≤5 times ULN."
"138",177,"NCT00987935",266793,1,3,3,"AEs with an onset during therapy with study treatment or within 28 days after discontinuation of study treatment (up to 1066 days)",NA,"Phase I Group II Nintedanib, 50 mg Bid","Oral administration of Nintedanib (BIBF 1120) 50 mg soft gelatine capsules twice daily (bid) for the Group II patients during Phase I"
"140",183,"NCT00716456",365149,1,3,3,NA,NA,"Cetuximab 250 mg/m2","Cetuximab 250 mg/m2 IV every two weeks"
"156",205,"NCT00121719",555446,1,3,3,"All adverse events (AEs) were collected for up to approximately 4 years.","Treatment-emergent adverse events were defined as AEs that emerged during treatment, having been absent at pre-treatment, or that worsened in severity relative to the pre-treatment state, or occurred within 7 days or 5 times the half-life (whichever was longer) post participant's last treatment. Only treatment-emergent AEs and SAEs were reported.","6.4 mg Lenvatinib","Six 1.0 mg lenvatinib tablets and four 0.1 mg lenvatinib tablets were taken orally, once daily. Lenvatinib was to be taken on an empty stomach shortly after waking. Participants were fasted for 2 hours following administration of lenvatinib and could drink only clear fluids during this time (grapefruit juice was to be avoided). If 1 of 3 participants experienced DLT during Cycle 1 (4 weeks) an additional 3 participants were to be treated at this dose level. If 5 of the 6 participants in the expanded dose level did not experience DLT during the first 4 weeks of therapy, no additional DLT was observed, the next dose level was opened for enrollment. If more than 1 participant experienced DLT during the first 4 weeks of therapy, dose escalation was stopped and theMTD was determined. An additional 12 participants were treated at the MTD level."
"157",206,"NCT00121719",555442,1,3,3,"All adverse events (AEs) were collected for up to approximately 4 years.","Treatment-emergent adverse events were defined as AEs that emerged during treatment, having been absent at pre-treatment, or that worsened in severity relative to the pre-treatment state, or occurred within 7 days or 5 times the half-life (whichever was longer) post participant's last treatment. Only treatment-emergent AEs and SAEs were reported.","20 mg Lenvatinib","Two 10 mg lenvatinib tablets were taken orally, once daily. Lenvatinib was to be taken on an empty stomach shortly after waking. Participants were fasted for 2 hours following administration of lenvatinib and could drink only clear fluids during this time (grapefruit juice was to be avoided). If 1 of 3 participants experienced DLT during Cycle 1 (4 weeks) an additional 3 participants were to be treated at this dose level. If 5 of the 6 participants in the expanded dose level did not experience DLT during the first 4 weeks of therapy, no additional DLT was observed, the next dose level was opened for enrollment. If more than 1 participant experienced DLT during the first 4 weeks of therapy, dose escalation was stopped and the MTD was determined. An additional 12 participants were treated at the MTD level."
"163",213,"NCT01824823",59060,1,2,2,"Assessed every 4 weeks while on treatment and for 30 days after the end of treatment.",NA,"Arm A (Afatinib)","Patients receive afatinib PO QD on days 1-28."
"169",219,"NCT01340794",155826,1,2,2,NA,NA,"Treatment: Pazopanib Without Run-in","Patients receive 800 mg pazopanib hydrochloride PO QD on days 1-28 of a 28 day cycle."
"172",226,"NCT01251653",182104,1,2,2,"From first drug administration until 28 days after last drug administration, up to 717 days",NA,"Afatinib 50mg and Gemcitabine 1250mg","Afatinib (film-coated tablet) 50 mg qd (once daily) was administered orally in combination with Gemcitabine 1250 mg/m2 administered as intravenous infusion on Days 1 and 8 of each 3- week treatment course."
"177",233,"NCT00964743",274550,1,2,2,"8 months","First On Study (9/10/09) to last Off Study (5/18/10)","Intrathecal DepoCyt and Oral Sorafenib","This is a single arm pilot study. Investigators planned to enroll approximately 10 patients to receive concurrent intrathecal DepoCyt and oral Sorafenib. DepoCyt: through a reservoir every 2 weeks for 5 doses, then every 4 weeks for an additional 5 doses (a total of 10 DepoCyt treatments). Oral Sorafenib: at 400 mg twice a day throughout the treatment course until disease progression or death."
"178",235,"NCT00891904",299088,1,2,2,NA,NA,"Biological/Vaccine: Cetuximab","All patients enrolled will receive cetuximab 400 mg/m 2 IV x 1 dose 1 week prior to delivery of SBRT. Patients will then receive 15 Gy x 1 using SBRT and cetuximab i.v.
250 mg/m2 weekly for 4 weeks (total of 5 doses at 250 mg/m2)."
"190",249,"NCT00095940",563875,1,2,2,"Adverse events (AEs) were collected from day 1 of starting treatment until 30 days after ceasing treatment (off study). AEs possibly, probably, or definitely attributed to the study drug that occured after the off study date were also collected.","One participant in the Medulloblastoma: No Surgery group did not receive any lapatinib as the patient experienced clinical progression prior to starting therapy. This patient is excluded from the adverse event reporting.","Medulloblastoma: Lapatinib Prior to Surgery","Participants with recurrent medulloblastoma who had surgical resection of the tumor at study enrollment and were randomized to receive lapatinib 7-14 days prior to surgery."
"191",250,"NCT00095940",563871,1,2,2,"Adverse events (AEs) were collected from day 1 of starting treatment until 30 days after ceasing treatment (off study). AEs possibly, probably, or definitely attributed to the study drug that occured after the off study date were also collected.","One participant in the Medulloblastoma: No Surgery group did not receive any lapatinib as the patient experienced clinical progression prior to starting therapy. This patient is excluded from the adverse event reporting.","Ependymoma: Lapatinib Prior to Surgery","Participants with recurrent medulloblastoma who had surgical resection of the tumor at study enrollment and were randomized to receive lapatinib 7-14 days prior to surgery."
"193",252,"NCT02037347",32543,1,1,1,NA,NA,"Palifermin","Palifermin 60 micrograms/kg/day IV for 3 consecutive days"
"225",287,"NCT01182610",204216,1,1,1,"Adverse events collected beginning on day 1 of study treatment through the End of Treatment visit (30 days post-operative, 6 weeks from last treatment administration if treatment failure, or 30 days from last dose of study treatment if early withdrawal).","Systematic Assessment- subjects were assessed for adverse events on day 1 of each cycle by either the research coordinator, treating physician, or other appropriate sub-investigator.","Treatment Group: Panitumumab, Paclitaxel, Carboplatin and 5FU","Panitumumab 9mg/kg on Days 1, 22, and 43; Paclitaxel 200mg/m2 on Days 1 and 22; Carboplatin AUC=6 on Days 1 and 22; 5FU 225mg/m2/day on Days 1-15 and 22-36"
"234",298,"NCT00932373",286666,1,1,1,"Baseline to the end of the study (up to 3 years 2 months)",NA,"Trastuzumab-MCC-DM 0.6 mg/kg Every 3 Weeks","Trastuzumab-MCC-DM 0.6 mg/kg administered intravenously (IV) once every 3 weeks"
"244",308,"NCT00857714",309413,1,1,1,"Up to 60 days",NA,"1500 mg Lapatinib for 14-21 Days","Patients took 1500 mg Lapatinib for 14-21 days until surgical excision."
"281",353,"NCT00096174",563796,0.96969697,64,66,"Assessed weekly while on treatment, and every 3 months for 2 years",NA,"Cisplatin, C225, Radiation","Cetuximab therapy: Patients receive an initial loading dose of cetuximab intravenously (IV) over 2 hours on day 1. Patients then receive cetuximab IV over 1 hour on days 8, 15, 22, 29, 36, 43, 50, and 57.
Chemoradiotherapy: Beginning on day 15 of cetuximab therapy, patients undergo radiotherapy once daily, 5 days a week, for at least 7 weeks. Patients also receive cisplatin IV over 1-2 hours on days 15, 36, and 57.
Cetuximab maintenance therapy: After the completion of chemoradiotherapy, patients continue to receive cetuximab IV over 1 hour once weekly for 6-12 months."
"303",377,"NCT00918385",291251,0.941176471,16,17,NA,NA,"Arm 2= Low AR Dasatinib","Low Androgen Receptor (AR) activity of < 0.50
Dasatinib: Dasatinib 100mg orally daily x 28 days per cycle. After first progression, Dasatinib 100mg orally each day in combination with Nilutamide 150mg orally each day for 28 days per cycle."
"306",380,"NCT01068769",240614,0.939393939,31,33,NA,NA,"Regorafenib","Regorafenib adminstered orally, 160 mg per day on days 1 through 21 of a 28 day cycle"
"316",393,"NCT00316888",511963,0.928571429,26,28,"Adverse events were assessed every cycle (1 cycle=28 days) while on treatment and for 30 days after the end of treatment. After discontinuation of treatment, severe (Grade ≥ 3) long term toxicity that had not been previously reported were collected via the Long term follow-up form using the following schedule: every 3 months within 2 years of registration, then every 6 months in years 2-5, annually afterward until year 10.",NA,"Arm I (Closed to Accrual as of 11/3/2008)","Patients receive cisplatin IV over 60 minutes on days 1, 29, 57, and 85 and fluorouracil IV continuously over 96 hours on days 1-4, 29-32, 57-60, and 85-88. Patients also receive cetuximab IV over 120 minutes on day 50 and then IV over 60 minutes on days 57, 64, 71, 78, 85, 92, and 99 and undergo radiotherapy once daily 5 days a week for 5 weeks, beginning on day 57. Treatment continues in the absence of disease progression or unacceptable toxicity.
cetuximab: Given IV
cisplatin: Given IV
fluorouracil: Given IV
radiation therapy: Given once daily 5 days a week for 5 weeks"
"322",399,"NCT00782834",339391,0.923076923,12,13,NA,NA,"Nilotinib Arm","All patients treated with nilotinib 400 mg BID orally daily; 4 weeks = one cycle"
"328",406,"NCT00306202",515604,0.916666667,22,24,"From the date of first dose until at least 30 days after the last dose of study drug (Median duration of therapy in months: Stratum 1=24.11 [Range: 2.27-50.63]; Stratum 2/3=3.02 [Range: 0.53-37.72]; Stratum 4=1.14 [Range: 0.03-3.38]",NA,"Stratum4 Ph- ALL/AML; Dasatinib 60 mg/m^2 Starting Dose","Participants with second or subsequent relapse of Ph- ALL or Ph- AML. Starting Dose Level of 60 mg/m^2; Escalated/Dose level 2 of 80 mg/m^2, Escalated/Dose level 3 of 100 mg/m^2, and Escalated/Dose level 4 of 120 mg/m^2. QD, as long as clinical benefit was maintained."
"333",411,"NCT00089297",567109,0.914285714,64,70,"Assessed weekly while on treatment and for 30 days after the end of treatment.",NA,"Cetuximab/Paclitaxel/Carboplatin","Induction: Cetuximab (C225) 400 mg/m2 at wk 1 then 250 mg/m2 for 5 weeks. Paclitaxel (P) 90 mg/m2 IV and carboplatin (C) AUC = 2 IV were given weekly.
Restaging biopsy of primary site scheduled at wk 7. Concurrent chemoradiation: Radiation at 200cGy/d/5 wks for a total of 50Gy and C225 at 250 mg/m2/wk. P following C225 at 30 mg/m2/wk and C following P at AUC = 1/week. Patients with a negative biopsy continued concurrent therapy to complete radiation (68-72Gy).
Restaging biopsy of primary site: Patients with positive biopsy at wk 7 or patients without a clinical complete response at the primary site after induction therapy had re-biopsy at wk 14. If the biopsy was negative, the patients continued concurrent therapy to complete radiation (68-72 Gy). If positive, resection of the primary site was done.
Additional concurrent chemoradiation: C225 at 250mg/m2/wk IV followed by P 30mg/m2/wk IV followed by C AUC = 1/wk and RT for 3 wks."
"352",438,"NCT01954745",42066,0.894736842,17,19,"October 1, 2013 through February 12, 2015","The most common drug-related adverse events were fatigue, elevated AST, and thrombocytopenia. Serious adverse events included but were not limited to neutropenia, hyperbilirubinemia, epistaxis, bowel perforation, enterocutaneous fistula, and hypertension.","Cabozantinib","Patients will be treated with cabozantinib 60 mg daily administered orally continuously for 28-day cycles. Tumor assessments will be performed every 8 weeks until documented disease progression by RECIST criteria or drug intolerance.
Cabozantinib: Cabozantinib 60 mg (free base weight) per day will be administered daily and continuously for a cycle length of 28 days. Subjects will be provided with a sufficient supply of study treatment and instructions for taking the study treatment on days without scheduled clinic visits. After fasting (with exception of water) for 2 hours, subjects will take study treatment daily with a full glass of water (minimum of 8 oz/ 240 mL) and continue to fast for 1 hour after each dose of study treatment."
"362",448,"NCT01557959",107717,0.886363636,39,44,NA,"44 of the 45 patients had completed therapy at the time of reporting. Adverse events reflect those 44 patients.","Treatment (Chemo, Chemoprotection, Antiangiogenesis Therapy)","Patients receive docetaxel IV over 1 hour on day 1, cisplatin IV over 1 hour on day 1, and pegfilgrastim subcutaneously on day 2. Treatment repeats every 2 weeks for 4 courses in the absence of disease progression or unacceptable toxicity. Beginning 2 weeks after completion of docetaxel, cisplatin, and pegfilgrastim, patients receive oral erlotinib hydrochloride once daily in the absence of disease progression or unacceptable toxicity."
"370",456,"NCT01462695",127997,0.875,14,16,NA,"One stratum A patient did not receive any study drug and was excluded from the summary of adverse events. SAE field contains NCI CTCAEs submitted via expedited reporting (NCI AdEERs / CAeRs) or grade 5 adverse events resulting in death. The AE field contains grade 3 and higher CTCAEs reported on study excluding those that were reported as SAEs.","Stratum A: Recurrent High Grade Glioma","Patients receive sunitinib malate orally (PO) once daily (QD) on days 1-28. Treatment repeats every 42 days for up to 18 courses in the absence of disease progression or unacceptable toxicity.
sunitinib malate: Given PO
diagnostic laboratory biomarker analysis: Correlative studies
pharmacological study: Correlative studies"
"378",468,"NCT00551759",425907,0.863636364,19,22,"Assessed every 6 weeks while on treatment and for 30 days after the end of treatment",NA,"Neoadjuvant Therapy, Surgery, Adjuvant Therapy","35 days of neoadjuvant chemoradiotherapy with oxaliplatin and infusional 5-fluorouracil plus cetuximab followed by post-operative docetaxel and cetuximab."
"396",490,"NCT00560352",421938,0.857142857,6,7,"Continuously from Day 1 until last day of study medication + 30 days (maximum reached: 10 months)",NA,"Dasatinib, 50 mg BID","Dasatinib, 50 mg administered twice daily (BID), with 1.0 mg/m^2 of bortezomib in 21-day cycles. Dexamethasone, fixed at 20 mg once daily (QD), was administered the day of and 1 day after each bortezomib dosing. In a 21-day cycle, bortezomib was administered by intravenous (IV) bolus twice weekly, on Days 1, 4, 8, and 11, followed by a 10-day (Days 12 to 21) rest period. In a 21-day cycle, dasatinib was taken orally every day, BID. In a 21-day cycle, dexamethasone was taken orally on Days 1, 2, 4, 5, 8, 9, 11, and 12, at the same time as dasatinib. On the days when bortezomib and dasatinib were administered together, the morning dose of dasatinib was to be followed 1-2 hours by the dose of bortezomib."
"404",498,"NCT00316888",511962,0.852941176,29,34,"Adverse events were assessed every cycle (1 cycle=28 days) while on treatment and for 30 days after the end of treatment. After discontinuation of treatment, severe (Grade ≥ 3) long term toxicity that had not been previously reported were collected via the Long term follow-up form using the following schedule: every 3 months within 2 years of registration, then every 6 months in years 2-5, annually afterward until year 10.",NA,"Arm II (Open to Accrual on 8/18/2009)","Patients receive cetuximab IV over 120 minutes on day 1 and then IV over 60 minutes on days 8, 15, 22, 29, 36, 43, and 50. Patients also receive cisplatin IV over 60 minutes on days 1 and 36, fluorouracil IV continuously over 96 hours on days 8-11 and 36-39, and undergo radiotherapy once daily 5 days a week for 5 weeks beginning on day 8. Treatment continues in the absence of disease progression or unacceptable toxicity.
cetuximab: Given IV
cisplatin: Given IV
fluorouracil: Given IV
radiation therapy: Given once daily 5 days a week for 5 weeks"
"420",517,"NCT00378703",491904,0.835164835,76,91,"Assessed every 4 weeks while on treatment and for 30 days after the end of treatment",NA,"Arm D (Sorafenib and Temsirolimus)","Patients receive sorafenib 200 mg PO BID on days 1-28 and temsirolimus as in Arm B in a 28-day cycle."
"423",520,"NCT01251653",182102,0.833333333,15,18,"From first drug administration until 28 days after last drug administration, up to 717 days",NA,"Afatinib 30mg and Docetaxel 75mg","Afatinib (film-coated tablet) 30 mg qd (once daily) was administered orally in combination with Docetaxel 75 mg/m2 administered as intravenous infusion on Day 1 of each 3- week treatment course."
"436",540,"NCT00658658",387553,0.833333333,5,6,"From first dose date to end of study date. The median duration of study is 47 days.","Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Summary of Adverse Events includes only those participants who received at least one dose of investigational product.","Age 12–17: 2.5 mg/kg QW","Participants aged 12 to 17 years received panitumumab 2.5 mg/kg administered by intravenous (IV) infusion weekly (QW) until the participant experienced disease progression, was unable to tolerate study drug, withdrew consent, or other reasons that warranted removal from the study."
"456",568,"NCT01309997",164185,0.826086957,19,23,"18 months",NA,"Imatinib as Secondary Therapy","Arm II = imatinib, adverse event occurred after the start date of imatinib. (All participants in this group received rituximab prior)."
"459",572,"NCT00726986",361518,0.823529412,14,17,"Patients were followed for adverse events while on treatment and post-treatment follow up for up to 1 year.",NA,"Sorafenib, Cisplatin, and Etoposide","Sorafenib, Cisplatin, and Etoposide for 4 cycles (months) during maintenance phase. If no disease progression continue with sorafenib for a maximum of 12 months."
"460",574,"NCT00378703",491905,0.822222222,74,90,"Assessed every 4 weeks while on treatment and for 30 days after the end of treatment",NA,"Arm C (Bevacizumab and Sorafenib)","Patients receive bevacizumab 5 mg/kg IV over 30-90 minutes on days 1 and 15 and sorafenib 200 mg PO BID on days 1-5, 8-12, 15-19, and 22-26 in a 28-day cycle."
"463",577,"NCT00100841",562565,0.818181818,54,66,NA,NA,"Treatment (Combination Chemotherapy)","Patients receive cetuximab IV over 60-120 minutes on day 1 in weeks 1-8. Patients also receive bevacizumab IV over 30-90 minutes, oxaliplatin IV over 2 hours, and leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV continuously over 48 hours on days 1 and 2 of weeks 1, 3, 5, and 7. Courses repeat every 8 weeks in the absence of disease progression or unacceptable toxicity.
cetuximab: Given IV
bevacizumab: Given IV
oxaliplatin: Given IV
leucovorin calcium: Given IV
fluorouracil: Given IV"
"470",584,"NCT01005914",259485,0.818181818,9,11,"All unexpected adverse events (AEs) related, probably related or possibly related to the study drug which are equal or greater than Grade 3 and serious adverse events (SAEs) were collected from first patient enrollment on 10/21/09 through 2010.","Adverse events collected:
Unexpected AEs (when type or severity isn't listed in Expected AE List)
Deaths within 30 days of drug admin.
Grade ≥ 3 (related to the following):
Allergic reactions
CNS thrombosis/embolism
Coagulopathy
Elevated AST, ALT
Hyperbilirubinemia
Hyperglycemia
Hypertriglyceridemia
Pancreatitis","Group 1","cyclophosphamide D1- 3: 300 m g/m2 IV 6 doses plus mesna 600 mg/ m2 /day cont. IV D1-3, cytarabine D2 & 3: 3g/m2 IV, dexD1-4; 11-14: 40 mg daily, doxorubicin hydrochloride D4: 50 mg/m2 IV
Drug:imatinib mesylate 600 mg/day
Drug:methotrexate Day 1: 1g/ m2 (200 mg/ m2load IV over 2 hours plus 800 mg/ m2 over 22 hours as an infusion
Drug: methylprednisolone Day 1-3: 50mg IV BID
Drug: pegaspargase Day 3/Day4: 2,500 IU/ m2 IV
Drug: vincristine sulfate Day 4 & 11: 2 mg IV
cyclophosphamide: Day 1- 3: 300 m g/m2 IV over 2-3 hours every 12 hours for 6 doses plus mesna 600 mg/ m2 /day continuous infusion Days 1-3
cytarabine: Day 2 & 3: 3g/m2 IV over 2 hours q12 X 4
dexamethasone: Day 1-4; 11-14: 40 mg daily
doxorubicin hydrochloride: Day 4: 50 mg/m2 IV over 2 hours
imatinib mesylate: 600 mg/day
methotrexate: D"
"475",592,"NCT00551421",425958,0.8125,13,16,"Adverse event information was collected between November 2007 and October 2010.","3 patients were enrolled to Dose Level 1. 1 subject developed gr. 3 diarrhea (hospitalized), and skin toxicity was seen among the 3 subjects. The study was amended and the loading dose of cetuximab was eliminated. We report the adverse event results of the subjects enrolled on the original and the amended protocol.","Pertuzumab and Cetuximab","Original Protocol: Patients received pertuzumab IV over 30-60 minutes on day 1 of each cycle (loading dose on cycle 1, day 1 only). Patients also receive cetuximab IV over 60-120 minutes on days 2 (loading dose), 8, and 15 of cycle 1 and on days 1, 8, and 15 in all subsequent cycles. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Amended Protocol, Phase I: Same as the Original Protocol (see above) except the Cetuximab loading dose was no longer given on cycle 1, day 2 (maintainance dose given).
Phase II: Patients receive treatment as in phase I. Pertuzumab is administered at the recommended phase II dose (determined in phase I).
Given IV: pertuzumab, cetuximab, irinotecan hydrochloride
Corrlateive studies: immunohistochemistry staining method, fluorescence in situ hybridization, gene expression analysis, mutation analysis, polymerase chain reaction, laboratory biomarker analysis"
"484",603,"NCT00101816",562122,0.808080808,80,99,NA,NA,"Imatinib-resistant","Defined as any of the following: i) Subjects initially diagnosed with chronic phase chronic myeloid leukemia (CML) who progressed to myeloid phase CML while on treatment with a prescribed imatinib dose of ≥400 mg/day. ii) Subjects initially diagnosed with accelerated phase CML who progressed to myeloid phase CML while on treatment with a prescribed imatinib dose of ≥600 mg/day (or 400 to <600 mg/day if subject is intolerant of ≥600 mg/day). iii) Subjects initially diagnosed with myeloid blast phase CML who meet the criteria for myeloid phase blast crisis after at least 4 weeks of treatment prescribed at a dose of ≥600 mg/day (or 400 to <600 mg/day if subject is intolerant of ≥600 mg/day). Each of these definitions includes subjects who had no response to imatinib (primary resistance) and those who responded and subsequently progressed to myeloid blast phase (acquired resistance). Oral dasatinib 70 mg BID, with dose modifications as necessary to manage disease progression or toxicity."
"488",608,"NCT00305877",515651,0.805970149,54,67,"Assessed every 2 weeks while on treatment and for 30 days after the end of treatment",NA,"Arm A (Cetuximab, Gemcitabine, Capecitabine, Radiation)","Patients receive cetuximab IV over 60-120 minutes on day 1, once weekly, in weeks 1-24; gemcitabine hydrochloride IV over 30 minutes on day 1, once weekly, in weeks 1-3, 13-15, 17-19, and 21-23; oral capecitabine twice daily on days 1-5, 5 days a week, in weeks 5-10. Patients also undergo radiotherapy once daily, 5 days a week, beginning in week 5 and continuing for approximately 5½ weeks (25 fractions)."
"490",610,"NCT01108445",227540,0.803921569,41,51,"Baseline to 40 months",NA,"Sunitinib","Subjects in this treatment arm will take sunitinib 50 mg daily by mouth on days 1 through 28 of each 42 day cycle.
Sunitinib: 50 mg daily by mouth on days 1 through 28 of each 42 day cycle."
"495",615,"NCT00042939",575185,0.8,36,45,"Assessed every 6 weeks while on treatment and for 30 days after the end of treatment.",NA,"Arm B: Irinotecan/Docetaxel/Cetuximab","Patients received Cetuximab intravenously once a week for 6 weeks. On day 1 of cycle 1 only, an initial dose of 400 mg/m² (over 120 minutes) was administered. Thereafter, a once-a-week maintenance dose of 250 mg/m² (infused over 60 minutes), was given. The infusion rate never exceeded 5 ml/minute.
On the day of the initial dose, the administration of Cetuximab was followed by the administration of docetaxel, after a 60-minute observation period. (The observation period was 30 minutes following maintenance doses.) Docetaxel was administered intravenously over 60 minutes at a dose of 35 mg/m². Docetaxel was diluted in 100-150 ml of infusion solution. After the completion of the docetaxel infusion, irinotecan was administered intravenously over 30 minutes at a dose of 50 mg/m².
Chemotherapy was administered once a week (days 1, 8, 15, 22) for 4 consecutive weeks followed by 2 weeks rest. Cetuximab was administered once a week for 6 consecutive weeks. A cycle of treatment was 6 weeks."
"503",625,"NCT02439138",6265,0.8,4,5,"Adverse events were collected from the time of screening until 30 days post treatment discontinuation, up to 16 weeks (median 4 weeks).",NA,"GS-1101","After the screening procedures confirms eligibility to participate in the research study. Treatment will be administered on an outpatient basis.
-- Idelalisib (GS-11-01) orally, predetermined dose twice daily per cycle for up to 6 cycles. After this initial 6 month period, for Cycles 7 and beyond, Idelalisib will be administered once a day until disease progression.
GS-1101"
"508",631,"NCT01214616",193345,0.8,4,5,"during the treatment period or up to 28 days after the completion of drug administration, up to 730 days",NA,"Afatinib 40 mg With Vinorelbine 25 mg/m^2 (Cohort 2)","Afatinib 40 mg oral administration once a day with vinorelbine 25 mg/m^2 intravenous injection weekly"
"513",640,"NCT00787852",337045,0.8,4,5,"Baseline then approximately 30 days post the last dose of drug, which could be up to 2.5 years.",NA,"Group 2","DAY Radiation 1-5 8-12 15-19 22-26 29-33 36-40 43-47 Paclitaxel 1 8 15 22 29 36 43 Carboplatin 1 8 15 22 29 36 43 Dasatinib ----------------------------------------------------------------------Maintenance Dasatinib RT: External radiotherapy, 64.8 Gy, for 35 fx Paclitaxel: 50 mg/m2/week over 1 hour IV infusion days 1, 8, 15, 22, 29, 36, 43 Carboplatin: AUC = 2 IV infusion days 1, 8, 15, 22, 29, 36, 43 Dasatinib Dose Level With chemoradiation Maintenance x 2 years* Dasatinib is to be taken 1x daily
70 mg daily"
"520",650,"NCT00458237",461374,0.8,4,5,"Assessed each cycle throughout treatment from time of first dose and up to day 30 post-treatment. Median duration of treatment was 2.4 months.","Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3.","Phase II: Everolimus (Maximum Tolerated Dose) and Trastuzumab","Cycle duration is 21 days. Participants receive trastuzumab 6 mg/kg [8 mg/kg loading dose] IV once every three weeks and take everolimus at the MTD (10 mg) by mouth daily on days 1-21. Participants are treated until disease progression or unacceptable toxicity."
"534",665,"NCT01309997",164184,0.789473684,15,19,"18 months",NA,"Rituximab as Secondary Therapy","Arm II = rituximab, adverse event occurred after the start date of rituximab. (All participants in this group received imatinib prior)."
"537",669,"NCT01514864",116375,0.785714286,11,14,NA,NA,"Dasatinib, 140 mg","Participants with nonsmall-cell lung cancer received dasatinib, 140 mg, once daily as a tablet until unacceptable toxicity or disease progression occurred. Data from both arms were combined for safety reporting, because the safety profile of dasatinib should not have be affected by the type of mutation in the tumor. In addition, pooling the data from both arms increased the robustness of the data set."
"547",681,"NCT00847015",314404,0.777777778,14,18,NA,NA,"Gemcitabine, Cisplatin, and Sunitinib","This is a phase II study of GCS (Gemcitabine, Cisplatin, and Sunitinib) as neoadjuvant chemotherapy in patients with muscle-invasive urothelial carcinoma of the bladder. Patients with muscle invasive urothelial carcinoma who are candidates for radical cystectomy will be enrolled.
Gemcitabine, Cisplatin, and Sunitinib: Patients will receive four cycles of GCS administered every 21 days followed by radical cystectomy. Sunitinib will be administered at a dose of 25mg orally once daily for 2 consecutive weeks followed by a 1 week rest period. Gemcitabine 1,000 mg/m2 and cisplatin 35 mg/m2 will be administered intravenously on days 1 and 8."
"550",685,"NCT01647711",90432,0.777777778,7,9,"From first treatment administration until 28 days after the last administration, up to 448 days",NA,"Afatinib 150mg","Patients received oral administration of afatinib 150mg film-coated tablet once daily for three days, repeated every 14 days, during each 28-day cycle."
"562",701,"NCT01084083",234316,0.775280899,69,89,"Assessed every cycle while on treatment and for 3 months after completion of concurrent treatment to capture late radiation toxicities",NA,"All Treated Patients","Patients receive cisplatin IV on day 1 and paclitaxel IV and cetuximab IV on days 1, 8, and 15. Treatment repeats every 21 days for 3 courses. Patients then undergo evaluation of response to induction therapy. Patients with a CR at the primary tumor site proceed to group 1 of concurrent low-dose IMRT and cetuximab. Patients with a PR or SD at the primary tumor site or those with grossly positive disease at the primary tumor site proceed to group 2 of concurrent standard dose IMRT and cetuximab.
Adverse events data were reported for all patients received at least one dose of protocol therapy."
"564",704,"NCT00123487",554724,0.773770492,236,305,"Day 1 up to 7 years","Participants who received at least one dose of study drug were analyzed. Participants were analyzed based on the treatment they actually received, not what they were randomized to receive.","Dasatinib 70 mg BID","Dasatinib was administered orally at a dose of 70 mg twice a day (BID) until disease progression, drug toxicity, withdrawal of consent, investigator or sponsor decision, pregnancy, or decision to do stem cell transplant."
"592",735,"NCT00392496",486985,0.764705882,13,17,NA,NA,"Arm I","This is a non-randomized, open-label, multicenter study. Patients receive sunitinib malate orally once daily on days 1-28. Treatment repeats every 4 weeks for a maximum of 12 courses in the absence of disease progression or unacceptable toxicity."
"603",750,"NCT00673049",381614,0.759036145,63,83,NA,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study. All treated subjects were analyzed for AEs and SAEs.","Erlotinib, Then Figitumumab","Figitumumab (20 mg/kg) was given as a single agent after participants had disease progression on erlotinib alone. Figitumumab was given in 3-week cycles as IV infusion on study Days 1 and 2 in Cycle 1, and on Day 1 every 3 weeks (from Day 1) thereafter."
"612",760,"NCT00520975",438994,0.755555556,34,45,"Assessed every cycle (1 cycle=4 weeks during Induction therapy, 1 cycle=3 weeks during Maintenance therapy) while on treatment and for 30 days after the end of treatment","After discontinuation of treatment, severe (Grade ≥ 3) long term toxicity that had not been previously reported were collected via the Long term follow-up form using the following schedule: every 3 months within 2 years of registration, then every 6 months in years 2-5, annually afterward until year 10.","Arm B (Chemotherapy and Bevacizumab)","INDUCTION THERAPY: Patients receive trastuzumab and paclitaxel with or without carboplatin as in Arm A. Patients also receive bevacizumab IV over 30-90 minutes on days 1 and 15. Treatment repeats every 4 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.
MAINTENANCE THERAPY: Beginning 1 week after the last dose of induction trastuzumab, patients receive trastuzumab IV over 30-90 minutes and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity.
Bevacizumab: Given IV
Carboplatin: Given IV
Paclitaxel: Given IV
Trastuzumab: Given IV"
"616",764,"NCT00123487",554725,0.75,228,304,"Day 1 up to 7 years","Participants who received at least one dose of study drug were analyzed. Participants were analyzed based on the treatment they actually received, not what they were randomized to receive.","Dasatinib 140 mg QD","Dasatinib was administered orally at a dose of 140 mg once a day (QD) until disease progression, drug toxicity, withdrawal of consent, investigator or sponsor decision, pregnancy, or decision to do stem cell transplant."
"620",769,"NCT00986674",267018,0.75,36,48,"Assessed every cycle (6 weeks) while on treatment and for 30 days after the end of treatment.","After off treatment, patients were assessed every 3 months if <2 years and every 6 months in year 3 to report any reportable long-term toxicity occurring prior to diagnosis of progression/relapse that has not been previously reported.","Arm III (Carboplatin, Paclitaxel, Cetuximab, Cixutumumab)","Patients receive carboplatin, paclitaxel, and cetuximab as in arm I. Patients also receive cixutumumab as in arm II. Treatment repeats every 42 days for 2 courses. Patients with stable or responding disease after 2 courses proceed to maintenance therapy with cetuximab as in arm I and cixutumumab as in arm II."
"623",773,"NCT00126594",553865,0.75,30,40,"Adverse event reporting from time of first intervention to follow up 30 days beyond last intervention. Overall study period: June 2005 to August 2013.","Revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 utilized for AE reporting until September 30, 2010. CTCAE version 4.0 utilized beginning October 1, 2010.","Sorafenib Tosylate, Recombinant Interferon Alfa-2b","Arm II: Sorafenib as in Arm I and low-dose Interferon alfa-2b 0.5 million units subcutaneously twice daily on days 1-28."
"632",784,"NCT01121575",223335,0.75,9,12,"Up to Maximum of treatment duration + 28 days for each participant (could be 295 days)","The same event may appear as both an AE and a SAE. However, what is presented are distinct events. The below tables included all causality SAEs (frequency threshold 0%) and AEs ( frequency threshold 5%).","Expansion Cohort 2","Participants were treated first with single agent dacomitinib at a dose determined by agreement between the investigator and the sponsor, and then, at progression, with combined maximum tolerated dose of crizotinib and dacomitinib (given orally on a continuous schedule in 21-day cycles of crizotinib 200 mg BID + dacomitinib 30 mg QD) as soon as feasible, and no later than 28 days after documentation of progressive disease. Expansion Cohort 2 used the same participant population as Expansion Cohort 1 and was designed to assess the clinical value of adding crizotinib to dacomitinib treatment after disease progression on dacomitinib alone."
"634",786,"NCT00071006",570784,0.75,9,12,NA,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.","Axitinib","Axitinib (AG-013736) tablet administered orally at a dose of 5 milligram (mg) twice daily (BID) continuously. Treatment was administered continuously until progression, relapse, failure, or disease transformation or toxicity occurred."
"638",791,"NCT01498458",119454,0.75,6,8,"24 months",NA,"Pazopanib Plus Capecitabine","There was only one arm in this study as this was a dose escalation study."
"648",803,"NCT00351039",501261,0.75,6,8,"26 months","All noted adverse events were reported on the accrued patients. Hence the threshold is Zero.","Experimental: Bevacizumab, Erlotinib, Pemetrexed","Treatment Regimen Item 1: Bevacizumab 10mg/Kg I. V. Day 1 and Day 15. Repeat cycles every 28 days. Treatment Regimen Item 2: Erlotinib(Tarceva™) 150mg Per Orally (PO) Once Daily (QD) for 7 days starting day 2 and day 15. Repeat cycles every 28 days. Treatment Regimen Item 3: Pemetrexed(Alimta™) 500mg/m2 I.V. Day 1 and Day 15. Repeat cycles every 28 days. The regimen then was modified to the following dose:
Bevacizumab 15mg/kg Day 1 every 21 days (Q21); Pemetrexed 500 mg/m2 Day 1 Q 21; Erlotinib 150 mg QD PO Day 2 to day 15 (Both days inclusive). This dose was then recommended to be Phase II dose."
"659",817,"NCT01004003",260204,0.75,3,4,"From first administration of the trial drug and until 28 days after the last administration of nintedanib or sorafenib, up to 1289 days",NA,"Phase I Group 2, 150mg Nintedanib Bid","Oral administration of Nintedanib (BIBF 1120) 150 mg soft gelatine capsules twice daily (bid). Phase I: A standard 3+3 dose escalation part to determine the MTD. Group 2 patients had a baseline Child-Pugh score of 7, or AST or ALT >2 to ≤5 times ULN."
"660",819,"NCT00978731",270243,0.75,3,4,NA,"The SAEs listed here differ from those present in the Outcome Measures. This is because the Outcome Measures present on-treatment SAEs and this section presents all SAEs. In addition, the AEs presented here differ from those in the Outcome Measures. This is because the AEs presented here do not include SAEs.","Participants With Myeloid Blast Phase CML","Participants continued on the last dose and schedule of dasatinib that was received within the previous protocol (CA180002; NCT00064233). A TDD of 50 mg, 75 mg, 105 mg, 120 mg, 140 mg or 180 mg dasatinib was taken QD or split into 2 doses and taken BID (TDD of 50 mg, 70 mg, 100 mg, 140 mg, 180 mg or 240 mg ). Participants were dosed on 1 of 3 schedules: 5 days on, 2 days off; 6 days on, 1 day off; or continuous daily dosing and were permitted to escalate or reduce by 1 dose level at a time, switch from QD dosing to BID dosing and vice versa provided they did not exceed a change of 1 dose level from the TDD. The weekly schedule was also permitted to be increased or decreased 1 level at a time."
"672",838,"NCT00195260",539808,0.75,3,4,NA,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.","Bosutinib 100 mg","Bosutinib 100 mg capsule orally once daily continuously in 21-day cycles until disease progression, unacceptable toxicity, or consent withdrawal."
"682",848,"NCT00673738",381114,0.740740741,20,27,"3 years",NA,"Cetuximab Plus Radiotherapy","Concurrent Cetuximab plus Conformal Thoracic Radiotherapy (CTRT)"
"687",855,"NCT00389974",487928,0.736842105,14,19,NA,NA,"Treatment (Sunitinib Malate)","Patients receive sunitinib malate PO daily for 4 weeks. Treatment repeats every 6 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients achieving CR or PR may receive 2 courses after CR or PR is reached.
sunitinib malate: Given PO"
"700",868,"NCT01461057",128488,0.733333333,11,15,"Randomization of first participant to clinical cutoff date (01 March 2015) (approximately 41 months)","An adverse event (AE) was defined as any untoward medical occurrence in a participant administered the investigational product which does not necessarily have a causal relationship with this treatment.","Pertuzumab 840/420 mg","Participants received pertuzumab as an intravenous (IV) infusion at a loading dose of 840 milligrams (mg) for cycle 1 and a dose of 420 mg every three weeks (Q3W) for cycles 2-6. Participants in both arms received trastuzumab, cisplatin, and capecitabine. Capecitabine 1000 milligram per meter squared (mg/m^2) was administered orally twice daily, from the evening of Day 1 to the morning of Day 15 of each cycle. Cisplatin 80 mg/m^2 was administered as an IV infusion on Day 1 of each cycle. Trastuzumab was administered as an IV infusion at a loading dose of 8 mg/kg for Cycle 1 and a dose of 6 milligram per kilogram (mg/kg) q3w for subsequent cycles."
"701",869,"NCT00330421",505425,0.733333333,11,15,NA,NA,"Group II (Metastatic or Inoperable Sarcomas)","Patients receive oral sorafenib twice daily on days 1-28. Treatment repeats every 28 days for 2 courses. Patients with responding or stable disease may continue sorafenib in the absence of disease progression or unacceptable toxicity. Biopsy tissue and blood samples are examined for biomarkers and IFP is measured at baseline and on days 28 and 56.
laboratory biomarker analysis : Correlative studies
sorafenib tosylate : Given PO
pharmacological study : Correlative studies
computed tomography : Correlative studies
dynamic contrast-enhanced magnetic resonance imaging : Correlative studies"
"709",877,"NCT00837876",317334,0.72972973,27,37,NA,NA,"Treatment","Sorafenib + Erlotinib"
"721",892,"NCT00126594",553866,0.725,29,40,"Adverse event reporting from time of first intervention to follow up 30 days beyond last intervention. Overall study period: June 2005 to August 2013.","Revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 utilized for AE reporting until September 30, 2010. CTCAE version 4.0 utilized beginning October 1, 2010.","Sorafenib Tosylate","Arm I: Oral Sorafenib 400 mg twice daily on days 1-28."
"727",901,"NCT00906698",295313,0.722222222,13,18,"First administration of trial medication until 28 days after last administration of trial medication.",NA,"Afatinib 40mg With Vinorelbine Per os","Continuous daily dosing of Afatinib 40mg orally and oral vinorelbine 60 mg/m2/week for days 1,8,15 of first cycle, and 80mg/m2 from day 22 first cycle onwards, weekly. Patients will be eligible for repeated treatment courses in the absence of clinical disease progression or undue toxicity ."
"732",907,"NCT01286753",170700,0.72,18,25,"Baseline until 28 days after the last dose of study treatment or until initiation of another anti-cancer therapy, whichever occurred first (up to approximately 4 years)","Safety population, defined as enrolled participants who received at least one dose of study treatment.","TKI Experienced","Vemurafenib 960 mg orally twice daily in participants previously treated with TKI therapy active against VEGFR."
"733",908,"NCT00520013",439267,0.72,18,25,"Assessed each cycle throughout consolidation treatment from time of first dose and up to day 30 post-treatment. Per protocol, consolidation treatment was a fixed duration of 1 year.","Serious and other AE data is only available for consolidation treatment reflecting the primary and secondary study objectives centered on the evaluation of consolidative regimens AE vs A.","Carboplatin/Paclitaxel/Bevacizumab Then Bevacizumab/Erlotinib","Induction (CTA): Patients received carboplatin IV AUC 5, paclitaxel IV 175 mg/m2 and bevacizumab IV 15 mg/kg on day 1 (+/- 3d) of a 21 day cycle for 6 cycles. Bevacizumab started with cycle 2.
Patients with disease progression based on radiographic evaluation after induction could not advance to the randomized consolidation phase.
Consolidation (AE): Patients received bevacizumab IV 15 mg/kg on day 1 (+/- 3d) of a 21 day cycle and oral erlotinib 150mg daily for 1 year."
"739",916,"NCT00054275",573039,0.717948718,28,39,"Patients will be evaluated for adverse events at each study visit for the duration of their participation in the study and for 30 days after the discontinuation of Tarceva.",NA,"Docetaxel and OSI-774","docetaxel IV over 1 hour once weekly for 3 weeks and oral erlotinib once daily"
"747",924,"NCT00459342",461156,0.714285714,25,35,"29 weeks","Treatment schedule included up to eight (8) possible 21-day (3-week) study cycles with follow up about 4-5 weeks after the last dose of Dasatinib.","Dasatinib","Oral dasatinib 100 mg (two 50 mg tablets) twice daily on days 1-21. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity."
"756",934,"NCT00263328",528191,0.714285714,10,14,"Adverse events (AEs; serious and nonserious) were recorded from the time the participant had taken at least 1 dose of trial treatment through the follow-up visit at Month 98 or 2 months following discontinuation of treatment.","The same event may appear as both an AE and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in 1 participant and as nonserious in another participant, or 1 participant may have experienced both a serious and nonserious event during the study.","Tofacitinib 15-10-5 mg BID","Participants receiving tofacitinib 15 mg, tablets, PO, BID at study entry (rollover from Parent Study A3921009) reduced the dose of tofacitinib to 10 mg BID on entry into Study A3921021. Within the window of Months 12-24 post-transplant, tofacitinib dosage was then tapered from 10 mg BID to 5 mg BID over 4 weeks (5 mg in the morning and 10 mg in the evening for 4 weeks, then 5 mg BID thereafter) and the participant remained on 5 mg BID throughout the duration of the study, for a maximum of 90 months. In addition, African-American participants may have received MMF, up to 3 gm per day through Month 6 post-transplant. Participants also received corticosteroids (prednisone ≤5 mg daily [or equivalent] through at least 12 months post-transplant. Thereafter, steroids may have been discontinued at the investigator's discretion."
"764",943,"NCT00941863",283490,0.714285714,5,7,"Time frame for expansion group is from start of treatment until April 2008, up to 6 years.","Acronyms in Adverse Event Section:
White Blood Cell (WBC) Absolute Neutrophil Count (ANC) Absolute Granulocyte Count (AGC) Alanine Transaminase (ALT) Aspartate Transaminase (AST) Grade (GR) Gastrointestinal (GI) Central Nervous System (CNS) Fibrillation/Flutter (FIB/FLUTT) Neutropenia (Neu) documented (doc)","Sorafenib 100 mg (50-mg Tablet)","Dose-escalation cohort 1: Sorafenib (Nexavar, BAY43-9006) 100 mg twice daily (50-mg tablet)"
"767",949,"NCT00467779",457611,0.714285714,5,7,"AEs were recorded from the Day 1 of treatment period until the 30 plus or minus 4 days after the last treatment (up to approximately 6 years) .",NA,"Stage 1 Cohort 08 - Cobimetinib 80 mg (21/7)","Participants received cobimetinib 80 mg via solution or capsule, once daily for Days 1-21 of each 28-day cycle. Treatment was continued until PD or unacceptable toxicity for up to 1 year at the discretion of investigator and beyond 1 year with the agreement of the sponsor."
"768",950,"NCT00195260",539805,0.714285714,5,7,NA,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.","Bosutinib 400 mg","Bosutinib 400 mg capsule orally once daily continuously in 21-day cycles until disease progression, unacceptable toxicity, or consent withdrawal."
"799",985,"NCT01708954",78387,0.7,28,40,"Assessed every 4 weeks while on treatment and for 30 days after the end of treatment",NA,"Arm B (Cabozantinib)","Patients receive cabozantinib 60mg PO daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
"808",995,"NCT00376948",492462,0.7,14,20,NA,NA,"Novasoy®, Gemcitabine & Erlotinib","Novasoy® 396 mg (177 mg of Isoflavones) twice-daily starting daay -7 until day 28; Gemcitabine 1000 mg/m2 days 1, 8, & 15; Erlotinib 150 mg day 1 until day 28
genistein
erlotinib hydrochloride
gemcitabine hydrochloride"
"823",1011,"NCT00195260",539803,0.7,7,10,NA,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.","Bosutinib 600 mg","Bosutinib 600 mg capsule orally once daily continuously in 21-day cycles until disease progression, unacceptable toxicity, or consent withdrawal."
"824",1013,"NCT00101816",562123,0.7,7,10,NA,NA,"Imatinib-intolerant","Defined as: i) Toxicity that was considered at least possibly related to imatinib ≤400 mg/day that led to a discontinuation of imatinib therapy ii) Ability to tolerate only <400 mg/day imatinib. A subject who tolerated 400 mg/day imatinib, but was intolerant of higher doses was not considered imatinib-intolerant. Receiving oral dasatinib at a starting dose of 70 mg twice daily (BID), with dose modifications as necessary for the management of disease progression or toxicity."
"831",1021,"NCT00392769",486935,0.696969697,23,33,"3 years and 5 months",NA,"Cetuximab","400 mg/m^2 intravenous (IV) over 120 Minutes, followed by weekly infusions at 250 mg/m^2 IV over 60 minutes."
"834",1026,"NCT00299741",517333,0.694444444,25,36,"Throughout treatment period",NA,"Metastatic Prostate Cancer Treated With Sunitinib","Sunitinib"
"842",1034,"NCT01462695",127996,0.692307692,9,13,NA,"One stratum A patient did not receive any study drug and was excluded from the summary of adverse events. SAE field contains NCI CTCAEs submitted via expedited reporting (NCI AdEERs / CAeRs) or grade 5 adverse events resulting in death. The AE field contains grade 3 and higher CTCAEs reported on study excluding those that were reported as SAEs.","Stratum B: Recurrent Ependymoma","Patients receive sunitinib malate orally (PO) once daily (QD) on days 1-28. Treatment repeats every 42 days for up to 18 courses in the absence of disease progression or unacceptable toxicity."
"847",1039,"NCT00245102",532801,0.692307692,9,13,NA,NA,"Undifferentiated Pleomorphic Sarcoma","Sorafenib 400 mg PO BID"
"852",1045,"NCT00527124",435716,0.689655172,20,29,NA,NA,"Arm I","Patients receive oral cediranib once daily on days 1-21, docetaxel IV over 1 hour on day 1, and oral prednisone twice daily on days 1-21."
"861",1055,"NCT00687297",376474,0.6875,22,32,"Adverse events were assessed every 3 weeks during induction and every 4 weeks during maintenance.","Serious adverse events are defined as events of grade 3 or higher that were considered possibly, probably, or definitely treatment-related. Other adverse events include grade 1 or 2 events possibly, probably or definitely treatment-related occurring at a rate of 5% or higher.","Treated on Vandetanib Maintenance","Adverse events among patients receiving Vandetanib using the maintenance phase of the study"
"872",1066,"NCT00977548",270547,0.685714286,24,35,"1 year, 9 months",NA,"Erlotinib Treatment","Erlotinib was given as an oral 150 mg daily dose for 16 weeks. The dose was adjusted for diarrhea, rash and pulmonary toxicity."
"885",1079,"NCT01057589",243764,0.681818182,45,66,NA,NA,"Pemetrexed Cisplatin Cetuximab","Pemetrexed 500 mg/m^2 administered by IV infusion followed by cisplatin 75 mg/m^2 administered by IV infusion both given on Day 1 of each 21 day cycle. Cetuximab 400 mg/m^2 administered by IV infusion initially as a loading dose in Week 1, subsequent weeks cetuximab 250 mg/m^2 administered by IV infusion once per week for a maximum of six 21 day cycles. At the discretion of the investigator participants who completed at least 4 cycles of triplet combination therapy could continue to receive pemetrexed plus cetuximab in the maintenance setting or as a monotherapy of pemetrexed or cetuximab alone in the absence of PD, unacceptable toxicity or any other withdrawal criterion up to 19 months. Participants also received Folic Acid and Vitamin B12 as standard of care dietary supplements."
"891",1085,"NCT00787267",337563,0.68,17,25,NA,NA,"Evalulable Patients That Received Dasatinib","Dasatinib: 70 mg PO twice daily until progression."
"893",1087,"NCT01117987",225031,0.679487179,53,78,NA,NA,"Core Placebo","Depending on the participants randomized treatment in the core study, CQTI571A2301 (NCT00902174), and their completion status in the core study, participants received imatinib at 200 mg qd, 400 mg qd, or 200 mg qd with an increase to 400 mg qd after 2 weeks, if tolerated."
"921",1123,"NCT00225784",535765,0.666666667,22,33,NA,NA,"Cetuximab/Gemcitabine/Radiotherapy","weekly cetuximab, twice-weekly gemcitabine and intensity modulated radiotherapy"
"928",1133,"NCT01461057",128487,0.666666667,10,15,"Randomization of first participant to clinical cutoff date (01 March 2015) (approximately 41 months)","An adverse event (AE) was defined as any untoward medical occurrence in a participant administered the investigational product which does not necessarily have a causal relationship with this treatment.","Pertuzumab 840/840 mg","Participants received 840 mg as an IV infusion Q3W for cycles 1-6. Participants in both arms received trastuzumab, cisplatin, and capecitabine. Capecitabine 1000 mg/m^2 was administered orally twice daily, from the evening of Day 1 to the morning of Day 15 of each cycle. Cisplatin 80 mg/m^2 was administered as an IV infusion on Day 1 of each cycle. Trastuzumab was administered as an IV infusion at a loading dose of 8 mg/kg for Cycle 1 and a dose of 6 mg/kg q3w for subsequent cycles."
"929",1134,"NCT01210495",194651,0.666666667,10,15,"Up to 28 days after last dose of study drug, for up to 3 years","The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.","Child-Pugh Class A","Participants with Child-Pugh Class A disease (score 5 or 6) were enrolled into the non-randomized portion at selected sites only at a starting axitinib dose of 5 mg twice daily (BID)."
"930",1135,"NCT01063075",242544,0.666666667,10,15,NA,NA,"Carboplatin and Cetuximab (D)","Group D:
Cycle 1 (1 week, combination therapy):
400 milligrams per square meter (mg/m ²) cetuximab administered intravenously (I.V) on day 1. Carboplatin area under the curve (AUC=5) administered I.V on day 1.
Optional 5- fluorouracil (FU) administered as a 96-hour continuous infusion (C.I.) of 1000 mg/ m ²/day administered starting on day 1."
"938",1144,"NCT01251653",182101,0.666666667,8,12,"From first drug administration until 28 days after last drug administration, up to 717 days",NA,"Afatinib 40mg and Docetaxel 75mg","Afatinib (film-coated tablet) 40 mg qd (once daily) was administered orally in combination with Docetaxel 75 mg/m2 administered as intravenous infusion on Day 1 of each 3- week treatment course."
"940",1146,"NCT01107418",227961,0.666666667,8,12,"Up to approximately 3 years",NA,"Cohort 3 - Vemurafenib 720 mg","Participants received vemurafenib film-coated tablets, orally, twice daily at a dose of 720 mg on Days 1 to 15 (a single morning dose was administered on Day 15). Starting at Day 22, participants received vemurafenib 960 mg film-coated tablets orally twice daily in 21-day cycles until the development of progressive disease, unacceptable toxicity, consent withdrawal, or any other criteria for removal."
"941",1147,"NCT00941863",283488,0.666666667,8,12,"Time frame for expansion group is from start of treatment until April 2008, up to 6 years.","Acronyms in Adverse Event Section:
White Blood Cell (WBC) Absolute Neutrophil Count (ANC) Absolute Granulocyte Count (AGC) Alanine Transaminase (ALT) Aspartate Transaminase (AST) Grade (GR) Gastrointestinal (GI) Central Nervous System (CNS) Fibrillation/Flutter (FIB/FLUTT) Neutropenia (Neu) documented (doc)","Sorafenib 400 mg (50-mg Tablet)","Dose-escalation cohort 3: Sorafenib (Nexavar, BAY43-9006) 400 mg twice daily (50-mg tablet)"
"969",1182,"NCT01169675",208548,0.666666667,4,6,"Starting with first administration of trial drug (Afatinib or Pemetrexed) and ending 28 days after the last administration of trial drug.",NA,"Pulsed Afatinib 70 mg","Pulsed Afatinib 70 mg plus Pemetrexed"
"971",1184,"NCT01121575",223337,0.666666667,4,6,"Up to Maximum of treatment duration + 28 days for each participant (could be 295 days)","The same event may appear as both an AE and a SAE. However, what is presented are distinct events. The below tables included all causality SAEs (frequency threshold 0%) and AEs ( frequency threshold 5%).","PF-02341066, 250 mg QD/ PF-00299804, 45 mg QD","Participants enrolled in dose escalation received combined oral crizotinib 250 mg BID and oral dacomitinib 45 mg. The first cycle was for 28 days thereafter, each cycle was 21 days."
"976",1194,"NCT00906698",295315,0.666666667,4,6,"First administration of trial medication until 28 days after last administration of trial medication.",NA,"Afatinib 50mg With Vinorelbine i.v.","Continuous daily dosing of Afatinib 50mg orally and weekly Vinorelbine 25 mg/m2 intravenously (days 1, 8, 15 and 22) in a 4-weekly course. Patients will be eligible for repeated treatment courses in the absence of clinical disease progression or undue toxicity ."
"981",1199,"NCT00631410",396261,0.666666667,4,6,"Up to 733 days (the last subject study discontinuation)","The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.","Treatment Arm B 50 mg/Day (2/2)","Sunitinib was administered orally in a 2 weeks on, 2 weeks off intermittent dosing regimen, at a starting dose of 50 mg/day (50 mg/day in Schedule 2/2).
FOLFOX was administered on an every-2-week cycle using the mFOLFOX6 regimen consisting of oxaliplatin 85 mg/meter^2 and l-leucovorin 200 mg/meter^2 as a 2-hour intravenous infusion followed by an intravenous bolus of fluorouracil 400 mg/meter^2 and a 46-hour intravenous infusion of fluorouracil 2,400 mg/meter^2 on Days 1 and 2 of each cycle."
"998",1225,"NCT02129062",24222,0.666666667,2,3,"Adverse event collection from start of treatment to 30 days following completion, approximately 16 weeks.",NA,"Treatment (Ibrutinib)","Ibrutinib 560 mg orally daily on days 1-28. Courses repeat every 4 weeks."
"999",1226,"NCT02091752",27809,0.666666667,2,3,NA,NA,"Ruxolitinib","All participants received ruxolitinib."
"1001",1229,"NCT01838642",57058,0.666666667,2,3,"17 months and 19 days","No participants were enrolled in the RET mutation negative group; study closed prematurely.","RET Mutation Positive Participants","Rearranged during transfection) (RET)
Ponatinib: Ponatinib tablets will be administered orally, continually, once daily at a dose of 30 mg. A cycle of ponatinib is defined as 28 consecutive days starting with the first day of the treatment cycle. Treatment will be administered primarily in an outpatient setting."
"1015",1250,"NCT01214616",193346,0.666666667,2,3,"during the treatment period or up to 28 days after the completion of drug administration, up to 730 days",NA,"Afatinib 20 mg With Vinorelbine 25 mg/m^2 (Cohort 1)","Afatinib 20 mg oral administration once a day with vinorelbine 25 mg/m^2 intravenous injection weekly"
"1016",1251,"NCT01169675",208551,0.666666667,2,3,"Starting with first administration of trial drug (Afatinib or Pemetrexed) and ending 28 days after the last administration of trial drug.",NA,"Continuous Afatinib 40 mg","Continuous Afatinib 40 mg plus Pemetrexed"
"1027",1263,"NCT01035658",249754,0.666666667,2,3,NA,NA,"Dose Level 1 Sequential","Systemic therapy with pazopanib and liposomal doxorubicin (Doxil). In this schedule, liposomal doxorubicin (30mg) was given on day 1, and pazopanib (400mg) was given days 3 - 26 of each 28 day cycle. Cycles will continue until disease progression, unacceptable toxicity or withdrawal.
Pazopanib: All patients will begin treatment with a 7-day run in period of single-agent pazopanib. Patients will receive pazopanib orally days 1-28 of a 28 day cycle.
Doxil: Liposomal doxorubicin (Doxil) will be administered IV on day 1 of a 28-day treatment cycle"
"1030",1273,"NCT00951665",279374,0.666666667,2,3,"Up to 30 days after the last dose of study treatment or study discontinuation/termination, whichever is later (Approximately 4 years)","SAEs and other AEs were collected in the safety population, which was defined as all participants who received at least a single dose of study medication. There was one SAE that lead to death and the preferred term was not captured for it. The same SAE was captured as ‘Death – unknown cause’ in the below SAE table.","Phase Ib Regimen 4","Participants received T-DM1 QW + paclitaxel QW + pertuzumab Q3W intravenously."
"1031",1274,"NCT00932373",286662,0.666666667,2,3,"Baseline to the end of the study (up to 3 years 2 months)",NA,"Trastuzumab-MCC-DM 4.8 mg/kg Every 3 Weeks","Trastuzumab-MCC-DM 4.8 mg/kg administered intravenously (IV) once every 3 weeks"
"1057",1307,"NCT00626639",397617,0.666666667,2,3,"Up to 15 weeks from first dose of IP","The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.","Palifermin","Three days before the start of radiotherapy (Day -3), participants received a single intravenous (IV) bolus injection of palifermin at 120 μg/kg. During radiotherapy (beginning on Day 1), participants received a weekly single IV bolus injection of palifermin at 120 μg/kg after the last radiation fraction of that week (usually on Fridays) until grade ≥3 oral mucositis occurred, or for a maximum 8 doses (completion of radiotherapy). Participants also received cisplatin 100 mg/m^2 on days 1, 22 and 43."
"1060",1312,"NCT00560352",421940,0.666666667,2,3,"Continuously from Day 1 until last day of study medication + 30 days (maximum reached: 10 months)",NA,"Dasatinib, 100 mg QD","Dasatinib, 100 mg, given QD with 1.3 mg/m^2 of bortezomib in 21-day cycles. Dexamethasone, fixed at 20 mg QD, was administered the day of and 1 day after each bortezomib dosing. In a 21-day cycle, bortezomib was administered by IV bolus twice weekly, on Days 1, 4, 8, and 11, followed by a 10-day (Days 12 to 21) rest period. In a 21-day cycle, dasatinib was taken orally every day, QD in the morning. In a 21-day cycle, dexamethasone was taken orally on Days 1, 2, 4, 5, 8, 9, 11, and 12, at the same time as dasatinib. On the days when bortezomib and dasatinib were administered together, the morning dose of dasatinib was to be followed 1-2 hours by the dose of bortezomib."
"1067",1321,"NCT00457743",461506,0.666666667,2,3,NA,NA,"SU-011248 75-mg","Subjects received sunitinib malate (SU-011248) at starting dose of 75-mg once daily. Treatment cycles were 6 weeks in duration, consisting of 4 weeks daily SU-011248 administration followed by 2 weeks off treatment.
Phase 1: If Dose Limiting Toxicity (DLT) was observed, the patients were withdrawn from the study treatment. Neither temporary discontinuation nor reduction was permitted.
Phase 2: The initial dose could be reduced to the recommended dose. Treatment cycles were repeated until a study treatment withdrawal criterion was met. If drug-related adverse event (grade>=3) was observed, temporary discontinuation or dose reduction were taken according to the criteria."
"1097",1361,"NCT00077376",569384,0.661016949,39,59,"Assessed every cycle (1 induction cycle = 4 weeks, 1 maintenance cycle = 3 weeks) while on treatment and for 30 days after the end of treatment.",NA,"Trastuzumab/Ixabepilone/Carboplatin","During the induction phase, patients were treated with Ixabepilone (BMS-247550) 15mg/m2 intravenously (IV) followed by carboplatin (AUC=2 IV) on days 1, 8 and 15 of a 28-day cycle for a maximum of 6 cycles. Trastuzumab was administered weekly (4mg/kg loading dose then 2mg/kg IV) starting on day 1. Routine premedication included H1 blocker (diphenhydramine 50 mg orally (PO) or IV), H2 blocker (ranitidine 150 mg PO or 50 mg IV or another equivalent H2 blocker), and at least a 5-HT3 antagonist and dexamethasone.
After completion of 24 weekly trastuzumab doses (induction therapy), trastuzumab were given at a dose of 6 mg/kg IV every 3 weeks (maintenance therapy) beginning one week after the 24th weekly dose. Trastuzumab were repeated every 21 days until disease progression or prohibitive toxicity."
"1145",1419,"NCT00247676",532155,0.648648649,24,37,NA,NA,"50 Milligram (mg) Sunitinib","Subjects received open-label sunitinib malate at a starting dose of 50 mg once daily for 4 consecutive weeks followed by a 2-week rest period to form a complete cycle of 6 weeks."
"1157",1433,"NCT00306891",515279,0.64516129,20,31,NA,NA,"Cediranib 30 - 90 mg Dose Escalation","Cediranib 30 - 90 mg Dose Escalation"
"1162",1438,"NCT00105443",561113,0.643097643,191,297,"Reporting Group (RG) 1 + 2: Data for Interim Analysis, cut-off Oct 17, 2006; RG 3: Data during and after unblinding (until Nov 21, 2008); RG 4: Data prior to date of unblinding (Feb 9, 2007); RG 5: Data after unblinding (Open Label; until Nov 21, 2008)","RG 1 + 3 description: All subjects randomized to Sorafenib treatment; RG 2 + 4 description: All subjects randomized to Placebo before unblinding (when they were on Placebo, before they had the opportunity to switch to Sorafenib treatment); RG 5 description: All placebo subjects who switched to Sorafenib treatment after unblinding occurred.","Sorafenib (Nexavar) Arm Complete (Incl. Open Label Phase)","Reporting Group 3 (RG 3): All participants that initially were randomized to Sorafenib treatment (data before unblinding (= Double-Blind phase) and after unblinding (= Open Label phase)), until Nov 21, 2008); Sorafenib 400 mg was administered orally at a dose of 400 mg (2 x 200 mg tablets) twice daily (bid); 2 dose reductions to predefined levels of 400 mg once daily (OD) and 400 mg every other day were permitted for adverse events related to study treatment. Note: Safety Data presented here include participants listed in Arms A1 and A2 of the Participant Flow section."
"1171",1447,"NCT01009983",258329,0.642857143,9,14,NA,NA,"Arm 1","Patients receive paclitaxel IV and carboplatin IV on days 1, 8, and 15. Patients also receive panitumumab IV on days 1 and 15.
panitumumab: Given IV
paclitaxel: Given IV
carboplatin: Given IV
laboratory biomarker analysis: Correlative study
immunohistochemistry staining method: Correlative study"
"1175",1451,"NCT00131937",551677,0.642857143,9,14,"Assessed every 4 weeks while on treatment and for 30 days after the end of treatment",NA,"Treatment (Sorafenib)","All patients who received Sorafenib treatment."
"1182",1458,"NCT00189488",540895,0.641025641,50,78,"125 Days","The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
Two participants were randomized to the Placebo arm but received palifermin inadvertently and were summarized in Palifermin arm.","Palifermin","Palifermin 60 μg/kg administered daily on 3 consecutive days prior to the day of start of the conditioning regimen and 180 μg/kg administered once prior to transplant and at least 96 hours from last palifermin dose of 60 μg/kg."
"1191",1468,"NCT01428219",136555,0.64,16,25,NA,NA,"Cabozantinib (XL184)","Cabozantinib is available in capsule form. The dose is 60 mg daily by mouth. Subjects with disease progression at 6 weeks who do not have significant toxicities may remain on therapy for an additional six weeks until a progression is confirmed. Further study drug administration beyond 12 weeks will be at the discretion of the investigator provided that the subject does not have disease progression, does not have unacceptable side effects, does not withdraw from study, or does not have a medical condition or illness that renders the subject unacceptable to receive further study drug."
"1194",1471,"NCT00367601",495441,0.64,16,25,NA,NA,"Single Arm Assignment","Bevacizumab + erlotinib; if no progressive disease observed, combination or single-agent treatment will continue until unacceptable toxicity or progressive disease.
Erlotinib: Erlotinib 150 mg qd days 1-21
Bevacizumab: Bevacizumab 15 mg/kg IV, day 1"
"1200",1477,"NCT00941863",283486,0.638655462,76,119,"Time frame for expansion group is from start of treatment until April 2008, up to 6 years.","Acronyms in Adverse Event Section:
White Blood Cell (WBC) Absolute Neutrophil Count (ANC) Absolute Granulocyte Count (AGC) Alanine Transaminase (ALT) Aspartate Transaminase (AST) Grade (GR) Gastrointestinal (GI) Central Nervous System (CNS) Fibrillation/Flutter (FIB/FLUTT) Neutropenia (Neu) documented (doc)","Sorafenib 400 mg (Expansion)","Dose-expansion cohort: Sorafenib (Nexavar, BAY43-9006) 400 mg twice daily (200-mg tablet) expansion"
"1214",1491,"NCT01260688",178744,0.636363636,7,11,NA,NA,"Arm II - Cediranib Alone",NA
"1233",1516,"NCT00111761",558769,0.631578947,12,19,"First dose through maximum of safety FU or 30 days after last dose (median 47 weeks follow-up)","The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.","Panitumumab Plus IFL",NA
"1236",1519,"NCT00237185",534064,0.630136986,46,73,NA,NA,"Imatinib Mesylate 400 mg","400 mg"
"1242",1526,"NCT00282048",523304,0.629032258,39,62,NA,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.","Axitinib","Axitinib (AG-013736) tablet 5 milligram (mg) orally twice daily (BID) for 4 consecutive weeks (28 days cycle) with no interval between cycles."
"1249",1536,"NCT00874848",304451,0.627118644,37,59,"Serious adverse events (SAEs) and non-serious AEs were collected from the first dose of investigational product to the discontinuation of study plus 30 days after the last dose of study drug or until the subject began alternative therapy.",NA,"Imprime PGG Arm","Imprime PGG Injection + Cetuximab + Paclitaxel/Carboplatin"
"1259",1549,"NCT00121719",555439,0.625,15,24,"All adverse events (AEs) were collected for up to approximately 4 years.","Treatment-emergent adverse events were defined as AEs that emerged during treatment, having been absent at pre-treatment, or that worsened in severity relative to the pre-treatment state, or occurred within 7 days or 5 times the half-life (whichever was longer) post participant's last treatment. Only treatment-emergent AEs and SAEs were reported.","25 mg Lenvatinib (MTD Cohort)","Participants in this cohort had the option of participating in the food-effect pilot study. Two 10 mg lenvatinib tablets and five 1.0 mg lenvatinib tablets were taken orally, once daily. Lenvatinib was to be taken on an empty stomach shortly after waking. Participants were fasted for 2 hours following administration of lenvatinib and could drink only clear fluids during this time (grapefruit juice was to be avoided). If 1 of 3 participants experienced DLT during Cycle 1 (4 weeks) an additional 3 participants were to be treated at this dose level. If 5 of the 6 participants in the expanded dose level did not experience DLT during the first 4 weeks of therapy, no additional DLT was observed, the next dose level was opened for enrollment. If more than 1 participant experienced DLT during the first 4 weeks of therapy, dose escalation was stopped and the MTD was determined. An additional 12 participants were treated at the MTD level."
"1260",1551,"NCT00987935",266790,0.625,10,16,"AEs with an onset during therapy with study treatment or within 28 days after discontinuation of study treatment (up to 1066 days)",NA,"Phase I Group II Nintedanib, 200 mg Bid","Oral administration of Nintedanib (BIBF 1120) 200 mg soft gelatine capsules twice daily (bid) for the Group II patients during Phase I"
"1264",1555,"NCT01744340",71265,0.625,5,8,"Adverse events were collected pre-study, within 72 hours of day 1 if each cycle, at day 8 of each cycle, at end of treatment visit and 30 days post last dose of drug.",NA,"Head and Neck","Cetuximab, 400 mg/m2 cycle 1 week 1, then 250 mg/m2/weekly there after Eribulin Mesylate 1.4mg/m2
Head and neck: Eribulin mesylate is administered by IV infusion over 2-5 minutes on day 1 and 8 of a 21 day cycle 1.4mg/m2 and Cetuximab 400 mg/m2 cycle 1 week 1, then 250 mg/m2/weekly thereafter
Dose Level 1: 0.7 mg/m2 IV infusion days 1 and 8 of 21 day cycle Dose Level 2: 1.0 mg/m2 IV infusion days 1 and 8 of 21 day cycle Dose Level 3: 1.4 mg/m2 IV infusion days 1 and 8 of 21 day cycle"
"1271",1569,"NCT00779311",340539,0.625,5,8,"Adverse events were collected beginning on day 1 of study treatment until one month after the end of study treatment.","Systematic Assessment - subjects were assessed for adverse events on day 1 of each cycle (every other week) by either the research coordinator, treating physician, or other appropriate sub-investigator.","Dose Level (DL) 1 for MTD Determination","All eligible patients will receive the mFOLFOX6 regimen at full dose followed by IV bevacizumab 5mg/kg on Day 1 of each treatment cycle, and sorafenib 200mg every other day."
"1272",1570,"NCT00708214",368257,0.625,5,8,"First administration of trial medication until 28 days after last administration of trial medication",NA,"Afatinib 30 mg With Letrozole","Patients received continuous daily dosing with Afatinib 30 mg therapy with letrozole 2.5 mg over 28-day treatment cycles until further disease progression."
"1273",1571,"NCT00658658",387549,0.625,5,8,"From first dose date to end of study date. The median duration of study is 47 days.","Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Summary of Adverse Events includes only those participants who received at least one dose of investigational product.","Age 1-11: 6 mg/kg Q2W","Participants aged 1 to 11 years received panitumumab 6 mg/kg administered by IV infusion Q2W until the participant experienced disease progression, was unable to tolerate study drug, withdrew consent, or other reasons that warranted removal from the study."
"1274",1572,"NCT00614393",402951,0.625,5,8,"Up to 30 days after last dose of study drug (Up to 33 months)","The APaT population consisted of all randomized participants who received ≥1 dose of study drug. Participants were included in the treatment group corresponding to the study drug they actually received.","Dalotuzumab 15 mg/kg /7.5 mg/kg Q2W (OL)","In the OL portion of the study, ≥6 participants received cetuximab 400 mg/m^2 Q1W + irinotecan Q1W at their pre-study dosage + OL dalotuzumab (loading dose of 15 mg/kg IV followed by a maintenance dose of 7.5 mg/kg 2 weeks later) to verify the safety of the regimen. In DB Week 1, participants received cetuximab 400 mg/m^2 IV + irinotecan IV. In DB Week 2, participants received cetuximab 250 mg/m^2 IV + irinotecan IV + DB dalotuzumab 15 mg/kg IV. In DB Week 3, participants received cetuximab 250 mg/m^2 IV + irinotecan IV. Starting with DB Week 4, participants received cetuximab 250 mg/m^2 IV Q1W + irinotecan IV Q1W + DB dalotuzumab 7.5 mg/kg IV Q2W for up to 32 months of treatment."
"1285",1583,"NCT01081041",235371,0.623376623,48,77,NA,"Serious adverse events (SAEs) and other non-serious AEs are reported for participants who received at least 1 dose of any drug (cetuximab, cisplatin, carboplatin, or 5-FU). Death due to progressive disease was not considered an AE.","Part 2: Cetuximab (US Commercial), Cis or Carbo, 5-FU","Combination Therapy (maximum 6 cycles):
US commercial cetuximab, manufactured by ImClone, 400 mg/m^2 IV infusion on Day 1 of Cycle 1; subsequently 250 mg/m^2 IV infusion weekly.
Cis 100 mg/m^2 or carbo AUC 5, up to a maximum 750 mg dose, IV infusion on Day 1 of every 21-day cycle, 1 hour after cetuximab infusion.
5-FU: 1000 mg/m^2 IV infusion on Days 1 through 4 of every 21-day cycle.
Monotherapy Therapy:
Participants who did not experience disease progression after 6 cycles of combination therapy continued on weekly US commercial cetuximab monotherapy 250 mg/m^2 until disease progression, unacceptable toxicity, or other withdrawal criteria were met."
"1287",1585,"NCT00193453",539948,0.623188406,43,69,NA,NA,"Intervention","Newly-diagnosed unresectable stage III/IV NSCLC patients were treated with docetaxel-30mg/m2 IV; gemcitabine-1000mg/m2 IV days 1, 8; cetuximab-400mg/m2 IV day 1, then 250 mg/m2 IV weekly. Patients received up to 6 cycles (21-d)."
"1292",1590,"NCT00509899",443525,0.621621622,23,37,NA,NA,"All QD","Participants received an initial dose of Ruxolitinib 25, 50, 100 or 200 mg once a day (qd). Participants could continue in the study on their prescribed regimen indefinitely if receiving benefit with dose adjustments for safety and efficacy. Since the numbers of patients in 3 of the qd treatment groups were small, the 4 qd doses were combined to allow meaningful comparisons against the bid treatment groups."
"1309",1613,"NCT00919061",291104,0.615384615,24,39,NA,NA,"Gemcitabine and Cisplatin Plus Sorafenib","This is a non-randomized, open label, single institution, phase II study of gemcitabine and cisplatin plus sorafenib for the treatment of patients with advanced or biliary tract carcinomas naïve to systemic therapy.
Gemcitabine and Cisplatin plus Sorafenib: Patients will receive treatment under the following schedule:
Gemcitabine: 800 mg/m2 over 30 minutes IV, weekly for 2 weeks, followed by a week off treatment.
Cisplatin: 20 mg /m2 over 30 minutes IV, weekly for 2 weeks, followed by a week off treatment.
Sorafenib: 400 mg PO once a day continuously. Three weeks of treatment correspond to one cycle."
"1310",1614,"NCT01286753",170701,0.615384615,16,26,"Baseline until 28 days after the last dose of study treatment or until initiation of another anti-cancer therapy, whichever occurred first (up to approximately 4 years)","Safety population, defined as enrolled participants who received at least one dose of study treatment.","TKI Naive","Vemurafenib 960 mg orally twice daily in participants naive to any prior systemic TKI therapy."
"1314",1618,"NCT02006667",35787,0.615384615,8,13,"Adverse events were reported from randomization until 30 days after the end of treatment.","This study did not include a separate analysis of non-serious AE's. In addition, only events by system organ class were provided, no preferred terms for individual events were available.","Trastuzumab/Gemcitabine/Cisplatin","Participants received gemcitabine 1200 mg/m^2, IV, on Days 1, 8, and 15 (for a maximum of six 4-week cycles); cisplatin 70 mg/m^2, IV, on Day 2 (for a maximum of six 4-week cycles); and trastuzumab 4 mg/kg, IV, on Day 3 of Cycle 1, followed by weekly doses of 2 mg/kg, IV, until disease progression."
"1316",1620,"NCT00882206",302006,0.615384615,8,13,NA,NA,"Decitabine / Vorinostat","This is a therapeutic trial investigating the combination of decitabine 15 mg/m2 and vorinostat 230 mg/m2 (maximum daily dose not to exceed 400 mg) in relapsed/refractory ALL/LL patients prior to induction chemotherapy.
cytarabine: At baseline when peripheral blood draw and bone marrow aspirate performed.
*Intrathecal Cytarabine administered dependent upon age - ranging from 30 mg to 70 mg.
decitabine: Days 1-4, 15 mg/m^2 intravenously (IV) over 1 hour
doxorubicin hydrochloride: Day 5, 60 mg/m^2 intravenously (IV) over 15 minutes
imatinib mesylate: 340 mg/m2 by mouth every day (rounded to the nearest 100 mg) for age <18 years and 400 mg orally every day for >18 years on Days 5-33.
methotrexate: **Intrathecal Methotrexate administered dependent upon age - ranging from 8 mg to 15 mg.
pegaspargase: 2,500 IU/m2 IM or IV q week (days 6, 12, 19, 26)
prednisone: 40mg/m2/day divided BID (days 5 – 33)
vincristine sulfate: 1.5mg/m2 (max 2 mg) iv push q week (days 5, 12)"
"1321",1625,"NCT00263328",528190,0.615384615,8,13,"Adverse events (AEs; serious and nonserious) were recorded from the time the participant had taken at least 1 dose of trial treatment through the follow-up visit at Month 98 or 2 months following discontinuation of treatment.","The same event may appear as both an AE and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in 1 participant and as nonserious in another participant, or 1 participant may have experienced both a serious and nonserious event during the study.","Tofacitinib 30-15-10 mg BID","Participants receiving tofacitinib 30 mg, tablets, PO, BID at study entry (rollover from Parent Study A3921009) tapered tofacitinib dosage from 30 mg BID to 15 mg BID over 4 weeks on entry into Study A3921021 (25 mg BID for 2 weeks, 20 mg BID for 2 weeks, then 15 mg BID thereafter). Within the window of Months 12-24 post-transplant, tofacitinib dosage was tapered from 15 mg BID to 10 mg BID and participants remained on 10 mg BID throughout the duration of the study, for a maximum of 90 months. Participants also received corticosteroids (prednisone ≤5 mg daily [or equivalent] through at least 12 months post-transplant. Thereafter, steroids may have been discontinued at the investigator's discretion."
"1324",1629,"NCT00986674",267020,0.613636364,27,44,"Assessed every cycle (6 weeks) while on treatment and for 30 days after the end of treatment.","After off treatment, patients were assessed every 3 months if <2 years and every 6 months in year 3 to report any reportable long-term toxicity occurring prior to diagnosis of progression/relapse that has not been previously reported.","Arm I (Carboplatin, Paclitaxel, Cetuximab)","Patients receive carboplatin IV over 15-30 minutes and paclitaxel IV over 3 hours on days 1 and 22 and cetuximab IV over 1-2 hours on days 1, 8, 15, 22, 29, and 36. Treatment repeats every 42 days for 2 courses. Patients with stable or responding disease after 2 courses proceed to maintenance therapy with cetuximab alone on days 1, 8, 15, 22, 29, and 36. Treatment with cetuximab repeats every 42 days in the absence of disease progression or unacceptable toxicity."
"1327",1632,"NCT00393068",486771,0.612903226,38,62,NA,NA,"Treatment","Prior to surgery study treatment will be given over a 6 weeks (Days 1-42) period. Beginning Day 1 and continuing through Day 35 patients will receive a continuous infusion of 5-FU by vein. A small portable pump will be used to administer this drug into a tube that has been surgically inserted into the patient's vein. On Day 1 and 22 patients will also receive the drugs paclitaxel, carboplatin and bevacizumab by vein. Erlotinib is given by mouth beginning on Day 1 and continuing through Day 45. Patients will receive radiation therapy daily, Monday through Friday, beginning Day 1-35 (approximately 5 weeks).
Surgery will be performed approximately 12-14 weeks after beginning this combined treatment."
"1329",1634,"NCT00105443",561112,0.612582781,185,302,"Reporting Group (RG) 1 + 2: Data for Interim Analysis, cut-off Oct 17, 2006; RG 3: Data during and after unblinding (until Nov 21, 2008); RG 4: Data prior to date of unblinding (Feb 9, 2007); RG 5: Data after unblinding (Open Label; until Nov 21, 2008)","RG 1 + 3 description: All subjects randomized to Sorafenib treatment; RG 2 + 4 description: All subjects randomized to Placebo before unblinding (when they were on Placebo, before they had the opportunity to switch to Sorafenib treatment); RG 5 description: All placebo subjects who switched to Sorafenib treatment after unblinding occurred.","Placebo Arm, Complete Double-Blind Phase","Reporting Group 4 (RG 4): All participants that initially were randomized to Placebo (data from Placebo patients before unblinding at Feb 09, 2007); Sorafenib-matching placebo tablets were orally administered twice daily (bid).
Note: Safety Data presented here include participants listed in Arms B1 and B2 of the Participant Flow section."
"1331",1636,"NCT01229150",188364,0.612244898,30,49,NA,"The combination of toxicities allows for a more robust understanding of the combined therapy toxicities. The dosage of the combination of erlotinib plus AZD6244 was the same whether the pt has a KRAS mutation versus KRAS wild type. KRAS is a molecular mutation and does not change whether or not a pt has toxicities to the combination of therapies.","KRAS Mut 2 & WT KRAS 2","KRAS Mutant patients randomized to combination therapy arm
AZD6244 + Erlotinib: For KRAS mutant patients and Wild-Type KRAS patients randomized to the combination arm (arms are stratified based on KRAS mutational status), AZD6244 150 mg qd (every day) + erlotinib mg qd."
"1332",1637,"NCT00664326",385207,0.612244898,30,49,NA,"Acronyms used in Adverse events section: Gastrointestinal (GI), Not Otherwise Specified (NOS), Absolute Neutrophil Count (ANC), Common Terminology Criteria for Adverse Events (CTCAE).","Regorafenib (Stivarga, BAY73-4506)","Participants received Regorafenib 160 mg per os (po) every day (qd) for 3 weeks on 1 week off of every 4 week cycle"
"1335",1640,"NCT01030718",251507,0.611111111,33,54,NA,NA,"All Treated Participants","Imatinib resistant or intolerant CML-CP disease cohort, Imatinib resistant or intolerant CML-AP/BP disease cohort, and Ph+ ALL subjects with resistance or intolerance to past therapy. The study drug was administered twice daily (BID). The starting dose level for this trial in each individual participant was the same dose level at the end of CA180031 (ie, 50mg, 70mg or 90mg BID on a continuous daily dosing schedule), allowed to modify within the range of 50 mg twice daily (BID) to 90 mg BID."
"1343",1652,"NCT00918385",291250,0.608695652,14,23,NA,NA,"Combination Nilutamide and Dasatinib",NA
"1346",1655,"NCT00309946",514011,0.607843137,31,51,"After completion of study treatment, patients are followed for up to 8 weeks.",NA,"Treatment (Enzyme Inhibitor Therapy)","Initial cediranib maleate dosing was 45 mg (once daily) during a 28-day cycle. Courses repeated every 28 days in the absence of disease progression or unacceptable toxicity. Due to substantial toxicity, the starting dose was subsequently lowered to 30 mg daily."
"1348",1657,"NCT00454779",462395,0.607142857,34,56,"The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date of the first-line treatment. The median time frame is 4.5 months for Panitumumab Plus Chemotherapy arm and 4.4 months for Chemotherapy Alone arm.","The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.","Panitumumab Plus Chemotherapy","Panitumumab + Docetaxel + Cisplatin, experiment"
"1356",1667,"NCT01117987",225032,0.606060606,40,66,NA,NA,"Core Imatinib","Depending on the participants randomized treatment in the core study, CQTI571A2301 (NCT00902174), and their completion status in the core study, participants received imatinib at 200 mg qd, 400 mg qd, or 200 mg qd with an increase to 400 mg qd after 2 weeks, if tolerated."
"1358",1670,"NCT01081041",235372,0.606060606,20,33,NA,"Serious adverse events (SAEs) and other non-serious AEs are reported for participants who received at least 1 dose of any drug (cetuximab, cisplatin, carboplatin, or 5-FU). Death due to progressive disease was not considered an AE.","Part 1: Safety Lead-In (Cetuximab, Cis or Carbo, 5-FU)","Combination Therapy (maximum 6 cycles):
US commercial cetuximab, manufactured by ImClone, 400 mg/m^2 IV infusion on Day 1 of Cycle 1; subsequently 250 mg/m^2 IV infusion weekly.
Cis 100 mg/m^2 or carbo AUC 5, up to a maximum 750 mg dose, IV infusion on Day 1 of every 21-day cycle, 1 hour after cetuximab infusion.
5-FU: 1000 mg/m^2 IV infusion on Days 1 through 4 of every 21-day cycle.
Monotherapy Therapy:
Participants who did not experience disease progression after 6 cycles of combination therapy continued on weekly US commercial cetuximab monotherapy 250 mg/m^2 until disease progression, unacceptable toxicity, or other withdrawal criteria were met."
"1363",1676,"NCT01161173",210765,0.60518732,210,347,NA,"Safety analysis population: All participants who received at least 1 dose of erlotinib.
The seriousness of adverse events was not captured in this observational study, therefore, all adverse events are reported as serious adverse events.","Erlotinib","Participants received erlotinib (Tarceva) at a dose determined by the investigator, guided by the recommendation in the Summary of Product Characteristics. The recommended daily dose of erlotinib is 150 mg orally once daily.
Erlotinib: Erlotinib was provided in the retail versions of the product."
"1368",1682,"NCT01104155",229146,0.603174603,38,63,"From date of administration of first dose up to 30 days after the last dose, or up to data cutoff (31 May 2013), up to approximately 3.25 years.","Treatment-emergent adverse events (TEAEs) included adverse events that occurred from the first dose of study drug to 30 days after the last dose of study drug, or that were present prior to the first dose of study drug administration but worsened in severity during the study.","Eribulin Mesylate, 21 Day Cycle","eribulin mesylate + erlotinib: 21-day Regimen: Eribulin mesylate given at a dose of 2 mg/m2 as a 2-5 min intravenous (IV) bolus on Day 1 and 150 mg of erlotinib given orally once daily, one hour before or two hours after the ingestion of food, on Days 2-16 of a 21-day cycle."
"1373",1687,"NCT00193596",539927,0.602150538,56,93,NA,NA,"Paclitaxel/Carboplatin/Etoposide/Gefitinib","Paclitaxel 200 mg/m2 by 1-hour IV infusion, day 1
Carboplatin area under the curve (AUC) 6.0 IV, day 1
Etoposide 50 mg alternating with 100 mg by mouth, days 1 and 10
Regimen A was repeated at a 21-day interval"
"1378",1692,"NCT00880334",302515,0.6,42,70,"Assessed each cycle throughout treatment from time of first dose and up to day 30 post-treatment. Median treatment duration for this study cohort approximated 2 cycles (range 1-31).","Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3.","Vandetanib and Docetaxel","Docetaxel: Given intravenously on Day 1 of each 21-day cycle Vandetanib: taken orally once a day, every day"
"1379",1693,"NCT00720109",364012,0.6,36,60,NA,"SAE field contains NCI CTCAEs submitted via expedited reporting (NCI AdEERs / CAeRs). The AE field contains grade 3 and higher CTCAEs reported on study excluding those that were reported as SAEs.","Treatment Induction (Enzyme Inhibitor Therapy & Chemotherapy)","See Detailed Description
Asparaginase: Given IT
Cyclophosphamide: Given IV
Cytarabine: Given IT or IV
Dasatinib: Given PO
Daunorubicin Hydrochloride: Given IV
Dexamethasone: Given IV or PO
Etoposide: Given IV
Filgrastim: Given IV or SC
Hydrocortisone Sodium Succinate: Given IT
Ifosfamide: Given IV
Laboratory Biomarker Analysis: Correlative studies
Leucovorin Calcium: Given IV or PO
Mercaptopurine: Given PO
Methotrexate: Given IT, PO, or IV
Methylprednisolone: Given IV
Pegaspargase: Given IM
Prednisone: Given PO or IV
Radiation Therapy: Some patients undergo cranial RT
Vincristine Sulfate: Given IV"
"1380",1694,"NCT00645593",390681,0.6,36,60,NA,NA,"Arm 2, Cetuximab, Gemcitabine and Cisplatin","Gemcitabine, Cisplatin and Cetuximab: Cisplatin will be administered intravenously at a dose of 70 mg/m2 per institutional standards on Day 1 of each cycle. Gemcitabine will be administered intravenously at a dose of 800 mg/m2 on Days 1, 8 and 15 of cycle. Cetuximab will be administered intravenously at a dose of 500 mg/m2 on Days 1 and 15 of each cycle. One treatment cycle is 28 days."
"1382",1697,"NCT00324415",509214,0.6,27,45,"3 years",NA,"Combined Modality Therapy","cisplatin, 5-flourouruacil, and irradiation plus cetuximab"
"1384",1700,"NCT00392444",486989,0.6,21,35,NA,NA,"Treatment (Sunitinib Malate)","Patients receive oral sunitinib malate once daily on days 1-28. Treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity."
"1388",1704,"NCT00661427",386465,0.6,18,30,NA,NA,"Arm A","Cetuximab infusion at 500 mg/m2 over 2 hours every other week."
"1390",1707,"NCT00470470",456567,0.6,18,30,NA,NA,"Treatment (Enzyme Inhibitor Therapy)","Patients receive oral imatinib mesylate 400 mg twice daily for up to 12 weeks in the absence of disease progression or unacceptable toxicity.
imatinib mesylate: Given orally
laboratory biomarker analysis: Correlative studies"
"1396",1715,"NCT01251653",182106,0.6,12,20,"From first drug administration until 28 days after last drug administration, up to 717 days",NA,"Afatinib 40mg and Gemcitabine 1000mg","Afatinib (film-coated tablet) 40 mg qd (once daily) was administered orally in combination with Gemcitabine 1000 mg/m2 administered as intravenous infusion on Days 1 and 8 of each 3- week treatment course."
"1398",1717,"NCT01099358",230306,0.6,12,20,NA,"All participants who received at least one dose of study drug.","Cetuximab and Cisplatin (C)","Cetuximab and Cisplatin (C)
Cycle 1 (4 weeks, combination therapy):
100 mg/m² Cisplatin admin I.V on week 1, day 1. 5- FU admin as a 96-hour C.I. of 1000 mg/m²/d admin starting on week 1, day 1. 400 mg/m² cetuximab admin I.V on week 2, day 1. 250 mg/m² cetuximab admin I.V on week 3 and 4, day 1.
Cycle 2-6 (3 weeks combination therapy):
100 mg/m² cisplatin admin I.V on week 1, day 1. 5- FU admin as a 96-hour C.I. of 1000 mg/m²/d admin starting on week 1, day 1. 250 mg/m² cetuximab admin I.V on week 1, 2, and 3, day 1.
After 6 cycles, participants may then receive weekly cetuximab monotherapy until progression of disease, unacceptable toxicity, or another withdrawal criterion is met.
Due to protocol amendment in September 2011, any newly enrolled participants were placed into cetuximab and cisplatin (C) arm only. After protocol amendment February 2014, any newly enrolled participants will be placed into cetuximab and cisplatin (D) arm only."
"1412",1731,"NCT00978731",270244,0.6,9,15,NA,"The SAEs listed here differ from those present in the Outcome Measures. This is because the Outcome Measures present on-treatment SAEs and this section presents all SAEs. In addition, the AEs presented here differ from those in the Outcome Measures. This is because the AEs presented here do not include SAEs.","Participants With CML; BID Dosing","Participants continued on the last dose and schedule of dasatinib that was received within the previous protocol (CA180002; NCT00064233). Treatment was received BID, with a TDD of 50 mg, 70 mg, 100 mg, 140 mg, 180 mg or 240 mg. Participants were dosed on 1 of 3 schedules: 5 days on, 2 days off; 6 days on, 1 day off; or continuous daily dosing and were permitted to escalate or reduce by 1 dose level at a time, switch from QD dosing to BID dosing and vice versa provided they did not exceed a change of 1 dose level from the TDD. The weekly schedule was also permitted to be increased or decreased 1 level at a time."
"1416",1735,"NCT00148109",547409,0.6,9,15,NA,NA,"Epidermal Growth Factor Receptor Negative","Sarcoma does not express Epidermal growth factor receptor. Patients received cetuximab 400 mg per meter squared IV followed by 250 mg per meter squared weekly"
"1425",1745,"NCT01117623",225242,0.6,6,10,"Adverse events were collected after signing the informed consent of the first participant until the end of study completion for the last patient, therefore for the study over a period of approximately 6 years and 9 months",NA,"Escalation Cohort: Regorafenib (Stivarga, BAY73-4506) 140 mg","Participants in the dose-escalation cohort received a single 140 mg oral CP tablet of regorafenib on Day 1 of Cycle 1 followed by 1 day off treatment. On Day 3, once-daily continuous dosing with 140 mg oral CP tablets was initiated. A cycle was defined as 21 days. For Cycle 2 and subsequent cycles, regorafenib was administered once daily continuously on a 21-day cycle."
"1435",1759,"NCT01418001",138588,0.6,3,5,NA,NA,"Level 1: Pazopanib 400 mg QD","Level 1: Pazopanib 400 mg QD - Gemcitabine and Docetaxel in Combination with Pazopanib"
"1441",1765,"NCT01035658",249756,0.6,3,5,NA,NA,"Dose Level 1","Systemic therapy with pazopanib and liposomal doxorubicin (Doxil). Single-agent pazopanib will be given for a 7 day run-in period, followed by a combination of pazopanib (400mg) and liposomal doxorubicin (40mg) administered in 28-day treatment cycles. Cycles will continue until disease progression, unacceptable toxicity or withdrawal.
Pazopanib: All patients will begin treatment with a 7-day run in period of single-agent pazopanib. Patients will receive pazopanib orally days 1-28 of a 28 day cycle.
Doxil: Liposomal doxorubicin (Doxil) will be administered IV on day 1 of a 28-day treatment cycle"
"1443",1768,"NCT00978731",270246,0.6,3,5,NA,"The SAEs listed here differ from those present in the Outcome Measures. This is because the Outcome Measures present on-treatment SAEs and this section presents all SAEs. In addition, the AEs presented here differ from those in the Outcome Measures. This is because the AEs presented here do not include SAEs.","Participants With Accelerated Phase CML","Participants continued on the last dose and schedule of dasatinib that was received within the previous protocol (CA180002; NCT00064233). A TDD of 50 mg, 75 mg, 105 mg, 120 mg, 140 mg or 180 mg dasatinib was taken QD or split into 2 doses and taken BID (TDD of 50 mg, 70 mg, 100 mg, 140 mg, 180 mg or 240 mg ). Participants were dosed on 1 of 3 schedules: 5 days on, 2 days off; 6 days on, 1 day off; or continuous daily dosing and were permitted to escalate or reduce by 1 dose level at a time, switch from QD dosing to BID dosing and vice versa provided they did not exceed a change of 1 dose level from the TDD. The weekly schedule was also permitted to be increased or decreased 1 level at a time."
"1444",1769,"NCT00976677",270940,0.6,3,5,"Assessed every 21 days while on treatment and for 30 days after the end of treatment.",NA,"Arm B","Patients receive paclitaxel and carboplatin (with or without bevacizumab) as in arm A. Patients also receive oral erlotinib hydrochloride once daily on days 1-21. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. After completion of 6 courses, patients with stable or responding disease may continue to receive erlotinib hydrochloride (with or without bevacizumab) as above in the absence of disease progression or unacceptable toxicity."
"1445",1770,"NCT00975806",271337,0.6,3,5,"Phase 1 Only. From the date of the first study drug dose to within 28 days after the study drug treatment was discontinued.","Median treatment duration with Lenalidomide and Sunitinib was shortest in Cohort A at 41 days (range = 17 to 189 days) and longest in Cohort G = 97 days (range: 60 to 125 days) of lenalidomide treatment and 97.5 days (range = 54 to 125 days) of Sunitinib","Cohort A","Lenalidomide 10 mg QD and sunitinib 37.5 mg QD on Days 1-21 of each 21-day cycle"
"1447",1772,"NCT00912912",293079,0.6,3,5,"Adverse event collection through each cycle, defined as a planned 6-week treatment interval (cycle) with participants to complete at least 2 cycles of therapy unless evidence of rapid disease progression.",NA,"Sunitinib Malate","Sunitinib Malate 50 mg capsules once a day (by mouth) for 4 weeks in a row in a 6 week cycle."
"1457",1782,"NCT00632489",395950,0.6,3,5,"18 Months",NA,"LBH589 and Lapatinib","LBH589 and Lapatinib
LBH589: LBH589 will be evaluated when administered twice weekly at the following possible dose levels: 20 mg, 30 mg, 45 mg, and 60 mg. Capecitabine will be paired with LBH589 and will range in dose from 825 mg/m2 to 1250 mg/m2 orally BID 14 of every 21 days. Treatment cycles will be 21 days in length. Once determined safe, 10 additional patients will be treated at the determined MTD to further assess safety.
Lapatinib: Lapatinib, 1000 mg PO daily will be added to this combination."
"1468",1796,"NCT00716625",365126,0.597728631,1000,1673,NA,"The frequency of adverse events. The same event may appear as both an adverse event and a serious adverse event. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.","Sunitinib Malate","Usually, 50 mg of sunitinib malate was orally administered to adult participants once daily in repetitive cycles of 4 weeks on treatment followed by 2 weeks off according to Japanese package insert."
"1469",1797,"NCT01321554",161176,0.597560976,49,82,"For each participant, from the first dose till 30 days after the last dose or the cut-off date for the primary analysis whichever was earlier or up to approximately 2.5 years","Safety was assessed by the monitoring and recording of all adverse events (AEs) and serious adverse events (SAEs); regular monitoring of hematology, clinical chemistry, and urine values; physical examinations; and regular measurement of vital signs, electrocardiograms (ECG), and echocardiograms.","Lenvatinib 24 mg (OOL Lenvatinib Treatment Period)","Placebo treated participants in the Randomization Phase who had progressive disease confirmed by IIR, and who requested treatment with lenvatinib"
"1481",1814,"NCT02105636",26349,0.594594595,66,111,"From first dose to last dose plus 30 days up to Primary Endpoint, approximately 18 months (November 2015)","Study initiated: May 2014; Primary Endpoint: November 2015 (study on-going)","Cetuximab/Methotrexate/Docetaxel","Participants were provided a dose of Cetuximab intravenous (IV) solution for injection at a dose of 400 milligram/meter squared (mg/m2) for the first dose followed that a doses of 250 mg/m2 weekly until disease progression OR a Methotrexate intravenous (IV) solution for Injection at a dose of 40 or 60 mg/m2 weekly until disease progression OR a Docetaxel intravenous (IV) solution for Injection at a dose of 30 or 40 mg/m2 weekly until disease progression. The decision regarding which treatment the participant received was at the discretion of the investigator and referred to as Investigators Choice."
"1487",1821,"NCT00148798",547361,0.593065693,325,548,"Time from first dose up to 30 days after the last dose of study treatment.","Treatment-emergent adverse events were defined as those with onset occurring at or after the first dosing day of study medication and up to 30 days after the last administration of any study drug or the clinical cut-off date.","Cetuximab Plus Chemotherapy","cetuximab given as an intravenous (i.v.) infusion every week (400mg/m^2 initial dose and 250mg/m^2 subsequent doses) until progressive disease (PD) + cisplatin 80mg/m^2 i.v. infusion on day 1 of each 3-week cycle + vinorelbine 25mg/m^2 i.v. infusion on days 1 and 8 of each 3-week cycle.
Safety population: includes all treated subjects."
"1490",1825,"NCT00033514",575894,0.592592593,16,27,"9.4 years",NA,"Treatment Phase 1 Plus Phase 2","trastuzumab: Day 1 4mg/kg IV 2 mg/kg IV weekly.
erlotinib hydrochloride: 50mg daily, 100 mg daily and 150 mg daily."
"1492",1827,"NCT01081041",235370,0.591549296,42,71,NA,"Serious adverse events (SAEs) and other non-serious AEs are reported for participants who received at least 1 dose of any drug (cetuximab, cisplatin, carboplatin, or 5-FU). Death due to progressive disease was not considered an AE.","Part 2: Cetuximab (Manufactured by BI), Cis or Carbo, 5-FU","Combination Therapy (maximum 6 cycles):
Cetuximab, manufactured by BI, 400 mg/m^2 IV infusion on Day 1 of Cycle 1; subsequently 250 mg/m^2 IV infusion weekly.
Cis 100 mg/m^2 or carbo AUC 5, up to a maximum 750 mg dose, IV infusion on Day 1 of every 21-day cycle, 1 hour after cetuximab infusion.
5-FU: 1000 mg/m^2 IV infusion on Days 1 through 4 of every 21-day cycle.
Monotherapy Therapy:
Participants who did not experience disease progression after 6 cycles of combination therapy continued on weekly BI-manufactured cetuximab monotherapy 250 mg/m^2 until disease progression, unacceptable toxicity, or other withdrawal criteria were met."
"1502",1839,"NCT00514943",441671,0.590163934,36,61,"1493 days",NA,"Afatinib 50 mg / Cetuximab 250mg/m2 - Stage 1","Patients were randomized to Afatinib monotherapy 50mg once daily (q.d.) in Stage 1 and if the patients had disease progression or intolerable AEs were crossed over to Cetuximab 250 mg/m2 given as 400mg/m2 once in the first week (load) followed by 250mg/m2 weekly thereafter in Stage 2."
"1504",1841,"NCT00475150",454688,0.58974359,23,39,NA,NA,"All Patients Receiving Cediranib Maleate","All patients receiving oral cediranib maleate, regardless of diagnosis were analyzed for toxicity."
"1511",1850,"NCT00323362",509917,0.588235294,10,17,"2 years",NA,"Gemcitabine Hydrochloride and Imatinib Mesylate","gemcitabine hydrochloride : 1000 mg/m2 given intravenously at a FDR of 10 mg/m2/min on Days 3 and 10, every 21 days.
imatinib mesylate : 400 mg/day orally, given Days 1-5 and 8-12 every 21 days"
"1528",1871,"NCT01246960",183413,0.585365854,48,82,NA,NA,"Ramucirumab and mFOLFOX6","Ramucirumab: 8 mg/kg intravenous infusion administered on Day 1 of each cycle (14 days/cycle). In Cycles 1 and 2, there was a 1-hour observation prior to administering mFOLFOX6.
mFOLFOX6: Administered intravenously per manufacturer’s instructions for each drug substance on Day 1 of each cycle (14 days/cycle).
Oxaliplatin: 85 mg/m^2
Leucovorin: 400 mg/m^2
5-FU: 400 mg/m^2 bolus
5-FU: 2400 mg/m^2 continuous given over 46-48 hours
Participants received study treatment every 2 weeks until disease progression, unacceptable toxicity, or another withdrawal criterion was met."
"1530",1873,"NCT00903175",296499,0.584033613,139,238,NA,NA,"Everolimus 1L/Sunitinib 2L","everolimus First Line: 10 mg orally, once daily, (two 5 mg tablets), continuous treatment. sunitinib Second Line: 50 mg orally, once daily, 4 weeks on treatment followed by 2 weeks off (4/2)"
"1534",1878,"NCT01253564",181362,0.583333333,14,24,"From baseline up to last dose (0.1 to 11.3 months) plus 28 days",NA,"Vemurafenib","Participants received vemurafenib tablets, 960 mg, BID, orally continuously until disease progression, unacceptable toxicity, withdrawal of consent, death, other reason deemed by investigator or study termination by the Sponsor."
"1539",1884,"NCT01179737",205167,0.583333333,7,12,"Adverse events were collected over the duration of treatment 140 days for cohort 1, 168 days for cohort 2 and up to 1092 days in the extension study","23 participants were enrolled into the study; 8 participants completed cohort 1 and 6 of these participants moved into cohort 1 expansion of which 5 participants completed Cohort 1 expansion. Of the 5 participants, 3 went into an Extension. None of the participants completed treatment as trial was terminated","Cohort 1: Nilotinib","Participants were assigned to receive nilotinib 50 mg during 14 days, followed by 150 mg during 14 days, followed by 300 mg during 140 days."
"1565",1916,"NCT00654420",388572,0.578947368,22,38,"Up to 47 months","All Participants as Treated (APaT) population; all allocated participants who received at least one dose of study treatment.","Ph II: Erlotinib","During the Phase II part of the study, participants were randomized to receive open-label erlotinib at 150 mg daily until disease progression or occurrence of unacceptable toxic effects."
"1568",1920,"NCT01229150",188362,0.578947368,11,19,NA,"The combination of toxicities allows for a more robust understanding of the combined therapy toxicities. The dosage of the combination of erlotinib plus AZD6244 was the same whether the pt has a KRAS mutation versus KRAS wild type. KRAS is a molecular mutation and does not change whether or not a pt has toxicities to the combination of therapies.","WT KRAS 1","Wild-Type KRAS patients randomized to monotherapy arm
Erlotinib: For Wild-Type KRAS patients randomized to the single agent arm, Erlotinib 150 mg qd"
"1569",1921,"NCT00906698",295316,0.578947368,11,19,"First administration of trial medication until 28 days after last administration of trial medication.",NA,"Afatinib 40mg With Vinorelbine i.v.","Continuous daily dosing of Afatinib 40mg orally and weekly Vinorelbine 25 mg/m2 intravenously (days 1, 8, 15 and 22) in a 4-weekly course. Patients will be eligible for repeated treatment courses in the absence of clinical disease progression or undue toxicity ."
"1581",1937,"NCT00154375",546150,0.576470588,49,85,NA,"Safety population = patients who were randomized to either Imatinib + Hydroxyurea (combination)[n=118] or to Hydroxyurea alone [n=118]. Every 6 wks, patients on Hydroxyurea alone switched to combination arm depending on response. So, for the safety analysis Hydroxyurea arm is divided into Hydroxyurea alone [n=118] or switch to combination [n=85].","Period After Switch to Combination","After every 6 weeks from randomization, depending on the assessment of therapeutic effect, patients were switched from Hydroxyurea (1500 mg/day p.o) to combination arm where patients were instructed to take a daily oral imatinib dose of 600 mg (600 mg at lunch time) and a daily oral hydroxyurea (HU) dose of 1000 mg (500 mg twice daily; in the morning and at bed time)."
"1582",1938,"NCT01062425",242676,0.576086957,53,92,"Subjects experiencing more than one of a given serious adverse event (SAE) are counted only once for that SAE. The same methodology was applied for non-serious adverse events (AE).","All randomized and eligible patients who started protocol treatment.","Cediranib, TMZ, and RT","Cediranib (3 days) followed by radiation therapy (RT) + daily temozolomide (TMZ) + cediranib followed by cediranib monotherapy (4 weeks) followed by TMZ + cediranib for 12 cycle maximum"
"1592",1948,"NCT00073307",570317,0.574074074,124,216,"In addition, 1 participant who was not randomized to double-blind treatment received sorafenib treatment on a compassionate-use basis in the crossover phase and was included in the safety population only.","DIC (disseminated intravascular coagulation), AT (Atrial tachycardia), NOS (not otherwise specified), GI (gastro-intestinal), CTCAE (Common Terminology Criteria for Adverse Events), ANC (absolute neutrophil count), CNS (central nervous system), CN (cranial nerve), GU (genitourinary)","Placebo ~31May2005, Then Switched to Sorafenib Only-30Jun2008","Sorafenib period only-30Jun2008: Subjects received matching placebo tablets administered orally twice a day(as of ~31 May 2005) when after unblinding subjects switched over to receive Sorafenib orally administered as 2 x 200 mg tablets bid (twice daily). Open Label/Sorafenib only period-30Jun2008"
"1600",1956,"NCT01325701",160115,0.571428571,40,70,NA,NA,"PCI-32765: 560 mg","Treatment Group 1: Subjects received 560 mg of ibrutinib once daily, on a continuous basis."
"1604",1960,"NCT00627042",397460,0.571428571,24,42,NA,NA,"Ramucirumab (IMC-1121B)","Ramucirumab (IMC-1121B): 8 milligrams per kilogram (mg/kg) administered intravenously over 1 hour, every 2 weeks. Treatment continued until there was evidence of disease progression, intolerable toxicity, or other withdrawal criteria were met."
"1605",1961,"NCT00459979",460899,0.571428571,16,28,NA,NA,"Sunitinib","sunitinib malate : Sunitinib will be dosed at 50 mg p.o. daily
conventional surgery : nephrectomy"
"1607",1963,"NCT00570401",418252,0.571428571,12,21,NA,NA,"Dasatinib","Dasatinib in Patients with Lung Adenocarcinoma Receiving Erlotinib with Acquired Resistance to EGFR Tyrosine Kinase Inhibitors (TKIs)"
"1609",1966,"NCT00859937",308741,0.571428571,8,14,"Up to 5 years","All serious adverse events were reported. Other adverse events occurring in ≥5% of the study subjects were reported.","Non Adenoid Cystic Carcinoma","Patients with non Adenoid cystic carcinoma of malignant salivary gland tumors receive oral dasatinib (70mg) twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
"1624",1986,"NCT00987935",266792,0.571428571,4,7,"AEs with an onset during therapy with study treatment or within 28 days after discontinuation of study treatment (up to 1066 days)",NA,"Phase I Group II Nintedanib, 100 mg Bid","Oral administration of Nintedanib (BIBF 1120) 100 mg soft gelatine capsules twice daily (bid) for the Group II patients during Phase I"
"1625",1987,"NCT00975806",271336,0.571428571,4,7,"Phase 1 Only. From the date of the first study drug dose to within 28 days after the study drug treatment was discontinued.","Median treatment duration with Lenalidomide and Sunitinib was shortest in Cohort A at 41 days (range = 17 to 189 days) and longest in Cohort G = 97 days (range: 60 to 125 days) of lenalidomide treatment and 97.5 days (range = 54 to 125 days) of Sunitinib","Cohort F","Lenalidomide 10 mg QD on Days 1-21 of each 21-day cycle and sunitinib 37.5 mg QD on Days 1-14 of each 21-day cycle"
"1631",1998,"NCT00537823",432192,0.571428571,4,7,NA,NA,"Arm 1 - Wildtype","Neoadjuvant therapy
Week 1
Leucovorin 400 mg/m^2 IV
Oxaliplatin 85 mg/m^2 IV Cetuximab 400 mg/m^2 IV
5FU bolus 400 mg/m^2
5FU CIVI 1200 mg/m^2/day over 46 hours
Weeks 2, 4, 6, 8 *Cetuximab 250 mg/m^2 IV weekly
Weeks 3, 5, 7
Leucovorin 400 mg/m^2 IV
Oxaliplatin 85 mg/m^2 IV Cetuximab 400 mg/m^2 IV
5FU bolus 400 mg/m^2
5FU CIVI 1200 mg/m^2/day over 46 hours
Wait 3-8 weeks after completion of therapy
Liver resection
Wait 4 weeks or until clinical status allows
Adjuvant Therapy
Week 1, 3, 5, 7, 9, 11, 13, 15
Leucovorin 400 mg/m^2 IV
Oxaliplatin 85 mg/m^2 IV Cetuximab 400 mg/m^2 IV
5FU bolus 400 mg/m^2
5FU CIVI 1200 mg/m^2/day over 46 hours
Weeks 2, 4, 6, 8, 10, 12, 16
*Cetuximab 250 mg/m^2 IV weekly"
"1653",2025,"NCT00903175",296498,0.567099567,131,231,NA,NA,"Sunitinib 1L/Everolimus 2L","sunitinib First Line: 50 mg orally, once daily, 4 weeks on treatment followed by 2 weeks off (4/2) everolimus Second Line: 10 mg orally, once daily (two 5 mg tablets), continuous treatment"
"1655",2028,"NCT00875433",304337,0.566666667,34,60,"First administration of trial medication until 28 days after last administration of trial medication",NA,"All Patients","Patients with tumours known to historically (over)express epidermal growth factor receptor (EGFR)/human epidermal growth factor receptor (HER) 2 with and without brain metastases, and patients with recurrent glioblastoma receiving an oral dose of Afatinib 50 mg once daily (qd)"
"1668",2047,"NCT00987935",266788,0.5625,18,32,"AEs with an onset during therapy with study treatment or within 28 days after discontinuation of study treatment (up to 1066 days)",NA,"Phase II Sorafenib, 400 mg Bid","Oral administration of Sorafenib 400 mg film coated tablets twice daily (bid) during Phase II"
"1672",2051,"NCT00094107",565398,0.5625,18,32,NA,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.","Axitinib","Axitinib (AG-013736) tablet administered orally at a dose of 5 mg BID in cycles of 4 weeks. Treatment was administered continuously until progression or unacceptable toxicity occurred."
"1675",2054,"NCT01264380",177183,0.5625,9,16,"Baseline up to 28 days after last dose (Week 114)",NA,"Vemurafenib (RO5185426)","Participants received vemurafenib tablet at 960 mg orally twice daily in 21-day cycles starting from Day 21 until disease progression, unacceptable toxicity, or consent withdrawal (Period C)."
"1677",2056,"NCT00597038",409461,0.5625,9,16,"First on treatment date to last off study date: 2 years, 4 months.",NA,"Phase I Dose Escalation","Dasatinib and Dacarbazine (DTIC). Dasatinib and Dacarbazine (DTIC). The first cohort was a dasatinib dose of 50 mg by mouth (PO) twice a day (BID) given days 2-19 with DTIC given at a dose of 800 mg/m2 once every 3 weeks. The dose escalation was continued until MTD and a recommended Phase II dose was established."
"1680",2059,"NCT00306891",515280,0.5625,9,16,NA,NA,"Cediranib 45 mg Fixed Dose","Part B: Cediranib 45 mg Fixed Dose"
"1684",2065,"NCT00044512",574691,0.562043796,77,137,NA,"Acronyms in Adverse Event section: Gastrointestinal (GI), Central Nervous System (CNS), Not Otherwise Specified (NOS), Absolute Neutrophil Count (ANC), Alanine Transaminase (ALT), Aspartate Transaminase (AST), Gamma Glutamyl Transpeptidase (GGT), Acute Respiratory Distress Syndrome (ARDS), Without grade 3 or 4 (W/O GR 3 or 4), Neutropenia (Neu)","Sorafenib 400 mg b.i.d.","Sorafenib (Nexavar, BAY43-9006) 400 mg administered b.i.d.Other AE section includes SAEs"
"1686",2067,"NCT00261846",528962,0.56097561,92,164,NA,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.","Advanced Phase","All participants who received bosutinib 500 mg orally once daily for 48 weeks in advanced phase (AP) and blast phase (BP) chronic myelogenous leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL)."
"1694",2077,"NCT00131911",551693,0.559139785,52,93,NA,NA,"All Patients","Patients receive 400 mg oral sorafenib twice daily on days 1-28."
"1702",2086,"NCT00871403",305247,0.557377049,34,61,NA,"Serious adverse events (SAEs) and non-serious AEs are presented for the entire treatment period (Combination Treatment Phase followed by the Monotherapy Phase). SAEs and AEs were collected in the Safety Population, comprised all participants who had received at least one dose of both drugs within the assigned regimen.","Pazopanib 800 mg Plus Pemetrexed 500 mg/m^2","Oral pazopanib 800 mg once daily plus intravenous (IV) pemetrexed 500 mg/ m^2 once every 3 weeks for 4 or 6 cycles during the Combination Treatment Phase. If participants experienced no disease progression, unacceptable toxicities, or death during the Combination Treatment Phase, they continued on pazopanib 800 mg monotherapy until disease progression, unacceptable toxicities, or death."
"1711",2097,"NCT00761345",348741,0.555555556,15,27,"3.5 years",NA,"Radiotherapy and Chemotherapy","gemcitabine will be administered at 1000mg/m2 IV on days 1 and 8 of each 21 day cycle. erlotinib at either 100mg (cohort 1-3) or 150mg (cohort 4) PO daily. Low dose fractionated radiotherapy (LDRT) will be given BID on days 1 and 2 and 8 and 9 of each 21 day cycle
gemcitabine: gemcitabine 1000mg/m2 days 1 and 8 of each 21 day cycle.
Erlotinib: Erlotinib 100mg or 150mg daily of each 21 day cycle
low dose fractionated radiotherapy: low dose fractionated radiotherapy day 1 and 2, day 8 and 9 of each 21 day cycle"
"1720",2109,"NCT00727506",361354,0.555555556,10,18,"Between first intake through 28 days after last drug intake.",NA,"Phase I - Afatinib 50 mg Plus Temozolomide 75mg/m^2","Patients receiving Afatinib 50mg once daily (q.d.) plus Temozolomide 75 mg/m^2 for 21 days followed by 7 days off - Phase I part"
"1726",2116,"NCT01423604",137641,0.555555556,5,9,"From the start of the study (first dose for that subject) until the end of the Adverse Event (AE) period (30 days after the last dose) or death, whichever was earlier (up to 8 months).","Safety evaluable population included all randomized subjects who received at least 1 dose of study drug.","Ruxolitinib (Safety Run-In)","Subjects received capecitabine 2000 mg/m^2 daily (taken as 1000 mg/m2 twice daily [BID]) + ruxolitinib 15 mg BID"
"1739",2132,"NCT00437073",469283,0.555555556,5,9,"All serious and non-serious on-therapy adverse events, defined as occurring from the first dose of investigational product until five days after the last dose (up to Week 37) were recorded, regardless of whether or not they were considered drug related.","Serious and non-serious adverse events were collected in members of the ITT Population, comprised of all participants who received at least one dose of study medication.","Lapatinib Plus Topotecan","Participants received a daily dose of 5 tablets of lapatinib (1250 milligrams [mg]) at approximately the same time every day, either 1 hour (or more) before breakfast or 1 hour (or more) after breakfast. Participants also received an intravenous (IV) infusion of topotecan 3.2 mg/m^2 over the course of at least 30 minutes on Days 1, 8, and 15 (+/- 2 days) of a 28-day treatment cycle."
"1752",2146,"NCT00520975",438995,0.553191489,26,47,"Assessed every cycle (1 cycle=4 weeks during Induction therapy, 1 cycle=3 weeks during Maintenance therapy) while on treatment and for 30 days after the end of treatment","After discontinuation of treatment, severe (Grade ≥ 3) long term toxicity that had not been previously reported were collected via the Long term follow-up form using the following schedule: every 3 months within 2 years of registration, then every 6 months in years 2-5, annually afterward until year 10.","Arm A (Chemotherapy and Placebo)","INDUCTION THERAPY: Patients receive trastuzumab IV over 30-90 minutes on days 1, 8, 15, and 22 and paclitaxel IV over 60 minutes with or without carboplatin IV over 60 minutes on days 1, 8, and 15. Patients also receive placebo IV over 30-90 minutes on day 1 and 15. Treatment repeats every 4 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.
MAINTENANCE THERAPY: Beginning 1 week after the last dose of induction trastuzumab, patients receive trastuzumab IV over 30-90 minutes and placebo IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity.
Carboplatin: Given IV
Paclitaxel: Given IV
Placebo: Given IV
Trastuzumab: Given IV"
"1753",2147,"NCT00105443",561111,0.553191489,26,47,"Reporting Group (RG) 1 + 2: Data for Interim Analysis, cut-off Oct 17, 2006; RG 3: Data during and after unblinding (until Nov 21, 2008); RG 4: Data prior to date of unblinding (Feb 9, 2007); RG 5: Data after unblinding (Open Label; until Nov 21, 2008)","RG 1 + 3 description: All subjects randomized to Sorafenib treatment; RG 2 + 4 description: All subjects randomized to Placebo before unblinding (when they were on Placebo, before they had the opportunity to switch to Sorafenib treatment); RG 5 description: All placebo subjects who switched to Sorafenib treatment after unblinding occurred.","Subjects Switching From Placebo to Sorafenib (Open Label Only)","Reporting Group 5 (RG 5): Participants initially randomized to Placebo who switched to Sorafenib in Open Label phase (data after unblinding only, from Feb 09, 2007 until Nov 21, 2008); Sorafenib 400 mg was administered orally at a dose of 400 mg (2 x 200 mg tablets) twice daily (bid). Note: Safety Data presented here include participants listed in Arm B2 of the Participant Flow section."
"1773",2174,"NCT00203931",538316,0.55,11,20,"up to 5 years","Serious adverse events of any grade are reported. For all other adverse events, only those grade 3 or higher were collected during the study. Adverse events are reported for the evaluable patients who received at least 3 doses of Cetuximab","Cetuximab","Cetuximab initial dosage of 400 mg/m2 over 120 minutes, followed by weekly infusions at 250 mg/m2 over 60 minutes."
"1780",2182,"NCT00716820",365071,0.548728814,259,472,NA,"The frequency of adverse events. The same event may appear as both an adverse event and a serious adverse event. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.","Sunitinib Malate","Usually, 50 mg of sunitinib malate was orally administered to adult participants once daily in repetitive cycles of 4 weeks on treatment followed by 2 weeks off according to Japanese package insert."
"1784",2186,"NCT01004003",260202,0.548387097,34,62,"From first administration of the trial drug and until 28 days after the last administration of nintedanib or sorafenib, up to 1289 days",NA,"Phase II, 200 mg Nintedanib Bid","Oral administration of Nintedanib (BIBF 1120) 200 mg soft gelatine capsules (two capsules of 100mg) twice daily (bid). Phase II: Patients were randomly assigned to open-label treatment with nintedanib or sorafenib. Patients were stratified for macrovascular invasion (MVI) and/or extra-hepatic spread (EHS). Patients had a baseline Child-Pugh score of 5 or 6, and AST and ALT ≤2 times the upper limit of normal (ULN)."
"1788",2191,"NCT00189488",540896,0.547945205,40,73,"125 Days","The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
Two participants were randomized to the Placebo arm but received palifermin inadvertently and were summarized in Palifermin arm.","Placebo","Placebo to 60 μg/kg palifermin administered daily on 3 consecutive days prior to the day of start of the conditioning regimen and placebo to 180 μg/kg palifermin administered once, prior to transplant and at least 96 hours from the previous placebo dose."
"1798",2201,"NCT00508404",443991,0.545454545,84,154,"The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 6.6 months.","Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.","Panitumumab Plus FOLFIRI","Participants received 6 mg/kg panitumumab intravenously (IV) once every 14 days in combination with FOLFIRI chemotherapy regimen consisting of irinotecan, infusional 5-fluorouracil, and leucovorin, until diagnosed with radiographic disease progression."
"1807",2212,"NCT00414388",477944,0.545454545,12,22,NA,NA,"Single Agent Sorafenib","Oral Single agent Sorafenib 400mg twice daily"
"1819",2226,"NCT00115739",557355,0.545454545,6,11,NA,NA,"Imatinib (Gleevec) Tablets","patients with Anaplastic thyroid cancer were administered Gleevec tablets From February 2004 to May 2007"
"1830",2238,"NCT00105443",561114,0.543046358,164,302,"Reporting Group (RG) 1 + 2: Data for Interim Analysis, cut-off Oct 17, 2006; RG 3: Data during and after unblinding (until Nov 21, 2008); RG 4: Data prior to date of unblinding (Feb 9, 2007); RG 5: Data after unblinding (Open Label; until Nov 21, 2008)","RG 1 + 3 description: All subjects randomized to Sorafenib treatment; RG 2 + 4 description: All subjects randomized to Placebo before unblinding (when they were on Placebo, before they had the opportunity to switch to Sorafenib treatment); RG 5 description: All placebo subjects who switched to Sorafenib treatment after unblinding occurred.","Placebo Arm Double-Blind Phase (Interim Data Only)","Reporting Group 2 (RG 2): All participants in Double-Blind phase randomized to Sorafenib-matching placebo (data before Oct 17, 2006); Sorafenib-matching placebo tablets were orally administered twice daily (bid).
Note: Safety Data presented here include participants listed in Arms B1 and B2 of the Participant Flow section."
"1832",2240,"NCT00193596",539926,0.542857143,57,105,NA,NA,"Irinotecan/Gemcitabine/Gefitinib","Irinotecan 100 mg/m2 IV, days 1 and 8
Gemcitabine 1000 mg/m2 IV, days 1 and 8
Regimen B was repeated at a 21-day interval"
"1838",2246,"NCT00828841",321122,0.542372881,128,236,"Adverse events collection began at the time the patient signed the informed consent and continued throughout the study until 30 days after the last dose.","Systematic Assessment - subjects were assessed for adverse events by a member of the research team every 1-2 weeks.","Platinum, Gemcitabine, Cetuximab (Arm B)","Patients with squamous or non-squamous histologies will receive gemcitabine with either carboplatin or cisplatin for a minimum of four and a maximum of six 21-day cycles, plus cetuximab, and then enter a maintenance phase with single-agent cetuximab. Cetuximab will be given on Day 1, and weekly during chemotherapy, followed by biweekly administration during the maintenance period. The choice of delivering four, five or six cycles of chemotherapy is at the investigator's discretion. The choice of platinum-based chemotherapy is also at the investigator's discretion.
Gemcitabine : Gemcitabine 1,000 mg/m2 Days 1 and 8 every 21 days
Cisplatin : Cisplatin 75 mg/m2 Day I every 21 days
Carboplatin : Carboplatin AUC 6 Day 1 every 21 days
Cetuximab : Cetuximab will be administered at a loading dose of 400 mg/m2 on Day 1, Cycle 1 and at a dose of 250 mg/m2 weekly during chemotherapy. During the maintenance period, cetuximab will be dosed at 500 mg/m2 every two weeks."
"1839",2248,"NCT01423604",137640,0.542372881,32,59,"From the start of the study (first dose for that subject) until the end of the Adverse Event (AE) period (30 days after the last dose) or death, whichever was earlier (up to 8 months).","Safety evaluable population included all randomized subjects who received at least 1 dose of study drug.","Ruxolitinib","Subjects received ruxolitinib 15 mg BID plus capecitabine at a starting dose of 2000 mg/m^2 (1000 mg/m^2 twice a day [BID])."
"1841",2250,"NCT00618982",400676,0.542168675,45,83,NA,"Abbreviations used in the Adverse Events section: Gastrointestinal (GI), Not Otherwise Specified (NOS), Absolute Neutrophil Count (ANC), Alanine aminotransferase (ALT), Aspartate aminotransferase (AST), Gamma glutamyl transpeptidase (GGT)","Sorafenib (Nexavar, BAY43-9006)","Intrapatient dose escalation of sorafenib from 400 mg orally twice daily (bid) for the first cycle,600 mg bid for the second cycle and 800 mg bid until disease progression, unacceptable toxicity or withdrawal of consent. Dose reductions due to toxicities were allowed."
"1843",2252,"NCT00073307",570318,0.542035398,245,452,"In addition, 1 participant who was not randomized to double-blind treatment received sorafenib treatment on a compassionate-use basis in the crossover phase and was included in the safety population only.","DIC (disseminated intravascular coagulation), AT (Atrial tachycardia), NOS (not otherwise specified), GI (gastro-intestinal), CTCAE (Common Terminology Criteria for Adverse Events), ANC (absolute neutrophil count), CNS (central nervous system), CN (cranial nerve), GU (genitourinary)","Sorafenib (Nexavar, BAY43-9006)-30Jun2008","Sorafenib was to be orally administered as 2 x 200 mg tablets bid (twice daily). Double Blind-30Jun2008. In addition, 1 participant who was not randomized to double-blind treatment received sorafenib treatment on a compassionate-use basis in the open-label/Sorafenib only phase and was included in the safety population only. Participants affected may deviate from double-blind phase due to data update and cleaning."
"1851",2261,"NCT00022490",576522,0.541666667,13,24,NA,NA,"Cytarabine/ Imatinib Mesylate","Cytarabine: Once daily subcutaneous injection of Ara-C (Cytarabine) at a dose of 20 mg (10 mg or 5 mg if they have been dose reduced) per square meter of calculated body surface area, on days 15-28 of each sequential 28 day cycle
Imatinib Mesylate: Once daily oral administration of STI571 (Imatinib Mesylate) at a dose of 400 mg for 12 months"
"1857",2270,"NCT00237185",534063,0.540540541,40,74,NA,NA,"Imatinib Mesylate 600 mg","600 mg"
"1862",2277,"NCT00589784",412022,0.54,27,50,NA,NA,"All Patients","All patients treated with Sunitinib (SU011248)"
"1868",2286,"NCT00101413",562485,0.538461538,28,52,"AE data were collected from Apr 2004 to Apr 2008",NA,"Sorafenib","Sorafenib (Nexavar, BAY43-9006) 400 mg twice daily (bid, bis in die) X 28 day cycles"
"1869",2287,"NCT00076011",569722,0.538461538,28,52,NA,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.","Axitinib","Axitinib (AG-013736) tablet administered orally at a dose of 5 milligram (mg) twice daily (BID) in cycles of 4 weeks. Treatment was administered continuously until progression or unacceptable toxicity occurred."
"1871",2290,"NCT00698815",373365,0.538461538,21,39,NA,"Adverse events were evaluated for 124 participants (41, 44 and 39 on Arm I, II and III, respectively).","Arm III (Pemetrexed and Sunitinib)","Patients receive pemetrexed disodium 500 mg/m^2 IV over 10 minutes on day 1 and sunitinib malate at 37.5 mg PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients with documented disease progression may then receive third-line therapy at the discretion of the treating physician."
"1872",2291,"NCT02013206",34784,0.538461538,14,26,"Up to 2 Years",NA,"Current/Former Smokers","Current Smokers (participants who smoked > 100 cigarettes in entire lifetime and either quit smoking < 1 year ago or were currently smoking) or Former Smokers (participants who smoked > 100 cigarettes in entire lifetime and quit smoking ≥ 1 year ago) received erlotinib [Tarceva] 150 mg orally daily, increasing to a maximum of 300 mg orally daily until disease progression or unacceptable toxicity."
"1897",2320,"NCT00678535",379720,0.535874439,239,446,"Time from first dose up to 30 days after the last dose of study treatment.","An AE is defined as any untoward medical occurrence in the form of signs, symptoms, abnormal laboratory findings, or diseases that emerges or worsens relative to Baseline during a clinical study with an IMP, regardless of causal relationship and even if no IMP has been administered.","Cetuximab Plus Capecitabine Plus Cisplatin","Cetuximab weekly (initial dose 400 milligram per square meter [mg/m^2] followed by 250 mg/m^2 intravenous infusion), cisplatin (3-week cycle, 80 mg/m^2 intravenous infusion on Day 1) and capecitabine (3-week cycle, 1000 mg/m^2 orally twice daily for 14 days ) until documented disease progression, unacceptable toxicity, or withdrawal of consent."
"1904",2329,"NCT00498797",446719,0.534883721,23,43,NA,NA,"Vandetanib","docetaxel/prednisolone/vandetanib"
"1913",2339,"NCT00094055",565416,0.533333333,32,60,NA,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.","Axitinib","Axitinib (AG-013736) tablet administered orally at a dose of 5 mg BID in cycles of 4 weeks. Treatment was administered continuously until progression or unacceptable toxicity occurred or the participant withdrew consent."
"1928",2357,"NCT00114244",557444,0.533333333,8,15,"Adverse Events occured over a 36 month period.","Other Adverse Events include all events that were not severe adverse events regardless of grade or relation to treatment.","Arm I (Sorafenib Tosylate)","Patients receive 400 mg oral sorafenib twice daily on days 1-28. Patients experiencing disease progression cross over to Arm II.
sorafenib tosylate: Given PO
laboratory biomarker analysis: Correlative studies"
"1937",2370,"NCT00372775",493467,0.53125,34,64,NA,"The same event may appear as both an adverse event (AE) and a serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in 1 subject and as nonserious in another subject, or 1 subject may have experienced both a serious and nonserious event during the study.","Sunitinib","Sunitinib 37.5 mg oral capsule daily"
"1945",2381,"NCT00671788",382056,0.529411765,18,34,"Adverse events were queried for and collected every cycle for the duration of treatment.",NA,"Dasatinib","Dasatinib 100 mg orally once daily every day continuously (one cycle = 28 days) until disease progression or adverse effects prohibit further therapy. If the patient does not experience any side effects when taking this dose of dasatinib for the first cycle of treatment, the dosage will be increased before starting the second cycle of treatment to 140 mg of dasatinib orally, 70 mg in the morning and 70 mg in the evening"
"1950",2388,"NCT00941863",283487,0.529411765,9,17,"Time frame for expansion group is from start of treatment until April 2008, up to 6 years.","Acronyms in Adverse Event Section:
White Blood Cell (WBC) Absolute Neutrophil Count (ANC) Absolute Granulocyte Count (AGC) Alanine Transaminase (ALT) Aspartate Transaminase (AST) Grade (GR) Gastrointestinal (GI) Central Nervous System (CNS) Fibrillation/Flutter (FIB/FLUTT) Neutropenia (Neu) documented (doc)","Sorafenib 400 mg (200-mg Tablet)","Dose-escalation cohort 4: Sorafenib (Nexavar, BAY43-9006) 400 mg twice daily (200-mg tablet)"
"1952",2391,"NCT00524121",437910,0.529411765,9,17,NA,NA,"Erlotinib in Combination With Radiotherapy","Erlotinib (150 mg) administered orally once daily starting day 1 and continued with radiotherapy (RT) and through day 365 (one year therapy duration). RT will be administered day 1-28 (Mon-Fri) in dose of 1.8 Gy per fraction."
"1957",2397,"NCT00095199",564558,0.528301887,84,159,"Randomization to 30 days after study therapy up to 72.8 months for Cetuximab & Pemetrexed (versus just Pemetrexed) and up to 64.3 months for Cetuximab + Docetaxel (versus just Docetaxel)",NA,"Cetuximab and Docetaxel","Cetuximab 400/250 mg/m^2 (initial/weekly) administered intravenously on Days 1, 8, and 15 (3-week) cycles until disease progression or unacceptable toxicity. Docetaxel 75 mg/m^2 administered intravenously on Day 1 of 3 weeks cycle for up to six (3-week) cycles."
"1961",2404,"NCT00673049",381615,0.527586207,153,290,NA,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study. All treated subjects were analyzed for AEs and SAEs.","Erlotinib","Erlotinib was taken as 150 mg daily at least 1 hour before or 2 hours after the ingestion of food."
"1972",2417,"NCT00504153",445182,0.526315789,10,19,"Patients were followed for approximately 2 months after study treatment, approximately 6 months.","All serious adverse events are reported here. The non-serious adverse (NSAE) events report includes those NSAEs assessed at grade 3 or higher.","Dasatinib (Tyrosine Kinase Inhibitor)","Patients receive oral dasatinib twice daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity."
"1973",2418,"NCT00331409",505506,0.526315789,10,19,NA,NA,"Everolimus and Imatinib Mesylate","Everolimus: 2.5 mg daily by mouth
Imatinib Mesylate: 600 mg daily by mouth"
"1978",2424,"NCT01117623",225244,0.525423729,31,59,"Adverse events were collected after signing the informed consent of the first participant until the end of study completion for the last patient, therefore for the study over a period of approximately 6 years and 9 months",NA,"Regorafenib (Stivarga, BAY73-4506) 100 mg","Participants received a single 100 mg oral CP tablet of regorafenib on Day 1 of Cycle 1 followed by 1 day off treatment. On Day 3, once-daily continuous dosing with 100 mg oral CP tablets was initiated. A cycle was defined as 21 days. For Cycle 2 and subsequent cycles, regorafenib was administered once daily continuously on a 21-day cycle. This arm includes the participants from the dose escalation cohort: Regorafenib 100 mg and the three Expansion Cohorts 'HCC Child-Pugh A Expansion Cohort: Regorafenib 100 mg', 'HCC Child-Pugh B Expansion Cohort: Regorafenib 100 mg', 'NSCLC Expansion Cohort: Regorafenib 100 mg'."
"1985",2435,"NCT01006980",259150,0.523809524,44,84,"Baseline through the end of study (maximum exposure: 57.07 months)",NA,"Vemurafenib After Crossover","Adverse events reported for this group include those occurring following switch to vemurafenib in those participants who switched from dacarbazine to vemurafenib during the study."
"1986",2436,"NCT01469546",126115,0.523809524,22,42,NA,"All 42 patients received treatment and were therefore evaluable for adverse events.","Axitinib (AG-013736)","Axitinib (AG-013736): The subjects will be started on treatment with 5 mg of Axitinib twice a day continuously, with subsequent dose escalation to 7 mg and then 10 mg twice a day in the absence of grade 2 or worse toxicities."
"1992",2442,"NCT00287222",521355,0.523809524,11,21,NA,NA,"Bevacizumab and Erlotinib","Subjects will be treated with bevacizumab and erlotinib"
"1995",2445,"NCT00828841",321121,0.523076923,68,130,"Adverse events collection began at the time the patient signed the informed consent and continued throughout the study until 30 days after the last dose.","Systematic Assessment - subjects were assessed for adverse events by a member of the research team every 1-2 weeks.","Platinum, Pemetrexed, Cetuximab (Arm C)","Patients with squamous histology will receive pemetrexed and either carboplatin or cisplatin for a minimum of four and a maximum of six 21-day cycles, plus cetuximab, and then enter a maintenance phase with single-agent cetuximab. Cetuximab will be given on Day 1, and weekly during chemotherapy, followed by biweekly administration during the maintenance period. The choice of delivering four, five or six cycles of chemotherapy is at the investigator's discretion. The choice of platinum-based chemotherapy is also at the investigator's discretion. Patients with non-squamous histology are not eligible for this arm.
Cisplatin : Cisplatin 75 mg/m2 Day I every 21 days
Carboplatin : Carboplatin AUC 6 Day 1 every 21 days
Cetuximab : Cetuximab will be administered at a loading dose of 400 mg/m2 on Day 1, Cycle 1 and at a dose of 250 mg/m2 weekly during chemotherapy. During the maintenance period, cetuximab will be dosed at 500 mg/m2 every two weeks."
"1998",2449,"NCT00614393",402952,0.522222222,94,180,"Up to 30 days after last dose of study drug (Up to 33 months)","The APaT population consisted of all randomized participants who received ≥1 dose of study drug. Participants were included in the treatment group corresponding to the study drug they actually received.","Dalotuzumab 10 mg/kg Q1W (BD)","In DB Week 1, participants received cetuximab 400 mg/m^2 IV loading dose and irinotecan IV at their pre-study dosage. Starting with DB Week 2, participants received cetuximab 250 mg/m^2 IV Q1W maintenance dose, irinotecan IV Q1W and DB dalotuzumab 10 mg/kg IV Q1W for up to 32 months of treatment."
"2018",2472,"NCT00459108",461266,0.52,13,25,NA,"Other adverse events include all grades and attributions to treatment not included in the Serious adverse event table.","Oral Dasatinib","Patients receive oral dasatinib at 70 mg twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
dasatinib: Given orally"
"2022",2479,"NCT00365391",496036,0.518518519,14,27,NA,NA,"Treatment (Bevacizumab and Erlotinib)","Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15 and oral erlotinib hydrochloride once daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo laboratory studies to determine EGFR and phosphorylated-EGFR protein levels using initial diagnostic biopsy specimens by IHC for correlation with clinical outcome. Levels of proteins through which EGFR signals, including Akt, phosphorylated-Akt, MAPK, and phosphorylated-MAPK, are also determined using initial diagnostic biopsy specimens by IHC and correlated with clinical outcome. Total and free serum vascular endothelial growth factor levels are determined at the start of study and prior to course 3 by ELISA."
"2028",2485,"NCT01529112",113250,0.516853933,46,89,"For each participant, from the first dose till 30 days after the last dose or up to approximately 2 years (data cut-off date of 21 January 2014)","Treatment emergent adverse events (TEAEs), defined as an AE (serious/non-serious) that started/increased in severity on/after the first dose of study medication up to 30 days after the final dose of study medication are presented in this section.","Lenvatinib","Participants received lenvatinib 24 mg orally, once daily continuously in each 28-day treatment cycle."
"2037",2496,"NCT00105443",561115,0.515151515,153,297,"Reporting Group (RG) 1 + 2: Data for Interim Analysis, cut-off Oct 17, 2006; RG 3: Data during and after unblinding (until Nov 21, 2008); RG 4: Data prior to date of unblinding (Feb 9, 2007); RG 5: Data after unblinding (Open Label; until Nov 21, 2008)","RG 1 + 3 description: All subjects randomized to Sorafenib treatment; RG 2 + 4 description: All subjects randomized to Placebo before unblinding (when they were on Placebo, before they had the opportunity to switch to Sorafenib treatment); RG 5 description: All placebo subjects who switched to Sorafenib treatment after unblinding occurred.","Sorafenib (Nexavar) Arm Double-Blind Phase (Interim Data Only)","Reporting Group 1 (RG 1): All participants in Double-Blind phase randomized to Sorafenib treatment (data before Oct 17, 2006); Sorafenib 400 mg was administered orally at a dose of 400 mg (2 x 200 mg tablets) twice daily (bid); 2 dose reductions to predefined levels of 400 mg once daily (OD) and 400 mg every other day were permitted for adverse events related to study treatment. Note: Safety Data presented here include participants listed in Arms A1 and A2 of the Participant Flow section."
"2039",2498,"NCT00832637",319609,0.515151515,17,33,"Patients are followed for at least one month following end of on-study treatment. All patients who discontinue the trial secondary to an adverse event are followed until resolution, stabilization or return to a baseline condition, an average of 24 weeks.",NA,"Gemcitabine, Cisplatin, Erlotinib","Cisplatin at a dose of 40 mg/m2 q 2 weeks along with gemcitabine, 1000mg/m2, and erlotinib 100 mg daily PO.
Cisplatin: Cisplatin 40 mg/ m2 on day 1 and day 15 in patients treated with Gem + Cis, with Cisplatin to be given following Gemcitabine. Cisplatin administration should be given along with hydration with NS at 250 mL/ hour for at least 4 hours pre-and during Cisplatin administration. Additionally, Cisplatin administration should be preceded by osmotic diuresis with Mannitol 25%, 12.5 grams.
Erlotinib: 100 mg orally daily.
Gemcitabine: 1000 mg/m2 on Days 1, 15 every 28 days. The clinical formulation is supplied in a sterile form for intravenous use only. Vials of gemcitabine contain either 200 mg or 1 g of gemcitabine HCl (expressed as free base) formulated with mannitol (200 mg or 1 g, respectively) and sodium acetate (12.5 mg or 62.5 mg, respectively) as a sterile lyophilized powder. Hydrochloric acid and/or sodium hydroxide may have been added for pH adjustment."
"2056",2516,"NCT01309997",164186,0.513513514,19,37,"18 months",NA,"Rituximab as Initial Therapy","Arm I = rituximab, adverse event occurred after the start date of rituximab and if applicable, prior to start date of imatinib."
"2062",2523,"NCT00436605",469443,0.512820513,20,39,NA,NA,"Treatment (Kinase Inhibitor Therapy)","Patients receive oral dasatinib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
"2071",2533,"NCT01282424",172387,0.512,64,125,"From enrollment until all subjects completed ≥ 24 weeks of evaluation (up to 24 months)",NA,"Idelalisib","Idelalisib 150 mg tablet administered orally twice daily until tumor progression or development of unacceptable toxicity."
"2082",2544,"NCT00492752",448511,0.510067114,76,149,"Reporting Group (RG) 1 + 2: Data from start of treatment until end of this trial (July 27, 2009); RG 3: Data after unblinding (August 19, 2007) until end of this trial (July 27, 2009).","Acronyms in Adverse Event section: Gastrointestinal (GI), Common Terminology Criteria for Adverse Events (CTCAE), not otherwise specified (NOS), absolute neutrophil count (ANC), Central nervous system (CNS), Partial thromboplastin time (PTT), Alanine transaminase (ALT), Aspartate transaminase (AST), Gamma glutamyl transpeptidase (GGT).","Sorafenib, All (Double-Blind and Open Label Phase)","Reporting Group 1 (RG 1): All participants randomized to Sorafenib treatment (data from start of treatment until end of trial [July 27, 2009]). Sorafenib administered orally at a dose of 400 mg (2 x 200 mg tablets) twice daily (bid); 2 dose reductions to predefined levels of 400 mg (2 x 200 mg tablets) once daily and 400 mg (2 x 200 mg tablets) every 2 days were permitted for treatment-emergent adverse events related to study treatment."
"2085",2547,"NCT01321554",161178,0.509578544,133,261,"For each participant, from the first dose till 30 days after the last dose or the cut-off date for the primary analysis whichever was earlier or up to approximately 2.5 years","Safety was assessed by the monitoring and recording of all adverse events (AEs) and serious adverse events (SAEs); regular monitoring of hematology, clinical chemistry, and urine values; physical examinations; and regular measurement of vital signs, electrocardiograms (ECG), and echocardiograms.","Lenvatinib (Randomization Phase)","Participants received blinded study drug (lenvatinib 24 mg/placebo, orally once daily) in 2:1 ratio until documentation of disease progression (confirmed by IIR), development of unacceptable toxicity, or withdrawal of consent."
"2094",2561,"NCT00949702",280818,0.507575758,67,132,"Screening through 6 months after the last patient enrolled",NA,"Vemurafenib 960 mg","Patients received vemurafenib 960 mg (four 240 mg tablets) bid (bis in die, twice daily) orally until disease progression, unacceptable toxicity, withdrawal of consent, or another reason as determined by the investigator."
"2095",2562,"NCT00796549",333682,0.507246377,35,69,"First administration of trial medication until 28 days after last administration of trial medication, up until 194 weeks",NA,"Afatinib 50mg","Afatinib 50mg film coated tablets where administered once daily as long as they were tolerated by patients, until a disease progression (according to the response evaluation criteria in solid tumors)"
"2101",2568,"NCT00932451",286521,0.505628518,539,1066,"Active reporting period is from the time of informed consent until at least 28 days after study treatment last dose. For serious adverse events: those with the possibility of being related to study drug must be reported as minimum thereafter.","All causality (serious and non-serious) AEs","Crizotinib 250 mg BID","Participants were administered crizotinib at a starting dose of 250 mg orally, BID on a continuous dosing period as two 100-mg tablets and one 50-mg tablet at approximately 12 hours apart the same time each day."
"2106",2573,"NCT00461708",460151,0.504347826,58,115,"Adverse events (AEs) were recorded at every study visit for up to a maximum of 24 treatment cycles.","All participants who received at least 1 dose of study treatment were included in the safety analysis.","Erlotinib, Gemcitabine: Rash Grade < 2","Participants with a rash Grade < 2 according to the National NCI-CTC V 3.0 received erlotinib, 100 mg, PO, once per day of Cycles 1 up through a maximum of Cycle 24 (4-week cycles) until disease progression, unacceptable toxicity, or treatment refusal by participant. Participants also received gemcitabine, 1000 mg/m^2, IV, over 30 minutes on Days 1, 8 and 15 of Cycles 1 up through a maximum of Cycle 24 (4-week cycles) until disease progression, unacceptable toxicity, or treatment refusal by participant."
"2115",2583,"NCT01345682",154720,0.503125,161,320,"From first administration of study medication (afatinib or methotrexate) and within 28 days after the last administration of study medication (data cut-off (07May2014)); Up to 29 months",NA,"Afatinib (BIBW 2992)","Oral administration of Afatinib (film-coated tablets). Starting dose 40 mg once daily; escalation to 50 mg/day and / or dose reduction to 40 mg/day (if applicable), 30 mg/day, or 20 mg/day (according to the protocol-defined dose escalation and dose reduction scheme) if required. No dose increase was allowed after a dose reduction."
"2116",2584,"NCT00122460",555001,0.502283105,110,219,"Time from first dose up to 30 days after the last dose of study treatment.","Treatment-emergent adverse events were defined as those with onset occurring at or after the first dosing day of study medication and up to 30 days after the last administration of any study drug or the clinical cut-off date.","Cetuximab Plus Chemotherapy","Subjects in will receive initial dose of 400 mg/m^2 cetuximab (over 2 hours) followed by weekly doses of 250 mg/m^2 (over 1 hour). All doses will be given by intravenous (IV) infusion. Subjects will receive either Cisplatin (100 mg/m^2 on day 1) + 5-FU (1000 mg/m^2 continuous IV from day 1 to day 4) every 3 weeks or Carboplatin (Area under the curve (AUC) 5 IV on day 1) + 5-FU (1000 mg/m^2 continuous IV from day 1 to day 4) every 3 weeks."
"2118",2586,"NCT00744497",354811,0.50065703,381,761,"Day 1 up to 30 days post last dose of study therapy","Study initiated: October 2008; Study Completion: July 2015","Dasatinib","Participants received dasatinib, 100 mg, orally once daily plus docetaxel, 75 mg/m^2, given intravenously every 3 weeks as a 1-hour infusion, plus prednisone, 5 mg, given orally twice daily"
"2125",2595,"NCT00368992",494943,0.5,51,102,"Weekly while on protocol treatment.",NA,"Carboplatin, Paclitaxel, Cetuximab, and Bevacizumab",NA
"2132",2602,"NCT01040832",248245,0.5,27,54,"Time from first dose up to Day 42 to 49 after last dose of trial treatment, reported between day of first participant randomized, that is, 17 Dec 2009 until cut-off date, (11 Jan 2012)","An AE is defined as any untoward medical occurrence in the form of signs, symptoms, abnormal laboratory findings, or diseases that emerges or worsens relative to Baseline during a clinical study with an IMP, regardless of causal relationship and even if no IMP has been administered.","Cetuximab Plus EMD 1201081","Cetuximab weekly (initial dose 400 milligram per square meter [mg/m^2] over 120 minutes followed by 250 mg/m^2 intravenous infusion over 60 minutes) and EMD 1201081 weekly (0.32 milligram per kilogram [mg/kg] by subcutaneous injection) was administered in 3-week treatment cycle until disease progression. Participants who had discontinued cetuximab due to toxicity in cetuximab monotherapy arm, continued to receive EMD 1201081 monotherapy until disease progression or participant elected to withdraw from the trial. The total treatment period was approximately 18 months."
"2136",2609,"NCT00709618",367944,0.5,22,44,"Serious adverse events (SAEs) and non-serious AEs were collected from the date of the first dose of study treatment until 30 days post last dose (up to 2 years after the start of the study).","SAEs and non-serious AE data are reported for the ITT Population, comprised of all participants who received at least one dose of investigational product.","Vinorelbine 20 mg/m^2 Plus Lapatinib 1500 mg","Participants received vinorelbine (20 mg/m^2) IV once weekly for 3 weeks (on Days 1, 8, and 15 of a 4-week cycle, followed by a rest week) plus oral lapatinib (1500 mg once daily). Participants received study treatment until disease progression or withdrawal."
"2145",2620,"NCT00514943",441673,0.5,18,36,"1493 days",NA,"Afatinib 50 mg / Cetuximab 250mg/m2 - Stage 2","Patients were randomized to Afatinib monotherapy 50mg once daily (q.d.) in Stage 1 and if the patients had disease progression or intolerable AEs were crossed over to Cetuximab 250 mg/m2 given as 400mg/m2 once in the first week (load) followed by 250mg/m2 weekly thereafter in Stage 2."
"2148",2623,"NCT01093222",231505,0.5,17,34,"Up to 3 years",NA,"Sorafenib and Erlotinib","Patients receive sorafenib tosylate 400 mg PO twice daily and erlotinib hydrochloride 100 mg PO once daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity."
"2153",2628,"NCT00094094",565407,0.5,16,32,NA,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.","Axitinib","Axitinib (AG-013736) tablet administered orally at a dose of 5 mg BID in cycles of 4 weeks. Treatment was administered continuously until progression or unacceptable toxicity occurred or the participant withdrew consent."
"2156",2631,"NCT00857246",309616,0.5,15,30,"Up to 1 year","All the adverse events (AEs) from the induction to adjuvant therapies are reported here regardless of attributions.","Induction/ Surgery/ chemoRT","Induction treatment (3 weeks/cycle x 4 cycles): Cisplatin and Irinotecan on days 1 and 8; Cetuximab on days 1, 8, and 15.
Surgery (starts 3-4 weeks after induction treatment).
Chemoradiation treatment (starts 4-6 weeks after surgery):
weeks 1-19: Cetuximab on day 1 of every week; week 1: 5-FU and Leucovorin (LV) x 5 days; weeks 2-4: recovery; weeks 5-9: radiation, 150 cGy x 5 fractions/week x 5 weeks; week 5: 5-FU+ LV on days 1-4; week 9: 5-FU+ LV on days 1-3; weeks 14 and 19: 5-FU+LV x 5days"
"2159",2636,"NCT00388037",488298,0.5,15,30,NA,NA,"Treatment (Sunitinib Malate)","Patients receive sunitinib malate PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
sunitinib malate: Given PO
laboratory biomarker analysis: Correlative studies"
"2171",2649,"NCT01567163",105743,0.5,11,22,NA,NA,"All Participants","Cycle 1: docetaxel 75-milligrams/square meter (mg/m^2) intravenous infusion administered on Day 1 of 3-week cycle
Cycle 2: ramucirumab 10-milligrams/kilogram (mg/kg) intravenous infusion, followed by docetaxel 75-mg/m^2 intravenous infusion administered on Day 1 of 3-week cycle
Cycle 3 and beyond: ramucirumab and docetaxel administered on Day 1 of each 3-week cycle"
"2175",2653,"NCT00467779",457605,0.5,11,22,"AEs were recorded from the Day 1 of treatment period until the 30 plus or minus 4 days after the last treatment (up to approximately 6 years) .",NA,"Stage 2A Cohort 30 - Cobimetinib 100 mg (Expansion) (14/14)","Participants received cobimetinib 100 mg via solution or capsule, once daily for Days 1-14 of each 28-day cycle. Treatment was continued until PD or unacceptable toxicity for up to 1 year at the discretion of investigator and beyond 1 year with the agreement of the sponsor."
"2178",2656,"NCT00291577",520042,0.5,11,22,NA,NA,"Sunitinib in Combination With Docetaxel","Sunitinib (SU011248) orally (PO) for 2 weeks every 3 weeks (2 weeks on, then 1 week off = Schedule 2/1) starting on Day 2 (Cycle 2, Day 3 only for those subjects included in the Pharmacokinetic [PK] study); starting dose 37.5 milligrams (mg) daily (QD). Docetaxel (Taxotere) administered Day 1 of each cycle via intravenous (IV) infusion every 3 weeks; starting dose 75 mg/m2."
"2185",2665,"NCT00624585",398297,0.5,9,18,"1 Year 4 Months",NA,"Dasatinib Dose Escalation","Patients were started on dasatinib at a continuous oral daily dose of 100 mg per day. At 8 weeks, if the initial dose was well tolerated and patient had not achieved a partial response, the dose could be increased to 150 mg per day. All patients were followed per protocol for a total core period of 16 weeks from the first dose. Responding patients could continue dasatinib treatment for up to 48 weeks in the absence of treatment failure, disease progression, limiting toxicity or death. Patients continuing after 48 weeks will be enrolled in a separate extension study for future follow up."
"2186",2666,"NCT00470535",456562,0.5,9,18,NA,NA,"Erlotinib (Tarceva)","Erlotinib 150mg orally daily for three weeks"
"2194",2676,"NCT00932373",286658,0.5,8,16,"Baseline to the end of the study (up to 3 years 2 months)",NA,"Trastuzumab-MCC-DM 2.4 mg/kg Weekly","Trastuzumab-MCC-DM 2.4 mg/kg administered intravenously (IV) once a week"
"2206",2690,"NCT00910039",293994,0.5,7,14,"Adverse event data was collected from on study date to off study for a period of about 2.5 years.",NA,"Sunitinib Malate","Oral sunitinib malate (37.5mg)once daily on days 1-28. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.
Patients undergo neuropsychological battery testing at baseline and periodically during study to assess cognitive function (memory, verbal fluency, visual-motor speed, executive function, and motor dexterity), activities of daily living, and quality of life."
"2208",2693,"NCT00387426",488502,0.5,7,14,"2 years",NA,"Sunitinib","37.5 mg orally daily for 6-week cycle"
"2214",2700,"NCT01769508",66601,0.5,6,12,"26 months",NA,"Combined Therapy","Combined Modality Treatment of Radiation therapy, 5-Fluorouracil, Oxaliplatin and Lapatinib followed by Surgery
5-Fluorouracil: 5-FU, 225 mg/m2 IVCI, during XRT.
Oxaliplatin: Oxaliplatin, 85 mg/m2 IV, Days 1, 15, 29.
Lapatinib: Lapatinib, Continuous PO daily dosing during XRT, dose determined during lead in portion
Radiation Therapy: Radiation therapy, 50.4 Gy (1.8 Gy/day or 28 fractions) M-F, Weeks1-6"
"2220",2708,"NCT00482703",452093,0.5,6,12,NA,NA,"Dasatinib 50 mg Twice-daily (BID) Starting Dose","Starting dose of 50 mg BID oral continuous daily dosing of Dasatinib (BMS-354825) for 24 weeks. One dose escalation allowed for nonresponding participants; dose reduction mandated according to the observed toxicity."
"2227",2716,"NCT00951665",279376,0.5,5,10,"Up to 30 days after the last dose of study treatment or study discontinuation/termination, whichever is later (Approximately 4 years)","SAEs and other AEs were collected in the safety population, which was defined as all participants who received at least a single dose of study medication. There was one SAE that lead to death and the preferred term was not captured for it. The same SAE was captured as ‘Death – unknown cause’ in the below SAE table.","Phase Ib Regimen 2","Participants received T-DM1 Q3W + paclitaxel QW + pertuzumab Q3W intravenously."
"2231",2721,"NCT00678288",379767,0.5,5,10,NA,"Acronyms in Adverse Event section: not otherwise specified (NOS), Alanine transaminase (ALT), Aspartate transaminase (AST)","Sorafenib (Nexavar, BAY43-9006)","Sorafenib 400 mg (two 200 mg tablets) twice daily (bid) per os (po), continuously."
"2232",2722,"NCT00555672",424178,0.5,5,10,NA,"The same event may appear as both an adverse event (AE) and a serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.","Sunitinib (37.5 mg) in Combination With Cisplatin and 5-FU","Sunitinib: 37.5 mg oral capsule daily for 2 weeks (Day 1 to 14) followed by 1 week (Day 15 to 21) off treatment. Cisplatin: 80 mg per meter squared (mg/m^2) on Day 1 of each 21-day cycle. 5-Fluorouracil (5-FU): 4000 mg/m^2 continuous infusion for 96 hours starting Day 1 and ending Day 5 of each 21-day cycle."
"2248",2739,"NCT01004003",260203,0.5,4,8,"From first administration of the trial drug and until 28 days after the last administration of nintedanib or sorafenib, up to 1289 days",NA,"Phase I Group 2, 200mg Nintedanib Bid","Oral administration of Nintedanib (BIBF 1120) 200 mg soft gelatine capsules (two capsules of 100mg) twice daily (bid). Phase I: A standard 3+3 dose escalation part to determine the MTD. Group 2 patients had a baseline Child-Pugh score of 7, or AST or ALT >2 to ≤5 times ULN."
"2253",2746,"NCT00467779",457607,0.5,4,8,"AEs were recorded from the Day 1 of treatment period until the 30 plus or minus 4 days after the last treatment (up to approximately 6 years) .",NA,"Stage 1A Cohort 03A - Cobimetinib 100 mg (14/14)","Participants received cobimetinib 100 mg via solution or capsule, once daily for Days 1-14 of each 28-day cycle. Treatment was continued until PD or unacceptable toxicity for up to 1 year at the discretion of investigator and beyond 1 year with the agreement of the sponsor."
"2254",2747,"NCT00462982",459576,0.5,4,8,NA,NA,"Sunitinib","Patients will be treated with 50 mg daily for four out of every six weeks."
"2261",2758,"NCT02231164",15961,0.5,3,6,"From first drug administration until 28 days after last drug administration.",NA,"Placebo","Placebo soft gelatin capsule matching that of nintedanib twice daily on Day 2 to 21 of each 21-day treatment course administered orally plus docetaxel 75 mg/m^2 on Day 1 of each 21-day treatment course administered via intravenous infusion. If required the dose of placebo could be reduced to 150 mg twice daily (b.i.d.) or 100 mg b.i.d and one dose reduction was permitted for docetaxel (according to the protocol-defined dose-reduction scheme). No dose increase was allowed after a dose reduction."
"2262",2759,"NCT02231164",15960,0.5,3,6,"From first drug administration until 28 days after last drug administration.",NA,"Nintedanib","Nintedanib 200 mg twice daily (b.i.d.) on Day 2 to 21 of each 21-day treatment course administered orally in the form of a soft gelatin capsule plus docetaxel 75 mg/m^2 on Day 1 of each 21-day treatment course administered via intravenous infusion. If required the dose of nintedanib, could be reduced to 150 mg b.i.d. or 100 mg b.i.d. and one dose reduction was permitted for Docetaxel (according to the protocol-defined dose-reduction scheme). No dose increase was allowed after a dose reduction."
"2264",2761,"NCT02005484",35853,0.5,3,6,"Weekly throughout the study.","All participants who received at least 1 dose of study treatment were included in the safety analysis population.","Trastuzumab Monotherapy","Participants received trastuzumab via IV infusion once weekly at an initial dose of 4 mg/kg at Visit 1, and 2 mg/kg at each subsequent visit for a maximum of 33 visits."
"2268",2769,"NCT01519323",115498,0.5,3,6,"All AEs were reported for approximately 2 years 11 months. Related serious adverse events were required to be reported regardless of the time elapsed from the last study drug administration, even if the study had been closed.","An AE was defined as any untoward medical occurrence in a participant administered the investigational product which does not necessarily have a causal relationship with this treatment.","Vemurafenib","Participants received vemurafenib into two separate cohorts with different starting doses based on greater than or equal to (>=)45 kilogram (kg) and other weighing less than (<)45 kg. The starting dose for participants (>=45 kg) was 720 milligram (mg) of vemurafenib by mouth twice daily (BID) and the next dose level for participants in this cohort was 960 mg by mouth BID. The starting dose level for participants weighing <45 kg was to be 480 mg of vemurafenib by mouth BID, but no participants were enrolled into this cohort."
"2280",2781,"NCT01117623",225243,0.5,3,6,"Adverse events were collected after signing the informed consent of the first participant until the end of study completion for the last patient, therefore for the study over a period of approximately 6 years and 9 months",NA,"Escalation Cohort: Regorafenib (Stivarga, BAY73-4506) 120 mg","Participants in the dose-escalation cohort received a single 120 mg oral CP tablet of regorafenib on Day 1 of Cycle 1 followed by 1 day off treatment. On Day 3, once-daily continuous dosing with 120 mg oral CP tablets was initiated. A cycle was defined as 21 days. For Cycle 2 and subsequent cycles, regorafenib was administered once daily continuously on a 21-day cycle."
"2281",2782,"NCT01099358",230307,0.5,3,6,NA,"All participants who received at least one dose of study drug.","Cetuximab on Cisplatin (B)","Cetuximab on Cisplatin (B)
Cycle 1:
400 mg/m² cetuximab admin I.V on week 1, day 1. 250 mg/m² cetuximab admin I.V on week 2 and 3, day 1.
Cycle 2:
100 mg/m² cisplatin admin I.V on week 1, day 1. 5- FU admin as a 96-hour C.I. of 1000 mg/m²/d admin starting on week 1, day 1- 4.
250 mg/m² cetuximab admin I.V on week 1-3, day 1.
Cycle 3 + :
100 mg/m² cisplatin admin I.V on week 1, day 1. 5- FU admin as a 96-hour C.I. of 1000 mg/m²/d admin starting on week 1, day 1-4.
250 mg/m² cetuximab admin I.V on week 1-3, day 1.
After 6 cycles, participants may then receive weekly cetuximab monotherapy until progression of disease, unacceptable toxicity, or another withdrawal criterion is met.
Due to protocol amendment in September 2011, any newly enrolled participants were placed into cetuximab and cisplatin (C) arm only. After protocol amendment February 2014, any newly enrolled participants will be placed into cetuximab and cisplatin (D) arm only."
"2285",2787,"NCT01004003",260209,0.5,3,6,"From first administration of the trial drug and until 28 days after the last administration of nintedanib or sorafenib, up to 1289 days",NA,"Phase 1 Group 1, 100mg Nintedanib Bid","Oral administration of Nintedanib (BIBF 1120) 100 mg soft gelatine capsules twice daily (bid). Phase I: A standard 3+3 dose escalation part to determine the maximal tolerated dose (MTD). Group 1 patients had a baseline Child-Pugh score of 5 or 6, and AST (aspartate aminotransferase ) and ALT (alanine transaminase) ≤2 times the upper limit of normal (ULN)."
"2302",2809,"NCT00658658",387550,0.5,3,6,"From first dose date to end of study date. The median duration of study is 47 days.","Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Summary of Adverse Events includes only those participants who received at least one dose of investigational product.","Age 1-11: 2.5 mg/kg QW","Participants aged 1 to 11 years received panitumumab 2.5 mg/kg administered by IV infusion QW until the participant experienced disease progression, was unable to tolerate study drug, withdrew consent, or other reasons that warranted removal from the study."
"2314",2825,"NCT00492752",448509,0.5,3,6,"Reporting Group (RG) 1 + 2: Data from start of treatment until end of this trial (July 27, 2009); RG 3: Data after unblinding (August 19, 2007) until end of this trial (July 27, 2009).","Acronyms in Adverse Event section: Gastrointestinal (GI), Common Terminology Criteria for Adverse Events (CTCAE), not otherwise specified (NOS), absolute neutrophil count (ANC), Central nervous system (CNS), Partial thromboplastin time (PTT), Alanine transaminase (ALT), Aspartate transaminase (AST), Gamma glutamyl transpeptidase (GGT).","Placebo, Open Label Only (Participants Switched to Sorafenib)","Reporting Group 3 (RG 3): Participants switched to Open-label Sorafenib treatment from Placebo ( Data after unblinding [August 19, 2007] until end of this trial [July 27, 2009]). Sorafenib administered orally at a dose of 400 mg (2 x 200 mg tablets) twice daily (bid); 2 dose reductions to predefined levels of 400 mg (2 x 200 mg tablets) once daily and 400 mg (2 x 200 mg tablets) every 2 days were permitted for treatment-emergent adverse events related to study treatment."
"2315",2826,"NCT00486954",451027,0.5,3,6,"Serious adverse events (SAEs) and non-serious AEs were collected from the first dose of investigational product to 30 days after the last dose (up to 51.7 weeks in the Pilot part and up to 110.3 weeks in the Randomized part).","SAEs and non-serious AEs were collected in members of the Safety Population in both the Pilot part and the Randomized part . For the Pilot part, MedDRA 12.1 was used; for the Randomized part, MedDRa 15.1 was used.","Lapatinib Plus Paclitaxel in Non-gastrectomy Participants","In the Pilot part, participants with non-gastrectomy (intact stomach) received 1500 milligrams (mg) of oral lapatinib once daily throughout the study duration (lapatinib was not administered on Day 1 of the first cycle). Participants received a paclitaxel 1-hour intravenous infusion weekly for 3 weeks of a 4-week cycle at 80 mg per square meters (m^2)."
"2316",2827,"NCT00467779",457613,0.5,3,6,"AEs were recorded from the Day 1 of treatment period until the 30 plus or minus 4 days after the last treatment (up to approximately 6 years) .",NA,"Stage 1 Cohort 06 - Cobimetinib 40 mg (21/7)","Participants received cobimetinib 40 mg via solution or capsule, once daily for Days 1-21 of each 28-day cycle. Treatment was continued until PD or unacceptable toxicity for up to 1 year at the discretion of investigator and beyond 1 year with the agreement of the sponsor."
"2317",2828,"NCT00467779",457606,0.5,3,6,"AEs were recorded from the Day 1 of treatment period until the 30 plus or minus 4 days after the last treatment (up to approximately 6 years) .",NA,"Stage 1A Cohort 04A - Cobimetinib 125 mg (14/14)","Participants received cobimetinib 125 mg via solution or capsule, once daily for Days 1-14 of each 28-day cycle. Treatment was continued until PD or unacceptable toxicity for up to 1 year at the discretion of investigator and beyond 1 year with the agreement of the sponsor."
"2319",2833,"NCT00195260",539802,0.5,3,6,NA,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.","MTD lead-in","Bosutinib 500 mg capsule orally once daily continuously in 21-day cycles until disease progression, unacceptable toxicity, or consent withdrawal."
"2328",2844,"NCT01594125",100568,0.5,2,4,"up to 67 days",NA,"Group II: Nintedanib 150mg Bid","Patients with moderate liver dysfunction according to their aspartate amino transferase (AST)/ alanine amino transferase (ALT) values (>2 x to <=5 upper limit of normal (ULN)) and Child-Pugh B (score 7) treated with Nintedanib 150mg twice daily"
"2335",2853,"NCT01260194",179120,0.5,2,4,"22 months",NA,"Trastuzumab","Trastuzumab was administered at a loading dose of 8 mg/kg on Day 1, followed by 6 mg/kg intravenous infusion every 3 weeks plus standard chemotherapy as per Investigator’s discretion or as per institutional practice, until disease progression, early withdrawal due to unmanageable toxicity, or consent withdrawal."
"2336",2854,"NCT01247922",183176,0.5,2,4,"From first dose of study drug to 30 days after last dose of study drug (The mean treatment duration was 170.5 days.)",NA,"Erlotinib","Participants who received erlotinib in a continuous oral dose of 85 mg/m^2 per day until dose modification, interruption or study discontinuation occurred."
"2337",2855,"NCT01179737",205165,0.5,2,4,"Adverse events were collected over the duration of treatment 140 days for cohort 1, 168 days for cohort 2 and up to 1092 days in the extension study","23 participants were enrolled into the study; 8 participants completed cohort 1 and 6 of these participants moved into cohort 1 expansion of which 5 participants completed Cohort 1 expansion. Of the 5 participants, 3 went into an Extension. None of the participants completed treatment as trial was terminated","Cohort 2: Nilotinib","Participants were assigned to receive nilotinib 300 mg during 168 days"
"2344",2862,"NCT01103323",229358,0.5,2,4,"AE was collected up to 30 days after end of study treatment (per protocol) over a period of approximately 3.7 years.","Disseminated Intravascular Coagulation (DIC), International Normalized Ratio (INR), Cardiac Troponin T (cTnT), Gastroihntestina (GI), Not Otherwise Specified (NOS), Aspartate Aminotransferase (AST), Genitourinary (GU), Alanine Aminotransferase (ALT), Acute Respiratory Distress Syndrome (ARDS), Absolute Neutrophil Count (ANC)","Placebo - Regorafenib After Unblinding","Participants in the placebo+BSC group switched to treatment with Regorafenib after unblinding. It is for Regorafenib treatment period only"
"2347",2865,"NCT01004003",260205,0.5,2,4,"From first administration of the trial drug and until 28 days after the last administration of nintedanib or sorafenib, up to 1289 days",NA,"Phase I Group 2, 100mg Nintedanib Bid","Oral administration of Nintedanib (BIBF 1120) 100 mg soft gelatine capsules twice daily (bid). Phase I: A standard 3+3 dose escalation part to determine the MTD. Group 2 patients had a baseline Child-Pugh score of 7, or AST or ALT >2 to ≤5 times ULN."
"2348",2868,"NCT00987935",266796,0.5,2,4,"AEs with an onset during therapy with study treatment or within 28 days after discontinuation of study treatment (up to 1066 days)",NA,"Phase I Group I Nintedanib, 100 mg Bid","Oral administration of Nintedanib (BIBF 1120) 100 mg soft gelatine capsules twice daily (bid) for the Group I patients during Phase I"
"2349",2870,"NCT00975806",271335,0.5,2,4,"Phase 1 Only. From the date of the first study drug dose to within 28 days after the study drug treatment was discontinued.","Median treatment duration with Lenalidomide and Sunitinib was shortest in Cohort A at 41 days (range = 17 to 189 days) and longest in Cohort G = 97 days (range: 60 to 125 days) of lenalidomide treatment and 97.5 days (range = 54 to 125 days) of Sunitinib","Cohort G","Lenalidomide 15 mg QD on Days 1-21 of each 21-day cycle and sunitinib 37.5 mg QD on Days 1-14 of each 21-day cycle"
"2355",2880,"NCT00906698",295314,0.5,2,4,"First administration of trial medication until 28 days after last administration of trial medication.",NA,"Afatinib 20mg With Vinorelbine Per os","Continuous daily dosing of Afatinib 20mg orally and oral vinorelbine 60 mg/m2/week for days 1,8,15 of first cycle, and 80mg/m2 from day 22 first cycle onwards, weekly. Patients will be eligible for repeated treatment courses in the absence of clinical disease progression or undue toxicity ."
"2366",2892,"NCT00658658",387551,0.5,2,4,"From first dose date to end of study date. The median duration of study is 47 days.","Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Summary of Adverse Events includes only those participants who received at least one dose of investigational product.","Age 12-17: 9 mg/kg Q3W","Participants aged 12 to 17 years received panitumumab 9 mg/kg administered by IV infusion every 3 weeks (Q3W) until the participant experienced disease progression, was unable to tolerate study drug, withdrew consent, or other reasons that warranted removal from the study."
"2370",2896,"NCT00599131",408950,0.5,2,4,NA,NA,"Chemotherapy/Radiation/Surgery","Patients will undergo induction chemotherapy with (TPF): Docetaxel (Taxotere) 75 mg/m2 and cisplatin 100 mg/m2 on day 1, and 5-FU 750 mg/m2 days 1-4.
On day 20 patients will receive a single dose of cetuximab (C-225) 400 mg/m2.
Depending upon disease response, patients will undergo salvage laryngectomy followed by radiation therapy and chemotherapy."
"2379",2906,"NCT00467779",457618,0.5,2,4,"AEs were recorded from the Day 1 of treatment period until the 30 plus or minus 4 days after the last treatment (up to approximately 6 years) .",NA,"Stage 1 Cohort 01 – Cobimetinib 0.05 mg/kg (21/7)","Participants received cobimetinib 0.05 mg/kg via solution or capsule, once daily for Days 1-21 of each 28-day cycle. Treatment was continued until PD or unacceptable toxicity for up to 1 year at the discretion of investigator and beyond 1 year with the agreement of the sponsor."
"2390",2920,"NCT00121719",555451,0.5,2,4,"All adverse events (AEs) were collected for up to approximately 4 years.","Treatment-emergent adverse events were defined as AEs that emerged during treatment, having been absent at pre-treatment, or that worsened in severity relative to the pre-treatment state, or occurred within 7 days or 5 times the half-life (whichever was longer) post participant's last treatment. Only treatment-emergent AEs and SAEs were reported.","0.2 mg Lenvatinib","Two 0.1 mg lenvatinib tablets were taken orally, once daily. Lenvatinib was to be taken on an empty stomach shortly after waking. Participants were fasted for 2 hours following administration of lenvatinib and could drink only clear fluids during this time (grapefruit juice was to be avoided). If 1 of 3 participants experienced dose-limiting toxicity (DLT) during Cycle 1 (4 weeks) an additional 3 participants were to be treated at this dose level. If 5 of the 6 participants in the expanded dose level did not experience DLT during the first 4 weeks of therapy, no additional DLT was observed, the next dose level was opened for enrollment. If more than 1 participant experienced DLT during the first 4 weeks of therapy, dose escalation was stopped and the maximum tolerated dose (MTD) was determined. An additional 12 participants were treated at the MTD level."
"2391",2921,"NCT00121719",555450,0.5,2,4,"All adverse events (AEs) were collected for up to approximately 4 years.","Treatment-emergent adverse events were defined as AEs that emerged during treatment, having been absent at pre-treatment, or that worsened in severity relative to the pre-treatment state, or occurred within 7 days or 5 times the half-life (whichever was longer) post participant's last treatment. Only treatment-emergent AEs and SAEs were reported.","0.4 mg Lenvatinib","Four 0.1 mg lenvatinib tablets were taken orally, once daily. Lenvatinib was to be taken on an empty stomach shortly after waking. Participants were fasted for 2 hours following administration of lenvatinib and could drink only clear fluids during this time (grapefruit juice was to be avoided). If 1 of 3 participants experienced DLT during Cycle 1 (4 weeks) an additional 3 participants were to be treated at this dose level. If 5 of the 6 participants in the expanded dose level did not experience DLT during the first 4 weeks of therapy, no additional DLT was observed, the next dose level was opened for enrollment. If more than 1 participant experienced DLT during the first 4 weeks of therapy, dose escalation was stopped and the MTD was determined. An additional 12 participants were treated at the MTD level."
"2409",2940,"NCT01781026",65026,0.5,1,2,"Adverse event dating was collected through the duration of the study (approximately 14 months)",NA,"Vemurafenib Administration","Vemurafenib 960 mg orally, twice a day"
"2411",2942,"NCT01761747",68971,0.5,1,2,NA,"One individual withdrew consent the day after enrolling on study and was not dosed. Therefore only two individuals were evaluable for treatment-related toxicities.","Ponatinib Treatment Arm","Ponatinib taken by mouth daily
ponatinib"
"2420",2952,"NCT01474551",124795,0.5,1,2,NA,NA,"Vemurafenib","This is a single institution phase II trial in stage III or IV melanoma patients with poor ECOG performance status (3 or 4). Patients must have melanoma with a BRAFV600E or BRAFV600K or mutation with measurable disease not curable by surgery.
Vemurafenib: All patients would be treated with vemurafenib given orally at 960 mg twice a day, which was the phase III dose. One cycle is 4 weeks long."
"2424",2956,"NCT01400451",141692,0.5,1,2,"From the first vemurafenib dose in the Lead In Period to the last dose of combination drugs in the Treatment Period + 90 days, up to last patient, last visit, approximately 2 years.","Final safety follow-up was 23 December 2013.","Lead- In Period 720 mg Vemurafenib Alone","These participants were receiving 720 mg vemurafenib in the Lead in Period prior to starting ipilimumab but after the DLTs were identified, ipilimumab was not started. Due to disease stabilization, they continued on 720 mg vemurafenib alone orally twice daily."
"2430",2962,"NCT01312818",163530,0.5,1,2,NA,NA,"Chemotherapy","bortezomib, vorinostat and dexamethasone combination, as well as intrathecal methotrexate and imatinib mesylate.
Bortezomib: 1.3 mg/m^2 by intravenous pyelogram (IVP) over 3-5 seconds on days 1, 4, 8 and 11.
Vorinostat: 180 mg/m^2 (max dose 400mg) by mouth (PO) divided twice a day (BID) on days 1-14
Dexamethasone: 6 mg/m^2 by mouth (PO) divided twice a day (BID) on days 4-15.
Methotrexate: Intrathecal Methotrexate at age based dose on day 1 (repeat on day 15 or 16 for CNS positive patients only)
Imatinib mesylate: For Ph+ acute lymphoblastic leukemia (ALL) patients only:
Imatinib Mesylate is allowable at 340 mg/m2 PO once a day (rounded to the nearest 100 mg) for age ≤18 years and 400 mg for >18 years on Days 1-16."
"2432",2964,"NCT01281865",172519,0.5,1,2,NA,NA,"Arm 2-Treatment (Everolimus and Imatinib Mesylate)","Cycle=28 days: Everolimus: 10 mg PO QD, STI571 (imatinib, Gleevec): 400 mg PO QD"
"2440",2972,"NCT01063075",242547,0.5,1,2,NA,NA,"Carboplatin and Cetuximab (A)","Group A:
Cycle 1 (3 weeks, combination therapy):
Carboplatin (AUC=5) administered I.V on week 1, day 1. 1000 mg/m ²/d 5-FU administered as a 96-hour C.I. starting on week 1, day 1.
400 mg/m ² cetuximab administered I.V on week 2, day 1. 250 mg/m ² cetuximab administered I.V on week 3, day 1.
Cycle 2 (3 weeks, combination therapy):
Carboplatin (AUC=5) administered I.V on week 1, day 1. 1000 mg/m ²/d 5-FU administered as a 96-hour C.I. starting on week 1, day 1. 250 mg/m ² cetuximab administered I.V on weeks 1- 3, day 1."
"2463",3000,"NCT00573755",417164,0.5,1,2,NA,NA,"Sorafenib Plus Aromatase Inhibitor","Patients receive oral sorafenib tosylate twice daily and oral letrozole, anastrozole, or exemestane once daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity."
"2477",3020,"NCT00095940",563874,0.5,1,2,"Adverse events (AEs) were collected from day 1 of starting treatment until 30 days after ceasing treatment (off study). AEs possibly, probably, or definitely attributed to the study drug that occured after the off study date were also collected.","One participant in the Medulloblastoma: No Surgery group did not receive any lapatinib as the patient experienced clinical progression prior to starting therapy. This patient is excluded from the adverse event reporting.","Medulloblastoma: No Lapatinib Prior to Surgery","Participants with recurrent medulloblastoma who had surgical resection of the tumor at study enrollment and were randomized to not receive lapatinib prior to surgery."
"2478",3021,"NCT00095940",563870,0.5,1,2,"Adverse events (AEs) were collected from day 1 of starting treatment until 30 days after ceasing treatment (off study). AEs possibly, probably, or definitely attributed to the study drug that occured after the off study date were also collected.","One participant in the Medulloblastoma: No Surgery group did not receive any lapatinib as the patient experienced clinical progression prior to starting therapy. This patient is excluded from the adverse event reporting.","Ependymoma: No Lapatnib Prior to Surgery","Participants with recurrent ependymoma who had surgical resection of the tumor at study enrollment and were randomized to not receive lapatinib 7-14 days prior to surgery."
"2507",3057,"NCT00111007",558796,0.492537313,66,134,NA,"Abbreviations used in the Adverse Events section: Absolute Neutrophil Count (ANC), Aspartate Aminotransferase (AST), Central Nervous System (CNS), Common Terminology Criteria for Adverse Events (CTCAE), Gastro-Intestinal (GI), Genito-Urinary (GU), National Cancer Institute (NCI), Not Otherwise Specified (NOS)","Sorafenib (Nexavar, BAY43-9006)","Sorafenib, 400 mg orally, 2 tablets (200 mg each) bid (bis in die [twice daily]) on Study Days 2 to 19 + Paclitaxel (225 mg/m^2 iv [Intravenous]) and Carboplatin (AUC [area under the curve] 6 iv) on Study Day 1 (21 days per cycle) for double-blind (DB) treatment. Subjects who discontinued DB treatment with complete response (CR), partial response (PR) or stable disease (SD) entered active follow up period. Subjects who discontinued DB treatment with disease progression (DP) entered long term follow up period."
"2510",3061,"NCT00117637",556699,0.491803279,30,61,NA,"Acronyms and abbreviations used: Common Terminology Criteria for Adverse Events (CTCAE); Not Otherwise Specified (NOS); Gastrointestinal (GI); Absolute Neutrophil Count (ANC); Alanine aminotransferase (ALT); Aspartate aminotransferase (AST); Central nervous system (CNS); Acute respiratory distress syndrome (ARDS)","Sorafenib 400 mg (After Interferon Therapy)","Interferon (IFN) a-2a was administered at a dose of 9 million international units(MIU) subcutaneously three times a week until progression (= first intervention period, 5.6 months [median]). Subjects initially started with a single dose of 3 MIU IFN and increased the dose as rapidly as possible to 9 MIU IFN three times a week within 1 or 2 weeks in first intervention period. After first progression, subjects received 2 tablets of Sorafenib (200 mg tablets) twice daily (BID) (ie 12-hourly) until the next progression (=second intervention period, 5.3 months [median])."
"2511",3062,"NCT00089648",566867,0.491803279,30,61,NA,NA,"Sunitinib","50 milligram/day for 4 consecutive weeks followed by a 2-week off-treatment period (6-week treatment cycle)."
"2514",3066,"NCT01006980",259152,0.491071429,165,336,"Baseline through the end of study (maximum exposure: 57.07 months)",NA,"Vemurafenib","Adverse events reported for this group include those occurring in participants receiving vemurafenib starting at their baseline visit.
Participants received continuous oral doses of vemurafenib (RO5185426) 960 mg twice a day. Participants took four 240 mg tablets in the morning and four 240 mg tablets in the evening (960 mg twice a day for a total daily dose of 1920 mg)."
"2515",3068,"NCT01238211",185812,0.490909091,27,55,NA,"Only 55 participants were evaluable for adverse events at the time of analysis.","Treatment (Daunorubicin Hydrochloride, Cytarabine, Dasatinib)","CONTINUATION THERAPY: dasatinib PO (100 mg) once daily for 12 months or relapse."
"2528",3082,"NCT00332163",505402,0.489361702,23,47,"The reporting time frame is from first dose date to 30 days since the last dose date. The median time frames for pre-emptive skin treatment and reactive skin treatment are 3.5 months and 4.7 months, respectively.","Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.","Reactive Skin Treatment","Participants received either FOLFIRI and panitumumab 6 mg/kg Q2W or irinotecan and panitumumab 9 mg/kg Q3W. Participants were treated for each individual skin toxicity occurrence according to prespecified guidelines and based on the type and severity. Treatment could include emollient, sunscreen, topical or oral steroids, antibiotics, or antihistamines, as required."
"2541",3098,"NCT00695292",374492,0.486486486,18,37,NA,NA,"Intervention","Patients in the study will receive the following for the duration of the study: irinotecan 60 mg/m2 intravenously on Days 1, 8, and 15 and carboplatin AUC=4 on Day 1. The study will consist of 28-day cycles, to a maximum of 6 cycles of therapy with irinotecan and carboplatin. After treatment with irinotecan and carboplatin, sunitinib will be given alone as maintenance therapy in all patients who have achieved study entry hematologic criteria and who do not have progressive disease or severe toxicity. During sunitinib maintenance therapy, patients will receive sunitinib at 25 mg orally daily. Sunitinib maintenance therapy will continue until progressive disease or irreversible toxicity occurs."
"2543",3102,"NCT01170663",208307,0.486238532,159,327,NA,"One (1) participant was randomized to the placebo group but received ramucirumab in error. This participant was included in the ramucirumab group in the Safety population (as treated).","Ramucirumab and Paclitaxel","8 mg/kg ramucirumab (IMC1121B) was administered by IV infusion on Days 1 and 15 in combination with 80 mg/m² administered by IV infusion on Days 1, 8, and 15 of a 28-day cycle."
"2545",3104,"NCT00509899",443528,0.485714286,17,35,NA,NA,"15 mg Bid","Participants received an initial dose of Ruxolitinib 15 mg twice a day (bid). Participants could continue in the study on their prescribed regimen indefinitely if receiving benefit with dose adjustments for safety and efficacy to a maximum of 25 mg bid."
"2549",3109,"NCT01017731",255838,0.484848485,32,66,NA,NA,"IMC-1121B (Ramucirumab)","Ramucirumab: 10 milligrams/kilogram (mg/kg) infused intravenously, every 3 weeks (Day 1 of every 21-day cycle). Treatment continued for a minimum of 9 weeks without a break in between until there was evidence of disease progression or intolerable toxicity.
Diphenhydramine: For Cycle 1 only, 25 to 50 milligrams (mg) diphenhydramine infused intravenously 1 day before ramucirumab therapy. For Cycles 1, 2, 3, and 4, 25 to 50 mg diphenhydramine infused intravenously 15 minutes before ramucirumab therapy. For Cycle 5 and beyond, premedication with diphenhydramine was at the discretion of the investigator. Each participant was administered the same dose of diphenhydramine at all time points.
Moxifloxacin: The first 16 participants enrolled received a single dose of moxifloxacin (400 mg tablet orally by mouth) 1 week prior to being treated with ramucirumab."
"2552",3114,"NCT00117637",556702,0.484536082,47,97,NA,"Acronyms and abbreviations used: Common Terminology Criteria for Adverse Events (CTCAE); Not Otherwise Specified (NOS); Gastrointestinal (GI); Absolute Neutrophil Count (ANC); Alanine aminotransferase (ALT); Aspartate aminotransferase (AST); Central nervous system (CNS); Acute respiratory distress syndrome (ARDS)","Sorafenib 400 mg in Period 1","Subjects received 2 tablets of Sorafenib (200 mg tablets) twice daily (bid) (ie 12-hourly) orally until progression in (= first intervention period, 5.7 months [median] ) and 3 tablets of Sorafenib twice daily (ie 12-hourly) orally until the following progression (= second intervention period, 3.6 months [median]) on a continuous basis."
"2554",3116,"NCT00424255",474189,0.484240688,169,349,"Serious adverse events (SAEs) and non-serious adverse events (AEs) were collected from the start of study medication until the follow up of treatment (average of 141 study weeks).","SAEs and non-serious AEs were reported for members of the Safety Population, comprised of all participants who were randomized and took at least one dose of study medication. Participants randomized to placebo who received >=1 dose of lapatinib in error were included in the lapatinib arm.","Lapatinib 1500 mg","Participants received lapatinib 1500 mg per oral monotherapy QD for 1 week, followed by radiotherapy of 2 Gy per day for 5 days per week (for a total of 66 Gy for up to 7 weeks). Participants received concurrent cisplatin 100 mg/m^2 IV on Days 1, 22, and 43 of radiotherapy. One week prior to the start of chemoradiotherapy, then concurrently for 6 to approximately 7 weeks with chemoradiotherapy, participants received lapatinib 1500 mg per oral administration QD, followed by maintenance lapatinib 1500 mg per oral monotherapy QD for up to 1 year or until evidence of disease relapse, whichever was sooner."
"2561",3125,"NCT00454805",462364,0.483870968,15,31,NA,NA,"Cediranib 45 mg","Cediranib 45 mg+Fulvestrant 250 mg
Patients randomised to the investigational arm (fulvestrant + cediranib) received treatment according to the following schedule:
Day 1: fulvestrant 500 mg im
Day 15: fulvestrant 250 mg im
Day 29, and every 28 days thereafter: fulvestrant 250 mg im
and daily: cediranib 45 mg (administered orally)"
"2564",3128,"NCT00360360",498035,0.483333333,29,60,NA,NA,"Bevacizumab/Paclitaxel/Carboplatin/Erlotinib","Bevacizumab 15mg/kg IV infusion,Day 1 Paclitaxel 175mg/m2, 1-3 hour IV infusion,Day 1 Carboplatin AUC 6.0 IV Day 1 Erlotinib 150 mg by mouth daily"
"2565",3130,"NCT00460265",460881,0.483076923,157,325,"The day of the first dose of study therapy through 33 days since the last dose date (up to 56 months)","The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.","Panitumumab Plus Chemotherapy",NA
"2568",3136,"NCT00423735",474447,0.482758621,14,29,NA,"Subjects experiencing more than one of a given serious adverse event (SAE) are counted only once for that SAE. The same methodology was applied for non-SAE adverse events (AE).","Stage 1B: Dasatinib up to 400mg/Day","Patients begin with oral 100mg dasatinib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression and unacceptable toxicity. Patients could escalate 50mg/day at each new cycle up to 400mg/day if they had not progressed to date and had not experienced dose-limiting toxicity.
dasatinib: Given orally"
"2572",3140,"NCT01378975",146511,0.482142857,27,56,"From signing of informed consent form up to 28 days after the last dose of study drug (Up to approximately 4 years)","The safety population included all participants who received at least one dose of study medication.","Cohort 2: Previously Treated Participants","Participants who were previously treated with brain SRT, WBRT, or surgery for their brain metastases and have progressed following this treatment, received Vemurafenib 960 milligram (mg) tablet orally, BID from Day 1 until development of progressive disease within the brain or outside of the brain (whichever occurred first), unacceptable toxicity, consent withdrawal, protocol violation endangering participant’s safety, death, reasons deemed by the investigator, or study termination by the Sponsor."
"2590",3165,"NCT01001299",260802,0.48,12,25,"Up to 28 days after the last dose of study drug (median treatment duration: 144 days)",NA,"Vemurafenib","Single oral doses of 5 probe drugs (caffeine 200 mg tablet, warfarin 10 mg tablet [with Vitamin K 10 mg {2*5 mg tablets}], omeprazole 40 mg capsule, dextromethorphan 30 mg syrup, and midazolam 0.075 mg/kg syrup) on Day 1, followed by 5-day washout. Vemurafenib 960 mg (4*240 mg film-coated tablets) orally twice daily on Day 6 to Day 19. Single oral doses of 5 probe drugs co-administered with vemurafenib 960 mg on Day 20, followed by vemurafenib 960 mg orally twice daily up to Day 28 and then vemurafenib 960 mg orally twice daily continuously in 28-day cycles until disease progression, toxicity, withdrawal of consent, loss to follow-up, or death (whichever occurred first)."
"2603",3178,"NCT00193258",539973,0.478723404,45,94,NA,NA,"Bevacizumab/Erlotinib/Imatinib","In the phase I portion: Bevacizumab 10 mg/kg slow IV infusion on days 1 and 15 of each 28-day course Erlotinib 150 mg orally daily Imatinib 300 mg orally daily or 400 mg orally daily In the phase II portion: Bevacizumab 10 mg/kg 30-60 minute IV infusion on days 1 and 15 of every 28 day cycle Erlotinib 150 mg orally daily Imatinib 400 mg orally daily"
"2609",3185,"NCT00101192",562520,0.47826087,33,69,"from study entry up to 5 years","All Adverse Events(AEs) occurring during treatment and up to 30 days after stopping the study treatment are reported. Also reported are Serious Adverse Events(SAEs) considered to be treatment related for up to 5 years after stopping study treatment.","Cetuximab","Cetuximab weekly (Cycle 1, day 1 initial loading dose of 400 mg/m2 IV. All subsequent Cetuximab doses are 250 mg/m2 IV) combined with Cisplatin on day 1 and day 8 (30 mg/m2) (one cycle will be three weeks) until disease progression or adverse effects prohibit further therapy."
"2611",3187,"NCT01222689",190521,0.47826087,22,46,NA,NA,"Treatment (Erlotinib Hydrochloride, Selumetinib)","Patients receive selumetinib PO QD and erlotinib hydrochloride PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
erlotinib hydrochloride: Given PO
selumetinib: Given PO
laboratory biomarker analysis: Correlative studies"
"2612",3188,"NCT00409565",480264,0.47826087,22,46,NA,NA,"Cetuximab Plus Bevacizumab","Cetuximab plus bevacizumab
Cetuximab: • Cetuximab 400 mg/m2 IV over 120 minutes on day 1 of cycle 1 ONLY
• Cetuximab dose will be 250 mg/m2 IV over 60 minutes weekly on ALL subsequent administrations
Bevacizumab: Once every 3 weeks, 15 mg/kg of bevacizumab will be given by IV infusion after cetuximab has been given"
"2615",3191,"NCT00459875",460912,0.47826087,11,23,NA,NA,"Sunitinib","The treatment will include Sunitinib malate 50 mg self-administered orally, once daily in the evening, without regard to meals, for 4 consecutive weeks (28 days) followed by 2 weeks (14 days) off, to comprise a complete cycle of 6 weeks.
sunitinib malate"
"2619",3195,"NCT00471328",456429,0.47761194,32,67,NA,NA,"Crossover Nilotinib Therapy","All patients who crossed over from control arm to nilotinib after completing the Core study or during the Extension study after disease progression were included in safety assessment."
"2621",3197,"NCT00227760",535634,0.477272727,21,44,NA,NA,"Treatment (Cediranib Maleate)","Patients receive cediranib maleate PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Cediranib Maleate: Given PO
Dynamic Contrast-Enhanced Magnetic Resonance Imaging: Correlative studies
Laboratory Biomarker Analysis: Correlative studies
Pharmacological Study: Correlative studies"
"2623",3199,"NCT01137604",217566,0.476190476,20,42,"For each participant, from the first patient first dose till 30 days after the last dose or the cut-off date of 19 March 2013 (ie, 2.4 years)",NA,"Cohort 1 - Lenvatinib","Participants with recurrent Grade 4 malignant glioma (ie, glioblastoma [GBM]) who were bevacizumab-naive; received lenvatinib capsules 24 mg taken orally, once daily continuously in 28-day cycles"
"2630",3206,"NCT00577382",415927,0.476190476,10,21,"AE assessment was ongoing from the start of study drug and up to day 30 post-treatment.","Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3.","Cohort A-Sunitinib Intermittent Dosing","Cohort A participants received 50 mg sunitinib orally daily for 4 weeks followed by a two-week break from treatment. These 6-week cycles would be repeated until progression or unacceptable toxicity up to 1 year."
"2635",3212,"NCT00148109",547408,0.476190476,10,21,NA,NA,"Epidermal Growth Factor Receptor Positive","Sarcoma expresses Epidermal growth factor receptor. Patients received cetuximab 400 mg per meter squared IV followed by 250 mg per meter squared weekly"
"2645",3228,"NCT00917384",291461,0.474576271,112,236,NA,NA,"IMC-1121B (Ramucirumab)","Participants received IMC-1121B (ramucirumab), administered via intravenous infusion every 2 weeks at a dose of 8 milligrams/kilogram (mg/kg), plus best supportive care (BSC) as determined by the investigator(s). Treatment continued until there was evidence of progressive disease (PD), the development of unacceptable toxicity, protocol noncompliance, or withdrawal of consent."
"2655",3239,"NCT00715403",365697,0.473684211,9,19,"From the first intake of trial medication until 28 days after last intake of medication, up to 1119 days",NA,"250mg BID","Patients were treated with 250 mg Nintedanib twice daily."
"2658",3244,"NCT00039377",575472,0.473684211,9,19,NA,NA,"Patients Without HLA-matched Sibling Donors","Patients undergo courses I-IV as in Detailed Description. Beginning 3-10 days after completion of course IV, patients without an HLA-matched sibling donor receive etoposide IV continuously and cytarabine IV over 2 hours on days 1-4. Patients also receive G-CSF SC beginning on day 14 and continuing until PBSC collection is complete. Patients receive imatinib mesylate PO twice daily beginning after completion of PBSC collection and continuing until 3 days before PBSCT. Patients then undergo TBI 2-3 times daily on days -8 to -5. Patients receive etoposide IV over 4 hours on day -4 and cyclophosphamide IV over 2 hours on day -2. Patients undergo PBSCT on day 0. Patients receive G-CSF SC beginning on day 0 and continuing until blood counts recover. Patients then undergo course VI as in Detailed Description."
"2661",3247,"NCT00676650",380201,0.473321859,275,581,NA,"The same event may appear as both an adverse event (AE) and a serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.","Sunitinib and Prednisone","Sunitinib capsules administered orally as a continuous daily dose in a continuous regimen, expressed as 4-week cycles; starting dose of 37.5 milligrams (mg) with option to increase dose to 50 mg at Cycle 3. Prednisone administered continuously at 5 mg orally twice a day (BID) as either a tablet, solution or concentrated solution."
"2676",3266,"NCT00384176",489962,0.471204188,90,191,NA,NA,"Cediranib 30 mg","Cediranib 30 mg/day + FOLFOX
The FOLFOX regimen in this study was a modified FOLFOX6 regimen, repeated every 2 weeks:
Oxaliplatin 85 mg/m2 with leucovorin 400 mg/m2 (or equivalent folinic acid preparation) administered intravenously over 2 hours on Day 1
5-FU 400 mg/m2 bolus immediately after completion of the oxaliplatin infusion on Day 1, followed immediately by 5-FU 2400 mg/m2 administered by a continuous iv infusion over 46 hours."
"2689",3280,"NCT00068380",571186,0.470588235,8,17,NA,"Other adverse events include all grades and all attributions to treatment not included in Serious adverse events table.","Treatment (Imatinib Mesylate)","Patients receive 400 mg oral imatinib mesylate twice daily on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
imatinib mesylate: Given orally
laboratory biomarker analysis: Correlative studies"
"2692",3283,"NCT00195260",539801,0.47,47,100,NA,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.","RP2D 400 mg","Participants with colorectal cancer, pancreatic cancer, NSCLC received RP2D of bosutinib (400 mg) capsule orally once daily continuously in 21-day cycles until disease progression, unacceptable toxicity, or consent withdrawal."
"2697",3290,"NCT01137604",217564,0.46875,15,32,"For each participant, from the first patient first dose till 30 days after the last dose or the cut-off date of 19 March 2013 (ie, 2.4 years)",NA,"Cohort 3 - Lenvatinib","Participants with recurrent GBM who had disease progression following prior bevacizumab treatment; received lenvatinib capsules 24 mg taken orally, once daily continuously in 28-day cycles"
"2729",3328,"NCT00756470",350822,0.466666667,7,15,"Adverse event collection approximately 26 weeks following the start of neoadjuvant chemotherapy. Overall study period: October 2008 to September 2013.",NA,"Neoadjuvant Lapatinib Plus Chemotherapy","Four cycles of Lapatinib and Paclitaxel followed by 4 cycles of Lapatinib plus 5-Fluorouracil, Cyclophosphamide, Epirubicin (FEC75). Cycle is 21 days.
Lapatinib alone at 1,000 mg orally once daily for a 2-week run-in period, followed by initiation of chemotherapy with 2 combination regimens of 4 cycles each.
Week 3 Paclitaxel 80 mg/m^2 weekly for 4 cycles (12 weeks) administered on Day 1, Day 8, and Day 15) of each cycle combined with Lapatinib 750 mg orally once daily.
Week 15, second combination treatment consisting of Lapatinib (1,000 mg orally once daily) combined with FEC75 (5-FU 500 mg/m2, epirubicin 75 mg/m^2, and Cyclophosphamide 500 mg/m^2 every 3 weeks for 4 cycles)."
"2732",3331,"NCT00525525",437360,0.466666667,7,15,"Duration of study treatment (up to 24 months after initial radiation)",NA,"Safety Lead-in Group","A safety lead-in group received bevacizumab and erlotinib added to TMZ after completion of radiation to rule out unexpected toxicity of the combination of drugs."
"2736",3336,"NCT01210495",194649,0.466165414,62,133,"Up to 28 days after last dose of study drug, for up to 3 years","The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.","Axitinib","Participants in this group received axitinib + best supportive care. Participants with Child-Pugh Class A disease (score 5 or 6) were enrolled into the randomized portion at a starting axitinib dose of 5 mg BID orally. Participants with Child-Pugh Class B disease (score 7) were to begin enrollment into the randomized portion of the study following determination of the recommended axitinib starting dose in the non-randomized portion. Study treatment was administered in cycles of 4 weeks in duration."
"2737",3337,"NCT01111461",226769,0.466165414,62,133,"From date of administration of first dose up to 30 days after the last dose, or up to data cut-off (21 May 2012), or up to approximately 26 months.","Treatment-emergent adverse events (TEAEs) and serious TEAEs were collected and reported. Safety analysis set included all participants who received at least one dose of study drug. AEs were graded using Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.","Lenvatinib 24 mg","Lenvatinib 24 mg was administered orally, once daily continuously in 28-day cycles"
"2744",3345,"NCT00932893",286404,0.465116279,80,172,"Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.","All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.","Crizotinib","Crizotinib (PF-02341066) 250 mg (administered as two 100-mg tablets and one 50-mg tablet) orally twice daily continuously in 21-day cycles. Treatment was continued until disease progression, unacceptable toxicity or withdrawal of consent occurred."
"2754",3357,"NCT00600015",408666,0.463855422,77,166,NA,NA,"All Study Participants","Reported SAEs and AEs for all study participants -
Combination Therapy: Erlotinib + Sorafenib Placebo: Erlotinib + Placebo"
"2755",3358,"NCT00828841",321123,0.463829787,109,235,"Adverse events collection began at the time the patient signed the informed consent and continued throughout the study until 30 days after the last dose.","Systematic Assessment - subjects were assessed for adverse events by a member of the research team every 1-2 weeks.","Paclitaxel, Carboplatin, Cetuximab (Arm A)","Patients with squamous or non-squamous histologies will receive carboplatin and paclitaxel for a minimum of four and a maximum of six 21-day cycles, plus cetuximab, and then enter a maintenance phase with single-agent cetuximab. Cetuximab will be given on Day 1, and weekly during chemotherapy, followed by biweekly administration during the maintenance period. The choice of delivering four, five or six cycles of chemotherapy is at the investigator's discretion.
Paclitaxel : Paclitaxel 200 mg/m2 Day 1 every 21 days
Carboplatin : Carboplatin AUC 6 Day 1 every 21 days
Cetuximab : Cetuximab will be administered at a loading dose of 400 mg/m2 on Day 1, Cycle 1 and at a dose of 250 mg/m2 weekly during chemotherapy. During the maintenance period, cetuximab will be dosed at 500 mg/m2 every two weeks."
"2762",3366,"NCT00730925",359943,0.463414634,19,41,"First administration of trial medication until 28 days after last administration of trial medication",NA,"Afatinib 50mg","Afatinib 50mg film coated tablets were administered once daily as long as they were tolerated by patients, until disease progression (according to the response evaluation criteria in solid tumors)"
"2764",3368,"NCT00476476",454284,0.463414634,19,41,"Assessed from time of first dose, weekly during treatment and through 30 days post-treatment.","Serious AEs were defined as treatment-related events of grade 3 or higher per CTCAEv3.
Other AEs were defined as treatment-related events of grades 1 or 2 per CTCAEv3.","Erlotinib","Patients rcvd oral erlotinib 150 mg/day. Cohort 1 pts would have at least 28 days and no more than 42 days of therapy in advance of definitive therapy (surgery or chemoradiation). Cohort 2 pts continued on therapy (28 days per cycle) until disease progression, unacceptable toxicity or withdrawal of consent. Two potential dose reductions were prescribed to 100 and 50 mg/day."
"2775",3384,"NCT00085839",567901,0.461538462,24,52,"While on study drug and 30 days after last dose","Adverse events are provided regardless of causality; safety population includes patients who received at least one dose of study drug.","Erlotinib","Erlotinib 150 mg/day continuous therapy"
"2778",3387,"NCT01325428",160200,0.461538462,12,26,"Part A: From first study drug administration in Part A to last study drug administration in Part A + up to 28 days (max. 728). Part B: From first study drug administration in Part B to last study drug administration in Part B + up to 28 days (max. 265).","The additional 28 days is the residual effect period which was added to the last study drug administration in each part. This may have been truncated in Part A where patients started Vinorelbine prior to the 28 days elapsing.","Part A: Afatinib Once Daily (OD).","Part A: Patients received Afatinib tablets, 40 mg taken orally Once Daily (OD) until progression of their disease. In case of treatment-related AEs, the 40 mg dose could be reduced by increments of 10 mg to 30 mg once daily or 20 mg once daily."
"2782",3391,"NCT00326872",508472,0.461538462,12,26,NA,NA,"Treatment (Cediranib Maleate)","Patients receive 30 mg oral AZD2171 once daily on days 1-28. Treatment repeats every 28 days for 26 courses in the absence of disease progression or unacceptable toxicity. Patients with responding or stable disease may continue treatment beyond 26 courses in the absence of disease progression or unacceptable toxicity."
"2789",3400,"NCT01032070",251187,0.461538462,6,13,"From the date of first dose of study drug until 30 days after the last dose. The median time on treatment was 52 days for erlotinib and 58 days for etoposide.",NA,"Erlotinib","Erlotinib was administered orally at a dose of 85 mg/m^2 per day continuously until either progression, death, patient request or investigator decision to discontinue study drug or intolerable toxicity."
"2791",3402,"NCT00991952",265508,0.461538462,6,13,NA,NA,"Irinotecan Hydrochloride and Alvocidib","Patients receive irinotecan hydrochloride IV over 30 minutes and alvocidib IV over 1 hour on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Irinotecan: 100 mg/m2 IV over 30 min on days 1 and 8 followed 7 hours later by Flavopiridol 60 mg/m2 IV over 1 hr on days 1 and 8"
"2795",3406,"NCT00639002",392757,0.461538462,6,13,"Baseline to end of study","Safety population: All subjects who were enrolled and took at least 1 dose of study medication.","Ruxolitinib","Patients received ruxolitinib 25 mg orally twice daily (bid) in each treatment cycle of 28 days until the following criteria were met: Disease progression at any time or stable disease for 3 cycles and did not meet a withdrawal criterion, or withdrew consent."
"2796",3407,"NCT00597116",409449,0.461538462,6,13,NA,"The enrolled and randomised population was Vandetanib 14 & Vinorelbine 11. However, demographic and baseline characteristics were analyzed for evaluable patients = safety population (Vandetanib 13 & Vinorelbine 10)","Vandetanib","Vandetanib 300 mg/day oral"
"2798",3409,"NCT00437073",469284,0.461538462,6,13,"All serious and non-serious on-therapy adverse events, defined as occurring from the first dose of investigational product until five days after the last dose (up to Week 37) were recorded, regardless of whether or not they were considered drug related.","Serious and non-serious adverse events were collected in members of the ITT Population, comprised of all participants who received at least one dose of study medication.","Lapatinib Plus Capecitabine","Participants received a daily dose of 5 tablets of lapatinib (1250 milligrams [mg]) at approximately the same time every day, either 1 hour (or more) before breakfast or 1 hour (or more) after breakfast. Participants also received capecitabine 2000 mg per meters squared (mg/m^2) per day, divided and administered orally twice daily, 12 hours apart, for 14 days, every 21 days. Capecitabine was taken with food or within 30 minutes after a breakfast meal with approximately 200 milliliters (ml) of water."
"2802",3413,"NCT00987935",266789,0.46031746,29,63,"AEs with an onset during therapy with study treatment or within 28 days after discontinuation of study treatment (up to 1066 days)",NA,"Phase II Nintedanib, 200 mg Bid","Oral administration of Nintedanib (BIBF 1120) 200 mg soft gelatine capsules twice daily (bid) during Phase II"
"2821",3432,"NCT00418938",477017,0.458646617,61,133,"The median reporting period was since randomization date to 65 months.","The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
Summary of Adverse Events includes only those subjects who received at least one dose of investigational product.","Panitumumab Plus FOLFIRI","subjects in this arm receive once-every-2-weeks (Q2W) FOLFIRI regimen plus panitumumab 6 mg/kg"
"2832",3444,"NCT00111761",558768,0.458333333,11,24,"First dose through maximum of safety FU or 30 days after last dose (median 47 weeks follow-up)","The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.","Panitumumab Plus FOLFIRI",NA
"2846",3458,"NCT01529112",113249,0.456521739,21,46,"For each participant, from the first dose till 30 days after the last dose or up to approximately 2 years (data cut-off date of 21 January 2014)","Treatment emergent adverse events (TEAEs), defined as an AE (serious/non-serious) that started/increased in severity on/after the first dose of study medication up to 30 days after the final dose of study medication are presented in this section.","Lenvatinib Matched Placebo","Participants received lenvatinib matched placebo orally, once daily continuously in each 28-day treatment cycle."
"2849",3462,"NCT00429299",472282,0.456521739,21,46,"Serious adverse events (SAEs) and non-serious AEs were collected from the first dose of randomized therapy to 30 days after the last dose of randomized therapy (up to Study Week 29).","SAEs and non-serious AEs were collected for all participants who received at least one dose of study medication.","CT Plus Trastuzumab and Lapatinib 1000 mg","Participants received CT, which included paclitaxel 80 mg/m^2 weekly for 12 weeks, followed by IV fluorouracil 600 mg/m^2, IV epidoxorubicin 75 mg/m^2, and IV cyclophosphamide 600 mg/m^2, once every 21 days for four treatment courses. Trastuzumab was administered throughout the course of the CT and for two weeks after the last CT administration. The first dose of trastuzumab was administered at 4 mg/kg IV for 60 minutes on the day of the first paclitaxel course. Subsequent administrations were given weekly at 2 mg/kg IV for 30 minutes. Participants received lapatinib 1000 mg/day orally on an empty stomach throughout the course of the CT and for three weeks after the last CT administration. Treatments were administered for 26 weeks prior to surgery. Following IDMC recommendations, lapatinib doses were reduced to 750 mg/day orally on an empty stomach."
"2852",3465,"NCT00699374",373215,0.456273764,240,526,NA,"The same event may appear as both an adverse event (AE) and a serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.","Sunitinib","Participants received sunitinib 37.5 milligram (mg) capsules by mouth once daily on a continuous daily dosing schedule. Dose reductions to either 25 mg or 12.5 mg were allowed. Treatment continued until disease progression, death, unacceptable toxicity, withdrawal of participant consent, need for different cancer treatment, or another withdrawal criterion was met."
"2857",3471,"NCT01168973",208767,0.454692557,281,618,"Randomization through 30 days following last infusion (up to Cycle 38, 21 days/cycle)","Safety Population: All randomized participants who received any quantity of study treatment, grouped by the treatment they actually received.","Placebo and Docetaxel","On Day 1 of each 21-day cycle, participants received placebo followed by docetaxel. Treatment continued until disease progression, unacceptable toxicity, or other withdrawal criteria were met.
Placebo (matching Ramucirumab DP): 10 mg/kg administered intravenously.
Docetaxel: 75 mg/m^2 (60 mg/m^2 for the countries of Korea and Taiwan only, with protocol amendment dated 22 May 2012) administered intravenously."
"2864",3481,"NCT00519077",439503,0.454545455,20,44,"Adverse events were recorded during the 9-month observation period (including treatment phase and follow-up).",NA,"Gefitinib","Patients were started on gefitinib 250 mg orally daily for 2 weeks. At 2 weeks, patients were reevaluated and given skin toxicity grade according to the National Cancer Institute Common Toxicity Criteria version 3.0 (CTC 3.0). Patients with grade 2 or greater skin toxicity remained on 250 mg daily; in patients with grade 0-1 skin toxicity the dose 250-mg oral dose-escalating dose; each patient received treatment at the dose that produced grade 2 skin toxicity until disease progression or withdrawal."
"2871",3488,"NCT00978731",270245,0.454545455,10,22,NA,"The SAEs listed here differ from those present in the Outcome Measures. This is because the Outcome Measures present on-treatment SAEs and this section presents all SAEs. In addition, the AEs presented here differ from those in the Outcome Measures. This is because the AEs presented here do not include SAEs.","Participants With Chronic Myelogenous Leukemia(CML);QD Dosing","Participants continued on the last dose and schedule of dasatinib that was received within the previous protocol (CA180002; NCT00064233). A total daily dose (TDD) of 50 mg, 75 mg, 105 mg, 140 mg or 180 mg dasatinib was taken once daily (QD). Participants were dosed on 1 of 3 schedules: 5 days, on 2 days off; 6 days on, 1 day off; or continuous daily dosing. Participants were permitted to escalate or reduce by 1 dose level at a time, switch from QD dosing to twice daily (BID) dosing and vice versa provided they did not exceed a change of 1 dose level from the TDD. The weekly schedule was also permitted to be increased or decreased 1 level at a time."
"2877",3494,"NCT00452387",463432,0.454545455,10,22,"Adverse events were collected beginning on day 1 of study treatment until one month after the end of study treatment.","Systematic Assessment - subjects were assessed for adverse events on day 1 of each cycle by either the research coordiantor, treating physician, or other appropriate sub-investigator.","Treatment Group: Mitoxantrone, Prednisone, Plus Sorafenib","The treatment plan for all subjects was mitoxantrone 12 mg/m2 IV every 21 days; sorafenib 400 mg po bid daily; and prednisone 5 mg po bid daily."
"2880",3498,"NCT01260688",178745,0.454545455,5,11,NA,NA,"Arm I - Cediranib Plus Dasatinib","Patients receive oral cediranib maleate once daily and oral dasatinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity"
"2881",3499,"NCT01174043",207096,0.454545455,5,11,"Up to 2 years",NA,"Erlotinib","Erlotinib: Erlotinib will be administered orally at 150 mg once a day, continuously. Each cycle will be 28 days and there will be no break between the cycles."
"2890",3509,"NCT00360971",497709,0.454545455,5,11,NA,"Subjects experiencing more than one of a given SAE (serious adverse event) are counted only once for that SAE. The same methodology was applied for non-SAE adverse events (AE). Mucositis was collected separately from other AE's using the World Health Organization (WHO) grading criteria.","Palifermin","Concurrent radiation therapy, cisplatin, and palifermin followed by neck dissection for indicated patients."
"2899",3520,"NCT00492752",448510,0.453333333,34,75,"Reporting Group (RG) 1 + 2: Data from start of treatment until end of this trial (July 27, 2009); RG 3: Data after unblinding (August 19, 2007) until end of this trial (July 27, 2009).","Acronyms in Adverse Event section: Gastrointestinal (GI), Common Terminology Criteria for Adverse Events (CTCAE), not otherwise specified (NOS), absolute neutrophil count (ANC), Central nervous system (CNS), Partial thromboplastin time (PTT), Alanine transaminase (ALT), Aspartate transaminase (AST), Gamma glutamyl transpeptidase (GGT).","Placebo, All (Double-Blind and Open Label Phase)","Reporting Group 2 (RG 2): All participants randomized to Sorafenib-matching Placebo (data from start of treatment until end of trial [July 27, 2009]). Treatment for Double-Blind phase (before unblinding [August 19, 2007]): Placebo tablets matching in appearance were orally administered twice daily (bid); Treatment for Open Label phase (after unblinding [August 19, 2007]): Sorafenib administered orally at a dose of 400 mg (2 x 200 mg tablets) twice daily (bid); 2 dose reductions to predefined levels of 400 mg (2 x 200 mg tablets) once daily and 400 mg (2 x 200 mg tablets) every 2 days were permitted for treatment-emergent adverse events related to study treatment."
"2902",3524,"NCT00949910",280731,0.452930459,2983,6586,"Up to approximately 4.5 years; assessed continuously during treatment (up to 3.5 years) and every 6 months thereafter","ITT/Safety Population. As planned only unexpected erlotinib-related adverse events (AEs) and erlotinib-related rash were to be reported, with the exception of serious adverse events (SAEs) and AEs leading to premature withdrawal which were collected regardless of causality.","Erlotinib","Erlotinib was given as a single agent in this EAP to participants with inoperable, locally advanced, recurrent, or metastatic NSCLC. Participants were treated with 150 mg oral erlotinib once daily until unacceptable toxicity, disease progression, or withdrawal for any other reason. The dose could be reduced in the event of toxicity, and some participants therefore received 50 or 100 mg once daily. The study completed after every participant had either died or been followed for 6 months after stopping erlotinib."
"2911",3535,"NCT01004003",260201,0.451612903,14,31,"From first administration of the trial drug and until 28 days after the last administration of nintedanib or sorafenib, up to 1289 days",NA,"Phase II, 400 mg Sorafenib Bid","Oral administration of Sorafenib 400 mg film coated tablets twice daily (bid). Phase II: Patients were randomly assigned to open-label treatment with nintedanib or sorafenib. Patients were stratified for macrovascular invasion (MVI) and/or extra-hepatic spread (EHS). Patients had a baseline Child-Pugh score of 5 or 6, and AST and ALT ≤2 times the upper limit of normal (ULN)."
"2913",3537,"NCT00193219",539979,0.451612903,14,31,NA,NA,"Bevacizumab/Cetuximab/FOLFOX","Bevacizumab 5 mg/kg IV Cetuximab 400 mg/m2 (first cycle only) IV on day 1 and 250 mg/m2 IV on day 8 with all subsequent cycles 250 mg/m2 IV on days 1 and 8 5-Fluorouracil 400 mg/m2 bolus IV bolus followed by 2400 mg/m2 administered as continuous IV infusion over 46 hours via pump (outpatient) Leucovorin 350 mg IV Oxaliplatin 85 mg/m2 IV"
"2918",3542,"NCT01168973",208768,0.451355662,283,627,"Randomization through 30 days following last infusion (up to Cycle 38, 21 days/cycle)","Safety Population: All randomized participants who received any quantity of study treatment, grouped by the treatment they actually received.","Ramucirumab and Docetaxel","On Day 1 of each 21-day cycle, participants received ramucirumab DP followed by docetaxel. Treatment continued until disease progression, unacceptable toxicity, or other withdrawal criteria were met.
Ramucirumab DP: 10 mg/kg administered intravenously.
Docetaxel: 75 mg/m^2 (60 mg/m^2 for the countries of Korea and Taiwan only, with protocol amendment dated 22 May 2012) administered intravenously."
"2930",3555,"NCT01104155",229145,0.45,27,60,"From date of administration of first dose up to 30 days after the last dose, or up to data cutoff (31 May 2013), up to approximately 3.25 years.","Treatment-emergent adverse events (TEAEs) included adverse events that occurred from the first dose of study drug to 30 days after the last dose of study drug, or that were present prior to the first dose of study drug administration but worsened in severity during the study.","Eribulin Mesylate, 28 Day Cycle","eribulin mesylate + erlotinib: 28-day Regimen: Eribulin mesylate given at a dose of 1.4 mg/m2 as a 2-5 min IV bolus on Days 1 and 8, and 150 mg of erlotinib given orally once daily, one hour before or two hours after the ingestion of food, on Days 15-28 of a 28-day cycle."
"2931",3556,"NCT01441596",133350,0.45,18,40,"From first drug administration until 28 days after end of treatment, up to 805 days",NA,"Afatinib Mono","Afatinib monotherapy administered orally: starting dose 40 mg per day, continuous treatment in a 3-weekly course. If well tolerated, the dose may be escalated to 50 mg."
"2939",3564,"NCT01169675",208552,0.45,9,20,"Starting with first administration of trial drug (Afatinib or Pemetrexed) and ending 28 days after the last administration of trial drug.",NA,"Continuous Afatinib 30 mg","Continuous Afatinib 30 mg plus Pemetrexed"
"2949",3579,"NCT00425854",473208,0.448275862,13,29,"First administration of trial medication until 28 days after last administration of trial medication",NA,"Cohort A","Patients with human epidermal growth factor 2- (HER2-) negative, oestrogen receptor- (ER-) negative, progesterone- (PgR-) negative tumours (triple negative tumours) receiving oral dose of Afatinib 50 mg once daily (qd)"
"2951",3584,"NCT00364013",496693,0.447863248,262,585,"The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm.","One participant was randomized to 'Panitumumab Plus FOLFOX’, but received ‘FOLFOX Alone’ so is counted in that group.
The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.","Panitumumab Plus FOLFOX","Participants received panitumumab, 6 mg/kg on Day 1 and FOLFOX chemotherapy regimen on Days 1 and 2 of each 14-day cycle until disease progression or unacceptable toxicity."
"2957",3592,"NCT00509899",443527,0.446808511,21,47,NA,NA,"25 mg Bid","Participants received an initial dose of Ruxolitinib 25 mg twice a day (bid). Participants could continue in the study on their prescribed regimen indefinitely if receiving benefit with dose adjustments for safety and efficacy."
"2965",3604,"NCT00525148",437626,0.444444444,44,99,"First administration of trial medication until 28 days after last administration of trial medication, up to 93 months.",NA,"BIBW 50mg","Subjects receiving starting doses 50 mg of Afatinib daily."
"2966",3606,"NCT01980628",38509,0.444444444,28,63,NA,NA,"Ibrutinib","ibrutinib capsules: 560 mg once daily
ibrutinib"
"2978",3621,"NCT00503750",445222,0.444444444,12,27,NA,NA,"Trastuzumab and Abraxane Followed Trastuzumab and Vinorelbine","Patients will be treated sequentially with preoperative trastuzumab and dose-dense ABI-007 followed by trastuzumab in combination with vinorelbine. Trastuzumab will be administered as a one-time loading dose of 4 mg/kg as a 90 minute infusion, followed by 20 weekly treatments at 2 mg/kg as a 30 minute infusion. ABI-007 will be administered every 2 weeks at a dose of 260mg/m2 as 30 minute infusion on the same days as trastuzumab for a total of 4 cycles (weeks 1 -8). Growth factor support with pegfilgrastim (Neulasta®) is required 24 to 48 hours following completion of each cycle of ABI-007. Beginning week 9, patients will then receive weekly vinorelbine at a dose of 25mg/m2 for 12 weeks on the same day as trastuzumab for a total of 4 cycles (weeks 9-20). As per standard treatment of HER2-positive breast cancers, patients will continue to receive trastuzumab every 3 weeks at 6 mg/kg beginning week 21 through week 52."
"2992",3637,"NCT02507375",3958,0.444444444,4,9,"Timeframe was up to 42 weeks","All participants who received at least 1 dose of both pertuzumab and erlotinib and had at least 1 post-baseline safety follow-up.","Cohort 2","Erlotinib 150 mg + pertuzumab 420 mg"
"3023",3675,"NCT00982488",268978,0.441176471,15,34,NA,NA,"Dasatinib, 50 mg QD to 120 mg BID, Advanced Phase, AP","Participants with advanced phase disease, accelerated phase (AP), were rolled over from previous studies CA180-039, CA180-043, and the SRC/ABL tyrosine kinase inhibition activity: Research trials (START). Participants continued on the previous study dose of dasatinib, ranging from 50 mg QD to 120 mg BID. Dose escalations to optimize response and dose reductions for toxicity were permitted. Participants received study medication until disease progression, unacceptable toxicity, failure to serve patient's best interest, withdrawal of consent, or study closure."
"3027",3679,"NCT00350727",501469,0.441176471,15,34,"Serious adverse events (SAEs) and non-serious AES in Phases I and II were collected from Day 1 of study treatment to study completion (up to 844 days for Phase I; up to 878 days for Phase II).",NA,"Phase I: Pazopanib 200-800 mg/Lapatinib 500-1500 mg","Starting dose of oral pazopanib of 200 milligrams (mg) once daily (OD) and oral lapatinib 1500 mg OD. The dose of pazopanib (200-800 mg) and lapatinib (500-1500 mg) in cohorts enrolled subsequent to the first dose cohort was determined by the toxicity profile of the combination therapy and the pharmacokinetic results from the prior cohort."
"3028",3680,"NCT00113763",557587,0.441048035,101,229,"First dose through maximum of safety FU or 30 days after last dose","The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Safety Analysis set includes all randomized patients, analyzed according to the treatment they actually received. Hence, 2 patients randomized to Panitumumab Plus BSC treatment group are analyzed in the BSC Alone group for safety.","Panitumumab Plus BSC","Panitumumab plus best supportive care (BSC). Panitumumab was administered by intravenous infusion at a dose of 6 mg/kg once every 2 weeks until participants developed progressive disease or were unable to tolerate study drug."
"3032",3686,"NCT00984282",268349,0.44,66,150,"Adverse event data were collected after signing the informed consent until 30 days after end of study treatment over a period of approximately three years.","Abbreviations used: Gastrointestinal (GI), Common Terminology Criteria for Adverse Events (CTCAE), Not Otherwise Specified (NOS), Absolute Neutrophil Count (ANC), Central Nervous System (CNS), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Cranial Nerve (CN), Range of Motion (ROM), Cerebrospinal Fluid (CSF), Genitourinary (GU).","Placebo, Open Label Only (Switch to Sorafenib)","Reporting Group 4: Participants on placebo who switched to sorafenib, received sorafenib 400 mg (2 x 200 mg) orally twice daily, 28 days comprise a cycle. Data were collected from the start of OL period to the data cutoff on 31 Aug 2012"
"3033",3688,"NCT01624467",94979,0.44,33,75,NA,"All participants who received at least 1 dose of study drug.","Necitumumab","800 mg necitumumab, administered once per week as an intravenous infusion (IV)"
"3035",3690,"NCT00326495",508610,0.44,22,50,NA,"Although 51 patients were accrued, only 50 were on study long enough for assessment.","BAY 43-9006 & Cetuximab","BAY 43-9006: Administered orally at a dose of 400 mg twice a day (BID)
BAY 43-9006: is a potent inhibitor of proto-oncogene c-Raf (c-raf), and wild-type and mutant proto-oncogene b-Raf (b-raf) in vitro.
Cetuximab will be given intravenously (IV) at a dose of 400 mg/m^2 initially as a loading dose on week 2, followed by 250 mg/m^2 weekly starting on week 3.
Cetuximab is a recombinant human/mouse chimeric monoclonal antibody which binds specifically to the extracellular domain of the epidermal growth factor receptor (epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 1 (HER1), c-ErbB) in normal and tumor cells, and competitively inhibits the binding of epidermal growth factor (EGF) and other ligands, such as transforming growth factor-alpha."
"3043",3700,"NCT00113516",557690,0.439393939,29,66,NA,"Part 1 = adverse events (AEs) reported occurred during chemotherapy treatment. Part 2 = AEs reported occurred on or after the first dose of sunitinib.","Sunitinib 50 mg (Part 2)",NA
"3044",3701,"NCT00399035",484058,0.439252336,94,214,NA,NA,"Cediranib 30mg","Cediranib 30mg/day + Folfox/Xelox"
"3048",3706,"NCT01152437",213745,0.43902439,18,41,"First administration of trial medication until 28 days after last administration of trial medication",NA,"Afatinib (Mutated)","Afatinib tablets once daily in patients with KRAS mutated metastatic colorectal cancer. Patients started on 40 mg and then increased to 50 mg after 4 weeks if well tolerated."
"3053",3713,"NCT00819780",323930,0.438848921,61,139,"The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm.","The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.","Panitumumab Plus mFOLFOX6","Participants received 6 mg/kg panitumumab administered by intravenous (IV) infusion and mFOLFOX6 chemotherapy regimen on Day 1 of every 14-day cycle."
"3055",3715,"NCT00154102",546240,0.438333333,263,600,"Time from first dose up to 30 days after the last dose of study treatment.","Treatment-emergent adverse events were defined as those with onset occurring at or after the first dosing day of study medication and up to 30 days after the last administration of any study drug or the clinical cut-off date.","Cetuximab Plus FOLFIRI","Cetuximab intravenous infusion of 400mg/m^2 for the first infusion then weekly intravenous infusion of 250mg/m^2. Bi-weekly Irinotecan infusion of 180mg/m^2, Folinic Acid infusion of 400mg/m^2 (racemic) or 200mg/m^2 (L-form), 5-Fluorouracil bolus of 400mg/m^2 followed by a 46-hour continuous infusion of 2400mg/m^2 Number of Cycles: until progression or unacceptable toxicity develops.
Safety population: includes all treated subjects."
"3059",3719,"NCT00795340",334055,0.437908497,67,153,"from the start of treatment to time of 4 weeks after stopped the treatment.",NA,"Cediranib","Patients receive oral cediranib once daily on days 1-21 and paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1."
"3066",3729,"NCT00094861",564989,0.4375,21,48,"From baseline up to Week 12","The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.","Palifermin","Participants received a single IV dose of palifermin at 180 μg/kg administered 3 days before the initiation of concurrent chemo/radiotherapy, then once weekly during Weeks 1 through 6, typically for a total of 7 doses."
"3073",3737,"NCT01107418",227960,0.4375,7,16,"Up to approximately 3 years",NA,"Cohort 4 - Vemurafenib 960 mg","Participants received vemurafenib film-coated tablets, orally, twice daily at a dose of 960 mg on Days 1 to 15 (a single morning dose was administered on Day 15). Starting at Day 22, participants resumed vemurafenib 960 mg film-coated tablets orally twice daily in 21-day cycles until the development of progressive disease, unacceptable toxicity, consent withdrawal, or any other criteria for removal."
"3079",3744,"NCT00397904",484219,0.4375,7,16,NA,NA,"Cetuximab, Cisplatin, and Irinotecan","Cetuximab will be combined with weekly irinotecan and cisplatin. Patients will receive cetuximab 400 mg/m2 on day 1, week 1. Following this loading dose, patients will receive weekly cetuximab 250 mg/m2 (day 8, 15, 22, etc.) until disease progression or unacceptable toxicity. Patients will continue to receive irinotecan and cisplatin weekly on day 1 and day 8, on an every 21 day cycle. The standard maximum doses are irinotecan 65 mg/m2 and cisplatin 30 mg/m2."
"3080",3745,"NCT00245102",532803,0.4375,7,16,NA,NA,"MPNST","Sorafenib 400 mg PO BID"
"3082",3747,"NCT00902174",296747,0.436893204,45,103,NA,"202 participants were randomized (103 imatinib & 99 placebo; however, one participant who was randomized to the placebo group did not receive study drug and was excluded from this analysis set. The safety set includes all participants who received study drug = 201 (103 imatinib, 98 placebo).","Imatinib","imatinib mesylate"
"3087",3753,"NCT00397488",484383,0.435897436,34,78,NA,NA,"Sunitinib","Sunitinib in patients with metastatic urothelial carcinoma."
"3092",3759,"NCT00453362",462792,0.435294118,37,85,"Screening to Day 112 assessment visit or study discontinuation or termination, whichever is earlier. On visits after Day 112, only Serious Adverse Events were recorded. (Up to 1 year)","Includes evaluation of all Safety-Evaluable Patients [n = 85].","Erlotinib","Erlotinib 150 mg/day taken orally at approximately the same time of day with 200 mL (6-8 Ounces) of water on an empty stomach. Participants received Erlotinib for 1 year or until they developed progressive disease or intolerable toxicity.
After 14 days and after 56 days of treatment with Erlotinib, participants underwent FDG-PET and FLT-PET scans. FDG-PET intravenous injection-dosage based on participant's weight not to exceed 15 mCi and FLT-PET intravenous dose of 7 mCi."
"3106",3775,"NCT00077974",569172,0.433962264,46,106,NA,NA,"Sunitinib Malate","50 milligrams per day on Schedule 4/2 (4 weeks daily treatment followed by 2 weeks off treatment in repeated 6-week cycles)"
"3108",3777,"NCT01040832",248244,0.433962264,23,53,"Time from first dose up to Day 42 to 49 after last dose of trial treatment, reported between day of first participant randomized, that is, 17 Dec 2009 until cut-off date, (11 Jan 2012)","An AE is defined as any untoward medical occurrence in the form of signs, symptoms, abnormal laboratory findings, or diseases that emerges or worsens relative to Baseline during a clinical study with an IMP, regardless of causal relationship and even if no IMP has been administered.","Cetuximab Monotherapy","Cetuximab weekly (initial dose 400 mg/m^2 over 120 minutes followed by 250 mg/m^2 intravenous infusion over 60 minutes) was administered in 3-week treatment cycle until disease progression. Participants who had discontinued cetuximab due to toxicity of cetuximab monotherapy, continued to receive EMD 1201081 monotherapy until disease progression or participant elected to withdraw from the trial. The total treatment period was approximately 18 months."
"3115",3784,"NCT00514943",441674,0.433333333,26,60,"1493 days",NA,"Cetuximab 250 mg/m2 / Afatinib 50 mg - Stage 1","Patients were randomized to Cetuximab 250 mg/m2 received 400mg/m2 once in the first week followed by 250 mg/m2 weekly thereafter in Stage 1 and if the patients had disease progression or intolerable AEs were crossed over to Afatinib 50 mg once daily (q.d.) for Stage 2."
"3132",3803,"NCT00698815",373366,0.431818182,19,44,NA,"Adverse events were evaluated for 124 participants (41, 44 and 39 on Arm I, II and III, respectively).","Arm II (Sunitinib)","Patients receive sunitinib malate at 37.5 mg PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients with documented disease progression may then receive pemetrexed disodium as in Arm I as third-line therapy."
"3145",3818,"NCT00777153",341169,0.4296875,55,128,NA,"Adverse events are assessed on all patients who meet the Safety set criteria i.e. all patients who were randomized and received at least one dose of study drug.
Safety Set: Cediranib 30 mg=128, Cediranib 20 mg + Lomustine=123, Placebo + Lomustine=64","Cediranib 30mg","Cediranib 30mg/Day"
"3157",3831,"NCT00499031",446694,0.428571429,15,35,"From study entry until disease progression or study withdrawal. Patients will then be monitored for delayed toxicity for a 5 year period.","From protocol activation through Sept. 30, 2010, Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 (CTCAE v3.0) are utilized for defining and grading specific adverse events reported through the AdEERS system. As of Oct. 1, 2010, CTCAE v 4.0 will be utilized for AE reporting. AEs are reported in ClinicalTrials.gov using CTCAE v3.0.","Treatment (Cetuximab)","Day 1: 400 mg/m2 loading dose of cetuximab IV over 120 minutes; Day 8 and weekly thereafter: 250 mg/m2 cetuximab IV over 60 minutes (one cycle = four weeks) until disease progression or adverse effects prohibit further therapy"
"3158",3832,"NCT00064350",571753,0.428571429,15,35,"Assessed every 4 weeks while on treatment and for 28 days after the end of treatment",NA,"Crossover: Sorafenib","Patients on the placebo arm who develop progressive disease may cross over to receive sorafenib, and 27 patients from the placebo arm received sorafenib in Step 3 (crossover). Due to drug dispensing error, even though some patients actually received straight sorafenib during Step 2 (randomization) treatment, they were thought to be randomized onto the placebo arm upon progression and unblinding (before finding out the fact of the dispensing error). Consequently, these patients were crossed over to Step 3, and there were 10 of them. In total, 37 patients registered to step 3 (crossover). Of these, 35 patients received treatment and were included in the toxicity analysis for the crossover (step 3) part."
"3168",3843,"NCT01121575",223340,0.428571429,6,14,"Up to Maximum of treatment duration + 28 days for each participant (could be 295 days)","The same event may appear as both an AE and a SAE. However, what is presented are distinct events. The below tables included all causality SAEs (frequency threshold 0%) and AEs ( frequency threshold 5%).","PF-02341066, 200 mg BID/ PF-00299804, 30 mg QD","Participants enrolled in dose escalation phase received combined oral crizotinib 200 mg BID and oral dacomitinib 30 mg. The first cycle was for 28 days thereafter, each cycle was 21 days."
"3176",3851,"NCT00095940",563869,0.428571429,6,14,"Adverse events (AEs) were collected from day 1 of starting treatment until 30 days after ceasing treatment (off study). AEs possibly, probably, or definitely attributed to the study drug that occured after the off study date were also collected.","One participant in the Medulloblastoma: No Surgery group did not receive any lapatinib as the patient experienced clinical progression prior to starting therapy. This patient is excluded from the adverse event reporting.","Ependymoma: No Surgery","Participants with recurrent ependymoma who did not have surgical resection of the tumor at study enrollment and were not eligible for the randomization to receive lapatinib or not prior to surgery."
"3178",3854,"NCT01868503",53592,0.428571429,3,7,NA,NA,"Treatment (Lapatinib Ditosylate, Radiation Therapy)","Patients receive lapatinib ditosylate PO QD on day 1 until completion of radiation therapy. Beginning on day 7, patients undergo radiation therapy for 5-7 weeks.
lapatinib ditosylate: Given PO
radiation therapy: Undergo radiation therapy
laboratory biomarker analysis: Correlative studies"
"3183",3859,"NCT01594125",100567,0.428571429,3,7,"up to 67 days",NA,"Group II: Nintedanib 200mg Bid","Patients with moderate liver dysfunction according to their aspartate amino transferase (AST)/ alanine amino transferase (ALT) values (>2 to <=5 x upper limit of normal (ULN)) and Child-Pugh B (score 7) treated with Nintedanib 200mg twice daily"
"3186",3863,"NCT01314105",162900,0.428571429,3,7,"From drug administration until analysis cut off date of 15 April 2014, up to 939 days",NA,"Nintedanib 150mg","Nintedanib (150 mg twice daily (BID), except the day of chemotherapy infusion) administered orally plus standard therapy of Carboplatin (Area Under the Curve (AUC) 5 mg/mL*min) and PLD (30 mg/m2) which were administered by intravenous infusion once every 28 days."
"3188",3865,"NCT01210495",194650,0.428571429,3,7,"Up to 28 days after last dose of study drug, for up to 3 years","The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.","Child-Pugh Class B","Participants with Child-Pugh Class B disease (score 7) at selected sites were initially enrolled only into the non randomized portion of this study to determine the recommended starting dose of axitinib for this population."
"3189",3866,"NCT01169675",208550,0.428571429,3,7,"Starting with first administration of trial drug (Afatinib or Pemetrexed) and ending 28 days after the last administration of trial drug.",NA,"Pulsed Afatinib 50 mg","Pulsed Afatinib 50 mg plus Pemetrexed"
"3196",3874,"NCT00998296",262305,0.428571429,3,7,"First treatment administration until cut-off date of 02Oct2014; up to 336 days",NA,"Pancreatic Adenocarcinoma","Patients with Pancreatic adenocarcinoma were to be treated with the study drug combination at the maximum tolerated dose (MTD) level determined for continuous afatinib and nintedanib dosing during the dose-escalation phase (oral administration of soft-gelatine capsule of Nintedanib 150 mg (b.i.d) plus film-coated tablet of Afatinib 30 mg (q.d)). This is a part of the expansion phase which follows on the dose-escalation phase."
"3199",3878,"NCT00858403",309191,0.428571429,3,7,"1 year, 4 months","From first participant on study date to last participant off study date.","Treatment With Dasatinib",NA
"3208",3888,"NCT00658658",387552,0.428571429,3,7,"From first dose date to end of study date. The median duration of study is 47 days.","Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Summary of Adverse Events includes only those participants who received at least one dose of investigational product.","Age 12-17: 6 mg/kg Q2W","Participants aged 12 to 17 years received panitumumab 6 mg/kg administered by IV infusion every 2 weeks (Q2W) until the participant experienced disease progression, was unable to tolerate study drug, withdrew consent, or other reasons that warranted removal from the study."
"3213",3895,"NCT00467779",457612,0.428571429,3,7,"AEs were recorded from the Day 1 of treatment period until the 30 plus or minus 4 days after the last treatment (up to approximately 6 years) .",NA,"Stage 1 Cohort 07 – Cobimetinib 60 mg (21/7)","Participants received cobimetinib 60 mg via solution or capsule, once daily for Days 1-21 of each 28-day cycle. Treatment was continued until PD or unacceptable toxicity for up to 1 year at the discretion of investigator and beyond 1 year with the agreement of the sponsor."
"3222",3905,"NCT00195260",539806,0.428571429,3,7,NA,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.","Bosutinib 300 mg","Bosutinib 300 mg capsule orally once daily continuously in 21-day cycles until disease progression, unacceptable toxicity, or consent withdrawal."
"3226",3909,"NCT00121719",555438,0.428571429,3,7,"All adverse events (AEs) were collected for up to approximately 4 years.","Treatment-emergent adverse events were defined as AEs that emerged during treatment, having been absent at pre-treatment, or that worsened in severity relative to the pre-treatment state, or occurred within 7 days or 5 times the half-life (whichever was longer) post participant's last treatment. Only treatment-emergent AEs and SAEs were reported.","32 mg Lenvatinib","Three 10 mg lenvatinib tablets and two 1.0 mg lenvatinib tablets were taken orally, once daily. Lenvatinib was to be taken on an empty stomach shortly after waking. Participants were fasted for 2 hours following administration of lenvatinib and could drink only clear fluids during this time (grapefruit juice was to be avoided). If 1 of 3 participants experienced DLT during Cycle 1 (4 weeks) an additional 3 participants were to be treated at this dose level. If 5 of the 6 participants in the expanded dose level did not experience DLT during the first 4 weeks of therapy, no additional DLT was observed, the next dose level was opened for enrollment. If more than 1 participant experienced DLT during the first 4 weeks of therapy, dose escalation was stopped and the MTD was determined. An additional 12 participants were treated at the MTD level."
"3231",3915,"NCT00614393",402949,0.427777778,77,180,"Up to 30 days after last dose of study drug (Up to 33 months)","The APaT population consisted of all randomized participants who received ≥1 dose of study drug. Participants were included in the treatment group corresponding to the study drug they actually received.","Dalotuzumab 15 mg/kg /7.5 mg/kg Q2W (DB)","In DB Week 1, participants received cetuximab 400 mg/m^2 IV + irinotecan IV at their pre-study dosage. In DB Week 2, participants received cetuximab 250 mg/m^2 IV + irinotecan IV + DB dalotuzumab 15 mg/kg IV. In DB Week 3, participants received cetuximab 250 mg/m^2 IV + irinotecan IV. Starting with DB Week 4, participants received cetuximab 250 mg/m^2 IV Q1W + irinotecan IV Q1W + DB dalotuzumab 7.5 mg/kg IV Q2W for up to 32 months of treatment."
"3238",3925,"NCT00753714",352088,0.426229508,26,61,NA,NA,"ZD6474 (Gemcitabine), Vandetanib","Gemcitabine administered intravenously at 1200 mg/m2 over 30 minutes on Days 1 and 8 of each 21-day cycle up to plus Vandetanib 100 mg orally once-daily, from Day 1. . Patients will receive gemcitabine for up to a maximum of 6 cycles, after which period patients should continue on daily oral dosing with vandetanib alone until progression. Once a patient has met the study criteria for disease progression on vandetanib/gemcitabine or placebo/gemcitabine, randomised treatment must be permanently discontinued."
"3240",3927,"NCT00058552",572314,0.426229508,26,61,NA,NA,"Pertuzumab 420 mg","Participants in this group received pertuzumab IV infusion at a loading dose of 840 mg for Cycle 1 (1 Cycle = 3 Weeks), followed by 420 mg for Cycles 2 and beyond, up to 1 year (17 cycles) or until disease progression."
"3241",3929,"NCT00103844",561802,0.425742574,43,101,NA,NA,"DASATINIB","Dasatinib 70 mg twice a day (BID)"
"3245",3935,"NCT00500760",446285,0.425287356,37,87,"The median reporting period was around 82 days in the Panitumumab Plus Chemoradiation arm, and around 80 days in the Chemoradiotherapy Alone arm.","The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.","Panitumumab Plus Chemoradiation","Participants received standard radiation therapy for 7 weeks, cisplatin 75 mg/m^2 and panitumumab 9 mg/kg intravenously on Days 1, 22 and 43."
"3253",3945,"NCT00494481",447812,0.424242424,14,33,NA,NA,"Vandetanib Plus Docetaxel","vandetanib 100 mg plus docetaxel"
"3260",3952,"NCT00389441",488095,0.423076923,22,52,NA,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.","Axitinib","Axitinib (AG-013736) tablet 5 milligram (mg) orally twice daily continuously in 28-day cycles until tumor progression, unmanageable toxicity, or withdrawal of consent occurred. Dose was increased (to 7 mg or 10 mg twice daily) or decreased (to 3 mg or 2 mg twice daily) based on the tolerability."
"3262",3954,"NCT00028002",576133,0.423076923,22,52,"Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event).","Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report on this website. Subjects experiencing more than one of a given SAE are counted only once for that SAE. Subjects experiencing more than one of a given Other (Not Including Serious) AE are counted only once for that Other (Not Including Serious) AE.","Imatinib Mesylate","Patients receive oral imatinib mesylate once daily. Treatment continues for 8 weeks in the absence of disease progression. Patients with disease progression are considered for immediate surgical resection. Otherwise, after 8 weeks, patients undergo surgical resection to debulk all gross tumor. Two to four weeks after surgery, patients receive oral imatinib mesylate once daily for 2 years."
"3280",3975,"NCT00430781",471545,0.421052632,32,76,"SAEs/AEs were assessed in par. receiving >=1 dose of study treatment at time of final PFS analysis (From Randomization [11 December 2006] until last par. had last visit [28 July 2011] in combined population of two monotherapy arms [up to 241.43 weeks])","Serious adverse events (SAEs) and adverse events (AEs) are reported for the Safety Population (all participants who received at least one dose of study drug).","Combination Therapy: Lapatinib 1500 mg and Pazopanib 800 mg","Lapatinib 1500 mg (6 x 250 mg tablets) and pazopanib 800 mg (2 x 400 mg tablets) daily"
"3292",3988,"NCT00704730",370558,0.420560748,90,214,"10 September 2008 - 15 June 2011","The safety data includes subjects who were randomized and treated. Of 330 subjects, 219 were randomized to receive XL184, 111 placebo. Seven subjects were randomized and not treated; there were 214 subjects treated with XL184 and 109 subjects who received placebo.","XL184 (Cabozantinib)","XL184 175 mg L-malate salt weight; 138 mg freebase equivalent weight, oral capsules once daily"
"3295",3991,"NCT00604383",406618,0.420289855,145,345,NA,NA,"Ruboxistaurin","One 32-mg tablet, orally, daily, for up to 42 months"
"3296",3993,"NCT01253070",181636,0.42,21,50,NA,"At the time of analysis, adverse event data was collected on 50 of 54 participants.","Treatment (Daunorubicin, Cytarabine, Sorafenib Tosylate)","INDUCTION THERAPY: Daunorubicin hydrochloride 60 mg/m^2/day by IV push or short IV on days 1-3, cytarabine 100 mg/m^2/day by continuous IV on days 1-7, and sorafenib tosylate 400 mg orally every 12 hours on days 1-7.
CONSOLIDATION THERAPY - Every 28 days for 2 cycles: Cytarabine 2 g/m^2/day by IV on days 1-5 and sorafenib tosylate 400 mg orally every 12 hours on days 1-28.
MAINTENANCE - Every 28 days for up to 12 cycles: Sorafenib tosylate 400 mg orally every 12 hours on days 1-28."
"3300",4000,"NCT01136967",217754,0.419354839,39,93,"For each participant, from the first patient first dose till 30 days after the last dose of study drug, up to approximately 2.9 years.",NA,"Cohort 1 (V600E BRAF Negative)","Cohort 1 (V600E BRAF negative) enrolled participants not harboring the V600E BRAF mutation with disease progression following up to 2 prior systemic anticancer regimens (excluding anti-VEGF) for unresectable Stage III or Stage IV melanoma. Participants received lenvatinib 24 mg orally, once daily continuously in 28-day cycles."
"3302",4002,"NCT01609543",97270,0.419354839,26,62,"Baseline up to 28 days after the last dose of study medication (up to 34 months)",NA,"Erlotinib Hydrochloride","Participants received a single 150 mg oral dose of erlotinib hydrochloride tablet daily from Day 1 until disease progression, death, unacceptable toxicity or consent withdrawal, whichever occurred first up to 34 months."
"3305",4006,"NCT00577382",415926,0.419354839,13,31,"AE assessment was ongoing from the start of study drug and up to day 30 post-treatment.","Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3.","Cohort B-Sunitinib Continuous Dosing","Cohort B participants received 37.5 mg sunitinib daily on a continuous basis until progression or unacceptable toxicity up to 1 year."
"3319",4021,"NCT01015118",256672,0.416851441,376,902,"First drug administration until data cut-off 29Apr2013, up to 41 months","Adverse Events were reported for the treated patients.","Nintedanib","Patients to receive Nintedanib 200 mg, taken twice daily, except the day of chemotherapy (carboplatin and paclitaxel) infusion, every 21 days for six courses."
"3325",4031,"NCT01204697",196221,0.416666667,15,36,"Up to 18 months",NA,"Erlotinib","Participants received erlotinib at a dose of 150 mg/day orally as monotherapy, up to PD, death, or unacceptable toxicity."
"3326",4032,"NCT01152437",213747,0.416666667,15,36,"First administration of trial medication until 28 days after last administration of trial medication",NA,"Afatinib (Wild-type)","Afatinib tablets once daily in patients with KRAS (v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) wild-type metastatic colorectal cancer. Patients started on 40 mg and then increased to 50 mg after 4 weeks if well tolerated."
"3331",4038,"NCT00385203",489622,0.416666667,10,24,NA,"Adverse events are reported for randomised patients who received at least one dose of treatment.","Cediranib 45 mg/Day GIST","Cediranib 45 mg/Day patients with Gastrointestinal Stromal Tumour (GIST): 24 patients randomised and received at least one dose of treatment (1 patient was not randomised or dosed and a further 1 patient was randomised but not dosed due to Incorrect enrolmentCediranib)"
"3342",4051,"NCT00815295",325783,0.416666667,5,12,NA,"The adverse events for this study were collected using Common Terminology Criteria for Adverse Events (CTCAE) version 3.0, and have been converted to CTCAE version 4.0 for entry into ClinicalTrials.gov.","Phase 2","Cetuximab was administered at the standard approved dose: 400 mg/m2 loading dose followed by 250 mg/m2 weekly. Sorafenib was administered orally twice daily at the MTD from Phase I."
"3344",4053,"NCT00684411",377630,0.416666667,5,12,"Toxicity was evaluated on treatment at weeks 1, 2, every 4 weeks from week 4 until week 28 and then every 12 weeks thereafter starting with week 36.","Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3.","Imatinib Mesylate","The initial starting dose of imatinib mesylate was 400 mg by mouth once daily but intra-patient dose escalation for patients who did not achieve complete response (CR) was built in upon restaging at weeks 8 and 16. At week 8, patients with partial response (PR) or stable disease (SD) were dose escalated to 600 mg. At week 16, if these patients continued in PR or SD, dose escalated to 800 mg and for patients on 400 mg dose escalated to 600 mg. Patients who experienced disease progression could be dose escalated per MD discretion. Patients were treated as long as receiving clinical benefit and no unacceptable toxicity."
"3347",4056,"NCT00536809",431682,0.416666667,5,12,"Phases I and II","GSK typically summarizes all AEs and all SAEs. The SAE summary will include participants with only an SAE. The data summarized below under the heading Other AEs (non-serious) are actually a summary of all AEs, which does include some SAEs.","Lap. 1000 mg/Oxaliplatin 130 mg/m^2/Capecitabine 1500 mg/m^2","Lapatinib (Lap.) 1000 milligrams (mg)/day administered orally on Days 1-21, oxaliplatin 130 mg/square meters (m^2) administered intravenously on Day 1, and capecitabine 1500 mg/m^2 administered orally twice a day on Days 1-14 of a 21-day cycle"
"3357",4066,"NCT00245063",532813,0.416666667,5,12,NA,"Other adverse events include all grades and attributions to treatment not included in the Serious table.","Arm A","Patients receive oral AZD2171 45 mg once daily for 28 days. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
cediranib maleate: Given PO"
"3358",4067,"NCT00121719",555445,0.416666667,5,12,"All adverse events (AEs) were collected for up to approximately 4 years.","Treatment-emergent adverse events were defined as AEs that emerged during treatment, having been absent at pre-treatment, or that worsened in severity relative to the pre-treatment state, or occurred within 7 days or 5 times the half-life (whichever was longer) post participant's last treatment. Only treatment-emergent AEs and SAEs were reported.","12 mg Lenvatinib","One 10 mg lenvatinib tablet and two 1.0 mg lenvatinib tablets were taken orally, once daily. Lenvatinib was to be taken on an empty stomach shortly after waking. Participants were fasted for 2 hours following administration of lenvatinib and could drink only clear fluids during this time (grapefruit juice was to be avoided). If 1 of 3 participants experienced DLT during Cycle 1 (4 weeks) an additional 3 participants were to be treated at this dose level. If 5 of the 6 participants in the expanded dose level did not experience DLT during the first 4 weeks of therapy, no additional DLT was observed, the next dose level was opened for enrollment. If more than 1 participant experienced DLT during the first 4 weeks of therapy, dose escalation was stopped and the MTD was determined. An additional 12 participants were treated at the MTD level."
"3363",4074,"NCT01578707",103942,0.415384615,81,195,"From first dose of study drug to within 30 days of last dose.","196 subjects were randomized to the Ofa arm with 191 received drug thus 5 patients were not included in the number of participants at risk.","Ibrutinib (Arm B)","A Bruton Tyrosine Kinase Inhibitor
ibrutinib: ibrutinib 420 mg (3 x 140-mg capsules) will be administered orally once daily until disease progression or unacceptable toxicity"
"3367",4079,"NCT00720941",363770,0.415162455,230,554,"Participants were analyzed from the time of the first dose of study drug to approximately one month after the discontinuation of study drug (up to Study Week 268).","Serious adverse events (SAEs) and non-serious AEs were collected in the Safety Population, comprised of all randomized participants who received at least one dose of study medication, according to the actual treatment received.","Pazopanib 800 mg","Participants were administered pazopanib 800 mg (2 x 400 mg tablets) orally OD continuously. Pazopanib was to be taken at least one hour before or at least two hours after a meal. Participants received study treatment until disease progression, death, unacceptable toxicity, or withdrawal of consent for any other reasons."
"3373",4085,"NCT01506596",118267,0.414634146,17,41,NA,NA,"Pazopanib","Pazopanib 800 mg orally once daily will be started on Cycle 1 Day 1 and will be administered continuously for a 28-day cycle. Study treatment may continue until disease progression or unacceptable toxicity.
pazopanib: Pazopanib 800 mg orally once daily will be started on Cycle 1 Day 1 and will be administered continuously for a 28-day cycle. Study treatment may continue until disease progression or unacceptable toxicity."
"3379",4092,"NCT00871169",305387,0.413793103,24,58,NA,"Study participants were assessed for toxicity at every scheduled study visit through a full clinical exam. Patient-reported toxicities were also collected.","Irinotecan, Oxaliplatin, and Cetuximab","The goal is to administer at least 4 cycles to each patient, but treatment may stop earlier if the treating physician deems stopping to be in the best interest of the patient. Repeated treatment may be given to patients who benefit (either complete or partial response or stabilization of disease)
Irinotecan, oxaliplatin, and cetuximab: Irinotecan at 90 mg/m2 intravenously every two weeks (administered over 60 minutes) + Oxaliplatin at 60 mg/m2 intravenously every two weeks(administered over 60 minutes) + Cetuximab at 250 mg/m2 intravenously every two weeks (administered over 90 minutes).
The treatment interval (one cycle) is every 14 days."
"3382",4095,"NCT00874848",304450,0.413793103,12,29,"Serious adverse events (SAEs) and non-serious AEs were collected from the first dose of investigational product to the discontinuation of study plus 30 days after the last dose of study drug or until the subject began alternative therapy.",NA,"Control Arm","Cetuximab + Paclitaxel/Carboplatin"
"3385",4098,"NCT00272987",525387,0.413793103,12,29,"Serious adverse events (SAEs) and non-serious AEs were collected from the first dose of investigational product to 30 days after the last dose of investigational product (up to Study Week 164).","SAEs and non-serious AEs were collected in members of the Safety Population, comprised of all randomized participants who received at least one dose of investigational product , according to the actual treatment received.","Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg","Participants received an intravenous (IV) infusion of paclitaxel 80 milligrams per meter squared (mg/m^2) over 60 minutes weekly for 3 weeks of a 4-week cycle plus an IV infusion of trastuzumab 4 mg per kilogram (mg/kg) loading dose and 2 mg/kg weekly plus a daily dose of 4 tablets of lapatinib (1000 mg) at approximately the same time every day, either 1 hour (or more) before a meal or 1 hour (or more) after a meal."
"3394",4108,"NCT00753688",352116,0.4125,99,240,"Serious adverse events (SAEs) and non-serious AEs were collected from Baseline through End of Study (average of 20 study weeks).","The Safety Population, comprised of all participants who had started their allocated treatment (at least one dose of the study drug), was used for all safety analyses.","Pazopanib","Pazopanib 200 milligrams (mg) and 400 mg film-coated tablets (containing pazopanib monohydrochloride) administered orally at a dose of 800 mg once daily for a duration until participants experienced disease progression, death, unacceptable toxicity, or participants withdrew consent"
"3395",4109,"NCT01147822",215019,0.412429379,73,177,"Participants were analyzed from the first dose of study medication until the follow-up contact (up to Study Week 156).","Serious adverse events (SAEs) and non-serious AEs were collected in the Safety Population, comprised of all randomized participants who received at least one dose of study medication, according to the actual treatment received.","Sunitinib 50 mg","Participants were administered sunitinib 50 mg capsules orally OD in 6-week cycles (4 weeks of treatment, followed by 2 weeks without treatment). Study treatment continued until participants experienced disease progression, death, or unacceptable toxicity, or withdrew consent for any other reason."
"3401",4118,"NCT00474812",454842,0.411764706,21,51,"Adverse Events that occur during treatment or within 30 Days of the last dose. The time frames for patients was 0-23 months.",NA,"Dasatinib Treatment","Patients receive oral dasatinib twice daily on days 1-28."
"3405",4123,"NCT01606748",97941,0.411764706,7,17,NA,"All participants who received at least one dose of study drug.","Necitumumab Cohort 2","Necitumumab administered on Day 3 of the 3-week PK run-in period as an IV infusion at an absolute dose of 800 mg. Necitumumab administered on Days 1 and 8 of every 3-week cycle as an IV infusion at an absolute dose of 800 mg.
Participants in Cohort 1 received necitumumab Process C drug product and participants in Cohort 2 received necitumumab Process D drug product.
Gemcitabine administered on Day 1 of the 3-week PK run-in period as an IV infusion at a dose of 1250 mg/m2.
Gemcitabine administered on Days 1 and 8 of every 3-week cycle as an IV infusion at a dose of 1250 mg/m2."
"3415",4136,"NCT01378975",146512,0.411111111,37,90,"From signing of informed consent form up to 28 days after the last dose of study drug (Up to approximately 4 years)","The safety population included all participants who received at least one dose of study medication.","Cohort 1: Previously Untreated Participants","Participants who had not received previous treatment for brain metastases [i.e., had never received brain stereotactic radiotherapy (SRT), whole-brain radiotherapy (WBRT), surgery, or any other treatment for their brain metastases] received Vemurafenib 960 milligram (mg) tablet orally, twice daily (BID) from Day 1 until development of progressive disease within the brain or outside of the brain (whichever occurred first), unacceptable toxicity, consent withdrawal, protocol violation endangering participant’s safety, death, reasons deemed by the investigator, or study termination by the Sponsor."
"3418",4139,"NCT01008475",258902,0.410958904,30,73,"From the first dose of study drug administration up to 50 days after the last dose of study drug administration","The safety analysis set included all subjects who received at least 1 dose of the trial medication. 1 subject who was randomized to EMD525797 1000 mg group received only SoC, therefore this subjects was reported under the SOC group.","Standard of Care (SoC)","Cetuximab was administered at a dose of 400 milligram per square meter (mg/m^2) on Day 1 Cycle 1 (Week 1) as intravenous (IV) infusion for 2 hours, and then at a dose of 250 mg/m^2 on Day 8 (Week 2) once weekly followed by irinotecan at a dose of 180 mg/m^2 as IV infusion for 30-90 minutes for every 2 weeks until radiographically documented progressive disease (PD) (as assessed by the investigator), unacceptable toxicity or eligibility for curative resection (investigator’s assessment), or withdrawal of consent."
"3423",4147,"NCT00333840",504892,0.410163339,226,551,NA,NA,"Imatinib (STI571)","In the first-line treatment period participants received imatinib 400 mg orally once daily in the morning. Hydroxyurea was permitted in the first 6 months to keep the white blood cell count (WBC) below 20.0 X 10^9/liter. If protocol specific criteria applied, participants were eligible to crossover to receive interferon-alpha (IFN-a) and cytarabine (ARA-C) in the second-line treatment period. Maximum study duration was 11.5 years."
"3425",4151,"NCT01232296",187312,0.409638554,34,83,NA,NA,"Sorafenib","400 mg tablet p.o. b.i.d."
"3430",4158,"NCT00994123",264510,0.409090909,18,44,"AEs were collected from a patient's first dose until 30 days after treatment termination. SAEs were collected from time of informed consent until 30 days after termination. If related, events could be reported at any time after termination.","All related AEs ongoing at the time of treatment discontinuation were followed until resolution. Investigators were to report any AEs/SAEs assumed to be related any time, even if occurring more than 30 days after last dose. Though different for each patient, on average, patients could be followed for related AEs/SAEs for ~1 year after termination.","Ph 2: Erlotinib","EGFR wild-type, EGFR-TKI naive patients randomized to receive:
daily 150 mg erlotinib p.o. alone"
"3433",4162,"NCT00638378",392885,0.409090909,9,22,NA,NA,"Ruxolitinib","Participants received ruxolitinib 25 mg orally twice daily in 12-hour intervals for 21-day cycles for as long as the study medication was tolerated and provided clinical benefit."
"3435",4165,"NCT00720941",363769,0.408759124,224,548,"Participants were analyzed from the time of the first dose of study drug to approximately one month after the discontinuation of study drug (up to Study Week 268).","Serious adverse events (SAEs) and non-serious AEs were collected in the Safety Population, comprised of all randomized participants who received at least one dose of study medication, according to the actual treatment received.","Sunitinib 50 mg","Participants were administered sunitinib 50 mg orally once daily in 6-week cycles (4 weeks of treatment, followed by 2 weeks without treatment). Participants received study treatment until disease progression, death, unacceptable toxicity, or withdrawal of consent for any other reasons."
"3443",4173,"NCT00399035",484057,0.408,204,500,NA,NA,"Cediranib 20mg","Cediranib 20mg/day + Folfox/Xelox"
"3447",4180,"NCT00095199",564560,0.407534247,119,292,"Randomization to 30 days after study therapy up to 72.8 months for Cetuximab & Pemetrexed (versus just Pemetrexed) and up to 64.3 months for Cetuximab + Docetaxel (versus just Docetaxel)",NA,"Cetuximab & Pemetrexed","Cetuximab 400/250 mg/m^2 (initial/weekly) administered intravenously on Days 1, 8, and 15 (3-week) cycles, until disease progression or unacceptable toxicity. Pemetrexed 500 mg/m^2 administered intravenously on day 1 of 3 weeks cycle until disease progression or unacceptable toxicity for up to six (3-week) cycles."
"3448",4181,"NCT01722487",75366,0.407407407,55,135,"From first dose of study drug to within 30 days of last dose or starting new anti-cancer therapy, whichever occurs earlier, up to 04May2015 ( data cutoff date for final analysis).","269 subjects were randomized on the study of which 2 subjects withdrew without treatment and were not included in the number of participants at risk. Investigators assess the occurrence of AEs and SAEs at all patient evaluation time points during the study.","PCI-32765","Ibrutinib 420 mg daily."
"3451",4184,"NCT00101400",562494,0.407407407,22,54,NA,"Acronyms used: Gastrointestinal (GI), Common Terminology Criteria for Adverse Events (CTCAE), Not Otherwise Specified (NOS), Central nervous system (CNS), Alanine aminotransferase (ALT), Aspartate aminotransferase (AST), Gammaglutamyltransferase (GGT).","Sorafenib (Nexavar, BAY43-9006)","Sorafenib 400 mg administered twice daily (b.i.d.)"
"3454",4188,"NCT00692770",374912,0.406871609,225,553,"From the date of signing informed consent up to 30 days post-treatment discontinuation","In the safety analysis set (SAF), subjects were analyzed as treated but not randomized, therefore, few subjects in the placebo group of the full analysis set were switched to the sorafenib group of the SAF. Hence, SAF for safety analyses comprised of 548 subjects in the placebo group and 559 subjects in the sorafenib group.","Sorafenib (Nexavar, BAY43-9006)","Participants received 2 tablets of Sorafenib (2×200 mg) orally twice daily (BID)"
"3455",4189,"NCT00777153",341167,0.40625,26,64,NA,"Adverse events are assessed on all patients who meet the Safety set criteria i.e. all patients who were randomized and received at least one dose of study drug.
Safety Set: Cediranib 30 mg=128, Cediranib 20 mg + Lomustine=123, Placebo + Lomustine=64","Lomustine 110mg","Lomustine 110mg/m2/Day + Placebo cediranib"
"3457",4191,"NCT00514943",441672,0.40625,13,32,"1493 days",NA,"Cetuximab 250 mg/m2 / Afatinib 50 mg - Stage 2","Patients were randomized to Cetuximab 250 mg/m2 received 400mg/m2 once in the first week followed by 250 mg/m2 weekly thereafter in Stage 1 and if the patients had disease progression or intolerable AEs were crossed over to Afatinib 50 mg once daily (q.d.) for Stage 2."
"3459",4193,"NCT00336856",504286,0.40625,13,32,NA,NA,"IRINOTECAN AND CETUXIMAB","Cetuximab administered at an initial dose of 500 mg/m2 intravenously (IV) over 120 minutes, followed by 500 mg/m2 every 2 weeks IV over 60 minutes.
Irinotecan administered at a dose of 150 or 180 mg/m2 IV over 60 minutes every two weeks."
"3466",4202,"NCT01085136",234024,0.405545927,468,1154,"From the signing of the informed consent to the final follow-up visit.","Part A-events that started within the period defined by the first administration of afatinib until randomization into Part B or 28 days after the last administration of afatinib, whichever occurred first. Part B -events that started within the period from randomization through 28 days after the last administration of trial medication.","Part A: Afatinib Monotherapy","Test product for Part A: Afatinib film-coated tablet dose: 50 mg/day, with dose reductions to 40 mg/day and 30 mg/day (following the protocol-defined dose reduction scheme) mode of admin.: Oral
Median duration of exposure was 86.0 days."
"3468",4206,"NCT00114244",557443,0.405405405,15,37,"Adverse Events occured over a 36 month period.","Other Adverse Events include all events that were not severe adverse events regardless of grade or relation to treatment.","Arm II (Sorafenib Tosylate, Gemcitabine Hydrochloride)","Patients receive 400 mg oral sorafenib as in Arm I and gemcitabine IV over 100 minutes on days 1, 8, and 15.
sorafenib tosylate: Given PO
gemcitabine hydrochloride: Given IV
laboratory biomarker analysis: Correlative studies"
"3471",4210,"NCT00252564",531178,0.404958678,49,121,"during the whole treatment period, up to 30 days following last dose","for treated patients only, assessed at each treatment visit","Arm B","(FOLF-CB): Cetuximab administered over 2 hours (first dose only; administer all other doses over 1 hour) followed by bevacizumab over 30 minutes, followed by LV over 30 minutes, followed by bolus 5-FU followed by infusional 5-FU.
Cetuximab --> bevacizumab --> LV --> bolus 5-FU --> infusional 5-FU"
"3474",4213,"NCT01003899",260227,0.404761905,17,42,"First administration of trial medication until 28 days after last administration of trial medication",NA,"Afatinib 40 mg","Afatinib 40 mg film coated tablets where administered on continuous daily dosing until progression, unacceptable adverse events or other reasons necessitating withdrawal"
"3482",4221,"NCT01136967",217753,0.404494382,36,89,"For each participant, from the first patient first dose till 30 days after the last dose of study drug, up to approximately 2.9 years.",NA,"Cohort 2 (V600E BRAF Positive)","Cohort 2 (V600E BRAF positive) enrolled participants harboring the activating BRAF mutations (mainly the V600E mutation) with disease progression following BRAF V600E-targeted therapy. Participants received lenvatinib 24 mg orally, once daily continuously in 28-day cycles."
"3484",4223,"NCT00544817",429234,0.404255319,19,47,NA,NA,"Combination Therapy","In the combined modality portion of the study, patients were administered:
Radiation Therapy - 2 Gy/fraction, Single daily fractions M-F, to 60 Gy total Temozolomide - 75 mg/m2 by mouth once daily
Patients took a four week break before beginning follow-up systemic therapy:
Temozolomide - 150 mg /m2 by mouth on days 1-5 every 28 days for 6 cycles Sorafenib - 400 mg by mouth twice a day for 6 months"
"3490",4232,"NCT01827254",58766,0.403846154,21,52,NA,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as non-serious in another subject, or one subject may have experienced both a serious and non-serious event during the study.","Metastatic Renal Cell Carcinoma (mRCC) Cohort","Participants diagnosed with mRCC who met the selection criteria and received first-line sunitinib as per standard local practice, followed by one or more lines of different treatments (bevacizumab with interferon, bevacizumab without interferon, sorafenib, axitinib, temsirolimus or everolimus), and, lastly were rechallenged with sunitinib between 2006 and May 2013 were included in this non-interventional study."
"3496",4238,"NCT00428220",472471,0.403587444,90,223,"From first day of treatment on the current study up to 28 days post the last dose of study treatment","The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.","Sunitinib","Participants receiving treatment on single-agent sunitinib on continuous dosing regimens returned for study visits at Day 28, and every 8 weeks thereafter. Participants on regimens other than single-agent sunitinib on continuous dosing followed the schedule of activities from their parent or extension protocol. Sunitinib-naïve participants (ie, those not treated with sunitinib in the previous parent study) received a starting dose of 37.5 mg sunitinib once daily."
"3508",4251,"NCT01085136",234023,0.401515152,53,132,"From the signing of the informed consent to the final follow-up visit.","Part A-events that started within the period defined by the first administration of afatinib until randomization into Part B or 28 days after the last administration of afatinib, whichever occurred first. Part B -events that started within the period from randomization through 28 days after the last administration of trial medication.","Part B: Afatinib Plus Paclitaxel","Test product for Part B: Afatinib film-coated tablet dose: 40 mg/day, with dose reductions to 30 mg/day and 20 mg/day (following the protocol-defined dose reduction scheme) mode of admin.: Oral
Concomitant therapy for Part B:Paclitaxel dose: 80 mg/m2 once weekly (7 weeks on/1 week off; 2 dose reductions were allowed following the protocol-defined dose reduction scheme and the current local summary of product characteristics) mode of admin.: Intravenous
Median duration of exposure was 132.5 days."
"3515",4259,"NCT00410826",479420,0.4,38,95,"Serious adverse events were collected from the first day of study therapy through 30 days following the last day of study therapy.","All grades of rash and pain were recorded. For all other adverse events, only grade 3 and higher events and events that led to a dose reduction or delay were recorded.","Arm B (Cisplatin, Radiotherapy, Erlotinib)","Patients receive cisplatin and radiotherapy as in Arm A. Patients also receive erlotinib hydrochloride PO QD on days -7 to 47."
"3516",4260,"NCT00117637",556701,0.4,36,90,NA,"Acronyms and abbreviations used: Common Terminology Criteria for Adverse Events (CTCAE); Not Otherwise Specified (NOS); Gastrointestinal (GI); Absolute Neutrophil Count (ANC); Alanine aminotransferase (ALT); Aspartate aminotransferase (AST); Central nervous system (CNS); Acute respiratory distress syndrome (ARDS)","Interferon Therapy in Period 1","Interferon (IFN) a-2a was administered at a dose of 9 million international units(MIU) subcutaneously three times a week until progression (= first intervention period, 5.6 months [median]). Subjects initially started with a single dose of 3 MIU IFN and increased the dose as rapidly as possible to 9 MIU IFN three times a week within 1 or 2 weeks in first intervention period. After first progression, subjects received 2 tablets of Sorafenib (200 mg tablets) twice daily (BID) (ie 12-hourly) until the next progression (=second intervention period, 5.3 months [median])."
"3521",4265,"NCT00392704",486940,0.4,24,60,NA,NA,"Intervention","All patients initially received treatment with paclitaxel 200 mg/m2, 3 hour IV infusion days 1 and 22; carboplatin area under the curve (AUC) 6.0 IV, days 1 and 22; 5-fluorouracil (5-FU) 200 mg/m2 daily by 24-hour continuous IV infusion, days 1 to 43; bevacizumab 15 mg/kg IV infusion days 1 and 22.
One to three weeks after completing neoadjuvant therapy, patients began treatment with concurrent chemoradiation, bevacizumab, and erlotinib. Radiation therapy began on day 1, with 1.8-Gy single daily doses, Monday through Friday, to a total dose of 68.4 Gy. Paclitaxel 50 mg/m2 was administered by 1-hour IV infusion on days 1 and 22. Erlotinib 150 mg by mouth daily began concurrently with radiation therapy and continued daily during the 7-week course of radiation."
"3522",4266,"NCT00984282",268350,0.4,22,55,"Adverse event data were collected after signing the informed consent until 30 days after end of study treatment over a period of approximately three years.","Abbreviations used: Gastrointestinal (GI), Common Terminology Criteria for Adverse Events (CTCAE), Not Otherwise Specified (NOS), Absolute Neutrophil Count (ANC), Central Nervous System (CNS), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Cranial Nerve (CN), Range of Motion (ROM), Cerebrospinal Fluid (CSF), Genitourinary (GU).","Sorafenib, Open Label Only (Sorafenib Continued)","Reporting Group 3: Participants on sorafenib who continued OL sorafenib treatment, received sorafenib 400 mg (2 x 200 mg) orally twice daily, 28 days comprise a cycle. Data were collected from the start of OL period to the data cutoff on 31 Aug 2012."
"3524",4268,"NCT00356889",499594,0.4,22,55,NA,NA,"Bevacizumab and Erlotinib Hydrochloride","Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15 and oral erlotinib hydrochloride daily on days 1-28. Courses repeat every 28 days in the absence of unacceptable toxicity or disease progression. Tumor tissue and blood specimens are collected periodically for correlative studies. Specimens are examined by immunohistochemistry for epidermal growth factor receptor (EGFR) and P-EGFR protein levels; AKT p-AKT, mitogen-activated protein kinase (MAPK) and P-MAPK protein levels; and vascular endothelial growth factor receptor (VEGFR)-1 and VEGFR-2 protein levels. EGFR mutations are detected by laser capture microdissection. Enzyme-linked immunosorbent assay is used to measure total and free serum VEGF levels."
"3530",4278,"NCT01133665",219228,0.4,16,40,NA,NA,"Cetuximab and Lenalidomide","Patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) were treated wıth cetuximab (500 mg/m2 IV every 2 weeks) and lenalidomide (25 mg orally or via feeding tube once daily)"
"3534",4282,"NCT01738438",72057,0.4,14,35,"Assessed each cycle throughout treatment from time of first dose and up to day 30 post-treatment. Treatment duration in cycles was a median (range) of 3 (1-17).","Maximum grade toxicity by type for a patient over time including only events with possible, probable or definite attribution was first calculated. Patients appear once for a given toxicity type. Serious and Other AEs were defined as events of grades 3-5 and grades1-2, respectively, based on CTCAEv3. 'Other’ events have no further specification.","Cabozantinib","Cabozantinib was given at a dose of 60 mg orally once per day for 21 day cycles. Treatment continued in the absence of disease progression or unacceptable toxicity."
"3539",4288,"NCT00457743",461507,0.4,12,30,NA,NA,"SU-011248 50-mg","Subjects received sunitinib malate (SU-011248) at starting dose of 50-mg once daily. Treatment cycles were 6 weeks in duration, consisting of 4 weeks daily SU-011248 administration followed by 2 weeks off treatment.
Phase 1: If Dose Limiting Toxicity (DLT) was observed, the patients were withdrawn from the study treatment. Neither temporary discontinuation nor reduction was permitted.
Phase 2: Treatment cycles were repeated until a study treatment withdrawal criterion was met. If drug-related adverse event (grade>=3) was observed, temporary discontinuation or dose reduction were taken according to the criteria.
From Phase 1 part of this study, 50-mg was determined as the maximum tolerated dose and the recommended dose."
"3544",4293,"NCT00113373",557749,0.4,10,25,"All Adverse Events (AEs) occurring during treatment and up to 30 days after stopping the study treatment are reported. Also reported are Serious Adverse Events (SAEs) considered to be treatment related for up to 5 years after stopping study treatment",NA,"Lapatinib","1500 mg of lapatinib orally every day (cycle = 28 days) until disease progression or adverse effects prohibit further therapy"
"3552",4301,"NCT01004159",260155,0.4,8,20,NA,NA,"Cetuximab With Irinotecan","cetuximab with irinotecan: Cetuximab administered 500mg/m2 over 120 minutes Irinotecan administered Q 3 weeks, Q 2 weeks or Q week x 4 every 6 weeks depending on patients previous treatment"
"3553",4302,"NCT00965731",274308,0.4,8,20,"Up to 28 days after the last dose of study treatment (up to approximately 20 months)","The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.","PF-02341066 (150 mg) and Erlotinib (100 mg)","PF-02341066 150 mg administered orally BID in combination with erlotinib 100 mg administered orally QD in a continuous schedule for 28 days (Cycle 1) and then in continuous 21-day cycles. Prior to combination treatment, participants completed a 7 to 14 day lead-in period where they received erlotinib 100 mg administered orally QD."
"3562",4312,"NCT00126568",553895,0.4,8,20,"Adverse events were collected weekly for the duration that the patients started on treatment to end of study.",NA,"BAY 43-9006","BAY 43-9006 (sorafenib) will be administered on a fixed daily oral dosing schedule of 400 mg twice daily. A cycle of therapy will be considered 28 days (4 weeks / 1 month)."
"3571",4322,"NCT01099358",230305,0.4,6,15,NA,"All participants who received at least one dose of study drug.","Cetuximab and Cisplatin (D)","Cetuximab and Cisplatin (D)
Cycle 1 (1 week, combination therapy):
400 milligrams per square meter (mg/m²) cetuximab administered (admin) intravenously (I.V) on week 1, day 1.
100 mg/m² cisplatin administered I.V on week 1, day 1. Optional 5- fluorouracil (FU) administered as a 96-hour continuous infusion (C.I.) of 1000 mg/m²/day (d) administered starting on week 1, day 1.
After 1 cycle, participants may continue treatment as determined by the physician until progression of disease, unacceptable toxicity, or another withdrawal criterion is met.
After protocol amendment February 2014, any newly enrolled participants will be placed into cetuximab and cisplatin (D) arm only."
"3584",4338,"NCT01502410",118568,0.4,4,10,NA,"SAE field contains NCI Common Terminology Criteria for Adverse Events (CTCAEs) submitted via expedited reporting (NCI AdEERs / CAeRs). The AE field contains grade 3 and higher CTCAEs reported on study excluding those that were reported as SAEs. Only Grade 3 and higher Adverse Events were collected/assessed in this study.","Group 1 Relapsed/Refractory Rhabdomyosarcoma","Patients with relapsed or refractory rhabdomyosarcoma receive sorafenib tosylate PO BID on days 1-28. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity."
"3589",4346,"NCT01028222",252249,0.4,4,10,NA,NA,"Crossover Nilotinib Treatment","Crossover nilotinib treatment"
"3597",4354,"NCT00614393",402950,0.4,4,10,"Up to 30 days after last dose of study drug (Up to 33 months)","The APaT population consisted of all randomized participants who received ≥1 dose of study drug. Participants were included in the treatment group corresponding to the study drug they actually received.","Dalotuzumab 10 mg/kg Q1W (OL)","In the OL portion of the study, ≥6 participants received cetuximab 400 mg/m^2 Q1W+ irinotecan Q1W at their pre-study dosage + OL dalotuzumab 10 mg/kg IV Q1W to verify the safety of the regimen. In DB Week 1, participants received cetuximab 400 mg/m^2 IV + irinotecan IV at their pre-study dosage. Starting with DB Week 2, participants received cetuximab 250 mg/m^2 IV Q1W + irinotecan IV Q1W + DB dalotuzumab 10 mg/kg IV Q1W for up to 32 months of treatment."
"3600",4359,"NCT00451048",463684,0.4,4,10,NA,NA,"Arm I","Patients will receive sunitinib by mouth once a day. Treatment may continue for as long as benefit is shown.
sunitinib malate: Given orally"
"3608",4368,"NCT02013765",34610,0.4,2,5,"Adverse events (AEs) and serious adverse events (SAEs) were recorded from study start to 30 days after the last dose of study drug.","All enrolled participants were included in the safety analysis.","Trastuzumab Monotherapy","Participants received an initial dose of trastuzumab 4 mg/kg, IV, on Day 1, followed by weekly doses of 2 mg/kg, IV, beginning on Day 8 until tumor progression, unacceptable toxicity, participant withdrawal, or termination by sponsor."
"3618",4380,"NCT01491633",120886,0.4,2,5,NA,NA,"Dasatinib","Dasatinib 140 mg by mouth each day
Dasatinib: 140 mg orally, daily in 28 day cycles"
"3639",4408,"NCT00864032",307230,0.4,2,5,NA,NA,"Sorafenib 200/400","Dose level 2. Sorafenib 200 mg PO Q AM and 400 mg PO Q PM"
"3643",4413,"NCT00787852",337046,0.4,2,5,"Baseline then approximately 30 days post the last dose of drug, which could be up to 2.5 years.",NA,"Group 1","DAY Radiation 1-5 8-12 15-19 22-26 29-33 36-40 43-47 Paclitaxel 1 8 15 22 29 36 43 Carboplatin 1 8 15 22 29 36 43 Dasatinib ----------------------------------------------------------------------Maintenance Dasatinib RT: External radiotherapy, 64.8 Gy, for 35 fx Paclitaxel: 50 mg/m2/week over 1 hour IV infusion days 1, 8, 15, 22, 29, 36, 43 Carboplatin: AUC = 2 IV infusion days 1, 8, 15, 22, 29, 36, 43 Dasatinib Dose Level With chemoradiation Maintenance x 2 years* Dasatinib is to be taken 1x daily 50 mg daily"
"3645",4415,"NCT00716456",365148,0.4,2,5,NA,NA,"Cetuximab 375 mg/m2","Cetuximab 375 mg/m2 IV every two weeks"
"3654",4425,"NCT00509899",443526,0.4,2,5,NA,NA,"50 mg Bid","Participants received an initial dose of Ruxolitinib 50 mg twice a day (bid). Participants could continue in the study on their prescribed regimen indefinitely if receiving benefit with dose adjustments for safety and efficacy."
"3655",4426,"NCT00474929",454805,0.4,2,5,"The adverse events reported here occurred during treatment. The maximum treatment length was 27, 28-day cycles.","Adverse events were collected at the end of each cycle.","Phase I, Dose Level 2","Phase I: Dose level 2: Sorafenib 400 mg twice daily, RAD001 5mg every day"
"3666",4438,"NCT00121719",555440,0.4,2,5,"All adverse events (AEs) were collected for up to approximately 4 years.","Treatment-emergent adverse events were defined as AEs that emerged during treatment, having been absent at pre-treatment, or that worsened in severity relative to the pre-treatment state, or occurred within 7 days or 5 times the half-life (whichever was longer) post participant's last treatment. Only treatment-emergent AEs and SAEs were reported.","25 mg Lenvatinib Fed/Fasted","Participants from the MTD Cohort who chose to participate in the food-effect pilot study were randomly assigned to this Cohort. Two 10 mg lenvatinib tablets and five 1.0 mg lenvatinib tablets were taken orally, once daily. The Day 15 dose of lenvatinib was taken in a fed state with a high fat meal and the Day 22 dose was taken in a fasted state. All other doses were taken on an empty stomach after waking, followed by fasting for 2 hours with only clear liquids allowed."
"3671",4443,"NCT00064350",571757,0.399399399,133,333,"Assessed every 4 weeks while on treatment and for 28 days after the end of treatment",NA,"Induction: Sorafenib","All patients who received induction treatment (333 patients), regardless of eligibility status, were included in the toxicity analysis."
"3677",4453,"NCT00753714",352087,0.396825397,25,63,NA,NA,"Placebo to Match ZD6474 (Gemcitabine), Vandetanib","Gemcitabine administered intravenously at 1200 mg/m2 over 30 minutes on Days 1 and 8 of each 21-day cycle up to plus Vandetanib 100 mg Matching Placebo orally once-daily, from Day 1. . Patients will receive gemcitabine for up to a maximum of 6 cycles, after which period patients should continue on daily oral dosing with placebo alone until progression. Once a patient has met the study criteria for disease progression on vandetanib/gemcitabine or placebo/gemcitabine, randomised treatment must be permanently discontinued"
"3679",4455,"NCT00494221",447886,0.396551724,23,58,NA,NA,"Cediranib 20 mg","Cediranib 20 mg"
"3694",4472,"NCT00339183",503665,0.395229983,232,587,"The median treatment period was approximately 6.2 months in the Panitumumab plus FOLFIRI arm, and 4.7 months in the FOLFIRI Alone arm.","One participant was randomized to Panitumumab Plus FOLFIRI, but received FOLFIRI Alone and is included in the FOLFIRI Alone group for safety analyses.
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.","Panitumumab Plus FOLFIRI","Participants received 6 mg/kg panitumumab IV plus a standard chemotherapy regimen (FOLFIRI) consisting of 5-FU, leucovorin and irinotecan. Treatment was administered in cycles every two weeks."
"3703",4482,"NCT01223027",190487,0.394366197,112,284,NA,"570 patients randomized, 564 patients included in the Safety Set. AEs were reported based on this set which consisted of all patients who received at least 1 dose of study treatment. Patients were analyzed according to treatment actually received which was defined as the treatment the patient received at the first day of study medication.","Sorafenib","Patients in the sorafenib control arm received 400 mg of sorafenib (2 x 200 mg tablets) taken orally twice daily."
"3709",4488,"NCT00126581",553888,0.393939394,39,99,NA,NA,"Arm B: Erlotinib/Carboplatin/Paclitaxel","Patients receive erlotinib as in arm I. Patients also receive paclitaxel IV over 1-3 hours and carboplatin IV over 15-30 minutes on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. After completion of 6 courses of treatment, patients may continue to receive erlotinib alone as above."
"3714",4493,"NCT00021229",576580,0.393939394,13,33,"Adverse events were assessed weekly during the first four weeks (course 1), every 2 weeks during the next 2 courses (8 weeks total), every 4 weeks for all subsequent courses (up to 13 courses), and through 30 days following the end of treatment.","Assessments were made routinely for all patients per the schedule of clinical and laboratory assessments outlined in the protocol.","Stratum IIA: Imatinib Mesylate","Children with recurrent high-grade gliomas not on enzyme-inducing anticonvulsant drugs (EIACDs) received imatinib twice daily at a starting dose of 350 mg/m2/day. Treatment cycles were 4 weeks (maximum tolerated dose (MTD) estimation period - first 4 weeks) and imatinib was continued for up to 52 weeks in the absence of progression or serious toxicity. Study participants did not receive radiation therapy in this stratum.
Because of concerns of intratumoral hemorrhage, the protocol was amended (08JAN2003) to extend the MTD estimation period to 8 weeks (courses 1 and 2).
Ten participants were enrolled on the phase I before the amendment and 23 after the amendment."
"3717",4497,"NCT00863746",307313,0.393063584,136,346,NA,NA,"Sorafenib (Nexavar, BAY43-9006)","Participants received 2 tablets of Sorafenib (2x200 mg) orally twice daily (BID)"
"3719",4499,"NCT00494221",447885,0.392857143,22,56,NA,NA,"Cediranib 30 mg","Cediranib 30 mg"
"3727",4509,"NCT01523587",114207,0.392097264,129,329,"From randomisation until analysis cut off of 19th December 2013.","For the safety analysis the treated set was used.","Afatinib Once Daily","40 mg once daily for the first 28-day treatment course. Dose escalation to 50 mg once daily was allowed at the beginning of the second 28-day treatment course, if patients met specified safety and compliance criteria. Dose reduction to 40 mg/day (if applicable), 30 mg/day, or 20 mg/day, was required in the presence of known drug-related adverse events."
"3730",4513,"NCT00294762",519096,0.391304348,27,69,"While on study drug and 30 days after last dose","Adverse events are provided regardless of causality; safety population includes patients who received at least one dose of study drug","Erlotinib","150 mg erlotinib daily"
"3740",4529,"NCT01250119",182645,0.390243902,16,41,"Adverse events were recorded from Visit 1 (Baseline) until 30 days after the Final/Withdrawal Visit.",NA,"Erlotinib 150 mg/Day","During the Treatment Phase participants found to have a tumor with EGFR exon 19 deletion or exon 21 (L858R) mutations received erlotinib 150 mg/day as a single oral dose until PD, death, unacceptable toxicity or withdrawal of consent."
"3741",4530,"NCT00319735",511343,0.390243902,16,41,NA,NA,"Single Arm Assignment","Cetuximab 400 mg/m2 IV over 120 minutes Day -14 (Loading Dose) Cetuximab 250 mg/m2 IV over 60 minutes Day -7 Cetuximab 250 mg/m2 IV over 60 minutes Days 1, 8, 15, 22, 29 and 36
Radiation Therapy: External beam radiation therapy, beginning on day 1, 4500 cGy to esophagus with boost of 540 cGy at 180 cGy per fraction for 6 weeks
Surgery: Surgical resection of primary tumor and adjacent mediastinal and/or celiac lymph nodes by a transthoracic approach after satisfactory hematologic and functional recovery within 8 weeks of completion of radiation therapy
Tissue Sample: For patients who give their consent, fresh frozen tissue will be obtained per EUS at baseline, per EUS 2 weeks after the initiation of chemotherapy, and at the time of surgery for pathology submission"
"3742",4531,"NCT00384176",489963,0.390070922,275,705,NA,NA,"Cediranib 20 mg","Cediranib 20 mg/day + FOLFOX
The FOLFOX regimen in this study was a modified FOLFOX6 regimen, repeated every 2 weeks:
Oxaliplatin 85 mg/m2 with leucovorin 400 mg/m2 (or equivalent folinic acid preparation) administered intravenously over 2 hours on Day 1
5-FU 400 mg/m2 bolus immediately after completion of the oxaliplatin infusion on Day 1, followed immediately by 5-FU 2400 mg/m2 administered by a continuous iv infusion over 46 hours."
"3752",4543,"NCT00429299",472284,0.388888889,14,36,"Serious adverse events (SAEs) and non-serious AEs were collected from the first dose of randomized therapy to 30 days after the last dose of randomized therapy (up to Study Week 29).","SAEs and non-serious AEs were collected for all participants who received at least one dose of study medication.","CT Plus Trastuzumab","Participants received chemotherapy (CT), which included paclitaxel 80 milligrams per meters squared (mg/m^2) weekly for 12 weeks, followed by intravenous (IV) fluorouracil 600 mg/m^2, IV epidoxorubicin 75 mg/m^2, and IV cyclophosphamide 600 mg/m^2, once every 21 days for four treatment courses. Trastuzumab was administered throughout the course of the CT and for two weeks after the last CT administration. The first dose of trastuzumab was administered at 4 milligrams per kilogram (mg/kg) IV for 60 minutes on the day of the first paclitaxel course. Subsequent administrations were given weekly at 2 mg/kg IV for 30 minutes. Treatments were administered for 26 weeks prior to surgery."
"3755",4547,"NCT01251653",182103,0.388888889,7,18,"From first drug administration until 28 days after last drug administration, up to 717 days",NA,"Afatinib 30mg and Docetaxel 60mg","Afatinib (film-coated tablet) 30 mg qd (once daily) was administered orally in combination with Docetaxel 60 mg/m2 administered as intravenous infusion on Day 1 of each 3- week treatment course."
"3757",4549,"NCT00998296",262306,0.388888889,7,18,"First treatment administration until cut-off date of 02Oct2014; up to 336 days",NA,"NSCLC","Patients with non-small cell lung cancer (NSCLC) receiving the study drug combination at the maximum tolerated dose (MTD) level determined for continuous afatinib and nintedanib dosing during the dose-escalation phase (oral administration of soft-gelatine capsule of Nintedanib 150 mg (b.i.d.) plus film-coated tablet of Afatinib 30 mg (q.d.)).
This is a part of the expansion phase which follows on the dose-escalation phase."
"3793",4593,"NCT00835978",317870,0.384615385,35,91,"3 years","The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.","Non-randomized Arm","Participants not eligible for randomization were assigned to receive axitinib 5 mg BID or a reduced dose per the dose modification guideline. Dose titration was not permitted in this treatment arm."
"3795",4595,"NCT00226811",535735,0.384615385,30,78,NA,NA,"50 mg Sunitinib","Sunitinib was administered orally daily for 4 weeks followed by a 2-week off-treatment period (Schedule 4 weeks on drug / 2 weeks off) in each cycle. The starting dose was 50 mg daily with provision for dose interruption and/or reduction based on tolerability. All subjects received repeated cycles of sunitinib until disease progression, occurrence of unacceptable toxicity, withdrawal of subject consent, or other withdrawal criteria were met."
"3799",4600,"NCT00785785",338102,0.384615385,15,39,NA,NA,"Crossover Nilotinib","exposure to imatinib and then nilotinib"
"3811",4613,"NCT01871805",53183,0.384615385,5,13,"From baseline to up to 28 days after the last dose of alectinib (up to Week 105; data cut-off date 24 October 2014)",NA,"Alectinib 600 mg (Fed): Phase I","Participants received single dose of 20 or 40 or 150 mg alectinib capsules orally to make a dose of 600 mg on Cycle 1 Day -3 and then received 600 mg BID dose for 3-weekly cycles until disease progression, death or withdrawal for any other reasons."
"3815",4617,"NCT00861913",307986,0.384615385,5,13,NA,NA,"Treatment (Pazopanib Hydrochloride)","Patients receive 800 mg oral pazopanib hydrochloride once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
"3818",4620,"NCT00716456",365147,0.384615385,5,13,NA,NA,"Cetuximab 500 mg/m2","Cetuximab 500 mg/m2 IV every two weeks"
"3820",4623,"NCT00514137",442060,0.384615385,5,13,NA,NA,"Treatment (Kinase Inhibitor Therapy)","Patients receive oral sunitinib malate once daily on days 1-42. Treatment repeats every 42 days for up to 12 courses in the absence of disease progression or unacceptable toxicity."
"3823",4628,"NCT00245063",532812,0.384615385,5,13,NA,"Other adverse events include all grades and attributions to treatment not included in the Serious table.","Arm B","Patients receive oral AZD2171 30 mg once daily for 28 days. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
cediranib maleate: Given PO"
"3833",4642,"NCT00124748",554377,0.382911392,121,316,NA,NA,"Imatinib 800mg","Patients randomized to receive 800 mg imatinib were to receive 400 mg twice daily (b.i.d.) oral administration, in the morning and the evening. All patients received the assigned dose starting on Day 0 (Visit 3). The dose of Imatinib could be interrupted or reduced based on guidelines defined in protocol."
"3839",4648,"NCT00705874",369956,0.382352941,13,34,NA,NA,"PG11047/Erlotinib","PG-11047 (infusion on Days 1, 8 and 15 of a 28 day cycle) in combination with Erlotinib (150 mg taken orally every day of each 28-day cycle)."
"3841",4650,"NCT00459862",460921,0.382352941,13,34,NA,NA,"Arm I","Patients receive oral pazopanib hydrochloride once daily on days 1-21. Treatment repeats every 21 days for 2 years in the absence of disease progression or unacceptable toxicity."
"3864",4677,"NCT00423735",474448,0.380952381,8,21,NA,"Subjects experiencing more than one of a given serious adverse event (SAE) are counted only once for that SAE. The same methodology was applied for non-SAE adverse events (AE).","Stage 1: Dasatinib 200mg/Day","Patients receive oral 100mg dasatinib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression and unacceptable toxicity
dasatinib: Given orally"
"3867",4680,"NCT00284180",522353,0.380952381,8,21,NA,NA,"Vinflunine/Trastuzumab",NA
"3868",4681,"NCT00126503",553923,0.380952381,8,21,NA,NA,"Phase II","Sorafenib will be taken orally once daily at 200 mg beginning on day -14 and continued for 28 days per cycle. There is no planned interruption. Bevacizumab 5mg/kg IV will be administered every 14 days (+/- 3 days) beginning on day 1."
"3880",4697,"NCT01523587",114206,0.379518072,126,332,"From randomisation until analysis cut off of 19th December 2013.","For the safety analysis the treated set was used.","Erlotinib Once Daily","150 mg once daily, with dose reduction to 100 mg/day or 50 mg/day in the presence of known drug-related adverse events."
"3881",4698,"NCT00457392",461640,0.379454927,181,477,NA,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.","Erlotinib","Placebo capsule matched to sunitinib administered orally daily (continuous regimen) in a 4 week cycle. Erlotinib 150 mg tablet orally daily."
"3882",4699,"NCT00798889",332082,0.379421222,118,311,NA,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.","Sunitinib","Sunitinib 50 mg capsule orally once daily in schedule 4/2 (4 weeks on treatment, 2 weeks off treatment) or schedule 2/1 (2 weeks on treatment, 1 week off treatment) or Schedule 2/2 (2 weeks on treatment, 2 weeks off treatment) or continuous dosing, based on investigator’s discretion."
"3888",4705,"NCT00611468",403695,0.379310345,11,29,"Adverse events were collected beginning on day 1 of study treatment until one month after the end of study treatment.","Systematic Assessment - subjects were assessed for adverse events weekly by either the research coordinator, treating physician, or other appropriate sub-investigator.","Treatment Group: Intravenous Topotecan and Oral Erlotinib","All subjects received both topotecan and erlotinib. Subjects were assigned to a Dosage Level at the time of enrollment. Dosage level 1 was topotecan 0.75mg/m2 and erlotinib 150mg. Dosage level 2 was topotecan 1.0mg/m2 and erlotinib 150mg. Dosage level 3 was topotecan 1.25mg/m2 and erlotinib 150mg. Topotecan was administered intravenously on days 1 through 5 of each cycle. Erlotinib was administered orally daily. Cycle length was 21 days."
"3892",4710,"NCT00312377",513558,0.378962536,263,694,NA,NA,"Vandetanib 100 mg Plus Docetaxel","Vandetanib 100 mg plus docetaxel"
"3895",4715,"NCT00430781",471543,0.378378378,28,74,"SAEs/AEs were assessed in par. receiving >=1 dose of study treatment at time of final PFS analysis (From Randomization [11 December 2006] until last par. had last visit [28 July 2011] in combined population of two monotherapy arms [up to 241.43 weeks])","Serious adverse events (SAEs) and adverse events (AEs) are reported for the Safety Population (all participants who received at least one dose of study drug).","Pazopanib Monotherapy","800 mg (2 x 400 mg tablets) of oral pazopanib daily"
"3896",4716,"NCT00057941",572359,0.378378378,28,74,"Assessed each cycle (4 weeks) while on treatment and for 30 days after the end of treatment",NA,"Arm II (Fulvestrant and ZD1839)","Patients receive fulvestrant intramuscularly on day 1 and oral gefitinib once daily on days 1-28."
"3898",4718,"NCT00338884",503839,0.378151261,45,119,NA,"The same event may appear as both an adverse event (AE) and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.","Sunitinib","37.5 mg oral sunitinib malate. Dose could have been reduced to 25 mg daily due to sunitinib related toxicities."
"3905",4727,"NCT00267748",526499,0.377622378,54,143,NA,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.","Sunitinib 37.5 mg","Sunitinib 37.5 mg continuous daily dosing (CDD) self administered orally once daily in the morning."
"3910",4733,"NCT02015676",34277,0.376811594,26,69,"BL, and Weeks 7, 13, 19, every 8 weeks thereafter until end of study.","All participants who received at least 1 dose of study treatment and at least 1 safety follow-up were included in the safety analysis.","Trastuzumab, Doxorubicin, Paclitaxel; Phase I & II","Participants received an initial loading dose of trastuzumab 4 mg/kg, IV, over 1.5 hours on Day 1 (Week 1), followed by 2 mg/kg, IV, over 30 minutes once per week from Week 2 to Week 52 or until disease progression; doxorubicin, 50 mg/m^2, IV, once every 3 weeks, starting at Week 1 for 6 cycles; and paclitaxel 80 mg/m^2, IV, once per week, from Week 19 until disease progression."
"3911",4734,"NCT01427933",136678,0.376811594,26,69,NA,"SAE's and other non-SAE's are treatment emergent.","Ramucirumab and Eribulin","Ramucirumab (IMC-1121B) 10 mg/kg administered by intravenous (IV) infusion on Day 1 of each 3-week cycle
Eribulin 1.4 mg/m² administered by IV bolus on Day 1 and Day 8 of each 3-week cycle"
"3913",4739,"NCT00699374",373214,0.376383764,204,542,NA,"The same event may appear as both an adverse event (AE) and a serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.","Sorafenib","Participants received sorafenib 400 mg tablets by mouth, twice daily (BID). Dose reduction to 400 mg once daily (QD) was allowed. Treatment continued until disease progression, death, unacceptable toxicity, withdrawal of participant consent, need for different cancer treatment, or another withdrawal criterion was met."
"3919",4748,"NCT00103207",561934,0.375,27,72,"Assessed every 4 weeks while on treatment and for 30 days after the end of treatment.",NA,"Cetuximab","All treated patients were evaluated for toxicities."
"3920",4749,"NCT00995007",264299,0.375,21,56,NA,NA,"Vandetanib With Carboplatin","ZD6474 (Vandetanib): Vandetanib is an oral medication known to block angiogenesis and has shown significant antitumor activity in laboratory and animal studies. Vandetanib appears to be well tolerated by patients at specific daily doses.
Carboplatin: Carboplatin is a drug that interrupts division of cancer cells and has been shown to be a useful drug in treatment of tumors known as gliomas. It is a useful drug for treating brain tumors, but researchers are interested in gathering more information about how it works as a treatment for patients who have not responded to initial surgery, radiation, or chemotherapy."
"3924",4755,"NCT01388790",144579,0.375,15,40,"Time from first dose up to 30 days after the last dose of study treatment or clinical cut-off date (14 August 2012) or date of death whichever is earlier.","An Adverse Event (AE) is defined as any untoward medical occurrence in the form of signs, symptoms, abnormal laboratory findings, or diseases that emerges or worsens relative to Baseline during a clinical study with an investigational medicinal product (IMP), regardless of causal relationship and even if no IMP has been administered.","Cetuximab Plus Cisplatin Plus S-1","Cetuximab once weekly (initial dose 400 milligram per square meter [mg/m^2] followed by subsequent 250 mg/m^2 intravenous infusion), cisplatin (60 mg/m^2 intravenous infusion on Day 8 of 5-week cycle maximum up to 8 cycles) and S-1, a combination of tegafur, gimeracil, and oteracil (40 to 60 mg/m^2 orally twice daily for first three consecutive weeks of 5-week cycle) was administered until disease progression, unacceptable toxicity, or withdrawal of consent."
"3929",4762,"NCT00243061",533197,0.375,9,24,NA,NA,"Treatment (Cediranib Maleate)","Patients receive oral AZD2171 once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
cediranib maleate: Given orally
laboratory biomarker analysis: Correlative studies
dynamic contrast-enhanced magnetic resonance imaging: Correlative studies"
"3949",4787,"NCT01325701",160114,0.375,3,8,NA,NA,"PCI-32765: 840 mg","Treatment Group 2: Subjects received 840 mg of ibrutinib once daily, on a continuous basis."
"3950",4788,"NCT01296035",168086,0.375,3,8,NA,NA,"Panitumuab and Gemcitabine","Panitumumab: Panitumumab 2.5 mg/kg on D1, D8, D15, and D22 and Gemcitabine 800 mg/m2 on D1, D8, and D15 of each 28 day cycle."
"3953",4792,"NCT01251653",182107,0.375,3,8,"From first drug administration until 28 days after last drug administration, up to 717 days",NA,"Afatinib 30mg and Gemcitabine 1250mg","Afatinib (film-coated tablet) 30 mg qd (once daily) was administered orally in combination with Gemcitabine 1250 mg/m2 administered as intravenous infusion on Days 1 and 8 of each 3- week treatment course."
"3958",4799,"NCT01117623",225245,0.375,3,8,"Adverse events were collected after signing the informed consent of the first participant until the end of study completion for the last patient, therefore for the study over a period of approximately 6 years and 9 months",NA,"Escalation Cohort: Regorafenib (Stivarga, BAY73-4506) 40 mg","Participants in the dose-escalation cohort received a single 40 mg oral CP tablet of regorafenib on Day 1 of Cycle 1 followed by 1 day off treatment. On Day 3, once-daily continuous dosing with 40 mg oral CP tablets was initiated. A cycle was defined as 21 days. For Cycle 2 and subsequent cycles, regorafenib was administered once daily continuously on a 21-day cycle."
"3966",4807,"NCT00871403",305248,0.375,3,8,NA,"Serious adverse events (SAEs) and non-serious AEs are presented for the entire treatment period (Combination Treatment Phase followed by the Monotherapy Phase). SAEs and AEs were collected in the Safety Population, comprised all participants who had received at least one dose of both drugs within the assigned regimen.","Pazopanib 600 mg Plus Pemetrexed 500 mg/m^2","Oral pazopanib 600 milligrams (mg) once daily plus intravenous pemetrexed 500 mg/meters squared (m^2) once every 3 weeks for 4 or 6 cycles during the Combination Treatment Phase."
"3977",4821,"NCT00417248",477237,0.375,3,8,"Duration of OnStudy time, up to two 28 day cycles.",NA,"Cisplatin/Etoposide/Radiotherapy Followed by Sorafenib","Cisplatin/Etoposide/Radiotherapy followed by Sorafenib in patients with inoperable stage III non-small cell lung cancer
Cisplatin: Cisplatin 50 mg/m2 IV, days 1 and 8 of 28 day cycle
Etoposide: Etoposide 50 mg/m2 IV, days 1-5 of 28 day cycle
Radiotherapy: Concurrent chest radiation (planned dose is 5940 cGy with an additional, optional boost of 1080 cGy to a total allowed dose of 7020 cGy)
Sorafenib: Maintenance therapy of Sorafenib 400 mg PO BID, to begin a minimum of 6 and maximum of 9 weeks from completion of chemo-radiotherapy until PD, intolerable toxicity, or up to 6 months"
"3989",4835,"NCT01597908",99853,0.374285714,131,350,"Serious adverse events (SAEs) and non-serious AEs were collected from the time the first dose of study treatment was administered until 30 days after discontinuation of study treatment (up to Study Week 93).","SAEs and non-serious AEs are reported for the Safety Population, comprised of all participants who were administered at least one dose of investigational treatment.","Dabrafenib Plus Trametinib","Participants received dabrafenib 150 mg orally BID and trametinib 2 mg orally once daily. Treatment continued until disease progression, death, unacceptable toxicity, or withdrawal of consent. Treatment beyond progression was allowed subject to consultation with the GlaxoSmithKline medical monitor."
"4004",4855,"NCT00101582",562279,0.372340426,35,94,"Approximately 8 weeks","The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.","Palifermin","Participants received a single intravenous dose of palifermin at 180 μg/kg three days before the start of radiotherapy, and then 7 once weekly palifermin doses at the same dose level during a 7-week radiotherapy/chemotherapy course."
"4010",4861,"NCT00984282",268352,0.371980676,77,207,"Adverse event data were collected after signing the informed consent until 30 days after end of study treatment over a period of approximately three years.","Abbreviations used: Gastrointestinal (GI), Common Terminology Criteria for Adverse Events (CTCAE), Not Otherwise Specified (NOS), Absolute Neutrophil Count (ANC), Central Nervous System (CNS), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Cranial Nerve (CN), Range of Motion (ROM), Cerebrospinal Fluid (CSF), Genitourinary (GU).","Sorafenib (Double Blind Only)","Reporting Group 1: Participants received 2 tablets of Sorafenib (2x200 mg) orally twice daily (12 hours apart without food), 28 days comprise a cycle. Data were collected from randomization to the end of double-blind period"
"4024",4881,"NCT00939627",284291,0.37037037,10,27,"2 years, 4 months","All participants who received treatment.","Arm B - Cetuximab and Sorafenib Tosylate","Patients received cetuximab IV over 60-120 minutes on days 1, 8, and 15 and oral sorafenib tosylate twice daily on days 1-21."
"4035",4893,"NCT00275028",524920,0.369565217,17,46,NA,NA,"Treatment (Cediranib Maleate)","Patients receive oral AZD2171 once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
cediranib maleate: Given orally
laboratory biomarker analysis: Correlative studies
pharmacological study: Correlative studies"
"4045",4904,"NCT00461708",460150,0.368421053,14,38,"Adverse events (AEs) were recorded at every study visit for up to a maximum of 24 treatment cycles.","All participants who received at least 1 dose of study treatment were included in the safety analysis.","Erlotinib, Gemcitabine: Rash Grade ≥ 2","Participants with a rash Grade ≥ 2 according to the NCI-CTC V 3.0 received erlotinib, 100 mg, PO, once per day of Cycles 1 up through a maximum of Cycle 24 (4-week cycles) until disease progression, unacceptable toxicity, or treatment refusal by participant. Participants also received gemcitabine, 1000 mg/m^2, IV, over 30 minutes on Days 1, 8 and 15 of Cycles 1 up through a maximum of Cycle 24 (4-week cycles) until disease progression, unacceptable toxicity, or treatment refusal by participant."
"4049",4908,"NCT01310855",163919,0.368421053,7,19,NA,NA,"Cediranbib & Placebo","Cediranib maleate 30mg od orally and placebo 500mg od orally. Each cycle of treatment lasts 6 weeks. Treatment will continue until confirmation of progression, patient decision or the development of unacceptable toxicity (if there is radiological progression only treatment can continue if the investigator has the opinion that the patient is receiving benefit.
cediranib maleate
Placebo"
"4056",4915,"NCT00661427",386464,0.368421053,7,19,NA,NA,"Arm B","Cetuximab infusion at 750 mg/m2 over 3 hours every other week."
"4067",4930,"NCT00721162",363644,0.366666667,22,60,NA,"Deaths due to progressive disease are not considered adverse events (AE). Four deaths due to progressive disease were recorded by the investigator as serious AEs (SAE) and are captured in the SAE summary.","Ramucirumab","Ramucirumab at 8 milligrams/kilogram (mg/kg) administered intravenously over 1 hour every other week (every 14 days) of a 28-day cycle."
"4073",4937,"NCT00606008",406103,0.366666667,11,30,"4 years, 8 months","Toxicity assessments were obtained after each cycle. Toxicity was graded according to NCI Common Terminology Criteria for Adverse Events (CTCAE), version 3.0. Response evaluations were performed using modified Macdonald criteria. Serious Adverse Events: =/> Grade 3 toxicities associated with sunitinib.","Sutent Treatment","Sutent was administered daily for 4 weeks at a dose of 50 mg followed by a 2 week study drug free break.
Sunitinib Malate : Initially, patients were started on sunitinib at a dose of 50 mg daily. If 50 mg daily resulted in unacceptable toxicity, 2 dose modifications were allowed (to 37.5 and to 25 mg daily, if necessary). Study patients who could not tolerate 25 mg daily of sunitinib were taken off study."
"4076",4940,"NCT00098345",563166,0.366666667,11,30,NA,NA,"Caprelsa (Vandetanib) 300 mg","Daily oral dose of Caprelsa (vandetanib) 300mg"
"4077",4943,"NCT00778830",340691,0.366336634,37,101,"From the start of the trial treatment up to the data cut-off date (31 March 2014)","A serious adverse event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect.","Cetuximab Plus FOLFIRI","Cetuximab was administered intravenously at a dose of 500 milligram per square meter (mg/m^2) biweekly until disease progression, death, or consent withdrawal. Irinotecan was administered intravenously at a dose of 180 mg/m^2 along with folinic acid intravenously at a dose of 400 mg/m^2 (racemic) or 200 mg/m^2 (L-form) and 5-fluorouracil at a dose of 400 mg/m^2 bolus followed by a 46-hour continuous infusion of 2,400 mg/m^2 given biweekly until disease progression, death, or consent withdrawal."
"4083",4951,"NCT01147822",215020,0.365591398,68,186,"Participants were analyzed from the first dose of study medication until the follow-up contact (up to Study Week 156).","Serious adverse events (SAEs) and non-serious AEs were collected in the Safety Population, comprised of all randomized participants who received at least one dose of study medication, according to the actual treatment received.","Pazopanib 800 mg","Participants were administered pazopanib 800 milligrams (mg) (2 x 400 mg tablets) orally once daily (OD) continuously. Pazopanib was to be taken at least one hour before or at least two hours after a meal. Study treatment continued until participants experienced disease progression, death, or unacceptable toxicity, or withdrew consent for any other reason."
"4086",4954,"NCT00811070",327872,0.365384615,19,52,NA,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as non-serious in another participant, or one participant may have experienced both a serious and non-serious event during the study.","Total Second-line","All participants who received bosutinib orally once daily in second-line chronic myelogenous leukemia (CML), who were imatinib resistant/refractory/intolerant."
"4091",4962,"NCT00057941",572360,0.364864865,27,74,"Assessed each cycle (4 weeks) while on treatment and for 30 days after the end of treatment",NA,"Arm I (Anastrozole and ZD1839)","Patients receive oral anastrozole and oral gefitinib once daily on days 1-28."
"4102",4979,"NCT00246571",532313,0.363636364,40,110,NA,"The same event may appear as both an adverse event (AE) and a serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.","Sunitinib","SU011248 (Sutent [sunitinib malate, hereafter referred to as sunitinib]) oral capsules, 37.5 milligrams (mg) once daily (QD) in a continuous regimen, expressed in 3-week cycles. 1-week treatment rests and dose reductions allowed for dose-limiting toxicity (DLT). Dose escalated to sunitinib 50 mg QD if minimal toxicities."
"4107",4988,"NCT01253369",181426,0.363636364,12,33,"Assessed each cycle throughout treatment from time of first dose and up to day 30 post-treatment.","Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv4. Other AEs were defined as events with treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv4.","Pazopanib","Pazopanib was given at a dose of 800 mg orally once per day for 28 day cycles (+/- 3 days). Patients received treatment as long as they were receiving clinical benefit."
"4119",5002,"NCT00350727",501467,0.363636364,8,22,"Serious adverse events (SAEs) and non-serious AES in Phases I and II were collected from Day 1 of study treatment to study completion (up to 844 days for Phase I; up to 878 days for Phase II).",NA,"Phase II: Biomarker Negative","All participants received pazopanib 400 mg QD and lapatinib 1000 mg QD. Biomarker-negative participants were those who did not express either EGFRvIII and/or PTEN."
"4123",5006,"NCT01647711",90431,0.363636364,4,11,"From first treatment administration until 28 days after the last administration, up to 448 days",NA,"Afatinib 160mg","Patients received oral administration of afatinib 160mg film-coated tablet once daily for three days, repeated every 14 days, during each 28-day cycle."
"4131",5014,"NCT00482703",452094,0.363636364,4,11,NA,NA,"Dasatinib 100 mg Once-daily (QD) Starting Dose","Starting dose of 100 mg QD oral continuous daily dosing of Dasatinib (BMS-354825) for 24 weeks. One dose escalation allowed for nonresponding participants; dose reduction mandated according to the observed toxicity."
"4141",5025,"NCT00574873",416845,0.362903226,90,248,NA,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.","Bosutinib","Bosutinib 500 milligram (mg) tablet orally once daily up to 5 years or until treatment failure, unacceptable toxicity, death, withdrawal of consent. Dose adjustments, if needed, included an escalation to bosutinib 600 mg tablet orally once daily or a reduction to bosutinib 300 mg tablet orally once daily."
"4152",5042,"NCT00454116",462842,0.361111111,13,36,NA,NA,"Vandetanib 300 mg Plus FOLFIRI","vandetanib 300 mg plus FOLFIRI"
"4166",5060,"NCT01393106",143327,0.36,9,25,"Up to Week 110","ITT Analysis Set","Idelalisib","Idelalisib up to 300 mg (75, 100, or 150 mg tablets) administered orally twice daily until tumor progression or development of unacceptable toxicity."
"4167",5061,"NCT01121575",223336,0.36,9,25,"Up to Maximum of treatment duration + 28 days for each participant (could be 295 days)","The same event may appear as both an AE and a SAE. However, what is presented are distinct events. The below tables included all causality SAEs (frequency threshold 0%) and AEs ( frequency threshold 5%).","Expansion Cohort 1","Participants enrolled in expansion cohort 1 received combined oral crizotinib and oral dacomitinib on a continuous daily schedule of crizotinib 200 mg BID + dacomitinib 30 mg QD. Each cycle was 21 days. If there was unacceptable toxicity or tolerability the dose could be adjusted to a lower combined dose. Expansion Cohort 1 was designed to examine the safety of crizotinib and dacomitinib administered concomitantly in NSCLC participants with acquired resistance to erlotinib or gefitinib."
"4172",5066,"NCT00532441",433880,0.36,9,25,"16 weeks",NA,"Erlotinib and Docetaxel","Erlotinib 150 mg p.o. daily, days 2-7, 9-14, 16-28
Docetaxel 30 mg/m2 IV over 30 min weekly x 3 weeks on days 1, 8 and 15
Erlotinib: Erlotinib 150 mg p.o. daily, days 2-7, 9-14, 16-28
Docetaxel: Docetaxel 30 mg/m2 IV over 30 min weekly x 3 weeks on days 1, 8 and 15"
"4173",5067,"NCT00529763",435200,0.36,9,25,NA,NA,"Accelerated Phase","Participants with AP advanced disease CML who received prior treatment with imatinib mesylate and can no longer be treated with this drug due to primary or acquired resistance or intolerance. Dasatinib was administered orally at a dose of 70 mg BID. Participants were treated until progression of disease or intolerable toxicity as determined by the treating physician."
"4175",5069,"NCT00463788",459257,0.359649123,41,114,"Time from first dose up to 30 days after last dose of study treatment, reported between day of first dose of study treatment, 20 June 2007, until cut-off date 05 April 2010","An AE was defined as any untoward medical occurrence in the form of signs, symptoms, abnormal laboratory findings, or diseases that emerges or worsens relative to baseline during a clinical study with an IMP, regardless of causal relationship.","Cisplatin and Cetuximab","Cisplatin 75 milligram per square meter (mg/m^2) intravenous (IV) infusion administered on Day 1 until every 3 weeks with a maximum of 6 cycles and cetuximab initially 400 mg/m^2 followed by 250 mg/m^2 IV infusion weekly."
"4187",5082,"NCT00125034",554206,0.358823529,61,170,"Time from first dose up to 30 days after the last dose of study treatment.","Treatment-emergent adverse events were defined as those with onset occurring at or after the first dosing day of study medication and up to 30 days after the last administration of any study drug or the clinical cut-off date.","Cetuximab Plus FOLFOX-4","Cetuximab plus 5-Fluorouracil(5-FU)/Folinic acid (FA) and oxaliplatin. Cetuximab will always be administered first, followed by oxaliplatin at least 1 hour later. Following completion of the oxaliplatin infusion or simultaneously with oxaliplatin FA will be administered (at a dose of 200 mg/m^2, infused over 120 minutes, on day 1 and day 2, every two weeks) and then 5-FU (as a bolus of 400 mg/m^2/day intravenously (IV) over 2-4 minutes followed by 600 mg/m^2/day infused over 22-hour, on day 1 and day 2, every two weeks). Until progression or unacceptable toxicity develops. Safety population: includes all treated subjects."
"4189",5087,"NCT00586495",412847,0.357894737,34,95,NA,"Acronyms used in Adverse Event section: Absolute Neutrophil Count (ANC), Alanine Transaminase (ALT), Aspartate Transaminase (AST), Common Terminology Criteria for Adverse Events (CTCAE), Creatine Phosphokinase (CPK), Gamma-Glutamyl Transpeptidase (GGT), Gastro-Intestinal (GI), Not Otherwise Specified (NOS).","Sorafenib (Nexavar, BAY43-9006)","Sorafenib 200 mg tablets (400 mg [2 x 200 mg tablets] twice daily [bid] or 400 mg once daily [od] or 400 mg every other day [qod]) administered orally"
"4192",5091,"NCT00261846",528964,0.357638889,103,288,NA,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.","CP2L-CML","All participants who received bosutinib 500 mg orally once daily for 48 weeks in chronic phase second-line (CP2L) chronic myelogenous leukemia (CML), who were imatinib (IM) resistant/refractory (R) and IM intolerant (I)."
"4194",5093,"NCT01271712",175404,0.357142857,20,56,"From randomization of the first subject until date of database cutoff (26 Jan 2012).","Acronyms used: International Normalized Ratio (INR).","Placebo, Open Label Only (Switch to Regorafenib)","Switch to Regorafenib (Open Label study phase only): Participants switched to Open label Regorafenib treatment from Placebo. Participants received Regorafenib (Stivarga) 160 mg (4 x 40 mg tablets) per os once daily, 3 weeks on therapy followed by 1 week off therapy to comprise a cycle of 4 weeks"
"4197",5097,"NCT00059787",572180,0.357142857,20,56,NA,NA,"Treatment (Paclitaxel, Carboplatin, Erlotinib Hydrochloride)","Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1. Patients also receive oral erlotinib daily. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve a pathologic complete response, those initially suboptimally debulked with a response, and patients who elect not to undergo surgical reassessment but who achieve a complete clinical response receive maintenance erlotinib for an additional 12 months.
paclitaxel: Given IV
carboplatin: Given IV
erlotinib hydrochloride: Given PO
laboratory biomarker analysis: Correlative studies"
"4208",5109,"NCT01152437",213746,0.357142857,5,14,"First administration of trial medication until 28 days after last administration of trial medication",NA,"Cetuximab (Wild-type)","Cetuximab 400 mg/m² on Day 1 and then 250mg/m² once a week, every week, intravenous (i.v.) in patients with KRAS wild-type metastatic colorectal cancer."
"4209",5110,"NCT01063075",242545,0.357142857,5,14,NA,NA,"Carboplatin and Cetuximab (C)","Group C:
Cycle 1 (4 weeks, combination therapy):
Carboplatin (AUC=5) administered I.V on week 1, day 1.1000 mg/m ²/day 5-FU administered as a 96-hour C.I. starting on week 1, day 1.
400 mg/m² cetuximab administered I.V on week 2, day 1. 250 mg/m ² cetuximab administered I.V on week 3 and 4, day1.
Cycle 2-6 (3 weeks, combination therapy):
Carboplatin (AUC=5) administered I.V on week1,day1.1000 mg/m ²/d 5-FU as a 96-hour C.I. starting on week1, day1. 250 mg/m ² cetuximab administered I.V on Week 1-3, day 1."
"4216",5118,"NCT00272987",525386,0.357142857,5,14,"Serious adverse events (SAEs) and non-serious AEs were collected from the first dose of investigational product to 30 days after the last dose of investigational product (up to Study Week 164).","SAEs and non-serious AEs were collected in members of the Safety Population, comprised of all randomized participants who received at least one dose of investigational product , according to the actual treatment received.","Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg","Participants received an IV infusion of paclitaxel 70 mg/m^2 over 60 minutes weekly for 3 weeks of a 4-week cycle plus an IV infusion of trastuzumab 4 mg/kg loading dose and 2 mg/kg weekly plus a daily dose of 4 tablets of lapatinib (1000 mg) at approximately the same time every day, either 1 hour (or more) before a meal or 1 hour (or more) after a meal. The paclitaxel dose was systematically increased to 80 mg/m^2 after 2 cycles if 70 mg/m^2 was tolerated."
"4226",5130,"NCT00244764",532845,0.355555556,80,225,"Until participant was off study, approximately 7.84 years",NA,"Pazopanib 800 mg","Pazopanib 800 milligrams (mg) (tablets) administered orally once a day"
"4231",5136,"NCT00064350",571756,0.355555556,16,45,"Assessed every 4 weeks while on treatment and for 28 days after the end of treatment",NA,"Randomization (Step 2): Sorafenib","After induction treatment, 59 patients were randomized to the sorafenib arm. Among these, 55 received treatment. However, due to drug dispensing error, 10 of them received mixed treatment with sorafenib and placebo and were categorized into Randomization (Step 2): Mixed group when reporting toxicities. As a result, 45 treated patients were included in the randomization (step 2): sorafenib group."
"4247",5155,"NCT00659438",386832,0.354166667,17,48,NA,"Safety analysis set is composed with all randomized subjects who received at least one dose of treatment. One patient mistakenly received vandetanib during 3 days while randomized to placebo. This patient was accounted in the vandetanib group in the safety population. So, safety analysis set is composed with 48 Vandetanib and 47 placebo patients.","Vandetanib","Bicalutamide 150mg + Vandetanib (ZD6474) 300mg"
"4248",5156,"NCT00126503",553924,0.354166667,17,48,NA,NA,"Phase I","Sorafenib will be taken orally twice daily beginning on day 1 and continued for 28 days which will be defined as a cycle. Bevacizumab will be administered once every 14 days (with up to a 3 day window before or after 14 days to allow for unforeseen scheduling problems) beginning on day 1."
"4260",5173,"NCT00871403",305246,0.352941176,12,34,NA,"Serious adverse events (SAEs) and non-serious AEs are presented for the entire treatment period (Combination Treatment Phase followed by the Monotherapy Phase). SAEs and AEs were collected in the Safety Population, comprised all participants who had received at least one dose of both drugs within the assigned regimen.","Cisplatin 75 mg/m^2 Plus Pemetrexed 500 mg/m^2","IV cisplatin 75 mg/m^2 plus intravenous pemetrexed 500 mg/m^2 once daily every 3 weeks for 4 or 6 cycles during the Combination Treatment Phase. Until Protocol Amendment 2, upon disease progression participants had the opportunity to receive pazopanib 800 mg monotherapy if the investigator considered it an appropriate treatment option after considering alternative options for second-line treatment."
"4261",5174,"NCT00773383",342896,0.352941176,12,34,"From start of treatment until 30 days after last dose (up to 64 weeks) or if the AE was related to study drug, up until the AE resolved",NA,"R1507","9 mg/kg once a week (qw) IV administered over 60-90 minutes erlotinib – 150 mg Once daily administration (qd) Oral administration(PO)"
"4265",5178,"NCT01100242",230088,0.352941176,6,17,"Up to 42 days following last on-study treatment",NA,"VELCADE and Sorafenib","VELCADE® (bortezomib) 1mg/m2 intravenously on days 1,4,8 & 11 and sorafenib at 200 mg orally twice per day. One full course is comprised of 21 days."
"4268",5181,"NCT00667420",383387,0.352941176,6,17,"From start of study drug (day 1) throughout time enrolled on study. (June 2008 - January 2011)","Adverse events seen in this study were not significantly different from those reported by Waddell T, et. al in Lancet Oncol. 2013 May;14(6):481-9. (NCT00824785). Therefore, only grade 3 and 4 adverse events have been reported here.","Epirubicin, Oxaliplatin, Capecitabine, Panitumumab Treatment","Panitumumab in Combination with Epirubicin, Oxaliplatin and Capecitabine (EOX-P)"
"4269",5183,"NCT00424385",473945,0.352941176,6,17,NA,NA,"Arm 1","Only 1 arm for the study - this arm gets both drugs, gleevec and sorafenib"
"4282",5199,"NCT00075270",569620,0.351535836,103,293,"Serious adverse events (SAEs) and adverse events were collected from the first dose of randomized therapy until 30 days after the last dose of randomized therapy (average of 26 weeks).","SAEs and AEs were collected in the Safety Population, comprised of all randomized participants who received at least one dose of investigational product (based on the actual treatment received if this differed from that to which the participant was randomized). Two participants randomized to the placebo group actually received lapatinib.","Lapatinib With Paclitaxel","Participants received lapatinib 1500 milligrams (mg) orally once daily (OD) with paclitaxel 175 mg/meters squared (m^2) intravenously (IV) over the course of 3 hours, every 3 weeks. The treatment group was stratified by sites of metastatic disease and stage of disease. Participants were treated until disease progression, unacceptable toxicity, or consent withdrawal."
"4287",5208,"NCT00952289",279062,0.350993377,53,151,"From randomization through data cut-off of the primary analysis (02 November 2010).",NA,"Placebo","Placebo tablets matching ruxolitinib were administered orally twice a day at a starting dose based on Baseline platelet count. Doses were titrated using the same guidelines as for active drug. Patients meeting pre-specified requirements were given the opportunity to cross over to ruxolitinib treatment."
"4293",5214,"NCT01027598",252464,0.350746269,47,134,"18 Months",NA,"Arm A","Erlotinib + Pazopanib
Erlotinib: 150 mg orally daily
Pazopanib: 600 mg orally daily"
"4301",5223,"NCT01256385",180467,0.35,14,40,NA,NA,"Arm A (Cetuximab and Temsirolimus)","Patients receive temsirolimus IV over 30-60 minutes and cetuximab IV over 1-2 hours once weekly. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity."
"4313",5237,"NCT00603915",406796,0.35,7,20,NA,NA,"GEMCITABINE AND CISPLATIN/CARBOPLATIN (GC) PLUS ERLOTINIB","patients with recurrent and/or metastatic NPC will be treated with 6 cycles of GC followed by maintenance erlotinib (150mg by mouth daily) for 6 cycles."
"4320",5244,"NCT01597908",99852,0.349570201,122,349,"Serious adverse events (SAEs) and non-serious AEs were collected from the time the first dose of study treatment was administered until 30 days after discontinuation of study treatment (up to Study Week 93).","SAEs and non-serious AEs are reported for the Safety Population, comprised of all participants who were administered at least one dose of investigational treatment.","Vemurafenib","Participants received vemurafenib 960 mg orally BID. Treatment continued until disease progression, death, unacceptable toxicity, or withdrawal of consent. Treatment beyond progression was allowed subject to consultation with the GlaxoSmithKline medical monitor."
"4323",5248,"NCT00481247",452829,0.348837209,90,258,"Randomization to end of study (December 2015)","Study initiated: September 2007; End of Study: December 2015","Dasatinib","Tablets, oral, dasatinib 100 mg once daily (QD)"
"4324",5249,"NCT00509041",443731,0.348837209,15,43,NA,NA,"Dasatinib","Use of dasatinib (50 mg orally twice a day) in treatment of pts with previously treated malignant mesothelioma"
"4329",5255,"NCT00063154",571922,0.348837209,15,43,NA,"Safety population: All participants who received any amount of pertuzumab.","Pertuzumab","Participants received pertuzumab intravenously on Day 1 of every 3 week cycle for up to 1 year (up to 17 treatment cycles). Subjects received pertuzumab at a loading dose of 840 mg in Cycle 1 followed by a dose of 420 mg in Cycles 2 and beyond."
"4332",5258,"NCT00656136",388048,0.348717949,136,390,"From the date of first drug intake up to 28 days after the last drug intake for on-treatment adverse events or the last patient out date on 4 October 2013.",NA,"Afatinib 50 mg/Day","Patients started with a 50 mg/day dose. Dose reductions were permitted by the protocol to 40 mg/day plus BSC or 30 mg /day plus BSC based upon prespecified Adverse Events and Common Terminology Criteria for Adverse Events (CTCAE) grade (Version 3.0)."
"4336",5264,"NCT01042288",247918,0.347826087,24,69,NA,NA,"Carboplatin/Pemetrexed/Panitumumab","Systemic Therapy
Carboplatin: Carboplatin AUC=6IV, Day 1 of Cycles 1-6 (Cycles are 3 weeks / 21 days in length)
Pemetrexed: Pemetrexed 500mg/m² IV, Day 1 of Cycles 1-6 (Cycles are 3 weeks / 21 days in length)
Panitumumab: Panitumumab 9mg/kg IV, Day 1 of Cycles 1-6 (Cycles are 3 weeks / 21 days in length)"
"4370",5303,"NCT00474786",454862,0.345238095,87,252,"5.3 years approximately","The same event may appear as both an AE and SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.","Sorafenib","Sorafenib 400 mg (two 200 mg tablets) by mouth (PO) twice daily (BID) administered in 6 week cycles for up to 24 months. In event of toxicity, dose could be modified or held according to the protocol or at the discretion of the investigator."
"4386",5321,"NCT01015118",256671,0.344444444,155,450,"First drug administration until data cut-off 29Apr2013, up to 41 months","Adverse Events were reported for the treated patients.","Placebo","Patients to receive two 100 mg capsules identical to those containing Nintedanib, taken twice daily, except the day of chemotherapy (carboplatin and paclitaxel) infusion, every 21 days for six courses."
"4393",5331,"NCT01049776",246178,0.34375,11,32,NA,NA,"Pazapanib (GW786034)","Pazopanib (GW786034): Pazopanib 800 mg daily x 12 weeks, (Cycle = 21 days) up to 24 months"
"4397",5336,"NCT00805194",330655,0.343558282,224,652,"From the first drug administration until 28 days after the last drug administration, up to 42 months","Number of participants at risk corresponds to all randomised patients who were documented to have taken at least 1 dose of study medication . Patients were allocated to the treatment groups according to the treatment actually received.","Nintedanib Plus Docetaxel","Nintedanib 200 mg twice daily administered orally in a form of a soft gelatin capsule plus docetaxel 75 mg/m2 once every 3 weeks administered via intravenous infusion over 1 hour (h)."
"4410",5349,"NCT00217399",536648,0.342857143,12,35,"4 years",NA,"Sorafenib and Anastrozole","A single arm of 35 patients with advanced or metastatic breast cancer receiving a combination of sorafenib and anastrozole."
"4411",5350,"NCT00267748",526500,0.342465753,50,146,NA,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.","Sunitinib 50 mg (Schedule 4/2)","Sunitinib 50 mg self administered orally, once daily in the morning for 4 consecutive weeks followed by 2 weeks off treatment to comprise a complete 6-weeks cycle."
"4413",5352,"NCT00883779",301261,0.342342342,76,222,"Up to 28 days after the last dose in the primary and post study treatment phases of the study (up to approximately 5.5 years)",NA,"Placebo","Participants received 1250 mg/m^2 of gemcitabine IV infusion on Day 1 and 8, carboplatin 5x AUC or cisplatin 75 mg/m^2 IV infusion on Day 1 and oral placebo daily from Day 15 to 28 every 4 weeks, continued for 6 cycles (28-day cycle) until PD, unacceptable toxicity or death in the primary study treatment phase. Participants who completed 6 cycles of treatment without PD or unacceptable toxicity, or if they withdrew early because of toxicity from the platinum-doublet chemotherapy, entered the post-study treatment phase and continued same treatment until PD, unacceptable toxicity or death. Participants who withdrew due to PD or toxicity from placebo could not enter the post-study treatment phase. Upon PD (during either the primary or post-study treatment phase), participants had the option to be crossed over to open-label erlotinib 150 mg/day outside the study (Off-study phase)."
"4421",5362,"NCT00073307",570320,0.341463415,154,451,"In addition, 1 participant who was not randomized to double-blind treatment received sorafenib treatment on a compassionate-use basis in the crossover phase and was included in the safety population only.","DIC (disseminated intravascular coagulation), AT (Atrial tachycardia), NOS (not otherwise specified), GI (gastro-intestinal), CTCAE (Common Terminology Criteria for Adverse Events), ANC (absolute neutrophil count), CNS (central nervous system), CN (cranial nerve), GU (genitourinary)","Sorafenib (Nexavar, BAY43-9006)-31May2005 DB","Sorafenib was to be orally administered as 2 x 200 mg tablets bid (twice daily). Double Blind period-31May2005"
"4425",5366,"NCT00193063",540004,0.341463415,14,41,NA,NA,"Intervention","All patients entering this trial received treatment with a combination of gemcitabine and trastuzumab. Gemcitabine 1000 mg/m2 was administered intravenously on days 1, 8,and 15 of a 28-day cycle. Trastuzumab was administered as a 4 mg/kg intravenous loading dose on day 1 and subsequently at a dose of 2 mg/kg on a weekly basis."
"4433",5374,"NCT00083616",568355,0.340659341,62,182,"From the first dose through maximum of safety follow-up or 30 days after last dose; maximum time on study treatment was 1.25 years.","The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.","Panitumumab",NA
"4434",5375,"NCT00778830",340690,0.340425532,64,188,"From the start of the trial treatment up to the data cut-off date (31 March 2014)","A serious adverse event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect.","Cetuximab Plus FOLFOX","Cetuximab was administered intravenously at a dose of 500 milligram per square meter (mg/m^2) biweekly until disease progression, death, or consent withdrawal. Oxaliplatin was administered intravenously at a dose of 100 mg/m^2 along with folinic acid intravenously at a dose of 400 mg/m^2 (racemic) or 200 mg/m^2 (L-form) and 5-fluorouracil at a dose of 400 mg/m^2 bolus followed by a 46-hour continuous infusion of 2,400 mg/m^2 given biweekly until disease progression, death, or consent withdrawal."
"4439",5382,"NCT00693992",374731,0.340206186,33,97,NA,"189 participants were evaluable for adverse events.","Arm I (Sunitinib Malate)","Patients receive sunitinib malate 37.5 mg PO once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Laboratory Biomarker Analysis: Correlative studies
Quality-of-Life Assessment: Ancillary studies
Sunitinib Malate: Given PO"
"4445",5390,"NCT01154140",212833,0.339181287,58,171,"From the first dose of study medication until 28 days after the last dose of study medication.","An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both serious and nonserious event. AEs were to be collected from first dose until 28 days after the last dose of study medication. SAEs could be collected after this timeframe if considered to be treatment related.","Crizotinib","Crizotinib capsules, 250 mg twice daily (BID), were administered orally at approximately the same time each day on a continuous daily dosing schedule. Each treatment cycle was defined as 3 weeks. Participants could continue crizotinib treatment beyond the time of RECIST defined Progressive Disease (PD), as determined by independent radiology review (IRR), at the discretion of the investigator if the participant was perceived to be experiencing clinical benefit."
"4452",5398,"NCT00920816",290722,0.338624339,64,189,"Baseline up to Week 107","Same event may appear as both AE and SAE. However, what is presented are distinct events. Event may be categorized as serious in 1 subject and nonserious in another subject, or 1 subject may have experienced both a serious and nonserious event during the study. Participants at risk = 189, 96, 135, 69 for each arm group, respectively.","Axitinib (First-line Participants)","Participants with no prior systemic first-line therapy received axitinib (AG-013736) tablet at a starting dose of 5 mg orally twice daily, dose adjustment was done based on the tolerability, as per investigator’s discretion. Study medication was administered in cycles of 4 weeks."
"4467",5417,"NCT00387764",488429,0.3375,27,80,"Serious adverse events (SAEs) and non-serious AEs were collected from the start of study medication to the end of the treatment period (up to 6.230 years).",NA,"Pazopanib 800 mg","Participants received pazopanib 800 milligrams (mg) once daily."
"4471",5421,"NCT00547157",427995,0.337078652,30,89,"The median reporting period was around 74 days in the Panitumumab Plus Radiotherapy arm, and around 74 days in the Chemoradiotherapy arm.","The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. One Subject who was randomized to Panitumumab+Radiotherapy but received Chemotherapy+Radiotherapy was summarized under Chemotherapy+Radiotherapy arm. So the number of participants under Chemotherapy+Radiotherapy arm is 62 (61+1).","Panitumumab Plus Radiotherapy","Panitumumab (9.0 mg/kg day 1, day 22, day 43) plus Accelerated Fractionation Radiotherapy"
"4478",5428,"NCT01001377",260769,0.335984095,169,503,"Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.","Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses.
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.","Cetuximab","Cetuximab 400 mg/m^2 as an initial dose, followed by 250 mg/m^2 intravenously (IV) every 7 days."
"4505",5458,"NCT01013740",257280,0.333333333,25,75,"In the RP, serious adverse events (SAEs) and non-serious AEs were collected from Screening until PD/treatment withdrawal (average of 27 study weeks). In the CP, SAEs and non-serious AEs were collected from the time of crossover until tre","Serious and non-serious adverse events were collected in members of the Safety Population, comprised of all participants who received at least one dose of study medication.","Lapatinib Plus Vinorelbine in the RP","Participants received a daily dose of 5 tablets of lapatinib (1250 mg) at approximately the same time every day, either 1 hour (or more) before food or 1 hour (or more) after food. Participants also received an intravenous (IV) infusion of vinorelbine 20 mg/m^2 over the course of 5 to 10 minutes on Days 1 and 8 of a 21-day treatment cycle. After disease progression in the Randomized Phase (in which participants received lapatinib plus capecitabine), participants were given the option of crossing over to the alternative treatment arm (lapatinib plus vinorelbine), and continuing in a post-progression Cross-over Phase."
"4513",5466,"NCT01196078",198572,0.333333333,19,57,"Adverse Events were monitored continuously during the study treatment and for 28 days after the last intake of study medication. Only SAE were recorded during post study treatment phase and for 28 days after the last intake of study medication.",NA,"Erlotinib","Participants received erlotinib 150 mg, tablets, orally, once a day until disease progression, unacceptable toxicity, or participant withdrawal."
"4528",5483,"NCT00727506",361351,0.333333333,13,39,"Between first intake through 28 days after last drug intake.",NA,"Phase II - Afatinib 40mg Plus Temozolomide 75 mg/m^2","Patients receiving Afatinib 40mg once daily (q.d.) plus Temozolomide 75 mg/m^2 for 21 days followed by 7 days off - Phase II part"
"4530",5485,"NCT00429299",472283,0.333333333,13,39,"Serious adverse events (SAEs) and non-serious AEs were collected from the first dose of randomized therapy to 30 days after the last dose of randomized therapy (up to Study Week 29).","SAEs and non-serious AEs were collected for all participants who received at least one dose of study medication.","CT Plus Lapatinib 1500 mg","Participants received CT, which included paclitaxel 80 mg/m^2 weekly for 12 weeks, followed by IV fluorouracil 600 mg/m^2, IV epidoxorubicin 75 mg/m^2, and IV cyclophosphamide 600 mg/m^2, once every 21 days for four treatment courses. Participants received lapatinib 1500 mg/day orally on an empty stomach throughout the course of the CT and for three weeks after the last CT administration. Treatments were administered for 26 weeks prior to surgery. Following Independent Data Monitoring Committee (IDMC) recommendations, lapatinib doses were reduced to 1250 mg/day orally on an empty stomach."
"4531",5486,"NCT01469052",126343,0.333333333,12,36,NA,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.","All Treated Participants","All participants of Cohorts 1 to 6 received oral doses of axitinib (AG-013736) (10 mg and 15 mg, QD; 2 mg, 5 mg, 10 mg, 20 mg and 30 mg, BID) tablet in fed or fasted state in cycles of 4 weeks, up to 8 cycles."
"4536",5491,"NCT00756444",350865,0.333333333,11,33,"54 Weeks","The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
Summary of Adverse Events includes only those subjects who received at least one dose of investigational product.","Panitumumab Plus Chemotherapy","Treatment will be administered in cycles repeated every 21 days. On day 1 of each cycle, panitumumab will be administered intravenously, prior to chemotherapy, at a dose of 9 mg/kg over 1 hour. Cisplatin will be administered intravenously on day 1 at a dose of 100 mg/m2 over 1 hour. 5-FU will be administered at a dose of 1000 mg/m2/day by continuous intravenous infusion on day 1 to 4 (96 hours)."
"4537",5492,"NCT00495625",447549,0.333333333,11,33,"3 Years and 4 Months","First Treatment Start Date: 10/13/06 Last Off Study Date: 2/19/10","Sunitinib Malate (SUO11248) Treatment","Once daily oral doses on days 1-28 of each 42-day cycle. The dose for the first 2 cycles was 37.5 mg daily for 28 days, every 42 days. Dose could be escalated to 50 mg daily for 28 days at the treating investigator's discretion."
"4541",5497,"NCT00290615",520508,0.333333333,10,30,NA,NA,"Capecitabine, Oxaliplatin, Bevacizumab, Cetuximab","Capecitabine - oral administration of 850 mg/m2 every 12 hours on days 1-14. Oxaliplatin - IV administration of 130 mg/m2 over 2 hours on day 1 of a cycle. Bevacizumab- IV administration of 7.5 mg/kg over 30-90 minutes on day 1 of a cycle.
Cetuximab at an initial dose of 400 mg/m2 over 120 minutes and subsequently 250 mg/m2 over 60 minutes on day 1 of a cycle.
Cycles are 21 days."
"4561",5518,"NCT00754325",351637,0.333333333,7,21,"Date of randomization to date of initial disease progression, or date of death (whichever occurs first), up to January 2014 (approximately 5 years)","Study initiated: September 2008; Study Completion: January 2014","Fulvestrant Crossover to Fulvestrant and Dasatinib","Arm 2b: Participants in this group started on the Fulvestrant only arm and later started receiving a drug regimen that consisted of both fulvestrant and dasatinib. These participants are all inclusive and not limited to Fulvestrant or Fulvestrant and Dasatinib treatment only. The timeframe for when these events occurred were not immediately available and may have been caused by previous exposure to Fulvestrant only (pre-crossover), therefore the events for this patient population are also reported separately.
Fulvestrant: Intramuscular injection (IM), loading dose (500 mg) on Day 1 followed by 500 mg on Day 15 of Cycle 1 (28-day cycle). In subsequent cycles, 500 mg IM administered on Day 1, up to 2 years.
Dasatinib: Tablets, Oral, 100 mg, once daily (QD), up to 2 years"
"4564",5521,"NCT00467779",457610,0.333333333,7,21,"AEs were recorded from the Day 1 of treatment period until the 30 plus or minus 4 days after the last treatment (up to approximately 6 years) .",NA,"Stage 2 Cohort 20 – Cobimetinib 60 mg (Expansion) (21/7)","Participants received cobimetinib 60 mg via solution or capsule, once daily for Days 1-21 of each 28-day cycle. Treatment was continued until PD or unacceptable toxicity for up to 1 year at the discretion of investigator and beyond 1 year with the agreement of the sponsor."
"4567",5525,"NCT00425854",473207,0.333333333,7,21,"First administration of trial medication until 28 days after last administration of trial medication",NA,"Cohort B","Patients with HER2-negative, ER-positive and/or PgR-positive tumours receiving oral dose of Afatinib 50 mg qd"
"4582",5540,"NCT01262820",178368,0.333333333,5,15,"4 years",NA,"Single Intervention","Subjects will take Pazopanib, 800 mg daily by mouth throughout the time in study
Pazopanib: Pazopanib, 800 mg by mouth daily each 21 day cycle"
"4595",5554,"NCT00369512",494759,0.333333333,5,15,"Adverse Events were reported during treatment and continued to 2 year follow-up.",NA,"Erlotinib","Erlotinib therapy for 2 weeks (150 mg po qd)(for those who are enrolled before surgery is done), surgery/biopsy up to 8 weeks recovery, radiation/Erlotinib therapy for 6 weeks (150mg po qd)."
"4603",5562,"NCT01594125",100570,0.333333333,4,12,"up to 67 days",NA,"Group I: Nintedanib 200mg Bid","Patients with mild liver dysfunction according to their aspartate amino transferase (AST)/ alanine amino transferase (ALT) values (<=2 x upper limit of normal (ULN)) and Child-Pugh A treated with Nintedanib 200mg twice daily"
"4605",5564,"NCT01212627",194195,0.333333333,4,12,"Baseline, treatment, 30 days post last dose of drug",NA,"Ridaforolimus,","Ridaforolimus: 20mg Daily, 5 days each week, on a 28 day cycle until progression
Ridaforolimus: Ridaforolimus 20 Daily, 5 days each week, (Mon-Fri) on a 28 day cycle
Ridaforolimus"
"4606",5565,"NCT01009203",258620,0.333333333,4,12,"3 years",NA,"Erlotinib and Temsirolimus","Erlotinib at 150 mg by mouth daily + Temsirolimus at 15 mg intravenously weekly. Each cycle is comprised of 28 days."
"4628",5595,"NCT00726232",361709,0.333333333,3,9,NA,NA,"ET: Ruxolitinib 50 mg QD","Participants with Essential Thrombocythemia received 50 mg Ruxolitinib orally once a day (QD) for 56 days (two 28-day cycles) during the dose-ranging phase. After patients completed 2 cycles of treatment at the randomized dose, Investigators were permitted to adjust the dose/regimen on an individual basis to achieve an optimal balance of efficacy and safety. Treatment continued until a patient met a withdrawal criterion, had intolerable toxicity, progression of disease, or withdrew consent."
"4630",5597,"NCT00722072",363164,0.333333333,3,9,NA,NA,"Sorafenib and Fulvestrant","Fulvestrant:Will be administered to the subject intramuscularly. Administered to all subjects during cycle 1 of treatment as follows:
500 mg IM on Day 1
250 mg IM on Day 15
Sorafenib: 800 mg/day administered as 400 mg bid (twice daily) each morning and evening approximately 12 hours apart. Treatment will begin on Day 1 of the study and continue daily until tumor progression or until an unacceptable toxicity occurs which would require delay, modification or discontinuation of study therapy."
"4636",5605,"NCT00329719",505713,0.333333333,3,9,NA,NA,"Phase II, Arm C","Patients receive sorafenib PO BID on days 1-8 (15 doses) and temsirolimus IV at the MTD on day 1. Patients undergo surgery on day 8. After recovering from surgery, patients receive sorafenib and temsirolimus as in phase I at the MTD (25mg temsirolimus and 200mg sorafenib).
sorafenib tosylate: Given PO
temsirolimus: Given IV
conventional surgery: Undergo surgery"
"4638",5607,"NCT00121719",555444,0.333333333,3,9,"All adverse events (AEs) were collected for up to approximately 4 years.","Treatment-emergent adverse events were defined as AEs that emerged during treatment, having been absent at pre-treatment, or that worsened in severity relative to the pre-treatment state, or occurred within 7 days or 5 times the half-life (whichever was longer) post participant's last treatment. Only treatment-emergent AEs and SAEs were reported.","12.5 mg Lenvatinib","One 10 mg lenvatinib tablet, two 1.0 mg lenvatinib tablets, and five 0.1 mg lenvatinib tablets were taken orally, once daily. Lenvatinib was to be taken on an empty stomach shortly after waking. Participants were fasted for 2 hours following administration of lenvatinib and could drink only clear fluids during this time (grapefruit juice was to be avoided). If 1 of 3 participants experienced DLT during Cycle 1 (4 weeks) an additional 3 participants were to be treated at this dose level. If 5 of the 6 participants in the expanded dose level did not experience DLT during the first 4 weeks of therapy, no additional DLT was observed, the next dose level was opened for enrollment. If more than 1 participant experienced DLT during the first 4 weeks of therapy, dose escalation was stopped and the MTD was determined. An additional 12 participants were treated at the MTD level."
"4654",5627,"NCT01400451",141694,0.333333333,2,6,"From the first vemurafenib dose in the Lead In Period to the last dose of combination drugs in the Treatment Period + 90 days, up to last patient, last visit, approximately 2 years.","Final safety follow-up was 23 December 2013.","Lead-In Period 960 mg Vemurafenib","Lead In Period: 28 Days of 960 mg vemurafenib orally twice daily (starting Day -27 or -13).
Events between the first vemurafenib dose and the day prior to the first ipilimumab dose."
"4658",5631,"NCT01251653",182105,0.333333333,2,6,"From first drug administration until 28 days after last drug administration, up to 717 days",NA,"Afatinib 40mg and Gemcitabine 1250mg","Afatinib (film-coated tablet) 40 mg qd (once daily) was administered orally in combination with Gemcitabine 1250 mg/m2 administered as intravenous infusion on Days 1 and 8 of each 3- week treatment course."
"4663",5637,"NCT01214616",193343,0.333333333,2,6,"during the treatment period or up to 28 days after the completion of drug administration, up to 730 days",NA,"Afatinib 40 mg With Vinorelbine 25 mg/m^2 (Cohort 3)","Afatinib 40 mg oral administration once a day with vinorelbine 25 mg/m^2 intravenous injection weekly; allowed for vinorelbine dose to be skipped for Common Toxicity Criteria for Adverse Effects (CTCAE) Grade 2 or worse neutropenia or thrombocytopenia"
"4668",5643,"NCT01121575",223339,0.333333333,2,6,"Up to Maximum of treatment duration + 28 days for each participant (could be 295 days)","The same event may appear as both an AE and a SAE. However, what is presented are distinct events. The below tables included all causality SAEs (frequency threshold 0%) and AEs ( frequency threshold 5%).","PF-02341066, 200 mg BID/ PF-00299804, 45 mg QD","Participants enrolled in dose escalation received combined oral crizotinib 200 mg BID and oral dacomitinib 45 mg. The first cycle was for 28 days thereafter, each cycle was 21 days."
"4675",5651,"NCT01005355",259737,0.333333333,2,6,NA,NA,"IMC-1121B 8 mg/kg (Cohort 2)","8 mg/kg IMC-1121B (ramucirumab) based on participant's body weight administered intravenously over 1 hour on Day 1 every 2 weeks for 6 weeks (1 cycle).
After 1 cycle of treatment, participants who had an objective response or stable disease were permitted to receive IMC-1121B (ramucirumab) at the same dose and schedule until disease progression or unacceptable toxicity occurred, or another withdrawal criterion was met."
"4676",5652,"NCT01005355",259736,0.333333333,2,6,NA,NA,"IMC-1121B 10 mg/kg (Cohort 3)","10 mg/kg IMC-1121B (ramucirumab) based on participant's body weight administered intravenously over 1 hour on Day 1 every 3 weeks for 6 weeks (1 cycle).
After 1 cycle of treatment, participants who had an objective response or stable disease were permitted to receive IMC-1121B (ramucirumab) at the same dose and schedule until disease progression or unacceptable toxicity occurred, or another withdrawal criterion was met."
"4687",5668,"NCT00824733",322138,0.333333333,2,6,"Adverse events were graded using the NCI Common Toxicity Criteria (CTC) version 3.0.",NA,"Arm I: Treatment (PF03512676 in Combination With Trastuzumab)","12 weekly treatments. Week 1-12 patients will receive Trastuzumab 2mg/kg IV(intervenous infusion). Patients who have not been treated wih Trastuzumab within 4 weeks will receive a loading dose of 4 mg/kg on week 1 and PF-03512676-0.16 mg/kg subcutaneous injection.Correlative studies will be drawn on week 1, 2, 6, 12 and 18.
Trastuzumab: IV at 2 mg/kg over 30 minutes on day 1 of each weekly cycle. Patients who have not received trastuzumab for 4 weeks or more will receive a loading dose of 4 mg/kg over 90 minutes day 1 of the first cycle. The dose of trastuzumab will be based on the patient's actual weight at the start of each 4 week treatment cycle.
PF03512676: Patients also receive PF03512676 subcutaneously on days 15 and 22 of course 1 and on days 1, 8, 15, and 22 of all subsequent courses.
Correlative Studies: Blood for performing the correlative studies will be drawn on week 1, 2, 6, 12 and 18."
"4690",5672,"NCT00732992",359251,0.333333333,2,6,NA,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.","Sunitinib 37.5 mg/Day Continuous Daily Dosing","Sunitinib 37.5 mg was administered continuously on a daily basis. Pemetrexed 500 mg/m^2 was administered as intravenous infusion over 10 minutes on the first day (Day 1) of each 21-day cycle."
"4692",5674,"NCT00727506",361356,0.333333333,2,6,"Between first intake through 28 days after last drug intake.",NA,"Phase I - Afatinib 20 mg Plus Temozolomide 75mg/m^2","Patients receiving Afatinib 20mg once daily (q.d.) plus Temozolomide 75 mg/m^2 for 21 days followed by 7 days off - Phase I part"
"4703",5686,"NCT00631410",396262,0.333333333,2,6,"Up to 733 days (the last subject study discontinuation)","The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.","Treatment Arm A 37.5 mg/Day (4/2)","Sunitinib was administered orally in a 4 weeks on, 2 weeks off intermittent dosing regimen, at a starting dose of 37.5 mg/day (37.5 mg/day in Schedule 4/2). FOLFOX was administered on an every-2-week cycle using the mFOLFOX6 regimen consisting of oxaliplatin 85 mg/meter^2 and l-leucovorin 200 mg/meter^2 as a 2-hour intravenous infusion followed by an intravenous bolus of fluorouracil 400 mg/meter^2 and a 46-hour intravenous infusion of fluorouracil 2,400 mg/meter^2 on Days 1 and 2 of each cycle."
"4708",5692,"NCT00561795",421017,0.333333333,2,6,"Enrollment to End of Study (up to a year)",NA,"A5-2","Paclitaxel 175 mg/m^2 plus carboplatin AUC5 intravenously (IV) on Day 1 of a 21-day cycle for 6 cycles plus pazopanib 400 mg/day orally starting on Day 1 for the duration of the study"
"4710",5696,"NCT00486954",451026,0.333333333,2,6,"Serious adverse events (SAEs) and non-serious AEs were collected from the first dose of investigational product to 30 days after the last dose (up to 51.7 weeks in the Pilot part and up to 110.3 weeks in the Randomized part).","SAEs and non-serious AEs were collected in members of the Safety Population in both the Pilot part and the Randomized part . For the Pilot part, MedDRA 12.1 was used; for the Randomized part, MedDRa 15.1 was used.","Lapatinib Plus Paclitaxel in Gastrectomy Participants","In the Pilot part, participants with gastrectomy (pylorus removed) received 1500 mg of oral lapatinib once daily throughout the study duration (lapatinib was not administered on Day 1 of the first cycle). Participants received a paclitaxel 1-hour intravenous infusion weekly for 3 weeks of a 4-week cycle at 80 mg/m^2."
"4712",5698,"NCT00474929",454807,0.333333333,2,6,"The adverse events reported here occurred during treatment. The maximum treatment length was 27, 28-day cycles.","Adverse events were collected at the end of each cycle.","Phase I, Dose Level 0","Phase I: Dose level 0: Sorafenib 200 mg twice daily, RAD001 5mg every other day"
"4715",5702,"NCT00442507",466835,0.333333333,2,6,NA,NA,"Erlotinib and Avastin","Patients will be treated with erlotinib 150 mg oral daily and Avastin 15 mg/kg intravenously each cycle of therapy (each cycle is 21 days or every 3 weeks). The first infusion of Avastin will be administered over 90 minutes. If tolerated, the second infusion will be given over 60 minutes and in 30 minutes for the subsequent treatments. Treatment will be administered until disease progression or intolerable side effects."
"4723",5712,"NCT00195260",539807,0.333333333,2,6,NA,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.","Bosutinib 200 mg","Bosutinib 200 mg capsule orally once daily continuously in 21-day cycles until disease progression, unacceptable toxicity, or consent withdrawal."
"4725",5714,"NCT00121719",555443,0.333333333,2,6,"All adverse events (AEs) were collected for up to approximately 4 years.","Treatment-emergent adverse events were defined as AEs that emerged during treatment, having been absent at pre-treatment, or that worsened in severity relative to the pre-treatment state, or occurred within 7 days or 5 times the half-life (whichever was longer) post participant's last treatment. Only treatment-emergent AEs and SAEs were reported.","16 mg Lenvatinib","One 10 mg lenvatinib tablet and six 1.0 mg lenvatinib tablets were taken orally, once daily. Lenvatinib was to be taken on an empty stomach shortly after waking. Participants were fasted for 2 hours following administration of lenvatinib and could drink only clear fluids during this time (grapefruit juice was to be avoided). If 1 of 3 participants experienced DLT during Cycle 1 (4 weeks) an additional 3 participants were to be treated at this dose level. If 5 of the 6 participants in the expanded dose level did not experience DLT during the first 4 weeks of therapy, no additional DLT was observed, the next dose level was opened for enrollment. If more than 1 participant experienced DLT during the first 4 weeks of therapy, dose escalation was stopped and the MTD was determined. An additional 12 participants were treated at the MTD level."
"4726",5715,"NCT00121719",555441,0.333333333,2,6,"All adverse events (AEs) were collected for up to approximately 4 years.","Treatment-emergent adverse events were defined as AEs that emerged during treatment, having been absent at pre-treatment, or that worsened in severity relative to the pre-treatment state, or occurred within 7 days or 5 times the half-life (whichever was longer) post participant's last treatment. Only treatment-emergent AEs and SAEs were reported.","25 mg Lenvatinib Fasted/Fed","Participants from the MTD Cohort who chose to participate in the food-effect pilot study were randomly assigned to this Cohort. Two 10 mg lenvatinib tablets and five 1.0 mg lenvatinib tablets were taken orally, once daily. The Day 15 dose of lenvatinib was taken in a fasted state and the Day 22 dose was taken in a fed state with a high fat meal. All other doses were taken on an empty stomach after waking, followed by fasting for 2 hours with only clear liquids allowed."
"4728",5718,"NCT00096486",563711,0.333333333,2,6,NA,NA,"Phase I: RAD001 5 mg, Gefitinib 250 mg","Phase I: RAD001 5 mg, Gefitinib 250 mg"
"4748",5741,"NCT01647711",90433,0.333333333,1,3,"From first treatment administration until 28 days after the last administration, up to 448 days",NA,"Afatinib 120mg","Patients received oral administration of afatinib 120mg film-coated tablet once daily for three days, repeated every 14 days, during each 28-day cycle."
"4749",5742,"NCT01594125",100569,0.333333333,1,3,"up to 67 days",NA,"Group II: Nintedanib 100mg Bid","Patients with moderate liver dysfunction according to their aspartate amino transferase (AST)/ alanine amino transferase (ALT) values (>2 to <=5 x upper limit of normal (ULN)) and Child-Pugh B (score 7) treated with Nintedanib 100mg twice daily"
"4771",5766,"NCT01287754",170420,0.333333333,1,3,"Up to 2 years","Only participants treated with erlotinib were assessed for adverse events.","Erlotinib","Participants positive for the EGFR mutation and who met eligibility criteria received treatment with erlotinib, 150 mg orally once daily until disease progression or unacceptable toxicity."
"4777",5773,"NCT01251653",182108,0.333333333,1,3,"From first drug administration until 28 days after last drug administration, up to 717 days",NA,"Afatinib 30mg and Gemcitabine 1000mg","Afatinib (film-coated tablet) 30 mg qd (once daily) was administered orally in combination with Gemcitabine 1000 mg/m2 administered as intravenous infusion on Days 1 and 8 of each 3- week treatment course."
"4783",5779,"NCT01218477",191510,0.333333333,1,3,NA,NA,"Dasatinib, 100/140 mg QD","Participants received dasatinib, 100/140 mg once daily (QD) (100 mg for those with CML-chronic phase; 140 mg for those with CML-advanced phase)"
"4784",5780,"NCT01179737",205166,0.333333333,1,3,"Adverse events were collected over the duration of treatment 140 days for cohort 1, 168 days for cohort 2 and up to 1092 days in the extension study","23 participants were enrolled into the study; 8 participants completed cohort 1 and 6 of these participants moved into cohort 1 expansion of which 5 participants completed Cohort 1 expansion. Of the 5 participants, 3 went into an Extension. None of the participants completed treatment as trial was terminated","Cohort 1: Placebo","Participants were assigned to receive placebo to nilotinib to match 50 mg and 150 mg capsules during 168 days."
"4789",5785,"NCT01088464",233085,0.333333333,1,3,"Baseline up to 24 weeks plus 30 days post last dose of study drug",NA,"Cohort 1: Necitumumab","Necitumumab 600 mg administered intravenously on Days 1 and 8 every 3 weeks of a 6-week cycle. After Cycle 1, participants showing objective response or stable disease were to receive necitumumab at same dose and schedule until disease progression or other withdrawal criteria were met."
"4793",5789,"NCT01063075",242546,0.333333333,1,3,NA,NA,"Carboplatin and Cetuximab (B)","Group B:
Cycle 1 (3 weeks, single-agent cetuximab):
400 mg/m² cetuximab administered I.V on week 1, day 1. 250 mg/m ² cetuximab administered I.V on weeks 2 and 3, day 1.
Cycle 2 (3 weeks, combination therapy):
Carboplatin (AUC=5) administered I.V week 1, day 1. 1000 mg/m ²/d 5-FU administered as a 96-hour C.I. starting on week 1, day 1. 250 mg/m ² cetuximab administered I.V weeks 1- 3,day 1."
"4801",5798,"NCT01005355",259738,0.333333333,1,3,NA,NA,"IMC-1121B 6 mg/kg (Cohort 1)","6 milligrams/kilogram (mg/kg) IMC-1121B (ramucirumab) based on participant's body weight administered intravenously over 1 hour on Day 1 every 2 weeks for 6 weeks (1 cycle).
After 1 cycle of treatment, participants who had an objective response or stable disease were permitted to receive IMC-1121B (ramucirumab) at the same dose and schedule until disease progression or unacceptable toxicity occurred, or another withdrawal criterion was met."
"4803",5800,"NCT01004003",260208,0.333333333,1,3,"From first administration of the trial drug and until 28 days after the last administration of nintedanib or sorafenib, up to 1289 days",NA,"Phase I Group 1, 150mg Nintedanib Bid","Oral administration of Nintedanib (BIBF 1120) 150 mg soft gelatine capsules twice daily (bid). Phase I: A standard 3+3 dose escalation part to determine the MTD. Group 1 patients had a baseline Child-Pugh score of 5 or 6, and AST and ALT ≤2 times the upper limit of normal (ULN)."
"4806",5806,"NCT00987935",266795,0.333333333,1,3,"AEs with an onset during therapy with study treatment or within 28 days after discontinuation of study treatment (up to 1066 days)",NA,"Phase I Group I Nintedanib, 150 mg Bid","Oral administration of Nintedanib (BIBF 1120) 150 mg soft gelatine capsules twice daily (bid) for the Group I patients during Phase I"
"4807",5807,"NCT00987935",266791,0.333333333,1,3,"AEs with an onset during therapy with study treatment or within 28 days after discontinuation of study treatment (up to 1066 days)",NA,"Phase I Group II Nintedanib, 150 mg Bid","Oral administration of Nintedanib (BIBF 1120) 150 mg soft gelatine capsules twice daily (bid) for the Group II patients during Phase I"
"4808",5809,"NCT00982488",268977,0.333333333,1,3,NA,NA,"Dasatinib, 50 mg QD to 120 mg BID, Advanced Phase, MBP","Participants with advanced phase disease, myeloid blast phase (MBP), were rolled over from previous studies CA180-039, CA180-043, and the SRC/ABL tyrosine kinase inhibition activity: Research trials (START). Participants continued on the previous study dose of dasatinib, ranging from 50 mg QD to 120 mg BID. Dose escalations to optimize response and dose reductions for toxicity were permitted. Participants received study medication until disease progression, unacceptable toxicity, failure to serve patient's best interest, withdrawal of consent, or study closure."
"4809",5812,"NCT00941863",283489,0.333333333,1,3,"Time frame for expansion group is from start of treatment until April 2008, up to 6 years.","Acronyms in Adverse Event Section:
White Blood Cell (WBC) Absolute Neutrophil Count (ANC) Absolute Granulocyte Count (AGC) Alanine Transaminase (ALT) Aspartate Transaminase (AST) Grade (GR) Gastrointestinal (GI) Central Nervous System (CNS) Fibrillation/Flutter (FIB/FLUTT) Neutropenia (Neu) documented (doc)","Sorafenib 200 mg (50-mg Tablet)","Dose-escalation cohort 2: Sorafenib (Nexavar, BAY43-9006) 200 mg twice daily (50-mg tablet)"
"4810",5813,"NCT00932373",286667,0.333333333,1,3,"Baseline to the end of the study (up to 3 years 2 months)",NA,"Trastuzumab-MCC-DM 0.3 mg/kg Every 3 Weeks","Trastuzumab-MCC-DM 0.3 mg/kg administered intravenously (IV) once every 3 weeks"
"4811",5814,"NCT00932373",286661,0.333333333,1,3,"Baseline to the end of the study (up to 3 years 2 months)",NA,"Trastuzumab-MCC-DM 1.2 mg/kg Weekly","Trastuzumab-MCC-DM 1.2 mg/kg administered intravenously (IV) once a week"
"4812",5815,"NCT00932373",286660,0.333333333,1,3,"Baseline to the end of the study (up to 3 years 2 months)",NA,"Trastuzumab-MCC-DM 1.6 mg/kg Weekly","Trastuzumab-MCC-DM 1.6 mg/kg administered intravenously (IV) once a week"
"4813",5816,"NCT00932373",286659,0.333333333,1,3,"Baseline to the end of the study (up to 3 years 2 months)",NA,"Trastuzumab-MCC-DM 2.0 mg/kg Weekly","Trastuzumab-MCC-DM 2.0 mg/kg administered intravenously (IV) once a week"
"4819",5822,"NCT00906698",295317,0.333333333,1,3,"First administration of trial medication until 28 days after last administration of trial medication.",NA,"Afatinib 20mg With Vinorelbine i.v.","Continuous daily dosing of Afatinib 20mg orally and weekly Vinorelbine 25 mg/m2 intravenously (days 1, 8, 15 and 22) in a 4-weekly course. Patients will be eligible for repeated treatment courses in the absence of clinical disease progression or undue toxicity ."
"4837",5847,"NCT00705874",369953,0.333333333,1,3,NA,NA,"PG11047/Sunitinib","PG-11047 (infusion on Days 1 and 8 of a 21 day cycle) in combination with Sunitinib (50 mg orally once daily, 4 weeks on treatment followed by 2 weeks off (42 day cycle))."
"4857",5877,"NCT00467779",457616,0.333333333,1,3,"AEs were recorded from the Day 1 of treatment period until the 30 plus or minus 4 days after the last treatment (up to approximately 6 years) .",NA,"Stage 1 Cohort 03 – Cobimetinib 0.20 mg/kg (21/7)","Participants received cobimetinib 0.20 mg/kg via solution or capsule, once daily for Days 1-21 of each 28-day cycle. Treatment was continued until PD or unacceptable toxicity for up to 1 year at the discretion of investigator and beyond 1 year with the agreement of the sponsor."
"4858",5878,"NCT00467779",457614,0.333333333,1,3,"AEs were recorded from the Day 1 of treatment period until the 30 plus or minus 4 days after the last treatment (up to approximately 6 years) .",NA,"Stage 1 Cohort 05 - Cobimetinib 20 mg (21/7)","Participants received cobimetinib 20 mg via solution or capsule, once daily for Days 1-21 of each 28-day cycle. Treatment was continued until PD or unacceptable toxicity for up to 1 year at the discretion of investigator and beyond 1 year with the agreement of the sponsor."
"4859",5879,"NCT00467779",457608,0.333333333,1,3,"AEs were recorded from the Day 1 of treatment period until the 30 plus or minus 4 days after the last treatment (up to approximately 6 years) .",NA,"Stage 1A Cohort 02A - Cobimetinib 80 mg (14/14)","Participants received cobimetinib 80 mg via solution or capsule, once daily for Days 1-14 of each 28-day cycle. Treatment was continued until PD or unacceptable toxicity for up to 1 year at the discretion of investigator and beyond 1 year with the agreement of the sponsor."
"4860",5881,"NCT00458237",461375,0.333333333,1,3,"Assessed each cycle throughout treatment from time of first dose and up to day 30 post-treatment. Median duration of treatment was 2.4 months.","Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3.","Phase I: Everolimus (Dose Level 2) and Trastuzumab","Cycle duration is 21 days. Participants receive trastuzumab 6 mg/kg [8 mg/kg loading dose] IV once every three weeks and take everolimus 10 mg by mouth daily on days 1-21. Participants are treated until disease progression or unacceptable toxicity."
"4861",5882,"NCT00457743",461508,0.333333333,1,3,NA,NA,"SU-011248 25-mg","Subjects received sunitinib malate (SU-011248) at starting dose of 25-mg once daily. Treatment cycles were 6 weeks in duration, consisting of 4 weeks daily SU-011248 administration followed by 2 weeks off treatment.
Phase 1: If Dose Limiting Toxicity (DLT) was observed, the patients were withdrawn from the study treatment. Neither temporary discontinuation nor reduction was permitted.
Phase 2: The initial dose could be increased to the recommended dose. Treatment cycles were repeated until a study treatment withdrawal criterion was met. If drug-related adverse event (grade>=3) was observed, temporary discontinuation or dose reduction were taken according to the criteria."
"4876",5902,"NCT00339144",503751,0.333333333,1,3,NA,NA,"Dasatinib 150 mg","Participants were administered an oral dose of 150 mg dasatinib tablet once daily for a period of 4 weeks. Initially, 3 participants were treated at one dose level. If no DLT was observed, the dose was escalated to next higher level. If a DLT was observed among 1 of 3 treated participants in the first course at a dose level, 3 participants were additionally enrolled and treated at the same dose level. If no further DLT was observed during the first course in these additional participants, the dose was escalated to next higher dose level. Dose was not escalated above 200 mg daily."
"4892",5920,"NCT00121719",555448,0.333333333,1,3,"All adverse events (AEs) were collected for up to approximately 4 years.","Treatment-emergent adverse events were defined as AEs that emerged during treatment, having been absent at pre-treatment, or that worsened in severity relative to the pre-treatment state, or occurred within 7 days or 5 times the half-life (whichever was longer) post participant's last treatment. Only treatment-emergent AEs and SAEs were reported.","1.6 mg Lenvatinib","One 1.0 mg lenvatinib tablet and six 0.1 mg lenvatinib tablets were taken orally, once daily. Lenvatinib was to be taken on an empty stomach shortly after waking. Participants were fasted for 2 hours following administration of lenvatinib and could drink only clear fluids during this time (grapefruit juice was to be avoided). If 1 of 3 participants experienced DLT during Cycle 1 (4 weeks) an additional 3 participants were to be treated at this dose level. If 5 of the 6 participants in the expanded dose level did not experience DLT during the first 4 weeks of therapy, no additional DLT was observed, the next dose level was opened for enrollment. If more than 1 participant experienced DLT during the first 4 weeks of therapy, dose escalation was stopped and the MTD was determined. An additional 12 participants were treated at the MTD level."
"4896",5926,"NCT00085566",567984,0.333333333,1,3,NA,NA,"RAD 001 50 mg","50 mg RAD 001 with Gefitinib in Patients with Glioblastoma Multiforme and Prostate Cancer"
"4917",5952,"NCT01335477",157458,0.328767123,72,219,"From the first drug administration until 28 days after the last drug administration, up to 425 days",NA,"Placebo","Oral administration of Placebo matching nintedanib soft gelatine capsules."
"4918",5953,"NCT00319254",511473,0.328767123,24,73,NA,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.","Bosutinib","Four bosutinib 100 milligram (mg) capsules, equivalent to 400 mg bosutinib orally once daily for 48 weeks, or until disease progression, unacceptable toxicity or withdrawal of consent occurred."
"4930",5969,"NCT00806819",329781,0.327731092,117,357,"From the first drug administration until 28 days after the last drug administration, up to 36 months","One patient in the nintedanib plus pemetrexed treatment arm reported a serious adverse event for which the preferred term was not yet coded until data cut-off (15 February 2013).","Placebo Plus Pemetrexed","Placebo soft gelatin capsule matching that of nintedanib 2 times daily on day 2 to 21 of each 21-day treatment course administered orally plus pemetrexed 500 mg/m2 on Day 1 of each 21-day treatment course administered via intravenous infusion. If required two dose reductions for pemetrexed were allowed (according to the protocol-defined dose-reduction scheme). No dose increase was allowed after a dose reduction."
"4957",5999,"NCT00710762",367392,0.325581395,14,43,"First drug administration until 28 days after last drug administration, up until 309 days",NA,"Nintedanib","Patients were treated with 250mg nintedanib twice daily."
"4962",6005,"NCT01708954",78388,0.325,13,40,"Assessed every 4 weeks while on treatment and for 30 days after the end of treatment",NA,"Arm A (Erlotinib)","Patients receive erlotinib 150mg PO daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
"4964",6007,"NCT00347919",502197,0.325,13,40,"Study Entry until 28 days after the last dose.",NA,"Cohort 2: Lapatinib 1500 mg/Pazopanib 800 mg","Lapatinib 1500 mg and Pazopanib 800 mg administered orally once a day"
"4971",6015,"NCT00531934",434145,0.324324324,24,74,"Adverse events (AEs) were recorded continuously until 30 days after the last treatment administration.",NA,"Erlotinib","Participants received erlotinib 150 mg/day, tablets, PO until progression or unacceptable toxicity."
"4973",6017,"NCT01090011",232621,0.324324324,12,37,"Up to 915 days","32 patients in the 'Afa40-mono' group had disease progression and were transitioned to treatment with 'Afa40+Ctx500'. Thus the total of 203 patients (4+126+37+36) minus the 321 patients counted in both 'Afa-mono' and 'Afa40+Ctx500' treatments arms equals 171, the total number of patients started in participant flow section.","Sequential Arm - Afatanib Monotherapy (Afa40 Mono)","Sequential Arm (includes patients who received afatinib monotherapy and upon progression the combination of afatinib and cetuximab at the MTD determined in the combination arm. Patients still needed to have met the criteria for AR to erlotinib or gefitinib) Afatinib 40 mg (Afa40 Mono)"
"4986",6032,"NCT00597038",409460,0.323529412,11,34,"First on treatment date to last off study date: 2 years, 4 months.",NA,"Phase II Dose Treatment","Dasatinib and Dacarbazine (DTIC). Dasatinib and Dacarbazine (DTIC). The recommended phase II dose was dasatinib 70 mg BID with dacarbazine 800 mgm^2."
"4989",6036,"NCT00418886",477044,0.323076923,84,260,NA,"Safety Analysis set used for reporting of safety. 260 for vandetanib and 273 for placebo.","Vandetanib Plus Pemetrexed","vandetanib (100 mg daily) plus pemetrexed (500 mg/m2 given on Day 1 of each 21-day cycle)"
"4994",6042,"NCT00546104",428566,0.322580645,10,31,NA,NA,"Dasatinib","50-100mg po bid"
"5023",6076,"NCT00585377",413186,0.32,16,50,NA,NA,"Arm 1","Bevacizumab and Erlotinib: Erlotinib 150 mg/day orally plus bevacizumab 15 mg/kg intravenously every 21 days"
"5038",6093,"NCT00015847",576639,0.32,8,25,NA,NA,"Imatinib Mesylate","Once daily oral administration of STI571 (imatinib mesylate) at a dose of 400 mg or 600mg for 12 months."
"5046",6103,"NCT00769067",345392,0.319148936,30,94,"Adverse events (AEs) were recorded from the time that the participant provided informed consent through and including 28 calendar days after the last administration of the investigational product.","The same event may appear as both an AE and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in 1 participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.","Erlotinib","Erlotinib 150 milligram (mg) tablet orally once daily continuously in 28-day cycles until unacceptable toxicity, tumor progression or death."
"5050",6107,"NCT01641939",91959,0.31884058,22,69,"Baseline up to data cut-off date 30-June-2015 (up to 2 years 3 months)","Safety Analysis Population included all participants who received at least one dose of study medication. The safety parameters were analyzed and presented according to the therapy participants received. Cumulative data (up to primary analysis cut-off date of 30-June-2015) are provided for both phase 2 and phase 3.","Trastuzumab Emtansine 3.6 mg","Trastuzumab emtansine was administered on Days 1 of a 21-day cycle at 3.6 mg/kg IV infusion until progression of disease, intolerable toxicity, initiation of another anticancer therapy, or participants and/or physician decision to discontinue."
"5054",6111,"NCT01650805",89889,0.318181818,49,154,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",NA,"Ponatinib 45 mg","ponatinib: 45 mg tablet, taken orally once daily"
"5056",6113,"NCT00696696",373916,0.318181818,14,44,"up to 1 year (treatment period plus 30 days after the treatment)","All the events were included regardless they were related or not related to the treatment drugs.","Combination GES","Combination of Gemcitabine, Erlotinib, and Sorafenib"
"5057",6114,"NCT00470054",456621,0.318181818,14,44,NA,"All 44 participants who received treatment were analyzed (including ineligible participants).","Dasatinib","Pts receive oral dasatinib 70 mg twice daily"
"5058",6115,"NCT00371254",494131,0.318181818,14,44,NA,NA,"All Participants","All treated participants who were administered a twice-daily oral dose of either 100 mg (TDD 200 mg) or 70 mg (TDD 140 mg) dasatinib tablet. Study treatment continued for as long as it was tolerated, or until PD, defined as appearance of new lesion/s, or >=20% increase in the sum of the LD of target lesions, relative to the smallest sum LD recorded since treatment start, or unequivocal progression of existing non-target lesions."
"5079",6139,"NCT00698815",373367,0.317073171,13,41,NA,"Adverse events were evaluated for 124 participants (41, 44 and 39 on Arm I, II and III, respectively).","Arm I (Pemetrexed)","Patients receive pemetrexed disodium 500 mg/m^2 IV over 10 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients with documented disease progression may then receive sunitinib malate as in Arm II as third-line therapy."
"5085",6145,"NCT00606502",405829,0.316831683,32,101,"Assessed every 2 weeks while on treatment through safety follow-up visit (35 +/-5 days post-last dose) or early termination visit (at time of withdrawal).","Events reported for all patients who received at least one dose of Pralatrexate or Erlotinib.","Erlotinib",NA
"5098",6162,"NCT00085566",567983,0.315789474,18,57,NA,NA,"RAD 001 70 mg","70 mg RAD 001 with Gefitinib in Patients with Glioblastoma Multiforme and Prostate Cancer"
"5104",6168,"NCT01026844",252586,0.315789474,6,19,NA,NA,"Erlotinib Plus HCQ (Hydroxychloroquine)","Erlotinib at 150mg QD and HCQ at escalating doses (400mg, 600mg, 800mg and 1000mg QD)"
"5109",6173,"NCT00508001",444125,0.315789474,6,19,NA,NA,"ZD6474 300","ZD6474 (Vandetanib) 300 mg ( one tablet per day, orally). plus Best Support Care"
"5112",6177,"NCT00350727",501468,0.315789474,6,19,"Serious adverse events (SAEs) and non-serious AES in Phases I and II were collected from Day 1 of study treatment to study completion (up to 844 days for Phase I; up to 878 days for Phase II).",NA,"Phase II: Biomarker Positive","All participants received pazopanib 400 mg twice daily (QD) and lapatinib 1000 mg QD. Biomarker-positive participants were those who expressed epithelial growth factor receptor vIII (EGFRvIII) and/or phosphate and tensin homolog (PTEN)."
"5123",6189,"NCT00364351",496641,0.314606742,196,623,NA,"Safety Analysis set used for erlotinib 150 mg, therefore number at risk is 614","Vandetanib","Vandetanib 300 mg"
"5125",6192,"NCT00805194",330654,0.314503817,206,655,"From the first drug administration until 28 days after the last drug administration, up to 42 months","Number of participants at risk corresponds to all randomised patients who were documented to have taken at least 1 dose of study medication . Patients were allocated to the treatment groups according to the treatment actually received.","Placebo Plus Docetaxel","Placebo soft gelatin capsule matching that of nintedanib 2 times daily plus docetaxel 75 mg/m2 once every 3 weeks administered via intravenous infusion over 1 hour (h)."
"5130",6197,"NCT01309997",164187,0.314285714,11,35,"18 months",NA,"Imatinib as Initial Therapy","Arm I = imatinib, adverse event occurred after the start date of imatinib and if applicable, prior to start date of rituximab."
"5137",6205,"NCT00698841",373345,0.31372549,16,51,"Baseline through Cycle 1 (28 days) and up to 30 following last dose of study medication (totaling up to 58 days)",NA,"Cetuximab","Cetuximab given by intravenous (IV) infusion at an initial dose of 400 mg/m^2 over 120 minutes on Day 1 followed by a weekly maintenance IV dose of 250 mg/m^2 over 60 minutes."
"5139",6207,"NCT00454363",462650,0.31372549,16,51,"Adverse events occurring within 30 days of last dose investigational drug, with each cycle 28 days for up to 12 cycles. Overall participation period April 2007 to March 2013.",NA,"Pazopanib","Oral pazopanib hydrochloride once daily on days 1-28."
"5140",6208,"NCT01996332",36695,0.313573407,566,1805,"From the administration of first dose of study medication to the end of study or until death.","Nonserious adverse events presented in this record include all adverse events reported during the study, not just nonserious events.","Erlotinib 150 mg/Day","Participants received erlotinib 150 mg/day, orally, until progressive disease or unacceptable toxicity."
"5176",6249,"NCT00021229",576579,0.3125,5,16,"Adverse events were assessed weekly during the first four weeks (course 1), every 2 weeks during the next 2 courses (8 weeks total), every 4 weeks for all subsequent courses (up to 13 courses), and through 30 days following the end of treatment.","Assessments were made routinely for all patients per the schedule of clinical and laboratory assessments outlined in the protocol.","Stratum IIB: Imatinib Mesylate","Children with recurrent high-grade gliomas on enzyme-inducing anticonvulsant drugs (EIACDs) received imatinib twice daily at a starting dose of 350 mg/m2/day. Treatment cycles were 4 weeks (maximum tolerated dose (MTD) estimation period - first 4 weeks) and imatinib was continued for up to 52 weeks in the absence of progression or serious toxicity. Study participants did not receive radiation therapy in this stratum.
Because of concerns of intratumoral hemorrhage, the protocol was amended (08JAN2003) to extend the MTD estimation period to 8 weeks (courses 1 and 2).
Eight participants were enrolled on the phase I before the amendment and eight after the amendment."
"5188",6263,"NCT00684983",377446,0.311111111,14,45,NA,NA,"Arm B","Patients receive capecitabine and lapatinib ditosylate as in arm I. Patients also receive cixutumumab IV over 1-1½ hours on days 1, 8, and 15. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. cixutumumab: Given IV, lapatinib ditosylate: Given PO and capecitabine: Given PO"
"5194",6269,"NCT01335464",157522,0.310679612,96,309,"From the first drug administration until 28 days after the last drug administration, up to 425 days",NA,"Nintedanib 150mg Bid","Oral administration of soft gelatine capsules of Nintedanib 150 mg twice daily (bid). Dose interruption and reduction to 100 mg bid dose were allowed to manage adverse events."
"5197",6274,"NCT00373425",493297,0.310606061,41,132,"From the first dose of study drug until 30 days after the last dose. Maximum time on treatment for the Randomized Cohort was 24 months; maximum time on treatment for the BPC was 13 months on blinded study drug and 26 months on open-label erlotinib.","One participant in the Randomized Cohort assigned to the erlotinib arm received placebo instead due to a dispensing error and is included in the placebo group for safety analyses. For the Breached Protocol Cohort safety analyses are based on the total no open-label and open-label populations.
Safety data are based on the 11 June 2014 cut-off date.","BPC-OLC: Erlotinib","The BPC open-label cohort (BPC-OLC) includes participants randomized prior to 07 November 2007 who received at least 1 dose of study drug after being randomized, who entered the open-label erlotinib period. Data presented for the BPC-OLC included data from both the blinded period and the open-label erlotinib period."
"5200",6277,"NCT00578071",415545,0.310344828,9,29,NA,NA,"Chemoradiation","Panitumumab, oxiplatin, capecitabine, radiation therapy"
"5210",6288,"NCT00678392",379749,0.309859155,110,355,NA,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.","Sorafenib","Sorafenib 400 mg tablet administered orally BID in cycles of 4 weeks."
"5212",6290,"NCT00883779",301260,0.309734513,70,226,"Up to 28 days after the last dose in the primary and post study treatment phases of the study (up to approximately 5.5 years)",NA,"Erlotinib","Participants received 1250 mg/m^2 of gemcitabine IV infusion on Day 1 and 8, carboplatin 5x AUC or cisplatin 75 mg/m^2 IV infusion on Day 1 and oral erlotinib 150 mg/day from Day 15 to 28 every 4 weeks, continued for 6 cycles (28-day cycle) until PD, unacceptable toxicity or death in the primary study treatment phase. Participants who completed 6 cycles of treatment without PD or unacceptable toxicity, or if they withdrew early because of toxicity from the platinum-doublet chemotherapy, entered the post-study treatment phase and continued same treatment until PD, unacceptable toxicity or death. Participants who withdrew due to PD or toxicity from erlotinib could not enter the post-study treatment phase. Upon PD (during either the primary or post-study treatment phase), participants were treated at the discretion of the investigators' discretion (Off-study phase)."
"5214",6292,"NCT00995007",264298,0.30952381,13,42,NA,NA,"Crossover to Vandetanib","ZD6474 (Vandetanib): Vandetanib is an oral medication known to block angiogenesis and has shown significant antitumor activity in laboratory and animal studies. Vandetanib appears to be well tolerated by patients at specific daily doses."
"5225",6305,"NCT00982488",268980,0.308108108,57,185,NA,NA,"Dasatinib, 50 mg QD to 120 mg BID, Chronic Phase","Participants with chronic phase disease were rolled over from previous studies CA180-039, CA180-043, and the SRC/ABL tyrosine kinase inhibition activity: Research trials (START). Participants continued on the previous study dose of dasatinib, ranging from 50 mg once daily (QD) to 120 mg twice daily (BID). Dose escalations to optimize response and dose reductions for toxicity were permitted. Participants received study medication until disease progression, unacceptable toxicity, failure to serve patient's best interest, withdrawal of consent, or study closure."
"5237",6320,"NCT01137604",217565,0.307692308,12,39,"For each participant, from the first patient first dose till 30 days after the last dose or the cut-off date of 19 March 2013 (ie, 2.4 years)",NA,"Cohort 2 - Lenvatinib","Participants with recurrent Grade 3 malignant glioma who were bevacizumab-naive; received lenvatinib capsules 24 mg taken orally, once daily continuously in 28-day cycles"
"5240",6323,"NCT00586105",413059,0.307692308,12,39,"From First Patient First Visit (FPFV) to Last Patient Last Visit (LPLV).","Acronyms used: Gastrointestinal (GI), Genitourinary (GU), Not Otherwise Specified (NOS), Absolute Neutrophil Count (ANC), Aspartate aminotransferase (AST), Partial Thromboplastin Time (PTT), Alanine aminotransferase (ALT), Common Terminology Criteria for Adverse Events (CTCAE)","Sorafenib (Nexavar, BAY43-9006)","400 mg (2 tablets of 200 mg) of sorafenib per oral (PO) twice daily (BID)"
"5241",6324,"NCT00515697",441036,0.307692308,12,39,NA,NA,"Ramucirumab","Ramucirumab at 8 milligrams per kilogram (mg/kg) infused intravenously over 1 hour, on Day 1 of every 14-day cycle. Treatment continued until there was evidence of disease progression or intolerable toxicity."
"5256",6340,"NCT00558103",422831,0.307692308,4,13,NA,NA,"Cohort 2: Pazopanib 800 mg","Participants received oral pazopanib 800 mg (4 x 200 mg tablets) QD. The study treatment continued until participants experienced disease progression, unacceptable toxicity, or death. Participants who received pazopanib monotherapy and experienced unequivocal disease progression were given the option to receive lapatinib monotherapy in an open-label extension phase."
"5257",6341,"NCT00538291",431763,0.307692308,4,13,"Adverse events occurred over a period of of 17 months.","Other adverse events include all grades and attribution to treatment that are not included in Serious adverse events","Arm 1","Cetuximab 400mg/m2 IV on day 1 over 2 hours then 250 mg/m2 over 1 hour weekly + Xeloda(Capecitabine) 1000mg/m2 BID on days 1-14 repeated every 21 days."
"5258",6342,"NCT00536575",431861,0.307692308,4,13,NA,NA,"Sorafenib/Bortezomib","The trial was designed as a single-arm Phase I/II study of sorafenib and bortezomib with dose optimization in initial patients. Phase I consisted of cohorts of 3 patients at each of three dose levels. Patients received bortezomib (Dose Level 1 - 1.3 mg/m2; Dose Level 2 - 1.6 mg/m2) by IV bolus on days 1, 8, 15, and 22 of each 5-week cycle with continuous oral dosing of sorafenib at 200 mg twice daily. Dose level 3 was planned as bortezomib 1.6 mg/m2 IV bolus on days 1, 8, 15, and 22 with sorafenib 400 mg by mouth twice daily throughout each 5-week cycle."
"5259",6343,"NCT00510653",443154,0.307692308,4,13,"7 years",NA,"Imatinib Mesylate","600 mg/day orally for 6 Weeks"
"5264",6348,"NCT00109031",559512,0.307692308,4,13,"40 days from first dose of palifermin","Seven participants received the wrong sequence of placebo and palifermin as follows (# participants [from assigned arm to actual treatment arm]): 2 participants (A to C), 2 participants (D to B), 1 participant (C to A), 1 participant (B to D), 1 participant (C to D). Adverse event data are summarized by actual treatment group.","Palifermin 180 μg/kg on Day −2 (C)","Palifermin 180 μg/kg on Day −2 and placebo on Days −1 and -3 prior to fTBI, and palifermin 60 μg/kg on Days 0, 1, and 2 after PBPC."
"5267",6351,"NCT00410761",479444,0.307359307,71,231,NA,NA,"Vandetanib 300 mg","Vandetanib (300 mg daily)"
"5283",6368,"NCT00329719",505714,0.306122449,15,49,NA,NA,"Phase II, Arm B","Patients receive sorafenib and temsirolimus at the MTD (25mg temsirolimus and 200mg sorafenib).
sorafenib tosylate: Given PO
temsirolimus: Given IV"
"5301",6394,"NCT01001377",260768,0.304435484,151,496,"Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.","Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses.
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.","Panitumumab","Panitumumab 6 mg/kg IV every 14 days."
"5306",6399,"NCT02013206",34783,0.304347826,7,23,"Up to 2 Years",NA,"Never Smokers","Never Smokers (participants who smoked ≤ 100 cigarettes in entire lifetime or had never smoked cigarettes) received erlotinib [Tarceva] 150 mg orally daily until disease progression or unacceptable toxicity."
"5310",6404,"NCT00203931",538315,0.304347826,7,23,"up to 5 years","Serious adverse events of any grade are reported. For all other adverse events, only those grade 3 or higher were collected during the study. Adverse events are reported for the evaluable patients who received at least 3 doses of Cetuximab","Cetuximab and Pemetrexed","Cetuximab initial dosage of 400 mg/m2 over 120 minutes, followed by weekly infusions at 250 mg/m2 over 60 minutes. Starting on day 15 and then subsequently on day 1 of each 21 day cycle, Pemetrexed 500 mg/m2."
"5325",6421,"NCT00454142",462768,0.303030303,10,33,"From the time of first treatment with pazopanib hydrochloride to up to 1 month after completion of treatment.",NA,"Treatment (Tyrosine Kinase Inhibitor)","Patients receive pazopanib hydrochloride PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
computed tomography : Correlative studies
pharmacological study : Correlative studies
pazopanib hydrochloride : Given PO"
"5327",6424,"NCT00373113",493409,0.302521008,72,238,NA,"The same event may appear as both an adverse event (AE) and a serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.","Sunitinib","37.5 mg daily, continuous dosing"
"5331",6428,"NCT00514683",441988,0.302325581,26,86,"First drug administration until 14 days after last drug administration",NA,"Nintedanib 50 qd","Patients were treated with 50mg nintedanib once daily"
"5343",6442,"NCT00934544",285955,0.301369863,44,146,NA,NA,"INC424/INCB018424","The starting dose of ruxolitinib tablets was determined based on baseline platelet count as follows: Subjects with baseline platelet count > 200, 000/µL began dosing at 20 mg bid (four 5 mg tablets bid) or Subjects with baseline platelet count of 100,000/µL to 200,000/µL (inclusive) began dosing at 15 mg bid (three 5 mg tablets bid).
A standardized dosing paradigm was used to determine dose adjustments for safety and efficacy so that each subject was titrated to their most appropriate dose."
"5348",6447,"NCT00678392",379750,0.300835655,108,359,NA,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.","Axitinib","Axitinib (AG-013736) 5 mg tablet administered orally BID in cycles of 4 weeks."
"5351",6450,"NCT00089635",566879,0.300492611,61,203,"First dose date through the safety follow-up visit. The median time frame is 2.6 months.","The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.","Panitumumab","Panitumumab was administered by intravenous (IV) infusion at a dose of 6 mg/kg once every 2 weeks until participants developed progressive disease, were unable to tolerate investigational product, or discontinued for other reasons."
"5360",6460,"NCT00533702",433176,0.3,15,50,NA,NA,"IMC-1121B (Ramucirumab)","IMC-1121B (ramucirumab): 10 mg/kg administered intravenously on Day 1 of 21-day cycle in the absence of disease progression, unacceptable toxicity, or other withdrawal criteria."
"5362",6462,"NCT00859937",308742,0.3,12,40,"Up to 5 years","All serious adverse events were reported. Other adverse events occurring in ≥5% of the study subjects were reported.","Adenoid Cystic Carcinoma","Patients with Adenoid cystic carcinoma of malignant salivary gland tumors receive oral dasatinib (70mg) twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
"5364",6464,"NCT00130520",551994,0.3,12,40,"Collected from the start of the 1st subject 6/2005 until the last subject was off treatment which was October 5, 2009 as the data was truncated for the purpose of the publication. Subjects came in for treatment every 2 weeks.",NA,"Bevacizumab and Erlotinib","This is an open label study. All subjects received erlotinib 150 mg/day orally and bevacizumab 10 mg/kg intravenously every 2 weeks until disease progression. Progression free survival (PFS) was defined as the time from the start of therapy to the time of the first documentation of progression, symptomatic deterioration, or death due to any cause"
"5367",6467,"NCT00525148",437627,0.3,9,30,"First administration of trial medication until 28 days after last administration of trial medication, up to 93 months.",NA,"BIBW 40mg","Subjects receiving starting doses 40 mg of Afatinib daily."
"5373",6473,"NCT01553851",108526,0.3,6,20,"Adverse events were collected for 4-6 weeks.","AE grade 3 or higher will be followed for 3-6 months and considered at least possibly related","GSK1120212","GSK1120212 2 mg PO daily for a total of 14 days with the intent of the last pill being the day before surgery.
GSK1120212: Trametinib (GSK1120212) is a selective MEK1 and MEK2 inhibitor with selective activity towards BRAF and RAS mutant cancer cell lines and hematopoietic cancer cells from AML and CML origins."
"5380",6481,"NCT00803647",331131,0.3,6,20,"8 months",NA,"Treatment","mFOLFOX7 (5-FU, leucovorin, oxaliplatin) + cetuximab"
"5381",6482,"NCT00748709",353538,0.3,6,20,"First administration of trial medication until 28 days after last administration of trial medication",NA,"Afatinib 50mg","Patients with genetically pre-screened cancers with EGFR and/or HER2 gene amplification or EGFR activating mutations treated with afatinib 50mg once daily."
"5393",6496,"NCT01502410",118567,0.3,3,10,NA,"SAE field contains NCI Common Terminology Criteria for Adverse Events (CTCAEs) submitted via expedited reporting (NCI AdEERs / CAeRs). The AE field contains grade 3 and higher CTCAEs reported on study excluding those that were reported as SAEs. Only Grade 3 and higher Adverse Events were collected/assessed in this study.","Group 2 Relapsed/Refractory Wilms Tumor","Patients with relapsed or refractory Wilms tumor receive sorafenib tosylate PO BID on days 1-28. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity."
"5418",6524,"NCT00385203",489621,0.3,3,10,NA,"Adverse events are reported for randomised patients who received at least one dose of treatment.","Cediranib 45 mg/Day STS","Cediranib 45 mg/Day patients with Soft Tissue Sarcomas (STS): 10 patients randomised and received at least one dose of treatment."
"5425",6531,"NCT00806819",329782,0.299711816,104,347,"From the first drug administration until 28 days after the last drug administration, up to 36 months","One patient in the nintedanib plus pemetrexed treatment arm reported a serious adverse event for which the preferred term was not yet coded until data cut-off (15 February 2013).","Nintedanib Plus Pemetrexed","Nintedanib 200 mg twice daily administered orally in a form of a soft gelatin capsule on day2 to 21 of each 21-day treatment course plus pemetrexed 500 mg/m2 on Day1 of each 21-day treatment course administered via intravenous infusion. If required the dose of nitedanib could be redused to 150 mg twice daily (b.i.d.) or 100 mg b.i.d. and two dose reductions for pemetrexed were allowed (according to the protocol-defined dose-reduction scheme). No dose increase was allowed after a dose reduction."
"5432",6540,"NCT01664533",86829,0.298245614,17,57,"Time frame is up to 2 years","Safety analysis population: All participants who received at least 1 dose of erlotinib.","Erlotinib","Selection of the dose of erlotinib most suitable for each participant was left to the discretion of the physician, guided by the recommendation in the Summary of Product Characteristics. The recommended daily oral dose of erlotinib is 150 mg."
"5434",6543,"NCT01335477",157457,0.29787234,98,329,"From the first drug administration until 28 days after the last drug administration, up to 425 days",NA,"Nintedanib 150mg Bid","Oral administration of soft gelatine capsules of Nintedanib 150 mg twice daily (bid). Dose interruption and reduction to 100 mg bid dose were allowed to manage adverse events."
"5447",6559,"NCT00281658",522988,0.297297297,66,222,NA,"Serious adverse events and adverse events were collected in the Safety Population, comprised of all randomized participants who received at least one dose of investigational product.","Lapatinib Plus Paclitaxel","Lapatinib 1500 milligrams (mg) administered once daily plus paclitaxel 80 mg/meters squared (m^2) administered intravenously (IV) weekly for 3 weeks every 4 weeks"
"5452",6564,"NCT00098254",563317,0.297297297,11,37,"5 years, 6 months, and 21 days",NA,"BAY 43-9006 (Sorafenib)","Self administered oral doses at 400 mg twice a day with 250 ml (8 oz.) of water each morning and evening (i.e., 12-hourly) continuously in a 28 day cycle. Tablets may be taken with or without food."
"5462",6575,"NCT00261846",528963,0.296610169,35,118,NA,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.","CP3L-CML","All participants who received bosutinib 500 mg orally once daily for 48 weeks in chronic phase third-line (CP3L) chronic myelogenous leukemia (CML), participants were imatinib (IM) resistant/intolerant (R/I) and dasatinib (D) resistant (R), dasatinib (D) intolerant (I), nilotinib (NI) resistant (R), and dasatinib and nilotinib resistant/intolerant (R/I) or nilotinib intolerant (I)."
"5463",6576,"NCT00920816",290720,0.296296296,40,135,"Baseline up to Week 107","Same event may appear as both AE and SAE. However, what is presented are distinct events. Event may be categorized as serious in 1 subject and nonserious in another subject, or 1 subject may have experienced both a serious and nonserious event during the study. Participants at risk = 189, 96, 135, 69 for each arm group, respectively.","Axitinib (Second-line Participants)","Asian participants with prior systemic first-line therapy containing sunitinib or cytokine received axitinib (AG-013736) tablet at a starting dose of 5 mg orally twice daily, dose adjustment was done based on the tolerability, as per investigator’s discretion. Study medication was administered in cycles of 4 weeks."
"5474",6587,"NCT00470847",456517,0.296296296,8,27,"May 2007- December 2009","Serious Adverse Events include all Participants N=35. Non-serious Adverse Events also include all participants N=35.","Dose Level 2","n=27 participants Maximum Tolerated Dose 1250 mg lapatinib daily"
"5477",6590,"NCT00902174",296746,0.295918367,29,98,NA,"202 participants were randomized (103 imatinib & 99 placebo; however, one participant who was randomized to the placebo group did not receive study drug and was excluded from this analysis set. The safety set includes all participants who received study drug = 201 (103 imatinib, 98 placebo).","Placebo","Placebo to imatinib"
"5478",6592,"NCT00091026",566170,0.295774648,21,71,NA,NA,"Arm I (Cetuximab, Gemcitabine Hydrochloride, Bevacizumab)","Patients receive cetuximab IV over 1-2 hours on days 1, 8, 15, and 22; gemcitabine IV over 30 minutes on days 1, 8, and 15; and bevacizumab IV over 30-90 minutes on days 1 and 15."
"5482",6596,"NCT00245102",532804,0.295454545,13,44,NA,NA,"Angiosarcoma","Sorafenib 400 mg PO BID"
"5509",6626,"NCT01235897",186386,0.294117647,5,17,"40 weeks","Toxicity assessment continued as long as patient received study treatment; the longest on-study duration was 40 weeks","MK-2206","MK-2206 : MK-2206 given orally at a dose of 135 mg weekly Trastuzumab : 2 mg/kg weekly after a 1-time loading dose of 4 mg/kg - trastuzumab Paclitaxel : 80 mg/m2 weekly - paclitaxel"
"5515",6632,"NCT00427973",472502,0.294117647,5,17,NA,"A total of 77 treatment cycles were administered, with a median of 3 cycles per patient (range: 1–15). Twelve of 17 patients required dose interruptions and subsequent reductions for the following reasons: gr 3 elevated AST (3), gr 3 hyperbilirubinemia (3), gr 3 elevated ALT (2), gr 3 dehydration (1), gr 2 diarrhea (1), and gr 1 proteinuria (2).","Singe Arm Open Label Study With AZD2171 at 30 mg Daily","Patients will receive AZD2171 (cediranib maleate) at 30 mg by mouth once a day. Treatment may continue for as long as benefit is shown. Patients will undergo MRI and CT scan of the liver before beginning treatment, 3 days after the first dose of AZD2171, and after finishing course one. Patients will also undergo blood collection periodically for laboratory studies. Laboratory biomarker analysis, computed tomography, dynamic contrast-enhanced magnetic resonance imaging, and pharmacological study will be performed.
cediranib maleate: Given orally
laboratory biomarker analysis
computed tomography
dynamic contrast-enhanced magnetic resonance imaging
pharmacological study"
"5524",6645,"NCT00821886",323440,0.293103448,17,58,NA,"Adverse Event analysis includes patients who were enrolled and treated","Ixabepilone/Trastuzumab/Carboplatin","Neoadjuvant treatment with Ixabepilone, Trastuzumab and Carboplatin, followed by surgery, peri-operative treatment and post-operative (adjuvant) treatment if patient deemed to be a surgical candidate
Ixabepilone: Ixabepilone 40mg/m2 IV infusion over 3 hours on day 1 of cycles 1-6 (all treatment cycles are 21 days in length)
Trastuzumab: Trastuzumab 8mg/kg IV over 90 minutes for the first infusion (Cycle 1, Day 1) with a 60 minute post-infusion observation period. Subsequent infusions (Day 1 of Cycles 2-6 with all cycles being 21 days in length) 6mg/kg over 30 minutes if the previous dose was well tolerated; peri-operative trastuzumab 6mg/kg IV every 3-4 weeks; post-operative trastuzumab 6mg/kg IV day 1 every 3 weeks until week 52
Carboplatin: Carboplatin AUC=6 IV per institutional guidelines on Day 1 of Cycles 1-6 (all treatment cycles are 21 days in length)"
"5527",6651,"NCT00405938",481685,0.292682927,12,41,NA,NA,"Bevacizumab/Fulvestrant","Bevacizumab/fulvestrant (with trastuzumab in HER2+ patients). Bevacizumab 10mg/kg IV every 2 weeks [patients who are also receiving trastuzumab have the option to receive their bevacizumab at 15 mg/kg every 3 weeks instead of 10 mg/kg every 2 weeks (see Trastuzumab section below)] fulvestrant (500 mg intramuscular on Day 1 of Cycle 1, followed by 250 mg intramuscular of fulvestrant on Day 15 of Cycle 1. On Day 1 of Cycle 2 and the first day of all subsequent cycles thereafter, patients in this treatment arm will receive 250 mg intramuscular of fulvestrant). Treatment will be given in 4-week cycles."
"5541",6671,"NCT00555672",424179,0.291666667,7,24,NA,"The same event may appear as both an adverse event (AE) and a serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.","Sunitinib (25 mg) in Combination With Cisplatin and 5-FU","Sunitinib: 25 milligram (mg) oral capsule daily for 2 weeks (Day 1 to 14) followed by 1 week (Day 15 to 21) off treatment. Cisplatin: 80 mg per meter squared (mg/m^2) intravenous on Day 1 of each 21-day cycle. 5-Fluorouracil (5-FU): 4000 mg/m^2 continuous infusion for 96 hours starting Day 1 and ending Day 5 of each 21-day cycle."
"5545",6675,"NCT01298323",167618,0.291262136,30,103,NA,"Of 103 patients randomized to vandetanib 300 mg+outreach arm, all except 1 patient took part in outreach program . This patient was withdrawn due to eligibility criteria failure and could not be contacted successfully. Hence the results have been summarized under vandetanib 300 mg for safety summaries.","Vandetanib 300mg","Vandetanib (3 x 100 mg tablet form) was dosed orally, once daily"
"5559",6689,"NCT00058552",572313,0.290322581,18,62,NA,NA,"Pertuzumab 1050 mg","Participants in this group received 1050 mg of pertuzumab IV infusion at each cycle (1 Cycle = 3 Weeks) up to 1 year (17 cycles) or until disease progression."
"5566",6696,"NCT00570232",418297,0.290322581,9,31,NA,NA,"Tarceva","All patients will be prescribed Tarceva 150mg daily
Erlotinib: 150 mg per day by mouth for 12 months"
"5569",6700,"NCT01641939",91960,0.290178571,65,224,"Baseline up to data cut-off date 30-June-2015 (up to 2 years 3 months)","Safety Analysis Population included all participants who received at least one dose of study medication. The safety parameters were analyzed and presented according to the therapy participants received. Cumulative data (up to primary analysis cut-off date of 30-June-2015) are provided for both phase 2 and phase 3.","Trastuzumab Emtansine 2.4 mg","Trastuzumab emtansine was administered on Days 1, 8, and 15 of a 21-day cycle at 2.4 mg/kg IV infusion until progression of disease, intolerable toxicity, initiation of another anticancer therapy, or participants and/or physician decision to discontinue."
"5570",6701,"NCT00486954",451025,0.290076336,38,131,"Serious adverse events (SAEs) and non-serious AEs were collected from the first dose of investigational product to 30 days after the last dose (up to 51.7 weeks in the Pilot part and up to 110.3 weeks in the Randomized part).","SAEs and non-serious AEs were collected in members of the Safety Population in both the Pilot part and the Randomized part . For the Pilot part, MedDRA 12.1 was used; for the Randomized part, MedDRa 15.1 was used.","Lapatinib Plus Paclitaxel in Randomized Part","Participants received 1500 mg of oral lapatinib once daily throughout the study duration. Participants received a paclitaxel 1-hour intravenous infusion weekly for 3 weeks of a 4-week cycle at 80 mg/m^2 (on Days 1, 8, and 15 of each cycle)."
"5574",6706,"NCT00430781",471544,0.289473684,22,76,"SAEs/AEs were assessed in par. receiving >=1 dose of study treatment at time of final PFS analysis (From Randomization [11 December 2006] until last par. had last visit [28 July 2011] in combined population of two monotherapy arms [up to 241.43 weeks])","Serious adverse events (SAEs) and adverse events (AEs) are reported for the Safety Population (all participants who received at least one dose of study drug).","Lapatinib Monotherapy","1500 mg (6 x 250 mg tablets) of oral lapatinib daily"
"5586",6719,"NCT00949650",280857,0.288209607,66,229,"First administration of trial medication until 28 days after last administration of trial medication.",NA,"Afatinib 40mg","Patients receiving Afatinib monotherapy 40mg once daily (q.d.)"
"5590",6723,"NCT01271712",175407,0.287878788,38,132,"From randomization of the first subject until date of database cutoff (26 Jan 2012).","Acronyms used: International Normalized Ratio (INR).","Regorafenib (Double Blind Only)","Regorafenib (Double Blind study phase only): Participants received Regorafenib (Stivarga) 160 mg (4 x 40 mg tablets) per os once daily, 3 weeks on therapy followed by 1 week off therapy to comprise a cycle of 4 weeks"
"5601",6734,"NCT00443534",466337,0.286885246,35,122,NA,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.","Sunitinib","Participants received sunitinib (SU011248) capsules in one of the standard sunitinib schedules: Schedule 4/2 [4 weeks on study drug, 2 weeks off treatment]; Schedule 2/1 [2 weeks on study drug, 1 week off treatment]; Schedule 2/2 [2 weeks on study drug, 2 weeks off treatment]; or continuous dosing). The starting dose for all dosing regimens except continuous dosing was 50 milligram (mg) orally once daily (37.5 mg orally once daily for continuous dosing)."
"5605",6738,"NCT00474929",454803,0.285714286,22,77,"The adverse events reported here occurred during treatment. The maximum treatment length was 27, 28-day cycles.","Adverse events were collected at the end of each cycle.","Phase II","Phase II: Sorafenib 200 mg twice daily, RAD001 5mg every day;"
"5608",6741,"NCT00371345",494061,0.285714286,20,70,NA,NA,"Dasatinib","Dasatinib was administered orally at 70 mg BID (TDD=140 mg) or 100 mg BID (TDD=200 mg)."
"5615",6749,"NCT00117637",556700,0.285714286,14,49,NA,"Acronyms and abbreviations used: Common Terminology Criteria for Adverse Events (CTCAE); Not Otherwise Specified (NOS); Gastrointestinal (GI); Absolute Neutrophil Count (ANC); Alanine aminotransferase (ALT); Aspartate aminotransferase (AST); Central nervous system (CNS); Acute respiratory distress syndrome (ARDS)","Sorafenib 600 mg (as Dose Escalation After 400 mg)","Subjects received 2 tablets of Sorafenib (200 mg tablets) twice daily (bid) (ie 12-hourly) orally until progression in (= first intervention period, 5.7 months [median] ) and 3 tablets of Sorafenib twice daily (ie 12-hourly) orally until the following progression (= second intervention period, 3.6 months [median]) on a continuous basis."
"5617",6751,"NCT01028222",252251,0.285714286,12,42,NA,NA,"Nilotinib","400 mg twice daily"
"5634",6772,"NCT00429949",472060,0.285714286,6,21,"Adverse events were collected from the start of treatment until 30 days following the completion of treatment (median duration of therapy was 51 days)",NA,"Dasatinib","Dasatinib will be administered continuously at an oral dose of 70 mg BID on Days 1-28 of each 28 day cycle.
In patients with stable disease after 8 weeks on therapy the dasatinib will be increased to 100 mg BID on Days 1-28 on each 28 day cycle."
"5637",6776,"NCT01661179",87662,0.285714286,4,14,NA,NA,"Vandetanib 300 mg","Vandetanib at 300 mg using 3 x 100 mg vandetanib tablets were dosed orally, once daily"
"5649",6790,"NCT00357734",499455,0.285714286,4,14,NA,NA,"Gefitinib (ZD1839)","ZD1839 at a daily dose of 250 mg or 500 mg depending on final dose in parent trial"
"5651",6792,"NCT01871805",53184,0.285714286,2,7,"From baseline to up to 28 days after the last dose of alectinib (up to Week 105; data cut-off date 24 October 2014)",NA,"Alectinib 460 mg (Fed): Phase I","Participants received single dose of 20 or 40 mg alectinib capsules orally to make a dose of 460 mg on Cycle 1 Day -3 and then received 460 mg BID dose for 3-weekly cycles until disease progression, death or withdrawal for any other reasons."
"5672",6815,"NCT00965731",274309,0.285714286,2,7,"Up to 28 days after the last dose of study treatment (up to approximately 20 months)","The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.","PF-02341066 (200 mg) and Erlotinib (100 mg)","PF-02341066 200 milligrams (mg) administered orally twice daily (BID) in combination with erlotinib 100 mg administered orally once daily (QD) in a continuous schedule for 28 days (Cycle 1) and then in continuous 21-day cycles. Prior to combination treatment, participants completed a 7 to 14 day lead-in period where they received erlotinib 100 mg administered orally QD."
"5695",6841,"NCT00544908",429189,0.285714286,2,7,"Other Adverse Events include all events that were not severe adverse events regardless of grade or relation to treatment.","Adverse events recorded over a period of 13 months.","Dasatinib","Dasatinib 70 mg po bid (1 cycle=28 days)"
"5702",6853,"NCT00195260",539804,0.285714286,2,7,NA,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.","Bosutinib 500 mg","Bosutinib 500 mg capsule orally once daily continuously in 21-day cycles until disease progression, unacceptable toxicity, or consent withdrawal."
"5709",6864,"NCT01027598",252463,0.28358209,19,67,"18 Months",NA,"Arm B","Erlotinib + Placebo
Erlotinib: 150 mg orally daily
Placebo: orally daily"
"5711",6866,"NCT00718315",364566,0.28358209,19,67,"Adverse Events were recorded from Day 0 to Day 45 (15 days after the End of study)",NA,"Verutex","Participants received erlotinib 150 mg daily and A thin film of the topical formulation of Verutex was applied to face, neck, and anterior and posterior chest twice daily (every 12 hours), as per medical guidance daily for 30 days"
"5728",6884,"NCT01660906",87724,0.282051282,11,39,"Date of fist dose of study drug to 30 days post discontinuation of the last dose, an average of 3 years","Study initiated: December 2012; Study Completion: October 2015","Dasatinib","Dasatinib: A 100 mg tablet was taken orally once a day for up to 12 months while on study."
"5744",6906,"NCT00266695",526869,0.280788177,57,203,NA,NA,"Ruboxistaurin","32 mg given once daily as oral tablet for 2 years."
"5749",6913,"NCT01544179",110157,0.28030303,37,132,"AEs were collected from signature of informed consent, throughout the treatment period until 30 days after discontinuation of the investigational product",NA,"Gefitinib","Gefitinib 250mg and cisplatin plus pemetrexed combination chemotherapy"
"5754",6918,"NCT00754325",351639,0.28,14,50,"Date of randomization to date of initial disease progression, or date of death (whichever occurs first), up to January 2014 (approximately 5 years)","Study initiated: September 2008; Study Completion: January 2014","Fulvestrant and Dasatinib","Arm 1: Participants in this group received a drug regimen that consisted of both fulvestrant and dasatinib.
Fulvestrant: Intramuscular injection (IM), loading dose (500 mg) on Day 1 followed by 500 mg on Day 15 of Cycle 1 (28-day cycle). In subsequent cycles, 500 mg IM administered on Day 1, up to 2 years.
Dasatinib: Tablets, Oral, 100 mg, once daily (QD), up to 2 years"
"5758",6923,"NCT00297596",517994,0.28,7,25,NA,NA,"Oxaliplatin/Trastuzumab","Patients with HER2 positive breast cancer received treatment with oxaliplatin 130 mg/m2 IV day 1 and trastuzumab 6 mg/kg (following 8 mg/kg loading dose during cycle 1). Cycles were repeated every 21 days. Oxaliplatin : Oxaliplatin will be administered at a dose of 130 mg/ m2 over 120 minutes on day 1 of each cycle, following standard antiemetic premedications. 21 day cycles. For the first cycle, trastuzumab will be administered before oxaliplatin; however for subsequent cycles, oxaliplatin will be infused prior to trastuzumab Trastuzumab : Trastuzumab will be administered as an 8 mg/kg loading dose by intravenous (IV) infusion over 90 minutes on day 1 of cycle 1. Subsequent doses will be administered as a 6 mg/kg IV dose over 30 minutes."
"5770",6939,"NCT00390611",487809,0.279069767,12,43,NA,NA,"Paclitaxel/Carboplatin/Sorafenib","Paclitaxel 175 mg/m2 1-3 hour IV infusion, Day 1 Carboplatin AUC 6 infused over 20 minutes IV, Day 1 Sorafenib 400mg PO bid
Sorafenib
Paclitaxel: Paclitaxel
Carboplatin: Carboplatin"
"5782",6953,"NCT00556049",424014,0.277777778,20,72,NA,NA,"Neutropenia","Sunitinib and gemcitabine
Gemcitabine: Intravenously on days 1 and 8 of each 21-day treatment cycle.
Sunitinib: Orally on days 1-14 of each 21-day treatment cycle"
"5787",6958,"NCT00365144",496221,0.277777778,10,36,"21 weeks","Participants were followed for adverse events while on study treatment; the longest duration on study was 7 cycles (x 3 weeks). Due to the severe illness of pancreatic cancer patients, the study did not collect AEs and SAEs unrelated to study treatment (due to disease).","Bevacizumab Plus Erlotinib","Patients received bevacizumab 15 mg/kg as a 60-90 minute infusion every 21 days (representing one treatment cycle) and erlotinib 150 mg by mouth daily"
"5794",6966,"NCT01310855",163920,0.277777778,5,18,NA,NA,"Cediranib & Gefitinib","Cediranib maleate 30mg od orally and gefitinib 500mg od orally. Each cycle of treatment lasts 6 weeks. Treatment will continue until confirmation of progression, patient decision or the development of unacceptable toxicity (if there is radiological progression only treatment can continue if the investigator has the opinion that the patient is receiving benefit.
cediranib maleate
gefitinib"
"5795",6967,"NCT01306643",165228,0.277777778,5,18,"30 days post last study treatment (up to 12 months)","ITT Analysis Set","Idelalisib","Idelalisib 150 mg tablet(s) administered orally twice daily for a maximum of twelve 28-day cycles"
"5801",6974,"NCT00454571",462615,0.277777778,5,18,"1 year",NA,"Pazopanib, Leuprolide Acetate, and Goserelin Acetate","Patients receive pazopanib hydrochloride PO QD on days 1-28 after treatment with leuprolide acetate and goserelin acetate. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
pazopanib hydrochloride: Given PO
leuprolide acetate
goserelin acetate"
"5807",6980,"NCT00952289",279063,0.277419355,43,155,"From randomization through data cut-off of the primary analysis (02 November 2010).",NA,"Ruxolitinib","Participants began treatment with ruxolitinib 15 or 20 mg taken orally twice a day based on Baseline platelet count. The dose was adjusted by the Investigator based on efficacy and safety to a maximum of 25 mg twice daily."
"5823",6997,"NCT01128543",220774,0.275862069,8,29,NA,NA,"Lapatinib 1250 mg and Vinorelbine 20 mg/m^2","Participants received 1250 milligram (mg) tablets lapatinib once a day and vinorelbine 20 mg/meters squared (m^2) intravenously on Day 1 and Day 8, and every 3 weeks."
"5827",7001,"NCT00392392",486993,0.275862069,8,29,NA,NA,"Nab-Paclitaxel/Bevacizumab/Trastuzumab","Patients received treatment with nab-paclitaxel (100 mg/m2 IV days 1, 8, 15) and carboplatin (AUC 6 IV day 1) every 28 days for 6 cycles. Trastuzumab (4 mg/kg loading dose, followed by 2 mg/kg) and bevacizumab (5 mg/kg IV) were administered weekly for 23 weeks, beginning concurrently with chemotherapy. Patients then underwent either mastectomy or breast conserving surgery and pathologic treatment responses were assessed. After surgery, trastuzumab 6 mg/kg and bevacizumab 15 mg/kg were administered at 3 week intervals for a total of 52 weeks."
"5842",7020,"NCT00297258",518070,0.274647887,39,142,"Entire Study (average of 8.24 years).",NA,"Pazopanib 800 mg","Pazopanib 800 milligram (mg) (tablets) administered orally once a day"
"5848",7026,"NCT00435409",469850,0.274418605,59,215,NA,"The same event may appear as both an adverse event (AE) and a serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.","Capecitabine","Capecitabine administered orally at a starting dose of 2500 mg/m^2 per day (1250 mg/m^2 BID) from Days 1-14 every 3 weeks. At the time of progression, participants could have been eligible to crossover to single agent sunitinib, administered orally at a starting dose of 37.5 mg daily continuously."
"5849",7027,"NCT00471497",456381,0.274368231,76,277,NA,"Safety set contained patients who received at least one dose of study medication. Patients were summarized according to the safety treatment allocation (the treatment they actually received first).","Nilotinib 400 mg BID","Patients who were randomized to this arm were to receive nilotinib 400 mg twice a day (BID) by mouth each morning and evening approximately 12 hours apart. If the morning or evening dose was delayed for more than 4 hours, the patient was to skip this dose and resume dosing with the next dose as per the original schedule in order to prevent overdosing. No imatinib washout period was necessary prior to administration of nilotinib. Nilotinib was not to be taken with food. No food was to be consumed for at least 2 hours before the dose was taken and no additional oral intake other than water was to be consumed for at least one hour after the dose was taken. Patients were instructed to swallow capsules whole with a full 8 ounce glass of water, and not to chew them. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits. Vomited doses were not to be repeated."
"5872",7051,"NCT00885755",300651,0.272727273,9,33,"From the date of Screening until 4 weeks after the last visit of the participant",NA,"All Participants","In Part 1 of the study, participants received standard first-line therapy with trastuzumab and, at the discretion of treating clinician, either paclitaxel or docetaxel. Trastuzumab was administered according to SMPC. Paclitaxel and docetaxel were administered according to one of following regimens: docetaxel 75 mg/m^2 or 100 mg/m^2 3-weekly (if docetaxel-naïve) or docetaxel 75 mg/m^2 3-weekly (if prior adjuvant docetaxel) or docetaxel 60 mg/m^2 3-weekly (if liver dysfunction due to metastatic involvement) or paclitaxel 80 mg/m^2 weekly or 175 mg/m^2 3-weekly until first disease progression. in Part II of the study, participants received capecitabine twice-daily 1000 mg/m^2 or higher, calculated based on BSA on days 1 to 14 while continuing trastuzumab treatment per standard practice until disease progression, unmanageable toxicity or participant request for discontinuation."
"5882",7061,"NCT00951665",279372,0.272727273,6,22,"Up to 30 days after the last dose of study treatment or study discontinuation/termination, whichever is later (Approximately 4 years)","SAEs and other AEs were collected in the safety population, which was defined as all participants who received at least a single dose of study medication. There was one SAE that lead to death and the preferred term was not captured for it. The same SAE was captured as ‘Death – unknown cause’ in the below SAE table.","Phase IIa Group B","Participants received MTD from Phase 1b , i.e. T-DM1 3.6mg/kg Q3W and paclitaxel 80mg/m^2 QW, plus pertuzumab Q3W intravenously."
"5896",7078,"NCT00834678",318899,0.272727273,3,11,"Adverse events were collected from beginning of cycle 1 treatment through end of treatment, for up to 2 years","This study will utilize the CTCAE (NCI Common Terminology Criteria for Adverse Events) Version 3.0 for toxicity and Serious Adverse Event reporting.","Bendamustine and Erlotinib","Bendamustine 100 or 120 mg/m2 IV on days 1 and 2 and erlotinib 100 or 150 mg po on days 5 – 21 of each 28 day cycle.
bendamustine: 100 or 120 mg/m2 IV on days 1 and 2
erlotinib: 100 or 150 mg po on days 5 – 21 of each 28 day cycle
Maintenance erlotinib: 150 mg po daily (days 1 - 28 of 28 day cycle)"
"5898",7080,"NCT00788775",337314,0.272727273,3,11,"AE assessment was ongoing from the start of study drug and up to day 30 post-treatment. Mean treatment duration was 5.5 months (range 0-45; no/with CNS mets 7.4m/ 3m).","Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3.","No CNS Metastastic Cohort","Nilotinib was given at a dose of 400 mg orally daily (200 mg pills twice per day). Patients received treatment up to 12 months as long as they were receiving clinical benefit. Patients were classified into two cohorts based upon presence or absence of measurable brain metastases."
"5912",7095,"NCT00109031",559513,0.272727273,3,11,"40 days from first dose of palifermin","Seven participants received the wrong sequence of placebo and palifermin as follows (# participants [from assigned arm to actual treatment arm]): 2 participants (A to C), 2 participants (D to B), 1 participant (C to A), 1 participant (B to D), 1 participant (C to D). Adverse event data are summarized by actual treatment group.","Palifermin 180 μg/kg on Day −1 (B)","Palifermin 180 μg/kg on Day −1 and placebo on Days −2 and −3 prior to fTBI, and palifermin 60 μg/kg on Days 0, 1, and 2 after PBPC."
"5913",7096,"NCT00334282",504741,0.272413793,79,290,"Date of study entry until 28 days after the last dose.",NA,"Pazopanib 800 mg","Pazopanib 800 mg (tablets) administered orally once a day"
"5918",7102,"NCT00590902",411696,0.271604938,22,81,NA,NA,"1 - OSI-774","OSI-774: erlotinib, TarcevaTM: 150 mg, 100 mg and 25 mg tablets"
"5920",7105,"NCT00481247",452828,0.271317829,70,258,"Randomization to end of study (December 2015)","Study initiated: September 2007; End of Study: December 2015","Imatinib","Tablets, oral, imatinib 400 mg once daily (QD)"
"5922",7107,"NCT01017874",255820,0.271186441,32,118,NA,"Study-specific clinical outcomes due to progressive disease were not considered to be a serious adverse event (SAE) unless the investigator deemed it related to the use of the study drug.","Gefitinib","Gefitinib: 250 mg administered orally once a day, every day of 21-day cycle, as a monotherapy"
"5923",7108,"NCT00753675",352142,0.271186441,16,59,NA,NA,"Arm A Vandetanib 300 mg","Vandetanib 300 mg as a once daily oral dose, from Day 1"
"5931",7117,"NCT00400569",483541,0.270833333,13,48,"4 years, 7 months",NA,"Experimental: Sunitinib Malate (SU011248) Treatment","Sunitinib malate, 50 mg daily, for 4 weeks every 6 weeks"
"5932",7118,"NCT00332163",505403,0.270833333,13,48,"The reporting time frame is from first dose date to 30 days since the last dose date. The median time frames for pre-emptive skin treatment and reactive skin treatment are 3.5 months and 4.7 months, respectively.","Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.","Pre-emptive Skin Treatment","Participants received either FOLFIRI and panitumumab 6 mg/kg once every 2 weeks (Q2W) or irinotecan and panitumumab 9 mg/kg once every 3 weeks (Q3W), and pre-emptive skin treatment which included skin moisturizer, sunscreen, 1% hydrocortisone cream, and an oral antibiotic for 6 weeks starting 24 hours prior to chemotherapy."
"5935",7122,"NCT00514683",441985,0.270588235,23,85,"First drug administration until 14 days after last drug administration",NA,"Nintedanib 150 Bid","Patients were treated with 150mg nintedanib twice daily"
"5940",7127,"NCT01204697",196220,0.27027027,10,37,"Up to 18 months",NA,"Docetaxel and Erlotinib","Participants received docetaxel at a dose of 75 mg/m^2 as an intravenous infusion on Day 1 of each 3-week cycle, and erlotinib at a dose of 150 mg/day orally from Day 2 to Day 16 of each 3-week cycle for 4 cycles, administered in absence of PD, death, or unacceptable toxicity. Following the 4 cycles, erlotinib 150 mg/day was administered orally as monotherapy up to PD, death or unacceptable toxicity."
"5942",7129,"NCT00217620",536616,0.27027027,10,37,"Patients assessed for adverse events 2 weeks after starting treatment and then after every cycle (28 days) for the duration of protocol treatment. Assessments continued until resolution of any adverse events up to 5 years after registration.",NA,"Sorafenib (BAY 43-9006)","Sorafenib (BAY 43-9006) 800 mg per day divided into two equal doses of 400 mg by mouth (PO). Patients received the drug continuously on a daily basis until progression; each cycle is 28 days. All eligible patients who received treatment were included in baseline measures."
"5948",7138,"NCT01335464",157523,0.269607843,55,204,"From the first drug administration until 28 days after the last drug administration, up to 425 days",NA,"Placebo","Oral administration of placebo matching nintedanib soft gelatine capsules."
"5952",7142,"NCT00392821",486900,0.269230769,21,78,NA,NA,"RAD001 and Sorafenib","RAD001 and Sorafenib
Sorafenib: Sorafenib
RAD001: RAD001"
"5954",7146,"NCT00446446",464980,0.269230769,14,52,"The reporting time frame for Adverse Events is from first dose date to 30 days since the last dose date date. The median time frame is 2.4 months.","Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.","Panitumumab","Participants received panitumumab as an intravenous infusion at a dose of 9 mg/kg every 21 days until disease progression, unacceptable toxicity, withdrawal of consent, death, or end of study."
"5961",7154,"NCT00244881",532838,0.269230769,7,26,"2 years",NA,"Treatment (Cediranib Maleate)","Patients receive oral AZD2171 once daily for 42 days. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity."
"5965",7158,"NCT00785785",338103,0.268987342,85,316,NA,NA,"Imatinib","Exposure to Imatinib only"
"5980",7175,"NCT00058539",572324,0.268292683,11,41,"Adverse events were collected from baseline until up to 30 days after the last dose of pertuzumab.",NA,"Pertuzumab","All the participants received a loading dose of 840 mg of pertuzumab on Day 1 of Cycle 1, followed by 420 mg on Day 1 of each subsequent 21-day cycle. Pertuzumab was administered as an IV infusion every 3 weeks for up to 1 year (17 cycles) for participants who showed no evidence of progression. Participants with evidence of disease progression could have continued pertuzumab therapy, at the discretion of the investigator, if they had improvement in pain without an increase in narcotic use and if they had no other therapeutic options."
"5982",7178,"NCT00509769",443593,0.267857143,30,112,"Adverse events were recorded from randomization through the end of the study.","Safety population: All patients who received any amount of trastuzumab emtansine.","Trastuzumab Emtansine 3.6 mg/kg","Patients received trastuzumab emtansine 3.6 mg/kg intravenously on Day 1 of each 21 day cycle for a maximum of 1 year. The total dose was dependent on the patient's weight on Day 1 of each cycle."
"5983",7179,"NCT00835978",317872,0.267857143,15,56,"3 years","The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.","Active Titration Arm","Participants initially received axitinib 5 mg twice a day (BID) + axitinib (blinded therapy) 2 mg BID. After at least 2 consecutive weeks, participants satisfying the dose titration criteria had their dose level increased by one additional dose level, to axitinib 5 mg BID + axitinib (blinded therapy) 5 mg BID, unless otherwise contraindicated per the investigator’s clinical judgment. The maximum total daily dose was 10 mg BID (axitinib 5mg BID + axitinib [blinded therapy] 5 mg BID)."
"5988",7185,"NCT00124748",554378,0.267515924,42,157,NA,NA,"Imatinib 400mg","Oral dose of 400mg imatinib once daily. All patients received the assigned dose starting on Day 0 (Visit 3). The dose of Imatinib could be interrupted, reduced, or escalated based on guidelines defined in protocol."
"5991",7188,"NCT00514683",441987,0.26744186,23,86,"First drug administration until 14 days after last drug administration",NA,"Nintedanib 50 Bid","Patients were treated with 50mg nintedanib twice daily"
"5999",7201,"NCT00842023",316205,0.266666667,12,45,"2 years",NA,"Nesiritide Infusion","2 mcg/kg bolus (optional) followed by 0.01 mcg/kg/min infusion for 48 hours."
"6009",7211,"NCT00509899",443529,0.266666667,8,30,NA,NA,"10 mg Bid","Participants received an initial dose of Ruxolitinib 10 mg twice a day (bid). Participants could continue in the study on their prescribed regimen indefinitely if receiving benefit with dose adjustments for safety and efficacy to a maximum of 25 mg bid."
"6026",7230,"NCT00507767",444142,0.266666667,4,15,"Treatment period three 4-week cycles for total of 12 weeks with follow up every 2 cycles following first cycle. Study data collection period for all participants was 18 months.",NA,"Dasatinib","100 mg orally twice daily"
"6052",7259,"NCT00428597",472390,0.265060241,22,83,NA,NA,"Sunitinib","Oral sunitinib 37.5 mg once daily on a continuous daily dosing schedule."
"6064",7273,"NCT00679211",379567,0.263636364,29,110,"From the date of first dose until 26 April 2011, approximately 25 months of follow-up.",NA,"Trastuzumab Emtansine","Trastuzumab emtansine (T-DM1) was administered to participants at a dose of 3.6 mg/kg by intravenous (IV) infusion every 3 weeks until documented disease progression, unmanageable toxicity, or study termination."
"6067",7276,"NCT00984282",268351,0.263157895,55,209,"Adverse event data were collected after signing the informed consent until 30 days after end of study treatment over a period of approximately three years.","Abbreviations used: Gastrointestinal (GI), Common Terminology Criteria for Adverse Events (CTCAE), Not Otherwise Specified (NOS), Absolute Neutrophil Count (ANC), Central Nervous System (CNS), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Cranial Nerve (CN), Range of Motion (ROM), Cerebrospinal Fluid (CSF), Genitourinary (GU).","Placebo (Double Blind Only)","Reporting Group 2: Participants received 2 tablets of Sorafenib-matching placebo orally twice daily (12 hours apart without food), 28 days comprise a cycle. Data were collected from randomization to the end of double-blind period."
"6073",7282,"NCT00405938",481686,0.263157895,10,38,NA,NA,"Bevacizumab/Anastrozole","Bevacizumab 10mg/kg IV every 2 weeks [patients who are also receiving trastuzumab have the option to receive their bevacizumab at 15 mg/kg every 3 weeks instead of 10 mg/kg every 2 weeks (see Trastuzumab section below)] and anastrozole (1 mg orally daily). Treatment will be given in 4-week cycles."
"6093",7305,"NCT01491672",120877,0.262295082,16,61,NA,NA,"Other Prior Anti VEGF","Participants, who received prior anti-VEGF other than sunitinib, received RAD001 10 mg orally once daily."
"6115",7331,"NCT00089999",566747,0.260869565,18,69,"Serious adverse events (SAEs) and non-serious AEs were collected from the first dose of investigational product to 30 days after the last dose (up to Study Week 192).","SAEs and non-serious AEs were collected in members of the Safety Population, comprised of all randomized participants who received at least one dose of investigational product , according to the actual treatment received.","Lapatinib 500 mg BID","Participants received lapatinib 500 mg orally BID. Treatment was continued for 12 weeks or until disease progression or withdrawal from treatment for another reason. After Week 12, participants with clinical benefit had the option to continue with the lapatinib therapy at the same dose and schedule, until disease progression, provided the treatment was tolerated."
"6138",7356,"NCT00537095",432525,0.260273973,19,73,NA,"For the efficacy part, 72 were randomized to received ZD6474 and 73 placebo. All For the safety part, 73 patients received at least one dose of ZD6474 and 72 placebo","ZD6474","ZD6474, Vandetanib 300mg"
"6146",7365,"NCT00553358",425331,0.25974026,40,154,NA,"Only events, assessments, and treatments with a start date on or before the end date of the neoadjuvant phase have been summarized. One non-serious event was reported as an uncoded event. A non-serious event of dental care was actually coded to Surgical and medical procedures.","Lapatinib 1500 mg","Oral lapatinib (1500 milligrams [mg] daily) for 6 weeks, followed by lapatinib plus weekly paclitaxel (80 mg per meters squared [mg/m^2]) intravenous (IV) for an additional 12 weeks"
"6154",7374,"NCT00126581",553889,0.259259259,21,81,NA,NA,"Arm A: Erlotinib","Patients receive oral erlotinib once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity."
"6168",7389,"NCT00423332",474673,0.25862069,15,58,NA,NA,"Cediranib OL","Open Label part"
"6169",7391,"NCT00404924",481982,0.258481422,160,619,NA,"The Safety Analysis Set included 922 patients (619 vandetanib & 303 placebo), which represents more than 99% of all randomized pts. 2 (1 in each arm) were excluded from the SAS as they were not dosed. Additionally 3 pts randomized to receive placebo received at least one dose of vandetanib, these 3 pts are included in the vandetanib arm in the SAS","Vandetanib","Vandetanib 300 mg"
"6179",7402,"NCT00866697",306649,0.257861635,123,477,NA,"Serious adverse events and non-serious adverse events were collected in members of the All Treated Population, comprised of all randomized participants who received at least one dose of investigational product, based on the actual treatment received if this differed from that to which the participant was randomized.","Pazopanib 800 mg","Participants received pazopanib 800 milligrams (mg) once daily for a maximum of 24 months."
"6183",7407,"NCT00073008",570394,0.257575758,17,66,NA,NA,"Lapatinib 500 mg BID","Oral lapatinib 500 mg twice daily (BID)"
"6189",7414,"NCT02480010",4938,0.257142857,9,35,"Adverse Events were recorded from the date of Screening until 7 weeks after the last infusion of study treatment.",NA,"Pertuzumab 420 mg - Cohort A","Participants in Cohort A received an IV loading dose of 840 mg pertuzumab on Day 1 of Cycle 1 (3-week cycles); from Cycle 2 onwards, participants received IV infusions of 420 mg on Day 1. Treatment continued for a maximum of 36 cycles or until study termination."
"6196",7422,"NCT00500292",446433,0.257142857,9,35,NA,NA,"Vandetanib 300 mg Plus FOLFOX","vandetanib 300 mg plus FOLFOX"
"6214",7442,"NCT00372567",493231,0.255813953,11,43,NA,"The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. One participant enrolled in the imatinib arm was inadvertently randomized (participant did not meet inclusion criteria) and was not treated in this study.","All Participants Who Received Sunitinib","Participants in Phase 1 sub- study and Phase 3 study"
"6216",7444,"NCT00364351",496640,0.255700326,157,614,NA,"Safety Analysis set used for erlotinib 150 mg, therefore number at risk is 614","Erlotinib","Erlotinib"
"6234",7463,"NCT00621049",399762,0.254545455,14,55,NA,NA,"Docetaxel/Carboplatin/Bevacizumab/Erlotinib","Docetaxel/Carboplatin/Bevacizumab/Erlotinib: Docetaxel 75mg/m2 IV D1 Carboplatin AUC=6 IV D1 Bevacizumab 15mg/kg IV D1
Docetaxel should be administered before carboplatin.
After completion of four cycles of treatment, patients in Cohort A will then proceed with Maintenance treatment defined as follows:
Maintenance Treatment for patients in Cohort A:
Bevacizumab 15mg/kg IV D1 Erlotinib 150mg PO daily
Treatment cycle = 21 days. Patients will complete 8 cycles (24 weeks) of maintenance therapy unless there is evidence of disease recurrence or unacceptable toxicity."
"6241",7471,"NCT01412957",139265,0.253968254,48,189,"From first dose until 30 days after last dose; median safety reporting periods were 4.2 months and 2.2 months for panitumumab plus BSC arm and BSC alone arm, respectively.","Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.","Panitumumab Plus BSC",NA
"6242",7472,"NCT01203787",196333,0.253968254,16,63,"Adverse events were collected during 6 months of treatment. First subject randomized 8/29/2011 and last subject completed 6 months of treatment on 3/10/14.",NA,"Sorafenib Standard Dosing Regimen","Sorafenib 400 mg (2 tablets of 200 mg) twice daily until end of treatment or week 24"
"6255",7488,"NCT01419197",138475,0.253101737,102,403,"Adverse events were collected from treatment initiation until 30 days following the last administration of study drug or study discontinuation on 31 August 2015 (up to approximately 4 years).","Safety population: All participants who received any amount of planned study treatment, according to treatment actually received. Data for participants in the Treatment of Physicians Choice (TPC) arm who switched treatment to receive trastuzumab emtansine (TE) following disease progression on TPC are presented separately. Median treatment duration of trastuzumab emtansine: 5.2 months (range 0.03-40.7),TPC: 2.7 months (range 0.03-31.0) and TE - Post TPC Treatment Switch: 4.5 months (range 1-43).","Trastuzumab Emtansine","Trastuzumab emtansine 3.6 mg/kg intravenously every 3 weeks until disease progression (as assessed by the investigator) or unmanageable toxicity."
"6276",7511,"NCT00090519",566351,0.250673854,93,371,NA,NA,"Ruboxistaurin","32 mg once daily (QD) oral for up to 36 months"
"6290",7528,"NCT00920816",290721,0.25,24,96,"Baseline up to Week 107","Same event may appear as both AE and SAE. However, what is presented are distinct events. Event may be categorized as serious in 1 subject and nonserious in another subject, or 1 subject may have experienced both a serious and nonserious event during the study. Participants at risk = 189, 96, 135, 69 for each arm group, respectively.","Sorafenib (First-line Participants)","Participants with no prior systemic first-line therapy received sorafenib tablet at a starting dose of 400 mg orally twice daily, dose adjustment was done based on the tolerability, as per investigator’s discretion. Study medication was administered in cycles of 4 weeks."
"6297",7535,"NCT00091026",566169,0.25,17,68,NA,NA,"Arm II (Gemcitabine Hydrochloride, Bevacizumab, Erlotinib)","Patients receive gemcitabine and bevacizumab as in arm I. Patients also receive oral erlotinib once daily on days 1-5, 8-12, and 15-26."
"6301",7539,"NCT00751036",352893,0.25,12,48,NA,NA,"Nilotinib 800 mg","Patients who were assigned to this treatment group received 400 mg. nilotinib bid."
"6311",7551,"NCT01983878",38186,0.25,9,36,NA,NA,"Ramucirumab 8 mg/kg","Ramucirumab 8 mg/kg administered IV once every 2 weeks. Treatment continued until there is evidence of PD, the development of unacceptable toxicity, protocol non-compliance, or withdrawal of consent."
"6329",7574,"NCT01233869",186857,0.25,6,24,"Baseline up to 30 days after last study drug administration","The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another participant, or one participant may have experienced both a serious and non-serious event during the study.","Bosutinib 400/200 mg/Day","Participants received bosutinib 400 mg and were dose-reduced to 200 mg tablet (based on protocol amendment) orally QD in the morning with food for 24 months in the ITP. After a 30-day washout period, participants who entered the ETP continued to receive bosutinib 200 mg orally QD for up to 46 months."
"6343",7590,"NCT00702689",371392,0.25,5,20,NA,NA,"Imatinib Mesylate in Patients With cGVHD","Cohort 1 - Pts 1-8:Adults: 400mg imatinib mesylate daily; Children: 260mg/m^2 daily (400mg maximum), followed by dose de-escalation for adverse events.
Cohort 2 - Pts 9-20:Adults - 100 mg oral dose daily (increase to 200 mg daily after 28 days if well tolerated). Children - 65 mg/m^2 oral dose daily (increase to 130 mg/m^2 daily after 28 days if well tolerated)"
"6352",7599,"NCT00272987",525385,0.25,5,20,"Serious adverse events (SAEs) and non-serious AEs were collected from the first dose of investigational product to 30 days after the last dose of investigational product (up to Study Week 164).","SAEs and non-serious AEs were collected in members of the Safety Population, comprised of all randomized participants who received at least one dose of investigational product , according to the actual treatment received.","Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg","Participants received an IV infusion of paclitaxel 80 mg/m^2 over 60 minutes weekly for 3 weeks of a 4-week cycle plus an IV infusion of trastuzumab 4 mg/kg loading dose and 2 mg/kg weekly plus a daily dose of 3 tablets of lapatinib (750 mg) at approximately the same time every day, either 1 hour (or more) before a meal or 1 hour (or more) after a meal. The lapatinib dose was systematically increased to 1000 mg after 2 cycles if the 750 mg dose was tolerated."
"6368",7616,"NCT00616109",401977,0.25,4,16,"Participants were evaluated for toxicity if they received sunitinib maintenance therapy (at least one dose) from onset of this therapy until the participant ended participation.","Treatment was held for Participants with grade 4 hematologic or grade 3-4 non-hematologic toxicities until resolution to grade 2 or less. Treatment was then restarted at a dose of 3.75 mg. A second dose reduction to 25 mg was permitted. Treatment discontinued for a third dose reduction or life-threatening, irreversible or unacceptable toxicity.","Sunitinib Maintenance Therapy","Sunitinib 50 mg po QD × 28 days followed by a 14 day break every 42 days until disease progression or unacceptable toxicity. Treatment to begin 28-42 days after day 1 of the last cycle of induction chemotherapy to allow confirmation of response or disease stability with chemotherapy."
"6382",7634,"NCT01121562",223349,0.25,3,12,NA,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.","Sunitinib","Sunitinib 37.5 mg was orally administered once daily in a continuous daily dosing regimen (1 cycle = 4 weeks)."
"6383",7635,"NCT01107418",227963,0.25,3,12,"Up to approximately 3 years",NA,"Cohort 1 - Vemurafenib 240 mg","Participants received vemurafenib film-coated tablet, orally, twice daily at a dose of 240 mg on Days 1 to 15 (a single morning dose was administered on Day 15). Starting at Day 22, participants received vemurafenib 960 mg film-coated tablets orally twice daily in 21-day cycles until the development of progressive disease, unacceptable toxicity, consent withdrawal, or any other criteria for removal."
"6384",7636,"NCT01107418",227962,0.25,3,12,"Up to approximately 3 years",NA,"Cohort 2 - Vemurafenib 480 mg","Participants received vemurafenib film-coated tablets, orally, twice daily at a dose of 480 mg on Days 1 to 15 (a single morning dose was administered on Day 15). Starting at Day 22, participants received vemurafenib 960 mg film-coated tablets orally twice daily in 21-day cycles until the development of progressive disease, unacceptable toxicity, consent withdrawal, or any other criteria for removal."
"6390",7644,"NCT00840450",316556,0.25,3,12,"treatment period (up to 5 months) plus 30 days after treatment or until the the adverse events have resolved or returned to pretreatment values or deemed irreversible.",NA,"Paclitaxel and Imatinib Mesylate (Gleevec)",NA
"6398",7652,"NCT00329719",505715,0.25,3,12,NA,NA,"Phase I, Arm A","Patients receive sorafenib orally (PO) twice daily (BID) on days 1-28 and temsirolimus intravenously (IV) over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of temsirolimus until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.
sorafenib tosylate: Given PO
temsirolimus: Given IV"
"6435",7692,"NCT00726232",361713,0.25,2,8,NA,NA,"PV: Ruxolitinib 25 mg BID","Participants with Polycythemia Vera received 25 mg Ruxolitinib orally twice a day (BID) for 56 days (two 28-day cycles) during the dose-ranging phase. After patients completed 2 cycles of treatment at the randomized dose, Investigators were permitted to adjust the dose/regimen on an individual basis to achieve an optimal balance of efficacy and safety. Treatment continued until a patient met a withdrawal criterion, had intolerable toxicity, progression of disease, or withdrew consent."
"6440",7698,"NCT00536107",432688,0.25,2,8,"From time consent was given to 28 days after last dose of study drug","Adverse event iformtaion was collectde at each study visit by Information volunteered by the patient, or the patient’s care giver; open-ended and non-leading verbal questioning of the patient; and observation by the investigational team, other care providers or relatives.","Gefitinib","gefitinib 250mg"
"6458",7718,"NCT01916109",47878,0.25,1,4,NA,NA,"Gemcitabine, Carboplatin, and Panitumumab (GCaP)","Gemcitabine, Carboplatin, and Panitumumab (GCaP) as Neoadjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer"
"6467",7729,"NCT01510756",117240,0.25,1,4,NA,NA,"Sorafenib","Sorafenib 400mg orally twice daily will be administered for three cycles (1 cycle = 28 days).
Sorafenib: Sorafenib 400mg orally twice daily will be administered for three cycles (1 cycle = 28 days). Subjects without significant toxicity or progressive disease may elect to continue treatment for a total of twelve cycles."
"6472",7735,"NCT01400451",141693,0.25,1,4,"From the first vemurafenib dose in the Lead In Period to the last dose of combination drugs in the Treatment Period + 90 days, up to last patient, last visit, approximately 2 years.","Final safety follow-up was 23 December 2013.","Lead-In Period 720 mg Vemurafenib","Lead In Period: 28 Days of 720 mg vemurafenib orally twice daily (starting Day -27 or -13).
Events between the first vemurafenib dose and the day prior to the first ipilimumab dose."
"6478",7741,"NCT01340794",155825,0.25,1,4,NA,NA,"Treatment: Pazopanib With Run-in","Patients receive 800 mg pazopanib hydrochloride PO QD on days 1-28 of a 28 day cycle."
"6502",7770,"NCT00905021",296027,0.25,1,4,"Medical evaluation every 4 weeks. The study does not have a fixed time frame for each participant. Duration of therapy depends on individule response, evidence of disease progression and tolerance.",NA,"Exemestane Plus Sutent","All patients enrolled on the study will receive treatment as follows:
Exemestane 25 mg by mouth every day.
Sunitinib 37.5 mg by mouth every day."
"6522",7791,"NCT00560352",421939,0.25,1,4,"Continuously from Day 1 until last day of study medication + 30 days (maximum reached: 10 months)",NA,"Dasatinib, 140 mg QD","Dasatinib, 140 mg, administered QD with 1.3 mg/m^2 of bortezomib in 21-day cycles. Dexamethasone, fixed at 20 mg QD, was administered the day of and 1 day after each bortezomib dosing.In a 21-day cycle, bortezomib was administered by IV bolus twice weekly, on Days 1, 4, 8, and 11, followed by a 10-day (Days 12 to 21) rest period. In a 21-day cycle, dasatinib was taken orally every day, QD in the morning. In a 21-day cycle, dexamethasone was taken orally on Days 1, 2, 4, 5, 8, 9, 11, and 12, at the same time as dasatinib. On the days when bortezomib and dasatinib were administered together, the morning dose of dasatinib was to be followed 1-2 hours by the dose of bortezomib."
"6524",7793,"NCT00557830",423135,0.25,1,4,"Adverse events were collected when the patient began taking sorafenib until one month after the end of study treatment.","Systematic assessment- subjects were assessed for adverse events every 4 weeks by either the research coordinator, treating physician, or other appropriate sub-investigator.","Group A: Escalated Dose","Eligible patients will be randomized 2:1 to either Group A (escalated dose regimen) or Group B (standard dose regimen). Patients randomized to Group A will receive sorafenib 600 mg bid for Weeks 5 through 8 (Dose Level 2). Patients who tolerate this dose through Week 8 will be further escalated to Dose Level 3 (800 mg po bid) for Weeks 9 through 12.
Sorafenib Escalated Dose :
Patients randomized to Group A will receive sorafenib 600 mg bid for Weeks 5 through 8 (Dose Level 2). Patients who tolerate this dose through Week 8 will be further escalated to Dose Level 3 (800 mg po bid) for Weeks 9 through 12."
"6539",7810,"NCT00339144",503750,0.25,1,4,NA,NA,"Dasatinib 200 mg","Participants were administered an oral dose of 200 mg dasatinib tablet once daily for a period of 4 weeks. Initially, 3 participants were treated at one dose level. If no DLT was observed, the dose was escalated to next higher level. If a DLT was observed among 1 of 3 treated participants in the first course at a dose level, 3 participants were additionally enrolled and treated at the same dose level. Dose was not escalated above 200 mg daily."
"6545",7816,"NCT00121719",555449,0.25,1,4,"All adverse events (AEs) were collected for up to approximately 4 years.","Treatment-emergent adverse events were defined as AEs that emerged during treatment, having been absent at pre-treatment, or that worsened in severity relative to the pre-treatment state, or occurred within 7 days or 5 times the half-life (whichever was longer) post participant's last treatment. Only treatment-emergent AEs and SAEs were reported.","0.8 mg Lenvatinib","Eight 0.1 mg lenvatinib tablets were taken orally, once daily. Lenvatinib was to be taken on an empty stomach shortly after waking. Participants were fasted for 2 hours following administration of lenvatinib and could drink only clear fluids during this time (grapefruit juice was to be avoided). If 1 of 3 participants experienced DLT during Cycle 1 (4 weeks) an additional 3 participants were to be treated at this dose level. If 5 of the 6 participants in the expanded dose level did not experience DLT during the first 4 weeks of therapy, no additional DLT was observed, the next dose level was opened for enrollment. If more than 1 participant experienced DLT during the first 4 weeks of therapy, dose escalation was stopped and the MTD was determined. An additional 12 participants were treated at the MTD level."
"6549",7820,"NCT00096486",563712,0.25,1,4,NA,NA,"Phase I: RAD001 10 mg, Gefitinib 250 mg","Phase I: RAD001 10 mg, Gefitinib 250 mg"
"6560",7831,"NCT00785785",338104,0.249221184,80,321,NA,NA,"Nilotinib","Exposure to Nilotinib only"
"6563",7834,"NCT02774278",505,0.249042146,65,261,"Up to 4 years","Safety analysis population (SAP) included all participants who received at least one dose of the trial medication and had a safety follow-up.","Erlotinib","Erlotinib was administered at 150 milligrams (mg) orally daily until disease progression, unacceptable toxicity or death."
"6593",7870,"NCT01037127",249416,0.245614035,14,57,"Serious AEs and non-serious AEs are presented from the date of the first dose of study medication until the last participant's last visit (up to 1130 days).",NA,"Trametinib 2 mg: Prior Standard Therapy","Participants who were previously treated with standard therapy, but not with BRAF inhibitors, received trametinib 2 mg tablets orally qd until treatment discontinuation criteria were met. Per the pre-specified study design, enrollment could have been stopped if objective response was observed in fewer than 3 participants among the first 30 participants enrolled. Per this criterion, 55 participants were enrolled in this cohort because objective responses occurred in 6 participants at the time of the interim analysis. Eligible participants who had been consented at the time the 55th participant was dosed were allowed to enroll. This led to the overenrollment of 2 participants (total of 57 participants in this cohort). An interim analysis was performed after 30 participants had completed the first target post-dose disease assessment at 8 weeks."
"6594",7871,"NCT00696072",374172,0.245614035,14,57,"First dose of study drug to last dose plus 30 days","Study initiated 2008 and completed 2014.","Dasatinib Plus Letrozole","Dasatinib + Letrozole: Tablets, Oral, once daily, up to 2 years
Dasatinib 100 mg + Letrozole 2.5 mg"
"6601",7878,"NCT01072175",239370,0.245283019,13,53,"Serious adverse events (SAEs) and non-serious AEs were collected from Baseline (Day 1) until Follow-up visit (up to approximately 103 weeks).","SAEs and non-serious Aes were collected in the All Treated Population which was based on the actual treatment received. For Part D, 3 participants received treatment that differed from the randomized treatment. For Part C: 1 participant received treatment that differed from the randomized treatment.","Part C: Dabrafenib 150 mg","Participants received dabrafenib 150 mg gelatin capsules BID."
"6603",7880,"NCT00391989",487072,0.245283019,13,53,"25 months.","Physicians reporting whenever a SAE happened.","Dasatinib","All patients registered in the study."
"6615",7894,"NCT00329719",505712,0.244444444,11,45,NA,NA,"Phase II, Arm D","Patients receive sorafenib and temsirolimus as in phase I at the MTD (25mg temsirolimus and 200mg sorafenib).
sorafenib tosylate: Given PO
temsirolimus: Given IV"
"6626",7905,"NCT02491892",4510,0.243902439,10,41,"Up to approximately 1 year (from start of treatment until up to 7 weeks following the last infusion)",NA,"Pertuzumab 420 mg","Participants received a loading dose of 840 mg via IV infusion at the first infusion of pertuzumab, followed by a maintenance dose of 420 mg every 3 weeks until unacceptable toxicity or disease progression."
"6630",7910,"NCT00727506",361352,0.243902439,10,41,"Between first intake through 28 days after last drug intake.",NA,"Phase II - Afatinib 40mg","Patients receiving Afatinib monotherapy 40mg once daily (q.d.) - Phase II part"
"6652",7934,"NCT01450319",131733,0.242857143,17,70,"AEs with onset from the date of enrollment up to 30 days after the last dose of study drug administration; assessed up to 3 years",NA,"Cetuximab","Cetuximab was administered intravenously at a dose of 500 milligram per square meter (mg/m^2) every 2 weeks until disease progression, death, or consent withdrawal."
"6672",7958,"NCT00133952",551325,0.241610738,36,149,NA,NA,"Ruboxistaurin","32 milligrams (mg) taken orally daily for up to 48 months"
"6678",7964,"NCT00320411",511059,0.24137931,14,58,NA,NA,"Lapatinib Monotherapy","Lapatinib: 1500 mg (six 250 mg tablets) orally once daily"
"6705",7992,"NCT00777179",341141,0.24,18,75,NA,NA,"Vandetanib","Vandetanib 300 mg, orally, once daily"
"6716",8003,"NCT01194869",199404,0.24,6,25,NA,NA,"Sorafenib","Sorafenib: Sorafenib 400 mg twice daily throughout the study. Patients will receive this as a single-agent for the first four weeks, then in combination with cisplatin followed by paclitaxel."
"6763",8055,"NCT00460798",460436,0.237529691,100,421,NA,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.","Sunitinib","Sunitinib malate (Sutent) was administered and dosed as stipulated in the Summary of Product Characteristics (SmPC) and was used solely in accordance with the medical and therapeutic needs. The recommended dose of Sutent was 50 mg once daily, administered orally over 4 weeks, followed by a rest period of 2 weeks (4/2 regimen). One treatment cycle = 6 weeks."
"6778",8071,"NCT00347919",502198,0.236842105,18,76,"Study Entry until 28 days after the last dose.",NA,"Cohort 1: Lapatinib 1000 mg/Pazopanib 400 mg","Lapatinib 1000 mg and Pazopanib 400 mg administered orally once a day"
"6790",8084,"NCT01321554",161177,0.236641221,31,131,"For each participant, from the first dose till 30 days after the last dose or the cut-off date for the primary analysis whichever was earlier or up to approximately 2.5 years","Safety was assessed by the monitoring and recording of all adverse events (AEs) and serious adverse events (SAEs); regular monitoring of hematology, clinical chemistry, and urine values; physical examinations; and regular measurement of vital signs, electrocardiograms (ECG), and echocardiograms.","Placebo (Randomization Phase)","Participants received blinded study drug (lenvatinib 24 mg/placebo, orally once daily) in 2:1 ratio until documentation of disease progression (confirmed by IIR), development of unacceptable toxicity, or withdrawal of consent."
"6792",8086,"NCT01064310",242285,0.236486486,35,148,"Participants were evaluated from Baseline until the end of the second treatment period (maximum of 22 weeks).","Adverse events and serious adverse events were collected for the Safety-Randomized Study Population, which included participants who received at least one dose of either sunitinib or pazopanib regardless of treatment period. Participants who received mixed treatment within a period were excluded.","Sunitinib","Participants received 4 overencapsulated capsules of sunitinib (either in Period 1 or Period 2), each containing 12.5 mg of sunitinib, OD orally for 4 weeks, followed by 2 weeks off treatment (matching placebo capsules to maintain blind), followed by 50 mg (4 x 12.5 mg) OD orally for 4 weeks. Study drug was taken orally OD without food at least one hour before or two hours after a meal. The capsules were swallowed whole and not crushed or broken. The time of day the study drug was taken remained relatively constant."
"6798",8092,"NCT01945021",43847,0.236220472,30,127,"AEs (non-serious) were collected from the time the patient took at least one dose of study treatment through 28 days after the last dose of study treatment. If a subject begins a new anticancer therapy, the AE reporting period for non serious AEs ends at the time the new treatment is started. The overall AE reporting period for the final analysis is 11 Oct 2013 (first patient first dose) to 30 Jul 2015 (last patient first visit plus 6 months).","SAE reporting began from the time that the subject provided informed consent through and including 28 days after the last dose of the crizotinib. Afterward, reporting occurred if the PI became aware of the SAE and at minimum, if the SAE was believed to be possibly related to crizotinib. Death was reported irrespective of any intervening treatment. The overall reporting period for SAEs for the final analysis was 25 Sep 2013 (date first patient consented) to 20 Jul 2015.","Crizotinib","Single-arm trial whereby all consented, enrolled, eligible patients receive crizotinib"
"6806",8100,"NCT00471497",456383,0.235714286,66,280,NA,"Safety set contained patients who received at least one dose of study medication. Patients were summarized according to the safety treatment allocation (the treatment they actually received first).","Imatinib 400 mg QD","Patients randomized to this arm were to receive 400 mg imatinib once a day (QD). If the patient required a dose escalation from 400 mg/day, the patient was to receive 400 mg imatinib twice daily orally. Imatinib was taken with food and a large glass of water. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits during the study. In cases of vomiting doses were not to be repeated."
"6814",8108,"NCT02087059",28085,0.235294118,12,51,NA,NA,"Ruxolitinib","Ruxolitinib was administered orally twice daily at the starting dose of 5 mg, 15 mg or 20 mg bid based on Baseline platelet counts. The dosage was subsequently adjusted for safety and efficacy so that each patient was titrated to their most appropriate dose."
"6826",8121,"NCT01169675",208549,0.235294118,4,17,"Starting with first administration of trial drug (Afatinib or Pemetrexed) and ending 28 days after the last administration of trial drug.",NA,"Pulsed Afatinib 60 mg","Pulsed Afatinib 60 mg plus Pemetrexed"
"6877",8180,"NCT00835978",317871,0.232142857,13,56,"3 years","The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.","Placebo Titration Arm","Participants initially received axitinib 5mg BID + placebo (blinded therapy) 2 mg BID. After at least 2 consecutive weeks, participants satisfying the dose titration criteria had their dose level increased by one additional dose level, to axitinib 5 mg BID + placebo (blinded therapy) 5 mg BID, unless otherwise contraindicated per the investigator’s clinical judgment. The maximum total daily dose was 10 mg BID (axitinib 5mg BID + placebo [blinded therapy] 5 mg BID)."
"6893",8200,"NCT00073008",570395,0.230769231,15,65,NA,NA,"Lapatinib 1500 mg QD","Oral lapatinib 1500 mg once daily (QD)"
"6923",8233,"NCT01013740",257278,0.230769231,3,13,"In the RP, serious adverse events (SAEs) and non-serious AEs were collected from Screening until PD/treatment withdrawal (average of 27 study weeks). In the CP, SAEs and non-serious AEs were collected from the time of crossover until tre","Serious and non-serious adverse events were collected in members of the Safety Population, comprised of all participants who received at least one dose of study medication.","Lapatinib Plus Vinorelbine in the CP","Participants received a daily dose of 5 tablets of lapatinib (1250 mg) at approximately the same time every day, either 1 hour (or more) before food or 1 hour (or more) after food. Participants also received an intravenous (IV) infusion of vinorelbine 20 mg/m^2 over the course of 5 to 10 minutes on Days 1 and 8 of a 21-day treatment cycle. After disease progression in the Randomized Phase (in which participants received lapatinib plus capecitabine), participants were given the option of crossing over to the alternative treatment arm (lapatinib plus vinorelbine), and continuing in a post-progression Cross-over Phase."
"6929",8239,"NCT00708214",368258,0.230769231,3,13,"First administration of trial medication until 28 days after last administration of trial medication",NA,"Afatinib 40 mg With Letrozole","Patients received continuous daily dosing with Afatinib 40 mg therapy with letrozole 2.5 mg over 28-day treatment cycles until further disease progression."
"6935",8246,"NCT00424515",473851,0.230769231,3,13,"AE assessment occurred every other month from the start of study drug and up to day 30 post-treatment.","Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3.","Mutated KIT","Imatinib was given at a dose of 400 mg orally daily (4 100 mg pills). Patients received treatment up to 12 months as long as they were receiving clinical benefit. Dosage may have been increased to twice daily if disease worsened and patient was in otherwise good clinical condition. Patients were classified into two cohorts based upon KIT molecular status."
"6942",8254,"NCT01254188",181259,0.2304038,97,421,NA,NA,"Nilotinib","Nilotinib 300 mg BID"
"6948",8262,"NCT01998919",36433,0.22972973,17,74,"Adverse events were recorded throughout primary and post-study treatment phases and for 28 days after last study dose.","The Safety Analysis Population (SAP) included all participants who received at least 1 dose/infusion and had at least 1 post-baseline safety assessment. For analysis, participants were assigned to the treatment group of the first received dose irrespective of subsequent changes in treatment.","Erlotinib Plus Chemotherapy","Participants received erlotinib tablets, 150 mg per day, PO on Days 15 to 28 of every 4-week cycle; participants also received platinum-based doublet chemotherapy: gemcitabine 1250 mg/m^2 via IV infusion on Days 1 and 8 and either cisplatin (75 mg/m^2) or carboplatin (5 x AUC), via IV infusion, per investigator discretion, on Day 1. Participants received study drugs for a maximum of 6 cycles until disease progression, unacceptable toxicity or death. After 6 cycles, participants may have continued to receive erlotinib monotherapy, 150 mg daily."
"6950",8264,"NCT00471497",456382,0.229390681,64,279,NA,"Safety set contained patients who received at least one dose of study medication. Patients were summarized according to the safety treatment allocation (the treatment they actually received first).","Nilotinib 300 mg BID","Patients who were randomized to this arm were to receive nilotinib 300 mg twice a day (BID) by mouth each morning and evening approximately 12 hours apart. If the morning or evening dose was delayed for more than 4 hours, the patient was to skip this dose and resume dosing with the next dose as per the original schedule in order to prevent overdosing. No imatinib washout period was necessary prior to administration of nilotinib. Nilotinib was not to be taken with food. No food was to be consumed for at least 2 hours before the dose was taken and no additional oral intake other than water was to be consumed for at least one hour after the dose was taken. Patients were instructed to swallow capsules whole with a full 8 ounce glass of water, and not to chew them. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits. Vomited doses were not to be repeated."
"6955",8269,"NCT00788957",337298,0.229166667,11,48,"From the first dose date to 33 days after the last dose of study drug, up to the data cutoff date of 23 July 2010. Median time on treatment was 5.2 months for Part 1, 2.8, 3.9 and 4.2 months for each Part 2 treatment arm respectively.","Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.","Part 2: Panitumumab Alone","Participants received panitumumab 6 mg/kg and placebo by intravenous infusion once every 2 weeks until progressive disease, intolerability, withdrawal, death or sponsor decision."
"6962",8277,"NCT00709826",367829,0.228571429,16,70,"First dose of study drug to 30 days after last dose of study drug","Only drug-related serious adverse events are listed.","Apricoxib/Gemcitabine/Erlotinib","Patients randomized to receive apricoxib + gemcitabine + erlotinib."
"6968",8284,"NCT00454116",462843,0.228571429,8,35,NA,NA,"Vandetanib 100 mg Plus FOLFIRI","vandetanib 100 mg plus FOLFIRI"
"6971",8287,"NCT01203787",196332,0.228070175,13,57,"Adverse events were collected during 6 months of treatment. First subject randomized 8/29/2011 and last subject completed 6 months of treatment on 3/10/14.",NA,"Sorafenib Ramp-Up Regimen","200 mg daily from Day 0-Day 13 200 mg twice daily from Day 14-Day 20 600 mg daily from Day 21-Day 27 400 mg twice daily beginning Day 28 until end of treatment or Week 24"
"6996",8321,"NCT00126555",553909,0.227272727,5,22,"Adverse event reporting up to 30 days after last dose investigational agent, up to 12 months following radiotherapy. Active study period June 2005 to September 2008.","One participant in Stratum I out of total 23 enrolled participants withdrew prior to any treatment and is not included in adverse event reporting.","Gefitinib, Radiotherapy, Surgery","Resectable Strata: Induction Gefitinib (60 days), Surgery followed 3-6 weeks later by daily Radiotherapy 5 days a week for approximately 6-7 weeks then after 4 weeks restart Maintenance Gefitinib for up to additional 12 months post radiation.
Unresectable Strata: Concomitant Radiation/Gefitinib and post-radiation (or post-surgery if surgery is indicated) Gefitinib. Daily Radiotherapy 5 days a week for approximately 6-7 weeks concurrent with Maintenance Gefitinib dose daily up to 12 months.
Gefitinib Induction Phase starting dose 250 mg/day, possible doubling to 500 mg/day for no response Day 15; Maintenance dose post radiation starts at same dose level as last dosing of Induction Phase."
"6998",8324,"NCT00574873",416844,0.227091633,57,251,NA,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.","Imatinib","Imatinib 400 mg tablet orally once daily up to 5 years or until treatment failure, unacceptable toxicity, death, withdrawal of consent. Dose adjustments, if needed, included an escalation to imatinib 600 mg tablet orally once daily or a reduction to imatinib 300 mg tablet orally once daily."
"7015",8343,"NCT01012258",257488,0.225806452,14,62,"Up to Day 60 after last trial treatment administration and before EOT","An adverse event (AE) was defined as any untoward medical occurrence in the form of signs, symptoms, abnormal laboratory findings, or diseases that emerges or worsens relative to baseline during a clinical study with an IMP, regardless of causal relationship and even if no IMP has been administered.","Cetuximab: Late Phase","Participants received cetuximab 400 milligram/square meter (mg/m^2) intravenous (IV) infusion over 120 minutes for 1 week, subsequently followed by 250 mg/m^2 IV infusion over 60 minutes, from week 2 to 7 along with concomitant boost radiotherapy: 72.0 Gray (Gy) total for 42 fractions in 6 weeks, initially, once-daily fractions: 32.4 Gy in 18 fractions of 1.8 Gy for 3.6 weeks (5 fractions/week), followed by twice-daily fractions 39.6 Gy in 24 fractions for 2.4 weeks: morning dose 1.8 Gy/fraction for a total of 12 fractions 5 fractions/week; evening dose 1.5 Gy/fraction for a total of 12 fractions 5 fractions/week. Doses were separated by at least a 6-hour interval. Late phase, i.e. adverse events which occur or worsen more than 60 days after the last trial treatment administration (cetuximab or radiotherapy), and before end of trial."
"7021",8349,"NCT00764309",347176,0.225806452,7,31,NA,NA,"Dasatinib",NA
"7061",8390,"NCT01491672",120878,0.224137931,13,58,NA,NA,"Prior Sunitinib","Participants, who received prior sunitinib therapy, received RAD001 10 mg orally once daily."
"7071",8403,"NCT01248936",182936,0.223719677,83,371,"Up to 1 Year","Serious adverse events and non-serious adverse events are reported in safety analysis set, which consists of all participants who received at least one dose of study medication and had a safety assessment performed post baseline.","Overall Trial","Participants received vemurafenib 960 mg orally two times a day for up to one year. Participants were treated until disease progression, unmanageable toxicity most probably attributable to vemurafenib, withdrawal of consent, and study termination by the sponsor"
"7074",8406,"NCT00083720",568343,0.223529412,19,85,"Adverse events were collected from the time that the patient received the initial cetuximab infusion and continued during the study until 30 days after the last dose of cetuximab.","The NCI-CTCAE V3.0 toxicity criteria was used to grading the severity of all AEs.","Cetuximab","Initial dose of 400 mg/m2 i.v. over 120 minutes, followed by 250 mg/m2 weekly i.v. over 60 minutes"
"7100",8437,"NCT01321554",161175,0.222222222,6,27,"For each participant, from the first dose till 30 days after the last dose or the cut-off date for the primary analysis whichever was earlier or up to approximately 2.5 years","Safety was assessed by the monitoring and recording of all adverse events (AEs) and serious adverse events (SAEs); regular monitoring of hematology, clinical chemistry, and urine values; physical examinations; and regular measurement of vital signs, electrocardiograms (ECG), and echocardiograms.","Lenvatinib 20 mg (OOL Lenvatinib Treatment Period)","Placebo treated participants in the Randomization Phase who had progressive disease confirmed by IIR, and who requested treatment with lenvatinib. The starting dose of lenvatinib during the OOL Lenvatinib Treatment Period was 24 mg once daily from 03 Oct 2011 until 15 Feb 2013. The starting dose was lowered at the request of the Data Monitoring Committee to 20 mg on 16 Feb 2013."
"7103",8440,"NCT00687440",376438,0.222222222,6,27,NA,NA,"Caelyx, Docetaxel, Trastuzumab",NA
"7106",8443,"NCT01606748",97942,0.222222222,4,18,NA,"All participants who received at least one dose of study drug.","Necitumumab Cohort 1","Necitumumab administered on Day 3 of the 3-week PK run-in period as an IV infusion at an absolute dose of 800 mg. Necitumumab administered on Days 1 and 8 of every 3-week cycle as an IV infusion at an absolute dose of 800 mg.
Participants in Cohort 1 received necitumumab Process C drug product and participants in Cohort 2 received necitumumab Process D drug product.
Gemcitabine administered on Day 1 of the 3-week PK run-in period as an IV infusion at a dose of 1250 mg/m2.
Gemcitabine administered on Days 1 and 8 of every 3-week cycle as an IV infusion at a dose of 1250 mg/m2."
"7112",8450,"NCT00694603",374553,0.222222222,4,18,NA,NA,"Cetuximab","Patients received intravenous cetuximab, 400 mg/m2, followed by weekly infusions of 250 mg/m2. Four weekly treatments constituted one cycle."
"7114",8452,"NCT00632541",395907,0.222222222,4,18,NA,NA,"Single Arm A","Sorafenib 200mg po daily, Bevacizumab 5mg/kg every other week, 1 Cycle = 4 weeks. Imaging every third cycle"
"7120",8459,"NCT00268346",526394,0.222222222,4,18,"From study start to 30 days after final treatment",NA,"No Prior Chem Therapy","Patients receive oral gefitinib once daily for at least 8 weeks in the absence of disease progression or unacceptable toxicity."
"7147",8489,"NCT00642746",391447,0.222222222,2,9,"Adverse Events have been collected since the study opened to enrollment to study closure, totaling 5.5 years.",NA,"FOLFIRI With Erlotinib",NA
"7156",8498,"NCT00482911",452443,0.222222222,2,9,NA,NA,"Cohort 2-sunitinib & Cyclophosphamide","2 participants started Cycle 1 with Dose B as described above and had adjusted-dosing as described for Cohort 1. The remaining 7 participants began Cycle 1 with 10 mg Len, 25 mg Cyc and 12.5 mg Sun once daily (Dose D-QD). Doses were adjusted in subsequent cycles depending on toxicity, including step up to 10/50/12.5 mg Len/Cyc/Sun once daily (Dose E-QD) and step down to Dose D once every other day (Dose D-QOD)."
"7167",8513,"NCT01183858",203888,0.221518987,35,158,"Randomization to End of Study: 14 October 2010 – 7 February 2014 (Up to 39.8 months)","Safety population: All participants who received at least 1 dose of study drug.","Erlotinib 300 mg","Erlotinib 300 mg single daily oral dose until disease progression."
"7172",8518,"NCT00385580",489553,0.221052632,21,95,NA,NA,"Dasatinib","All treated participants"
"7186",8534,"NCT00073528",570284,0.220183486,144,654,"Serious adverse events (SAEs) and non-serious AEs were collected during screening (within 4 weeks prior to the first dose), during study treatment (up to a maximum study duration of 46 months), and up to 30 days post-study.","SAEs and AEs were collected for the Safety Population, which included all randomized participants who had received at least 1 dose of study treatment, based on the actual treatment received if this differed from that to which the participant was randomized.","Letrozole 2.5 mg Plus Lapatinib 1500 mg","Participants received 6 tablets of lapatinib orally daily (250 mg lapatinib/tablet for a total of 1500 mg of lapatinib/day; approximately at the same time each day), either 1 hour (or more) before breakfast or 1 hour (or more) after breakfast. Participants also received 1 tablet of letrozole 2.5 mg orally daily, preferably with the daily dose of lapatinib. The maximum treatment period was up to 46 months."
"7199",8548,"NCT01496313",119822,0.219512195,9,41,NA,NA,"Vandetanib 300 mg","Oral blinded tablet, taken once daily"
"7200",8549,"NCT01340651",155872,0.219512195,9,41,"Adverse events were collected from Baseline through the end of the study","Safety population: All enrolled participants who took at least 1 dose of study drug.","Ruxolitinib - After Week 16","At Week 16, participants transitioned to ruxolitinib 10, 15, or 20 mg immediate release (IR) orally twice daily up to when the last participant completed Week 36 or the commercial availability of ruxolitinib IR, whichever was earlier; the dose received was based on platelet counts at the time of transition."
"7201",8550,"NCT01271712",175405,0.219512195,9,41,"From randomization of the first subject until date of database cutoff (26 Jan 2012).","Acronyms used: International Normalized Ratio (INR).","Regorafenib, Open Label Only (Regorafenib Continued)","Continue Regorafenib (Open Label study phase only): Participants continue to receive Regorafenib (Stivarga) 160 mg (4 x 40 mg tablets) per os once daily, 3 weeks on therapy followed by 1 week off therapy to comprise a cycle of 4 weeks"
"7221",8575,"NCT00524303",437866,0.21875,7,32,NA,"In the Safety Population, serious and non-serious adverse events were collected from all randomized participants who received at least one dose of investigational product and was based on the actual treatment received if this differed from that to which the participant was randomized.","Trastuzumab","Participants received trastuzumab alone (a loading dose of 4 milligrams [mg]/kilogram [kg] on Day 1, followed by a dose of 2 mg/kg on Day 1 of Week 2 and weekly thereafter). Participants were treated with trastuzumab in a 2-week run-in period. On Day 14, a second core needle biopsy was performed, followed by initiation of chemotherapy with 2 combination regimens of 4 cycles each (1 cycle=3 weeks): FEC75 (5-fluorouracil [5-FU] 500 mg/meters squared [m^2], epirubicin 75 mg/m^2, cyclophosphamide 500 mg/m^2 x 4 cycles on Day 1), then paclitaxel (80 mg/m^2 x 4 cycles on Day 1, Day 8, and Day 15) in combination with trastuzumab."
"7235",8590,"NCT00089999",566748,0.217391304,15,69,"Serious adverse events (SAEs) and non-serious AEs were collected from the first dose of investigational product to 30 days after the last dose (up to Study Week 192).","SAEs and non-serious AEs were collected in members of the Safety Population, comprised of all randomized participants who received at least one dose of investigational product , according to the actual treatment received.","Lapatinib 1500 mg QD","Participants received lapatinib 1500 mg orally QD. Treatment was continued for 12 weeks or until disease progression or withdrawal from treatment for another reason. After Week 12, participants with clinical benefit had the option to continue with the lapatinib therapy at the same dose and schedule, until disease progression, provided the treatment was tolerated."
"7238",8594,"NCT00751036",352892,0.217391304,10,46,NA,NA,"Imatinib 800 mg","Patients who were assigned to this treatment group received 400 mg. imatinib bid."
"7248",8607,"NCT00245102",532799,0.217391304,5,23,NA,NA,"Other Histology","Sorafenib 400 mg PO BID"
"7253",8613,"NCT00550173",426946,0.21686747,18,83,NA,"One participant was assigned to Pemetrexed (single therapy) but received Erlotinib (single therapy) at the first cycle, this leads to the discrepancy of participants for the safety analysis.","Erlotinib","Participants received erlotinib 150 mg, administered orally once daily in each 21 day cycle until disease progression or unacceptable toxicity developed up to 39 months."
"7266",8629,"NCT02491892",4509,0.216216216,8,37,"Up to approximately 1 year (from start of treatment until up to 7 weeks following the last infusion)",NA,"Pertuzumab 1050 mg","Participants did not receive a loading dose, but received pertuzumab 1050 mg via IV infusion every 3 weeks until unacceptable toxicity or disease progression."
"7267",8630,"NCT00837148",317509,0.216216216,8,37,NA,NA,"Soft Tissue Sarcoma Patients","Sorafenib and Dacarbazine in Soft Tissue Sarcoma"
"7316",8685,"NCT00982488",268979,0.214285714,3,14,NA,NA,"Imatinib, 400 mg BID, Chronic Phase","Participants with chronic phase disease received 400 mg of imatinib BID. Dose reduction to 600 mg/day (300 mg BID) was permitted, provided the participant had not previously received that dose prior to entry into CA180-017. Participants received study medication until disease progression, unacceptable toxicity, failure to serve patient's best interest, withdrawal of consent, or study closure."
"7318",8688,"NCT00862836",307485,0.214285714,3,14,NA,NA,"Vandetanib 100 mg","Once daily oral Vandetanib 100 mg added to standard therapy (pegylated liposomal doxorubicin 50 mg/m2 iv every 4 weeks)"
"7325",8696,"NCT00096200",563790,0.214285714,3,14,"Adverse events collected during treatment for all patients over a 7 year period from 2004-2011.","Serious Adverse Event and Adverse Event data reported on Arm A includes events from Arm C patients while on Arm A.","Arm A","Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression crossover to arm II"
"7336",8710,"NCT00820755",323602,0.212903226,33,155,"Time from Baseline up to 30 days after the last dose of study treatment.","One participant who was randomized to ‘Cetuximab 500 mg/m^2 Every 2 Weeks’ arm actually received ‘Cetuximab 250 mg/m^2 Weekly’ treatment and was counted in this group for safety analysis","Cetuximab 250 mg/m^2 Weekly","Participants who were free of disease progression at the end of combination therapy, entered in the maintenance therapy period. In the maintenance period, participants received cetuximab 250 mg/m^2 as intravenous infusion weekly, until PD, unacceptable toxicity, or withdrawal of consent."
"7358",8736,"NCT01990261",37547,0.212121212,7,33,"Up to 12 months",NA,"Erlotinib","Participants diagnosed with locally advanced or metastatic non-small cell lung with known carcinoma epidermal growth factor receptor (EGFR) status received erlotinib at a dose determined by the investigator, guided by the recommendation in the Summary of Product Characteristics."
"7364",8743,"NCT00872989",304906,0.212121212,7,33,"Toxicity assessments was evaluated before each treatment cycle (21 days), up to 5 years.",NA,"Vandetanib","Adverse events are analyzed in the subset of patients who received at least one dose of drug."
"7365",8744,"NCT00821327",323520,0.212121212,7,33,"During the whole treatment period, up to 30 days following last dose.","For treated patients only, assessed at each treatment visit.","Study Arm: Advanced/Metastatic UC","Gemcitabine, Cisplatin, Sunitinib
Gemcitabine, Cisplatin, Sunitinib: Patients will receive gemcitabine 800 mg/m2 IV (Days 1 and 8), cisplatin 60 mg/m2 IV (Day 1), and sunitinib 37.5 mg PO daily (Days 1-14) of each 21-day cycle.
2. One cycle of treatment is defined as 21 days (3 weeks). Restaging studies will be performed after every 3 cycles of therapy.
3. Successive cycles will be initiated every 3 weeks, and will be continued through 6 cycles unless a patient shows evidence of disease progression or intolerable toxicity."
"7375",8754,"NCT00791778",335589,0.211382114,26,123,"From the start of treatment up to 30 days after last study drug administration.","Acronyms used: Gastrointestinal (GI), Genitourinary (GU), Not Otherwise Specified (NOS), Absolute Neutrophil Count (ANC), Aspartate aminotransferase (AST), Alanine aminotransferase (ALT), Common Terminology Criteria for Adverse Events (CTCAE)","Sorafenib (Nexavar, BAY43-9006)","Participants received 2 sorafenib tablets (200 mg each) per oral twice daily (bid)"
"7384",8763,"NCT01227577",189109,0.2109375,27,128,NA,NA,"Nilotinib","Participants received 300 mg twice daily (b.i.d.). Dose increases to 400 b.i.d. were permitted, per Investigator's discretion."
"7395",8776,"NCT00955916",277991,0.210526316,8,38,"1 year, 10 months",NA,"CLAG Regimen With Gleevec®","Combined chemotherapy treatment (CLAG regimen) with Gleevec® (imatinib mesylate).
Gleevec®: Imatinib mesylate 400 mg orally twice daily was administered on day 2 to day 15. Re-induction was allowed if participant had partial response (PR).
CLAG Regimen: The CLAG regimen consisted of: Cladribine, 5 mg/m^2 administered via 2 hour IV daily for 5 consecutive days starting on day 2; Cytarabine, 2 mg/m^2 administered through a 4 hour IV starting 2 hours after the ignition of Cladribine for 5 days starting on day 2; granulocyte colony-stimulating factor (G-CSF): 300 mcg subcutaneous (SC) for 6 days starting 12-24 hours (Day 1) before the first dose of Cladribine."
"7406",8787,"NCT00684983",377447,0.210526316,4,19,NA,NA,"Arm A","Patients receive oral capecitabine twice daily on days 1-14 and oral lapatinib ditosylate once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. lapatinib ditosylate: Given PO and capecitabine: Given PO"
"7419",8804,"NCT00490139",449357,0.209528439,431,2057,"Serious adverse events (SAEs) and non-serious AEs were collected from randomization until 10 years post-study entry.","SAEs and non-serious AEs are reported for the Safety Population, comprised of all randomized participants who were administered at least one dose of investigational targeted treatment, as recorded on the “administration of study drug” Case Report Form pages, but excluding any post-event treatments and not considering compliance.","Lapatinib","Participants received treatment per one of the following three designs. Design 1: oral lap 1500 mg daily for 52 weeks. Design 2: oral lap 750 mg daily concomitantly with weekly paclitaxel 80 mg/m^2 IV or docetaxel 75 mg/m^2 IV every 3 weeks, for 12 weeks. After completion of paclitaxel or docetaxel, participants received oral lap at an increased dose of 1500 mg daily for 40 weeks. Design 2B: oral lap 750 mg daily concomitantly with docetaxel 75 mg/m^2 every 3 weeks and carboplatin AUC6 IV, for 18 weeks. After completion of docetaxel and carboplatin, oral lap was given at an increased dose of 1500 mg for 34 weeks. Participants also received adjuvant radiotherapy and adjuvant anti-estrogen therapy when clinically indicated."
"7422",8808,"NCT00514683",441986,0.209302326,18,86,"First drug administration until 14 days after last drug administration",NA,"Nintedanib 100 Bid","Patients were treated with 100mg nintedanib twice daily"
"7437",8827,"NCT00490139",449359,0.208636584,430,2061,"Serious adverse events (SAEs) and non-serious AEs were collected from randomization until 10 years post-study entry.","SAEs and non-serious AEs are reported for the Safety Population, comprised of all randomized participants who were administered at least one dose of investigational targeted treatment, as recorded on the “administration of study drug” Case Report Form pages, but excluding any post-event treatments and not considering compliance.","Lapatinib plusTrastuzumab","Participants (par.) received treatment per one of three designs. D1: oral lapatinib (OL) 1000 milligrams (mg) daily with trastuzumab (tras) (8 milligrams per kilogram [mg/kg] intravenous [IV] loading dose [LD], followed by 6 mg/kg IV every 3 weeks [E3W]) for 52 weeks (wks). D2: OL 750 mg daily plus wkly tras (4 mg/kg LD, followed by 2 mg/kg IV) concomitantly (conc.) with wkly paclitaxel (pac) 80 mg per squared meter (mg/m^2) IV or docetaxel (doc) 75 mg/m^2 IV E3W for 12 wks. After completion of pac or doc, par. received OL at an increased dose of 1000 mg daily in combination with tras (6 mg/kg without a LD) E3W for 40 wks. D2B: OL 750 mg plus wkly tras (4 mg/kg IV LD, followed by 2 mg/kg IV wkly) conc. with doc 75 mg/m^2 E3W and carboplatin (carb) AUC6 IV for 18 wks. After completion of doc and carb, par. received tras E3W (6 mg/kg without a LD) plus OL 1000 mg daily for 34 wks. Par. also received adjuvant radiotherapy and adjuvant anti-estrogen therapy when clinically indicated."
"7441",8831,"NCT01515306",116356,0.208333333,5,24,NA,"Deaths due to progressive disease were not considered adverse events (AEs).","Part A: Paclitaxel and Ramucirumab (IMC-1121B)","Cycle 1: paclitaxel 80 milligrams/square meter (mg/m²) administered on Day 1 of 2-week cycle.
Cycle 2: ramucirumab (IMC-1121B) 8 milligrams/kilogram (mg/kg) administered on Day 1 and Day 15, paclitaxel 80 mg/m² administered on Day 1, Day 8 and Day 15 of 4-week cycle.
Cycle 3 and beyond: ramucirumab (IMC-1121B) 8 mg/kg administered on Day 1 and Day 15, paclitaxel 80 mg/m² administered on Day 1, Day 8 and Day 15 of each 4-week cycle."
"7454",8845,"NCT00785785",338101,0.208,26,125,NA,NA,"Crossover Imatinib","exposure to nilotinib and then imatinib"
"7457",8849,"NCT00760877",348999,0.207920792,21,101,NA,NA,"Nilotinib","Nilotinib"
"7469",8863,"NCT01233869",186859,0.206896552,12,58,"Baseline up to 30 days after last study drug administration","The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another participant, or one participant may have experienced both a serious and non-serious event during the study.","Bosutinib 200 mg/Day","Participants received bosutinib 200 mg tablet orally once daily (QD) in the morning with food for 24 months in the Initial Treatment Period (ITP). After a 30-day washout period, participants who entered the Extended Treatment Period (ETP) continued to receive bosutinib 200 mg orally QD for up to 46 months."
"7477",8872,"NCT01469000",126376,0.206349206,26,126,NA,"All participants who received at least 1 dose of study drug.","250 mg Gefitinib/500 mg Pemetrexed","250 milligrams (mg) Gefitinib taken orally once daily (QD) and 500 milligrams per square meter (mg/m²) Pemetrexed taken intravenously (IV) once every 3 weeks concurrently with Gefitinib QD."
"7478",8874,"NCT00281957",523319,0.206349206,13,63,"While the patient is on treatment until resolution of acute toxicities with maximum grade reported","Regular investigator assessments are reported after each cycle of protocol treatment","Arm I","Sorafenib and Temsirolimu"
"7490",8888,"NCT00734851",357981,0.205882353,7,34,"36 Months","The adverse events were gathered in Common Terminology Criteria for Adverse Events v.3.0, and have been converted to v.4.0 for entry into ClinicalTrials.gov","Multimodality","4 cycles of 70 mg/m2 Docetaxel + 37.5 mg daily Sunitinib for 14 days followed by a 7 day break for 3 cycles + external beam radiotherapy to 66 Gray over 6-7 weeks"
"7491",8890,"NCT00524303",437865,0.205882353,7,34,NA,"In the Safety Population, serious and non-serious adverse events were collected from all randomized participants who received at least one dose of investigational product and was based on the actual treatment received if this differed from that to which the participant was randomized.","Lapatinib","Participants received lapatinib alone (1250 mg orally [PO] once daily [QD]). Participants were treated with lapatinib in a 2-week run-in period. On Day 14, a second core needle biopsy was performed, followed by initiation of chemotherapy with 2 combination regimens of 4 cycles each (1 cycle=3 weeks): FEC75 (5-FU 500 mg/m^2, epirubicin 75 mg/m^2, cyclophosphamide 500 mg/m^2 x 4 cycles on Day 1), then paclitaxel (80 mg/m^2 x 4 cycles on Day 1, Day 8, and Day 15) in combination with lapatinib."
"7492",8893,"NCT00127933",553386,0.205882353,7,34,"Cycle 1, Cycle 2, Cycle 3, Cycle 4, at Surgery, and the month 1 visit during the postoperative follow-up period","Intensity of AEs was graded according to the NCI CTCAE version 3.0 on a 5-point scale (grade 1 to 5), clinical laboratory parameters (hematology, chemistry, and urinalysis as clinically indicated), and vital signs.","HER2-Neu Positive","Dose and route per treatment cycle (Q3W):
Capecitabine: 825 mg/m2, orally, twice daily, days 1-14 Docetaxel: 75 mg/m2, IV infusion, day 1 Trastuzumab: loading dose 4 mg/kg, 90-min IV infusion; thereafter, 2 mg/kg, 30-min IV infusion, weekly
HER2-neu positive: capecitabine + docetaxel + trastuzumab
Duration: Four 3-week treatment cycles"
"7500",8903,"NCT01535729",111942,0.205194805,79,385,"Up to Month 40 (Maximum follow-up)","SAF.","NSCLC Elderly Participants","Elderly Participants (≥ 65 years) with locally advanced or metastatic NSCLC, on erlotinib (Tarceva®) prescribed in accordance with the terms of the marketing authorization, were observed for maximum of 12 months."
"7509",8913,"NCT00795002",334167,0.205128205,8,39,"1 cycle of therapy",NA,"Arm I","Patients receive alvocidib IV over 1 hour on days 1-3, cytarabine IV continuously over 72 hours on days 6-8, and mitoxantrone hydrochloride IV over 60-120 minutes on day 9."
"7510",8914,"NCT00795002",334166,0.205128205,8,39,"1 cycle of therapy",NA,"Arm II","Patients receive alvocidib IV over 30 minutes followed by alvocidib IV over 4 hours on days 1-3. Patients also receive cytarabine and mitoxantrone hydrochloride as in arm I."
"7528",8935,"NCT00246571",532312,0.203883495,21,103,NA,"The same event may appear as both an adverse event (AE) and a serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.","Standard of Care","One of the following regimens was administered (at investigator's discretion): oral capecitabine 1000-1250 milligrams per square meter (mg/m^2) twice daily (BID) Days 1-14, every 3 weeks; vinorelbine 25-30 mg/m^2 rapid intravenous (IV) infusion or 60-80 mg/m^2 oral weekly, expressed in 3-week cycles; docetaxel 75-100 mg/m^2 via IV infusion every 3 weeks; paclitaxel 175-200 mg/m^2 via IV infusion every 3 weeks; paclitaxel 80-90 mg/m^2 weekly, in a continuous regimen expressed in 3-week cycles or 3 weeks of treatment followed by 1 week of rest; gemcitabine 800-1250 mg/m^2 via IV infusion, Days 1 and 8 every 3 weeks. If Response Evaluation Criteria in Solid Tumors (RECIST) defined progression was met, participants could receive sunitinib, 37.5 mg oral capsules QD, in continuous 3-week cycles."
"7541",8948,"NCT00793871",334444,0.203389831,12,59,NA,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.","Sutent (Sunitinib Malate)","The starting dose of sunitinib was 50 mg orally once daily as a single agent for 4 consecutive weeks followed by a 2-week off-treatment period to form a complete cycle of 6 weeks (schedule 4/2). Participants experiencing dose-limiting toxicity attributed to study medication had dose interrupted or reduced depending on individual tolerability. If dose reductions were required, the dose of 37.5 mg was achieved by administration of 3 × 12.5 mg capsules, and the dose of 25 mg was achieved by administration of 2 × 12.5 mg capsules. There was no limit for number of cycles for this study, study treatment was permanently discontinued upon disease progression, occurrence of unacceptable toxicity, withdrawal of participant consent, or another withdrawal criterion was met."
"7549",8957,"NCT00920816",290719,0.202898551,14,69,"Baseline up to Week 107","Same event may appear as both AE and SAE. However, what is presented are distinct events. Event may be categorized as serious in 1 subject and nonserious in another subject, or 1 subject may have experienced both a serious and nonserious event during the study. Participants at risk = 189, 96, 135, 69 for each arm group, respectively.","Sorafenib (Second-line Participants)","Asian participants with prior systemic first-line therapy containing sunitinib or cytokine received sorafenib tablet at a starting dose of 400 mg orally twice daily, dose adjustment was done based on the tolerability, as per investigator’s discretion. Study medication was administered in cycles of 4 weeks."
"7550",8958,"NCT00679341",379528,0.202898551,14,69,"Adverse events were collected from randomization until 30 days following the last treatment, until the early termination visit, or until treatment-related adverse events resolved or stabilized, whichever occurred first.","Safety population: All randomized patients who received at least 1 dose of study treatment. In the trastuzumab + docetaxel (T+D) group, 2 patients received no treatment and 2 patients received a dose of trastuzumab emtansine (TE) and were included in that group for safety analyses, resulting in 66 patients in the T+D group and 69 in the TE group.","Trastuzumab Emtansine","Patients received trastuzumab emtansine 3.6 mg/kg intravenously (IV) administered over 30-90 minutes every 3 weeks on Day 1 of each 21-day cycle."
"7552",8960,"NCT00371566",493943,0.202898551,14,69,"Started prior to and during Lapatanib/Placebo phase, during or after chemoradiotherapy phase.","Safety population used in this analysis consisting of all randomized subjects who took at least one dose of study medication. This population was based on the actual treatment received, if different to the randomized treatment allocation.","Lapatinib","Subjects who were given once daily dose of oral lapatinib 1500 mg for 2 -6 weeks, followed by 4 weeks of standard treatment of radiotherapy (of mor than or equal to 65 Gy) and concurrent platinum-based chemotherapy (based on the institutions standard care)."
"7564",8975,"NCT01419197",138473,0.20212766,19,94,"Adverse events were collected from treatment initiation until 30 days following the last administration of study drug or study discontinuation on 31 August 2015 (up to approximately 4 years).","Safety population: All participants who received any amount of planned study treatment, according to treatment actually received. Data for participants in the Treatment of Physicians Choice (TPC) arm who switched treatment to receive trastuzumab emtansine (TE) following disease progression on TPC are presented separately. Median treatment duration of trastuzumab emtansine: 5.2 months (range 0.03-40.7),TPC: 2.7 months (range 0.03-31.0) and TE - Post TPC Treatment Switch: 4.5 months (range 1-43).","Trastuzumab Emtansine - Post TPC Treatment Switch","Participants, who switched treatment in the Treatment of Physician's Choice arm to trastuzumab emtansine, were administered trastuzumab emtansine 3.6 mg/kg intravenously every 3 weeks until disease progression (as assessed by the investigator) or unmanageable toxicity."
"7570",8981,"NCT00674973",380810,0.201923077,21,104,"Adverse events were assessed from baseline up to 28 days after discontinuation of study drug (up to 30 months)",NA,"Erlotinib","Participants with advanced pancreatic carcinoma with ECOG PS score of 0 to 2, who had failed 1 prior regimen of chemotherapy or who were considered unsuitable for chemotherapy, received erlotinib 150 mg orally once daily until PD, unacceptable toxicity, withdrawal, or death."
"7575",8986,"NCT01132846",219123,0.201680672,24,119,NA,NA,"Placebo","Drug: Placebo
Participants will receive placebo in place of low dose dopamine or low dose nesiritide depending on randomization.
Placebo: Participants will be randomized to receive Low dose Dopamine or placebo plus optimal diuretic or Low dose Nesiritide or placebo plus optimal diuretic."
"7589",9001,"NCT01342965",155325,0.2,22,110,NA,"Safety analysis set: All participants who had received at least 1 dose of study medication.","Erlotinib","Participants received erlotinib 150 mg orally once daily until progressive disease or unacceptable toxicity."
"7597",9011,"NCT00445848",465311,0.2,17,85,"Toxicity assessment was evaluated after each cycle (21 days) while on protocol therapy.",NA,"Erlotinib and Bevacizumab","Patients received erlotinib 150 mg daily with bevacizumab at 15mg/kg until progression or prohibitive toxicity."
"7607",9022,"NCT00305760",515689,0.2,12,60,NA,NA,"Cyclophosphamide, Pancreatic Tumor Vaccine, Cetuximab","Cetuximab: Cetuximab will be administered at an initial dose of 400 mg/m2, followed by weekly doses of 250 mg/m2 for a total of 6 cycles that last 3 weeks each.
Pancreatic tumor vaccine: Vaccine will be administered one day after cyclophosphamide (day 1) every three weeks for 6 cycles.
Cyclophosphamide: Cyclophosphamide 250 mg/m2 will be administered one day prior to vaccination (day 0) every three weeks for 6 cycles."
"7614",9030,"NCT01378962",146525,0.2,10,50,"Up to 1 year after enrollment of the last participant (maximum up to 27 months)",NA,"Erlotinib 150 mg","Erlotinib 150 mg tablet orally once daily up to end of study (12 months) or until disease progression, unacceptable toxicity or consent withdrawal."
"7624",9043,"NCT01496313",119823,0.2,8,40,NA,NA,"Vandetanib 150 mg","Oral blinded tablet, taken once daily"
"7634",9054,"NCT00599313",408925,0.2,7,35,"During the whole treatment period, up to 30 days following last dose.","For treated patients only, assessed at each treatment visit.","Sunitinib Malate","Sunitinib Malate (Sutent) (50 mg/day on Days 1-28 of 42-day cycles)"
"7638",9058,"NCT00367679",495418,0.2,7,35,"All AEs and SAEs were to be collected and recorded from receipt of first dose of pazopanib until 28 days following cessation of pazopanib, regardless of initiation of new cancer therapy.",NA,"Pazopanib 800 mg","Pazopanib 800 milligrams (mg) (tablets) administered orally once a day for a minimum of 2 and a maximum of 6 weeks"
"7655",9077,"NCT00694096",374701,0.2,5,25,NA,NA,"Arm 1 - Sunitinib 37.5 mg","Sunitinib: Imaging studies with complete analyses for patients prior to initiation of sunitinib therapy at 37.5 mg orally/day, and at time points between 1 and 4 weeks after initiation of sunitinib therapy."
"7659",9081,"NCT00372567",493230,0.2,5,25,NA,"The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. One participant enrolled in the imatinib arm was inadvertently randomized (participant did not meet inclusion criteria) and was not treated in this study.","Imatinib","All participants who received Imatinib"
"7681",9106,"NCT00364611",496579,0.2,4,20,"From treatment initiation up to 30 days following the last dose of study medication (upto April 2012)","All participants (except one) were off study treatment on 30 June 2011. An initial safety analysis was performed using the cut-off date of June 2011. One participant continued till 19 April 2012. For this participant, adverse events were collected upto April 2012 and included in the final safety analysis.","Docetaxel, Bevacizumab and Trastuzumab","Stratum 2: HER2 Positive participants with metastatic breast cancer treated with DBT (docetaxel, bevacizumab, and trastuzumab) IV q3w until treatment discontinuation criteria (unacceptable toxicity, disease progression or death) are met"
"7687",9112,"NCT00087152",567564,0.2,4,20,"Every 3 weeks while on treatment for up to 3 years.",NA,"Imatinib Mesylate and Capecitabine","Imatinib Mesylate 400 mg by mouth daily for 21 day cycle. Capecitabine 1,000 mg/m^2 by mouth twice daily Days 1-14 of each 21 day cycle."
"7706",9132,"NCT00932373",286663,0.2,3,15,"Baseline to the end of the study (up to 3 years 2 months)",NA,"Trastuzumab-MCC-DM 3.6 mg/kg Every 3 Weeks","Trastuzumab-MCC-DM 3.6 mg/kg administered intravenously (IV) once every 3 weeks"
"7718",9144,"NCT00387335",488536,0.2,3,15,"Up to two years","Common Terminology Criteria for Adverse Events (CTCAE v3.0). Reported are grade 1 or higher adverse events.","Sunitinib -- Cohort A","Patients receive oral sunitinib malate once daily on days 1-28. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity. ECOG Performance Status 0 -1."
"7727",9154,"NCT01682135",83476,0.2,2,10,NA,NA,"Cohort 2 - 10mg/kg/3w Ramucirumab","10mg/kg ramucirumab administered IV every 3 weeks for 6 weeks (one cycle). When a pre-defined percentage of participants completed Cycle 1 without experiencing a DLT, dose escalation was initiated with the start of Cohort 3."
"7738",9166,"NCT01313663",163160,0.2,2,10,"Participants were analyzed from the time the first dose of study treatment was administered until 28 days following discontinuation of study treatment regardless of initiation of a new cancer therapy or transfer to hospice (up to Study Week 55).","Serious adverse events (SAEs) and non-serious AEs were collected in the Safety Population, comprisedof all participants who were randomized and took at least one dose of study medication. This population was based on the actual treatment received, if it differed from that to which the participant was randomized.","Pazopanib 800 mg","Participants received pazopanib 800 milligrams (mg) orally once a day at approximately the same time each day, either 1 hour before a meal or 2 hours after a meal. The tablets were to be swallowed whole and were not to be crushed or broken. Participants received study treatment until disease progression, death, unacceptable adverse event, withdrawal of consent, or physician decision. Participants who withdrew due to an adverse event or disease progression were followed for survival."
"7809",9245,"NCT01057017",243852,0.2,1,5,"from time of signing consent to 30 days post last dose of drug (occurred up to approximately 10 months)",NA,"Intervention","Bevacizumab: 7.5mg/kg, IV over 30-90 minutes every 3 weeks until disease progression.
Panitumumab Dose Level 1: 6mg/kg over 60-120 minutes every 3 weeks until disease progression Dose Level 2: 9mg/kg over 60-120 minutes every 3 weeks until disease progression"
"7813",9250,"NCT00988169",266624,0.2,1,5,NA,NA,"Oral Erlotinib and Pulsed Doses of Oral AT-101","Treatment-naïve advanced (Wet Stage IIIB and IV)NSCLC patients with EGFR activating mutations."
"7822",9259,"NCT00906698",295312,0.2,1,5,"First administration of trial medication until 28 days after last administration of trial medication.",NA,"Afatinib 50mg With Vinorelbine Per os","Continuous daily dosing of Afatinib 50mg orally and oral vinorelbine 60 mg/m2/week for days 1,8,15 of first cycle, and 80mg/m2 from day 22 first cycle onwards, weekly. Patients will be eligible for repeated treatment courses in the absence of clinical disease progression or undue toxicity ."
"7844",9283,"NCT00522301",438681,0.2,1,5,NA,NA,"Oral Sorafenib (BAY43-9006)","Sorafenib will be administered as 400 mg orally daily x 28 days (continuous)."
"7846",9287,"NCT00474929",454806,0.2,1,5,"The adverse events reported here occurred during treatment. The maximum treatment length was 27, 28-day cycles.","Adverse events were collected at the end of each cycle.","Phase I, Dose Level 1","Phase I: Dose level 1: Sorafenib 200 mg twice daily, RAD001 5mg every day"
"7847",9288,"NCT00474929",454804,0.2,1,5,"The adverse events reported here occurred during treatment. The maximum treatment length was 27, 28-day cycles.","Adverse events were collected at the end of each cycle.","Phase I, Dose Level 3","Phase I: Dose level 3: Sorafenib 400 mg twice daily, RAD001 10mg every day"
"7857",9299,"NCT00303966",516053,0.2,1,5,"up to 6 months","Grade 3 or higher adverse events are reported.","Treatment (Sorafenib Tosylate)","Patients receive oral sorafenib twice daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity."
"7861",9303,"NCT00118053",556390,0.2,1,5,"3 years",NA,"Docetaxel, Carboplatin and Trastuzumab","A total of six cycles of TCH [(Taxotere® (75 mg/m2) + Carboplatin (AUC = 6) + Herceptin® (2 mg/kg weekly after a 4 mg/kg load on Day 1)] will be administered every 3 weeks.Three weeks after receiving the sixth cycle of TCH, all patients will be restaged.
Those determined to have localized and operable disease will undergo a modified radical mastectomy or lumpectomy and axillary node dissection. After recovery from surgery, the patients will receive whole breast or chest wall irradiation (as determined by radiologist) with concurrent Herceptin® (6 mg/kg). Following radiation, patients will continue Herceptin® (6 mg/kg) every 3 weeks until they have been on study for a total of 52 weeks.
If patients are staged and are negative they will continue Herceptin® (6 mg/kg)every 3 weeks until they have been on study for a total of 52 weeks."
"7897",9345,"NCT00718315",364567,0.196969697,13,66,"Adverse Events were recorded from Day 0 to Day 45 (15 days after the End of study)",NA,"Stiemicyn","Participants received erlotinib 150 mg daily and A thin film of the topical formulation of Stiemicyn was applied to face, neck, and anterior and posterior chest twice daily (every 12 hours), as per medical guidance daily for 30 days."
"7909",9358,"NCT00238121",533900,0.196428571,11,56,NA,NA,"Sorafenib",NA
"7914",9363,"NCT01203917",196289,0.196261682,21,107,NA,NA,"Gefitinib 250 mg",NA
"7916",9366,"NCT01064310",242284,0.196078431,30,153,"Participants were evaluated from Baseline until the end of the second treatment period (maximum of 22 weeks).","Adverse events and serious adverse events were collected for the Safety-Randomized Study Population, which included participants who received at least one dose of either sunitinib or pazopanib regardless of treatment period. Participants who received mixed treatment within a period were excluded.","Pazopanib","Participants received 4 overencapsulated tablets of pazopanib (either in Period 1 or Period 2), each containing 200 mg of pazopanib, OD orally for 10 weeks. Study drug was taken orally OD without food at least one hour before or two hours after a meal. The capsules were swallowed whole and not crushed or broken. The time of day the study drug was taken remained relatively constant."
"7937",9391,"NCT00431067",470702,0.195121951,8,41,"From first dose of study medication to 28 days after study drug discontinuation.",NA,"Afatinib 50 mg","Patients received continuous daily dosing with Afatinib 50 mg therapy over 28-day treatment cycles until further disease progression or undue toxicity."
"7953",9412,"NCT00836745",317562,0.194444444,7,36,NA,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.","Sunitinib","Participants who received sunitinib capsule once daily as per local product information, were followed up for 1 year or till the occurrence of disease progression, early discontinuation of sunitinib therapy (due to unacceptable toxicity, participant’s request or lost to follow up), or death, whichever occurred earlier. Sunitinib dose was adjusted solely according to medical and therapeutic needs."
"7954",9413,"NCT00768144",345659,0.194444444,7,36,"Assessed each cycle throughout treatment from time of first dose and up to day 30 post-treatment.",NA,"Sunitinib","Sunitinib : Taken orally once a day in the evening"
"7968",9430,"NCT00463788",459255,0.193548387,6,31,"Time from first dose up to 30 days after last dose of study treatment, reported between day of first dose of study treatment, 20 June 2007, until cut-off date 05 April 2010","An AE was defined as any untoward medical occurrence in the form of signs, symptoms, abnormal laboratory findings, or diseases that emerges or worsens relative to baseline during a clinical study with an IMP, regardless of causal relationship.","Cisplatin Alone Switched to Cetuximab","On progression, participants in the cisplatin group had the option to switch to cisplatin (75 mg/m^2 IV infusion) plus cetuximab (initially 400 mg/m^2 followed by 250 mg/m^2 IV infusion) if the progressive disease was reported during the 6 cisplatin cycles or to cetuximab alone (initially 400 mg/m^2 followed by 250 mg/m^2 IV infusion) if the progression was reported after the 6 cisplatin cycles."
"7971",9435,"NCT00373425",493301,0.193126023,118,611,"From the first dose of study drug until 30 days after the last dose. Maximum time on treatment for the Randomized Cohort was 24 months; maximum time on treatment for the BPC was 13 months on blinded study drug and 26 months on open-label erlotinib.","One participant in the Randomized Cohort assigned to the erlotinib arm received placebo instead due to a dispensing error and is included in the placebo group for safety analyses. For the Breached Protocol Cohort safety analyses are based on the total no open-label and open-label populations.
Safety data are based on the 11 June 2014 cut-off date.","RC: Erlotinib","Participants in the randomized cohort (RC) who received 150 mg/day erlotinib orally for 2 years or until relapse, death, participant request or investigator decision to discontinue study drug, or intolerable toxicity."
"7975",9439,"NCT00356811",499636,0.192982456,11,57,"Serious adverse events (SAEs) and non-serious adverse events (AEs) were collected from the start of study medication until 28 days after the last dose (up to Study Week 381).","SAEs and non-serious AEs are reported for members of the ITT Population, comprised of all participants who received study medication.","Lapatinib Plus Paclitaxel","Participants received lapatinib 1500 mg orally OD with paclitaxel, administered as a 1-hour IV infusion at a dose of 80 mg/m^2 on Days 1, 8, and 15 (±2 days) of a 28-day treatment cycle for at least 6 months. Participants were treated until disease progression, unacceptable toxicity, or consent withdrawal."
"7979",9446,"NCT00820755",323603,0.192307692,30,156,"Time from Baseline up to 30 days after the last dose of study treatment.","One participant who was randomized to ‘Cetuximab 500 mg/m^2 Every 2 Weeks’ arm actually received ‘Cetuximab 250 mg/m^2 Weekly’ treatment and was counted in this group for safety analysis","Cetuximab 500 mg/m^2 Every 2 Weeks","Participants who were free of disease progression after combination therapy, they administered with cetuximab 500 mg/m^2 intravenously for 2 weeks, for up to PD, development of unacceptable toxicities, or withdrawal of consent after the end of combination therapy."
"7986",9454,"NCT00939627",284292,0.192307692,5,26,"2 years, 4 months","All participants who received treatment.","Arm A - Cetuximab","Patients were to receive cetuximab IV over 60-120 minutes on days 1, 8, and 15 and oral placebo twice daily on days 1-21. After 19 patients were enrolled, the trial was amended to remove the placebo (and blinding) due to issues with placebo tablet solubility."
"7998",9466,"NCT00494299",447842,0.192139738,44,229,NA,"Acronyms in Adverse Event section: - Absolute Neutrophil Count (ANC) - Alanine Transaminase (ALT) - Aspartate Transaminase (AST) - Atrioventricular (AV) - Central Nervous System (CNS) - Gastrointestinal (GI) - International Normalized Ratio (INR) - Not Otherwise Specified (NOS)","Sorafenib (Nexavar, BAY43-9006)","Sorafenib (Nexavar, BAY43-9006) administered orally at a dose of 400 mg (2 x 200 mg tablets) twice daily (bid) (morning and evening, every 12 hours as far as possible); Dose modification (delayed or reduced) was permitted due to toxicity."
"8035",9509,"NCT00565370",419960,0.19047619,4,21,NA,NA,"XP Plus Sorafenib","Capecitabine and cisplatin plus sorafenib"
"8063",9543,"NCT00423332",474675,0.188679245,10,53,NA,NA,"Cediranib DB","Double Blind part"
"8066",9547,"NCT01183858",203889,0.188311688,29,154,"Randomization to End of Study: 14 October 2010 – 7 February 2014 (Up to 39.8 months)","Safety population: All participants who received at least 1 dose of study drug.","Erlotinib 150 mg","Erlotinib 150 mg single daily oral dose until disease progression."
"8075",9556,"NCT00829166",320873,0.187755102,92,490,"Only study-related serious adverse events (SAEs) were reported from randomization to first treatment; all SAEs and non-SAEs were reported from start of treatment until 30 days after treatment; and thereafter only treatment related SAEs were reported until data cut-off date of 21-Sep-2015 (up to 6 years and 7 months). For participants who crossed over from lapatinib + capecitabine to trastuzumab emtansine, data is reported from time of cross-over until 21-Sep-2015 (up to 3 years and 2 months).","Safety population included participants who received at least 1 dose of study medication. Safety analyses were based on the actual treatment received.","Trastuzumab Emtansine","Participants received trastuzumab emtansine 3.6 mg/kg IV infusion over 30-90 minutes on Day 1 of each 21-day treatment cycle until PD (as assessed by the investigator), unmanageable toxicity, or study termination."
"8099",9584,"NCT00752986",352507,0.1875,3,16,NA,NA,"Vandetanib at the Dose of 100 mg","vandetanib at the dose of 100 mg orally once-daily plus placebo to match vandetanib 300 mg orally once-daily plus fulvestrant LD (500 mg im. at day 1 and 250 mg at day 14, 28 and thereafter every 28th day +/- 3)"
"8131",9623,"NCT01490866",121197,0.185714286,13,70,"Up to 3 years","Safety population included all patients who received at least one dose of any study drug.","FOLFOX/Bevacizumab and Axitinib",NA
"8162",9657,"NCT00656136",388049,0.184615385,36,195,"From the date of first drug intake up to 28 days after the last drug intake for on-treatment adverse events or the last patient out date on 4 October 2013.",NA,"Placebo","Patients received matching placebo for 50 mg, 40 mg or 30 mg afatinib tablets starting with 50 mg/day. Dose reductions were managed in the same way as for the afatinib arm."
"8177",9675,"NCT00064350",571755,0.184210526,7,38,"Assessed every 4 weeks while on treatment and for 28 days after the end of treatment",NA,"Randomization (Step 2): Placebo","After induction treatment, 46 patients were randomized to the placebo arm. Among these, 40 received treatment. However, due to drug dispensing error, 2 of them received mixed treatment with sorafenib and placebo and were categorized into Randomization (Step 2): Mixed group when reporting toxicities. As a result, 38 treated patients were included in the randomization (step 2): placebo group."
"8197",9697,"NCT00513292",442306,0.183098592,26,142,NA,NA,"Arm B","Patients receive paclitaxel IV once weekly and trastuzumab IV once weekly for 12 weeks. Beginning 7 days after the completion of paclitaxel and trastuzumab, patients receive FEC comprising fluorouracil IV, epirubicin IV, and cyclophosphamide IV on day 1. Treatment repeats every 21 days for 4 courses. Patients also receive trastuzumab IV once weekly for an additional 12 weeks. Within 6 weeks after completion of FEC and trastuzumab, patients undergo surgery. Beginning 3-4 weeks after surgery, patients receive trastuzumab as in arm I. epirubicin hydrochloride: Given IV, cyclophosphamide: Given IV, paclitaxel: Given IV, trastuzumab: Given IV, therapeutic conventional surgery: Undergo surgery, laboratory biomarker analysis: Correlative studies"
"8221",9727,"NCT00731211",359788,0.181818182,10,55,NA,NA,"Pazopanib","800 mg of pazopanib orally each day continuously
Pazopanib: 800 mg of pazopanib orally each day continuously"
"8226",9735,"NCT02480010",4937,0.181818182,6,33,"Adverse Events were recorded from the date of Screening until 7 weeks after the last infusion of study treatment.",NA,"Pertuzumab 1050 mg - Cohort B","Participants in Cohort B received 1050 mg pertuzumab as an IV infusion on Day 1 of each 3-week cycle for a maximum of 36 cycles or until study termination."
"8246",9755,"NCT00385996",489091,0.181818182,4,22,"26 months",NA,"Erlotinib","Erlotinib 150 mg po daily."
"8266",9777,"NCT00811070",327871,0.181818182,2,11,NA,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as non-serious in another participant, or one participant may have experienced both a serious and non-serious event during the study.","Exploratory Third-line","All participants who received bosutinib 500 mg orally once daily in third-line chronic myelogenous leukemia (CML), participants were with imatinib resistant/refractory/intolerant followed by dasatinib or nilotinib resistant/refractory/intolerant."
"8273",9785,"NCT00525161",437602,0.181818182,2,11,NA,NA,"Sorafenib & Endocrine Therapy","Sorafenib & Endocrine Therapy
sorafenib: 400 mg PO (orally) twice daily for 12 months from study enrollment or until disease progression, whichever occurs first."
"8282",9796,"NCT00322452",510294,0.18121911,110,607,NA,NA,"Gefitinib","Gefitinib 250mg daily"
"8304",9824,"NCT01245062",183722,0.180094787,38,211,"Participants were analyzed from the first dose of study medication to 28 days after discontinuation of study medication (average of 4.8 months in the Randomization Phase and 2.72 months in the Cross-over Phase).","Serious adverse events (SAEs) and non-serious AEs were collected in the Safety Population, comprised of all randomized participants included in the study who received at least one dose of study medication.","Trametinib","Participants with histologically confirmed cutaneous advanced or metastatic melanoma (Stage IIIC or Stage IV), with a BRAF (a human gene encoding for protein called B-Raf, which is involved in a signalling pathway and is important for cell growth) V600 E/K mutation-positive tumor sample as determined via the central BRAF mutation assay, received a Trametinib 2 mg tablet once daily until disease progression, death, or withdrawal."
"8327",9849,"NCT00718315",364568,0.179104478,12,67,"Adverse Events were recorded from Day 0 to Day 45 (15 days after the End of study)",NA,"Fisiogel","Participants received erlotinib 150 mg daily and A thin film of the topical formulation of Fisiogel was applied to face, neck, and anterior and posterior chest twice daily (every 12 hours), as per medical guidance daily for 30 days."
"8346",9869,"NCT00609804",404336,0.178571429,5,28,"18 months",NA,"Sorafenib","Sorafenib: Sorafenib 400 mg twice daily by mouth. Study treatment will be given in cycles of 28 days. Patients will be re-staged every 2 treatment cycles (every 8 weeks). Patients with an objective response or stable disease will continue study treatment. Patients will continue until disease progression or intolerable toxicity occurs."
"8375",9906,"NCT01132846",219122,0.176470588,21,119,NA,NA,"Low Dose Nesiritide","Drug: Nesiritide
Participants could be randomized to receive low dose nesiritide or placebo during the first 72 hours in the trial.
Participants randomized to the low dose nesiritide arm will receive nesiritide of 0.005 ug/kg/min or placebo during the first 72 hours in the trial."
"8400",9936,"NCT00461851",460105,0.176470588,3,17,NA,NA,"Chemotherapy Plus Sorafenib","Gemcitabine 1000 mg/m2 weekly x 2 weeks plus carboplatin AUC (Area under curve) 5 every 3 weeks plus sorafenib x 6 cycles then maintenance sorafenib alone
Gemcitabine: Gemcitabine will be given at a standard dose schedule of 1000 mg/m² on day 1 and 8.
Carboplatin: Carboplatin will be given on day 1 to an AUC of 5.
Sorafenib: Sorafenib will be administered orally daily on days 2-19 at 400 mg bid"
"8402",9938,"NCT00364286",496240,0.176470588,3,17,"6 Years, 3 Months",NA,"Dasatinib","Dasatinib 50mg Orally twice daily."
"8448",9994,"NCT00760877",348997,0.173913043,8,46,NA,NA,"Imatinib Subset That Crossed Over to Nilotinib","Imatinib subset that crossed over to nilotinib"
"8489",10038,"NCT01530334",112995,0.172413793,10,58,"24 months","Adverse Events and Serious Adverse Events were collected from the time of screening informed consent throughout the treatment period, until 30 days after discontinuation of gefitinib treatment. Adverse events were based on sign and symptoms reported by the patients and on examinations and test","Gefitinib","250 mg/die, oral"
"8551",10114,"NCT00474994",454760,0.169811321,9,53,NA,NA,"Sunitinib (Sutent®, SU11248) in Non-GIST Sarcomas","Sunitinib (Sutent®, SU11248) in Non-GIST Sarcomas"
"8555",10119,"NCT00490139",449358,0.16955684,352,2076,"Serious adverse events (SAEs) and non-serious AEs were collected from randomization until 10 years post-study entry.","SAEs and non-serious AEs are reported for the Safety Population, comprised of all randomized participants who were administered at least one dose of investigational targeted treatment, as recorded on the “administration of study drug” Case Report Form pages, but excluding any post-event treatments and not considering compliance.","Trastuzumab Followed by Lapatinib","Participants received treatment per one of the following three designs. Design 1: weekly tras for 12 weeks (4 mg/kg IV loading dose, followed by 2 mg/kg IV weekly), followed by a 6-week washout period, followed by oral lap 1500 mg daily for 34 weeks. Design 2: weekly tras (4 mg/kg IV loading dose, followed by 2 mg/kg IV) concomitantly with weekly paclitaxel 80 mg/m^2 IV or docetaxel 75 mg/m^2 IV every 3 weeks for 12 weeks, followed by a 6-week washout period, followed by oral lap 1500 mg daily for 34 weeks. Design 2B: weekly tras (4 mg/kg IV loading dose, followed by 2 mg/kg IV weekly) concomitantly with docetaxel 75 mg/m^2 every 3 weeks and carboplatin AUC6 IV for 18 weeks, followed by a 6-week washout period, followed by oral lap 1500 mg daily for 28 weeks. Participants also received adjuvant radiotherapy and adjuvant anti-estrogen therapy when clinically indicated."
"8572",10137,"NCT00820222",323702,0.168539326,45,267,"Participants were analyzed from the first dose of study medication until 30 days after the last dose of study medication (average of 10 months).","Serious adverse events (SAEs) and non-serious AEs were collected in the Safety Population, comprised of all randomized participants who received at least one dose of study medication, according to the actual treatment received.","Trastuzumab Plus Capecitabine","Participants received an IV infusion of trastuzumab 8 mg/kg on Day 1, followed by a 6 mg/kg infusion every 3 weeks. Participants also received capecitabine 2500 mg/m^2 per day (divided and administered orally twice daily, 12 hours apart), for 14 days, every 21 days. Capecitabine was taken with food or within 30 minutes after food. Participants received study medication until disease progression, unacceptable toxicity, or participant withdrawal."
"8594",10162,"NCT00684645",377536,0.166666667,31,186,NA,"The same event may appear as both an adverse event (AE) and a serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.","Sunitinib","The use and dosage recommendations for Sunitinib (Sutent) were in accordance with the local Summary of Product Characteristics."
"8607",10175,"NCT00652340",389225,0.166666667,13,78,"First dose of study drug to 30 days after last dose of study drug.","Only drug related serious adverse events are listed.","Apricoxib/Erlotinib","Patients randomized to receive apricoxib and erlotinib."
"8621",10192,"NCT00671437",382155,0.166666667,7,42,NA,NA,"Arm 1 (Cetuximab)","Whole body FDG-PET/CT scan and CT scan of neck and chest (within 28 days of Day 1)
Cetuximab 400 mg/m2 IV over 2 hours on day 1 and 250 mg/m2 IV over 1 hour on days 8, 15, 22, 29, 36, 43, and 50.
Whole Body FDG-PET/CT scan and CT scan of neck and chest on Day 57 (prior to cetuximab infusion)
Cetuximab 250 mg/m2 IV over 1 hour on Day 57
Cetuximab 250 mg/m2 IV over 1 hour weekly until progressive disease"
"8627",10200,"NCT00281632",523014,0.166666667,6,36,NA,NA,"Pazopanib 800 mg","800 milligrams (mg) pazopanib administered orally once daily"
"8638",10214,"NCT00096200",563789,0.166666667,5,30,"Adverse events collected during treatment for all patients over a 7 year period from 2004-2011.","Serious Adverse Event and Adverse Event data reported on Arm A includes events from Arm C patients while on Arm A.","Arm B","Patients receive oral sorafenib twice daily on days 2-19. Patients also receive carboplatin IV over 30 minutes and paclitaxel IV over 3 hours on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity."
"8664",10243,"NCT00471536",456370,0.166666667,3,18,NA,NA,"Treatment (Enzyme Inhibitor Therapy)","Patients receive oral pazopanib hydrochloride once daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity."
"8680",10262,"NCT01281865",172520,0.166666667,2,12,NA,NA,"Arm 1-Treatment (Everolimus and Imatinib Mesylate)","Cycle=28 days: Everolimus: 5 mg PO QD, STI571 (imatinib, Gleevec): 400 mg PO QD"
"8689",10271,"NCT00752986",352506,0.166666667,2,12,NA,NA,"Vandetanib at the Dose of 300 mg","vandetanib at the dose of 300 mg orally once-daily plus placebo to match vandetanib 100 mg orally once-daily plus fulvestrant LD (500 mg im. at day 1 and 250 mg at day 14, 28 and thereafter every 28th day +/- 3)"
"8704",10287,"NCT00314262",512905,0.166666667,2,12,NA,NA,"Erlotinib & Celecoxib","Erlotinib & Celecoxib: Erlotinib given orally, once daily (dose escalation from 50 mg, 75 mg, or 100 mg) continuously for 6 months in the phase I portion.
Celecoxib given 400 mg orally BID continuously for 6 months."
"8711",10294,"NCT00064350",571754,0.166666667,2,12,"Assessed every 4 weeks while on treatment and for 28 days after the end of treatment",NA,"Randomization (Step 2): Mixed","After induction treatment, patients with stable disease were randomized to receive either sorafenib or placebo. Due to drug dispensing error, 10 patients from the sorafenib arm and 2 patients from the placebo arm (12 pts in total) received mixed treatment with sorafenib and placebo and were categorized into Randomization (Step 2): Mixed group when reporting toxicities."
"8732",10320,"NCT01682135",83477,0.166666667,1,6,NA,NA,"Cohort 1 - 6mg/kg/2w Ramucirumab","6mg/kg ramucirumab administered IV every 2 weeks for 6 weeks (one cycle). When a pre-defined percentage of participants completed Cycle 1 without experiencing a DLT, dose escalation was initiated with the start of Cohort 2."
"8735",10323,"NCT01647711",90434,0.166666667,1,6,"From first treatment administration until 28 days after the last administration, up to 448 days",NA,"Afatinib 90mg","Patients received oral administration of afatinib 90mg film-coated tablet once daily for three days, repeated every 14 days, during each 28-day cycle."
"8736",10324,"NCT01647711",90430,0.166666667,1,6,"From first treatment administration until 28 days after the last administration, up to 448 days",NA,"Afatinib 200mg","Patients received oral administration of afatinib 200mg film-coated tablet once daily for three days, repeated every 14 days, during each 28-day cycle."
"8759",10347,"NCT01372384",147868,0.166666667,1,6,"Upto 24 months","Serious adverse events and non-serious adverse events are reported in Safety Analysis Set, which consists of all participants who received at least one dose of study medication and had a safety assessment performed post baseline.","Erlotinib","Participants received recommended dose of Erlotinib (150 mg/day). No dose escalation of erlotinib was permitted. Participants were treated until disease progression, unacceptable toxicity, death or participant request for discontinuation."
"8764",10352,"NCT01314105",162899,0.166666667,1,6,"From drug administration until analysis cut off date of 15 April 2014, up to 939 days",NA,"Nintedanib 200mg","Nintedanib (200 mg twice daily (BID), except the day of chemotherapy infusion) administered orally plus standard therapy of Carboplatin (Area Under the Curve (AUC) 5 mg/mL*min) and PLD (30 mg/m2) which were administered by intravenous infusion once every 28 days."
"8778",10367,"NCT01088464",233083,0.166666667,1,6,"Baseline up to 24 weeks plus 30 days post last dose of study drug",NA,"Cohort 3: Necitumumab","Necitumumab 800 mg administered intravenously on Days 1 and 8 every 3 weeks of a 6-week cycle. After Cycle 1, participants showing objective response or stable disease were to receive necitumumab at same dose and schedule until disease progression or other withdrawal criteria were met."
"8783",10372,"NCT01035658",249753,0.166666667,1,6,NA,NA,"Dose Level 2 Sequential","Systemic therapy with pazopanib and liposomal doxorubicin (Doxil). In this schedule, liposomal doxorubicin (40mg) was given on day 1, and pazopanib (400mg) was given days 3 - 26 of each 28 day cycle. Cycles will continue until disease progression, unacceptable toxicity or withdrawal.
Pazopanib: All patients will begin treatment with a 7-day run in period of single-agent pazopanib. Patients will receive pazopanib orally days 1-28 of a 28 day cycle.
Doxil: Liposomal doxorubicin (Doxil) will be administered IV on day 1 of a 28-day treatment cycle"
"8787",10377,"NCT01003938",260218,0.166666667,1,6,NA,"All adverse events are reported regardless of relationship to the therapy.","Topotecan and Erlotinib","On Day 1 of each treatment cycle, topotecan 0.4 mg/m^2/day was administered via continuous infusion for 9 days beginning on Day 1, every 21 days cycle. Plus erlotinib 150 mg daily for 9 days every 21 days cycle."
"8807",10403,"NCT00732992",359250,0.166666667,1,6,NA,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.","Sunitinib 50 mg/Day Schedule-2/1","Sunitinib 50.0 mg was administered continuously on a daily basis for 2 weeks, followed by 1 week off treatment.
Pemetrexed 500 mg/m^2 was administered as intravenous infusion over 10 minutes on the first day (Day 1) of each 21-day cycle."
"8828",10425,"NCT00577707",415708,0.166666667,1,6,NA,NA,"Patients With Stage IB-IIIA NSCLC With EGFR Mutations","Phase II Study of Erlotinib and Chemotherapy for Patients with Stage IB-IIIA NSCLC with EGFR Mutations"
"8830",10427,"NCT00555620",424302,0.166666667,1,6,NA,"The same event may appear as an adverse event (AE) and serious AE (SAE). However, what is presented are distinct events. An event may be serious in 1 participant and nonserious in another, or 1 participant may have experienced both a serious and nonserious event during the study. Event assessments were made on a regular schedule as per protocol.","SU 37.5 mg, CIS 60 mg/m^2, CAP 1600 mg/m^2","Sunitinib (SU): 37.5 milligram (mg) oral capsule daily for 2 weeks (14 days) followed by 1 week (7 days) off treatment (Schedule 2/1). Cisplatin (CIS): 60 mg per meter squared (mg/m^2) intravenous (IV) on Day 1 of each 21-day cycle. Capecitabine (CAP): 800 mg/m^2 oral tablets twice-a-day (BID) on Days 1-14 of each 21-day cycle."
"8884",10490,"NCT00434161",470357,0.165137615,18,109,"Adverse Events were collected for a period of up to 222 days.",NA,"Palifermin Before and After","Subjects to receive palifermin before- and after-high dose chemotherapy (total of 6 doses). A total of 115 subjects were randomized to treatment and 113 received at least one dose of study treatment. Due to protocol deviations additional 4 patients randomized to Palifermin Before and After group were included Palifermin Before Only group and therefore a total of 109 subjects were included in this safety analysis set."
"8896",10502,"NCT00826540",321720,0.164556962,13,79,NA,NA,"Treatment (Sorafenib Tosylate and Bevacizumab)","bevacizumab: Given IV"
"8900",10506,"NCT00320385",511081,0.164383562,24,146,"Serious adverse events (SAEs) and non-serious AEs were collected from Baseline to conclusion or withdrawal from study; time from the first dose of treatment until 30 days after the last dose of study treatment (up to 216 weeks).","SAEs and AEs were collected in the Safety Population, which consisted of all randomized participants who received at least one dose of investigational product, and was based on the actual treatment received, if this differed from that to which the participant was randomized.","Lapatinib","Participants received Lapatinib 1500 mg tablets orally daily 1 hour before or after breakfast."
"8910",10516,"NCT00070499",570828,0.163934426,20,122,"While the patient is on treatment until resolution of acute toxicities with maximum grade reported","Regular investigator assessments are reported after each cycle of protocol treatment","Dasatinib","Patients received 100 mg dasatinib daily"
"8948",10556,"NCT00608868",404599,0.162337662,25,154,NA,"An adverse event is the development of an undesirable medical condition or the deterioration of a pre-existing medical condition following or during exposure to a pharmaceutical product, whether or not considered causally related to the product.","Gefitinib","gefitinib tablet 250 mg orally"
"9019",10642,"NCT00508001",444124,0.16,4,25,NA,NA,"ZD6474 100","ZD6474 (Vandetanib) 100 mg (one tablet per day, orally). plus Best Support Care"
"9031",10656,"NCT01801111",62304,0.15942029,22,138,"From Baseline to cut off (maximum 53 weeks of drug exposure)","Safety population.","Alectinib","Participants received alectinib 600 mg, capsule, orally, BID, continuously starting on Cycle 1 (28-day cycle), Day 1 until disease progression, death, or withdrawal for any other reasons."
"9072",10702,"NCT01402817",141134,0.157894737,3,19,"Adverse events were collected for the duration of the time subjects were taking drug and 30 days following completion of therapy",NA,"Sutent®/Sunitinib","Upon enrollment, subjects will receive Sutent® orally. Adults (Age >18) will receive 25mg. Children will receive 10mg/m2/day. All subjects will take the daily dose for 28 days followed by a 14 day rest period. If subjects tolerate the initial dose, adults will be increased to 37.5mg and children will be increased to 15mg/m2/day. Again, subjects will take that dose for 28 days followed by a rest period of 14 days. Adults who tolerate the increase will go up to the maximum dose of 50mg.The maximum dose for children is 15mg/m2/day."
"9087",10717,"NCT00320190",511284,0.157894737,3,19,"Baseline to Month 12 and Month 12 to Month 24",NA,"Dasatinib, 100 mg","Dasatinib, 100 mg, administered orally once daily."
"9089",10719,"NCT00243347",533145,0.157894737,3,19,NA,NA,"Cediranib 30 mg","Cediranib 30mg/Day"
"9097",10727,"NCT00436566",469447,0.157407407,17,108,NA,"Adverse event data is not available on one patient, thus, only 108 patients were included in adverse events table.","AC/PTL","Standard doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (80 mg/m^2) x 12 with concurrent standard dose trastuzumab (weekly x 12, then repeat 3 weeks for an additional 9 months) plus daily lapatinib (modified to 750 mg during Paclitaxel + Trastuzumab + Lapatinib (PTL) and 1000 mg during trastuzumab + lapatinib (TL)) for a total of 12 months."
"9111",10743,"NCT01245062",183720,0.156862745,8,51,"Participants were analyzed from the first dose of study medication to 28 days after discontinuation of study medication (average of 4.8 months in the Randomization Phase and 2.72 months in the Cross-over Phase).","Serious adverse events (SAEs) and non-serious AEs were collected in the Safety Population, comprised of all randomized participants included in the study who received at least one dose of study medication.","Cross-over From Chemotherapy to Trametinib","Following independent review confirmation of disease progression, participants randomized to chemotherapy were allowed to cross-over to Trametinib."
"9114",10747,"NCT00477464",454162,0.156862745,8,51,NA,NA,"Lapatinib 1250 mg and Capecitabine 2000 mg/m^2","Participants took lapatinib and capecitabine. Lapatinib was orally administered at 1250 milligrams (mg) once daily. Capecitabine was orally administered at 1000 mg per square meter (mg/m^2) twice daily on the first day through the fourteenth day of each 21-day cycle."
"9119",10752,"NCT00373425",493299,0.156716418,21,134,"From the first dose of study drug until 30 days after the last dose. Maximum time on treatment for the Randomized Cohort was 24 months; maximum time on treatment for the BPC was 13 months on blinded study drug and 26 months on open-label erlotinib.","One participant in the Randomized Cohort assigned to the erlotinib arm received placebo instead due to a dispensing error and is included in the placebo group for safety analyses. For the Breached Protocol Cohort safety analyses are based on the total no open-label and open-label populations.
Safety data are based on the 11 June 2014 cut-off date.","BPC-NOLC: Erlotinib/Placebo","The BPC no open-label cohort (BPC-NOLC) includes participants randomized prior to 07 November 2007 who did not participate in the open-label erlotinib period and who were previously randomized to receive either erlotinib or placebo in the blinded period, and received at least one dose of erlotinib."
"9122",10755,"NCT00471276",456459,0.156626506,13,83,NA,"The same event may have appeared as both an adverse event (AE) and a serious AE (SAE). However, what was presented were distinct events. An event may have been categorized as serious in 1 subject and as nonserious in another subject, or 1 subject may have experienced both a serious and nonserious event during the study.","Sunitinib","Sunitinib 37.5 milligrams (mg) daily by oral capsule in continuous daily dose (CDD) schedule. Dose adjustments, if needed, included a reduction to 25mg daily or escalation to 50mg daily anytime after Week 12."
"9134",10770,"NCT01301729",166465,0.15625,5,32,"Up to 28 days after the last dose of the study drug (up to 28 months)","An AE was defined as any adverse medical event that occurred after the participant used the investigational medicinal product (IMP) or other intervention behaviors specified by the protocol in the clinical trial regardless of relationship to the study treatment.","Trastuzumab","Participants with metastatic breast cancer received a loading dose of 4 milligrams per kilograms (mg/kg) of trastuzumab intravenously (IV) followed by 2 mg/kg of trastuzumab IV once a week along with docetaxel 100 milligrams per meter square (mg/m^2), every 3 weeks or paclitaxel 90 mg/m^2 once a week until progression of disease, occurrence of intolerable toxicity, the participant discontinues the study or dies."
"9154",10795,"NCT01043874",247601,0.155555556,7,45,NA,NA,"Nilotinib","Nilotinib 400 mg BID"
"9156",10797,"NCT00544167",429338,0.155555556,7,45,NA,NA,"Doxorubicin/Cyclophosphamide Then Paclitaxel/Sorafenib","All patients received doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 (AC) both administered intravenously day 1 every 3 weeks for four cycles, followed by paclitaxel 175 mg/m2 intravenously day 1 every 3 weeks for four cycles or 80 mg/m2 for twelve weeks (physician discretion), combined with sorafenib 400 mg orally twice daily. Sorafenib was held during radiation therapy where indicated and resumed once completed. Sorafenib was continued for a total of 12 months and in combination with adjuvant hormonal therapy where indicated."
"9167",10808,"NCT00760877",348998,0.155339806,16,103,NA,NA,"Imatinib","Imatinib"
"9173",10819,"NCT01121393",223495,0.154811715,37,239,"From first administration of study medication up until 28 days after the last administration of study medication up to 1284 days","The treated set (TS) included all randomised patients documented to have taken at least 1 dose of study medication. Analysis of Adverse Events (AE) was based on the concept of treatment-emergent AEs. AEs with onset after the first administration of study drug and within 28 days after the last administration were considered to be on-treatment.","Afatinib 40mg","Patients receiving Afatinib film-coated tablets 40 q.d., orally"
"9204",10852,"NCT00409006",480401,0.153846154,6,39,NA,NA,"Pemetrexed/Cisplatin/Gefitinib","Pemetrexed 500 milligrams per meters squared (mg/m2) plus cisplatin 75 mg/m2 administered by intravenous (IV) infusion once every 3 weeks for 4 cycles without progression followed by gefitinib 250 mg administered orally, once daily, until disease progression or unacceptable toxicity."
"9205",10853,"NCT00306891",515281,0.153846154,6,39,NA,NA,"Cediranib 45 mg Part A","Part A: Cediranib 45 mg"
"9206",10854,"NCT00281957",523318,0.153846154,6,39,"While the patient is on treatment until resolution of acute toxicities with maximum grade reported","Regular investigator assessments are reported after each cycle of protocol treatment","Arm II","Sorafenib and Tipifarnib"
"9240",10889,"NCT01255137",180082,0.153846154,2,13,NA,NA,"Adrenal Cortex Neoplasms","Aggressive cancer that starts in the adrenal gland located at the top of the kidneys.
Axitinib : 5 mg tab orally twice a day with food every 28 days"
"9246",10895,"NCT01032850",250938,0.153846154,2,13,"3 years",NA,"Arm 1: Sorafenib & Capecitabine","Intervention: Sorafenib & Capecitabine: Sorafenib twice a day by mouth (400 mg) Capecitabine twice a day by mouth (850 mg)
Sorafenib & Capecitabine: Intervention: Sorafenib twice a day by mouth (400 mg), Capecitabine twice a day by mouth (850 mg). One cycle of treatment will consist of capecitabine on days 1-7 and 15-22 while sorafenib will be given daily continuously. Cycles will be repeated every 28 days."
"9264",10915,"NCT00271011",525985,0.153846154,2,13,NA,NA,"Mitomycin C, Irinotecan and Cetuximab","Patients will receive mitomycin C 7 mg/m2 as a bolus infusion on day -1 of each 28 day cycle.
Patients will receive cetuximab 400 mg/m2 loading dose over 90 minutes cycle 1, day 1. All subsequent weekly cetuximab treatments will be 250 mg/m2 as a 60 minute infusion days 1, 8, 15, and 22 of each 28 day cycle.
Patients will receive irinotecan 140 mg/m2 as a 90 minute infusion on days 1 and 15 of each 28 day cycle after cetuximab infusion. Patients found to be homozygous for UGT1A1*28 allele will receive irinotecan 110 mg/m2."
"9309",10964,"NCT00425386",473041,0.152173913,7,46,NA,NA,"Sunitinib and Erlotinib","Erlotinib: Dose Level 0 = 50 mg/day, continuous daily; 0.5= 75 mg/day, continuous daily;
100 mg/day, continuous daily; 1.5= 125 mg/day, continuous daily;
150 mg/day, continuous daily
Sunitinib: 50 mg daily, 4 weeks on, 2 weeks off"
"9310",10965,"NCT00245102",532802,0.152173913,7,46,NA,NA,"Leiomyosarcoma","Sorafenib 400 mg PO BID"
"9349",11013,"NCT00073528",570285,0.150641026,94,624,"Serious adverse events (SAEs) and non-serious AEs were collected during screening (within 4 weeks prior to the first dose), during study treatment (up to a maximum study duration of 46 months), and up to 30 days post-study.","SAEs and AEs were collected for the Safety Population, which included all randomized participants who had received at least 1 dose of study treatment, based on the actual treatment received if this differed from that to which the participant was randomized.","Letrozole 2.5 mg Plus Placebo","Participants received 6 tablets of placebo, identical in appearance to lapatinib tablets, orally daily (approximately at the same time each day), either 1 hour (or more) before breakfast or 1 hour (or more) after breakfast. Participants also received 1 tablet of letrozole 2.5 milligrams (mg) orally daily, preferably with the daily dose of lapatinib. The maximum treatment period was up to 46 months."
"9402",11073,"NCT00512902",442339,0.15,3,20,NA,NA,"Imatinib","Systemic Sclerosis patients administered oral 600 mg imatinib once per day for up to one year."
"9425",11098,"NCT00527111",436288,0.149253731,10,67,"During the whole treatment period, up to 30 days following last dose.","For treatment patients only, assessed at each treatment visit.","Chemoradiotherapy Plus Cetuximab","Pelvic irradiation plus 5-fluorouracil plus cetuximab
Cetuximab
5-fluorouracil
Pelvic irradiation"
"9435",11109,"NCT00849472",313053,0.148514851,15,101,NA,NA,"AC, Followed by Weekly Paclitaxel and Concurrent Pazopanib","Participants were treated with intravenous (IV) doxorubicin (60 milligrams per meters squared [mg/m^2]) and cyclophosphamide (AC) (600 mg/m^2) every 21 days for 4 cycles. This was followed by weekly paclitaxel (WP) 80 mg/m^2 IV on Days 1, 8, and 15 every 28 days for 4 cycles given concurrently with oral pazopanib 800 mg (2 tablets taken at the same time each day, either 1 hour before or 2 hours after a meal) taken daily and continuing until 7 days before surgery. Pazopanib was resumed at the same oral dose 4-6 weeks after surgery and was continued daily for 6 months."
"9459",11133,"NCT00563316",420510,0.148148148,4,27,"The reporting time frame for Adverse Events is from first dose date to 30 days since the last dose date, until the data cut-off date of 16 July 2009. The median time frame is 5.7 months.","Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.","Panitumumab With Irinotecan","Participants received panitumumab 6 mg/kg and irinotecan 180 mg/m² administered by intravenous (IV) infusion every 2 weeks until disease progression or intolerance of panitumumab, irinotecan or both."
"9512",11190,"NCT01340651",155873,0.146341463,6,41,"Adverse events were collected from Baseline through the end of the study","Safety population: All enrolled participants who took at least 1 dose of study drug.","Ruxolitinib - Weeks 1-16","Participants began administration with 25 mg ruxolitinib sustained release (SR) once daily (QD). After 8 weeks, if there was inadequate efficacy, the dose level could be titrated to 50 mg SR QD or 25 mg SR every other day (QOD) alternating with 50 mg SR QOD."
"9520",11198,"NCT00475670",454529,0.146341463,6,41,"Adverse events and serious adverse events were recorded from study start to 28 days after the last dose of study drug. Serious adverse events that were related to study medication or were cardiac are reported until 2 years after enrollment.","The safety analysis population included all participants who received at least 1 dose of either trastuzumab or taxane.","Trastuzumab, Taxane","Participants received either an initial loading dose of trastuzumab 4 mg/kg IV on Day 1, followed by 2 mg/kg IV once per week, or an initial loading dose of 8 mg/kg IV on Day 1, followed by 6 mg/kg IV every 3 weeks, until disease progression, unacceptable toxicity, withdrawal or death. Participants also received one of the following taxanes (at the investigator’s discretion) for at least 18 weeks: docetaxel 100 mg/m^2, IV, once every 3 weeks, OR, paclitaxel 75 mg/m^2, IV, once per week, OR, paclitaxel 175 mg/m^2, IV, once every 3 weeks."
"9628",11316,"NCT00130689",551983,0.142857143,5,35,"Assessed each cycle throughout treatment from time of first dose and up to day 30 post-treatment.","Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3.","Cetuximab","Patients received cetuximab at an initial dose of 400 mg/m2 administered IV over 120 min, followed by weekly infusions at 250 mg/m2 administered IV over 60 min. Once cycle was 4 weeks of therapy. Patients received treatment until disease progression or unacceptable toxicity."
"9667",11357,"NCT00112736",557982,0.142857143,3,21,"Adverse Events were collected weekly for the first cycle and then at the start of each cycle while on treatment and at time of off study.",NA,"Phase I (Erlotinib & Temsirolimus)","PHASE I: Oral erlotinib 1 daily days 1-28 (150mg), temsirolimus IV 30 minutes days 1, 8, 15, 22 (dose escalation). Every 28 days until disease progression or unacceptable toxicity.
erlotinib: Given orally
temsirolimus: Given IV
pharmacological study: Correlative studies"
"9707",11406,"NCT01871805",53185,0.142857143,1,7,"From baseline to up to 28 days after the last dose of alectinib (up to Week 105; data cut-off date 24 October 2014)",NA,"Alectinib 300 mg (Fasted): Phase I","Participants received single dose of 20 or 40 mg alectinib capsules orally to make a dose of 240 or 300 mg on Cycle 1 Day -3 and then received 300 mg BID dose for 3-weekly cycles until disease progression, death or withdrawal for any other reasons."
"9729",11431,"NCT01121575",223338,0.142857143,1,7,"Up to Maximum of treatment duration + 28 days for each participant (could be 295 days)","The same event may appear as both an AE and a SAE. However, what is presented are distinct events. The below tables included all causality SAEs (frequency threshold 0%) and AEs ( frequency threshold 5%).","PF-02341066, 250 mg BID/ PF-00299804, 30 mg QD","Participants enrolled in dose escalation received combined oral crizotinib 250 mg BID and oral dacomitinib 30 mg. The first cycle was for 28 days thereafter, each cycle was 21 days."
"9750",11453,"NCT00726232",361712,0.142857143,1,7,NA,NA,"PV: Ruxolitinib 50 mg QD","Participants with Polycythemia Vera received 50 mg Ruxolitinib orally once a day (QD) for 56 days (two 28-day cycles) during the dose-ranging phase. After patients completed 2 cycles of treatment at the randomized dose, Investigators were permitted to adjust the dose/regimen on an individual basis to achieve an optimal balance of efficacy and safety. Treatment continued until a patient met a withdrawal criterion, had intolerable toxicity, progression of disease, or withdrew consent."
"9751",11454,"NCT00708214",368259,0.142857143,1,7,"First administration of trial medication until 28 days after last administration of trial medication",NA,"Afatinib 50 mg With Letrozole","Patients received continuous daily dosing with Afatinib 50 mg therapy with letrozole 2.5 mg over 28-day treatment cycles until further disease progression."
"9770",11474,"NCT00387335",488535,0.142857143,1,7,"Up to two years","Common Terminology Criteria for Adverse Events (CTCAE v3.0). Reported are grade 1 or higher adverse events.","Sunitinib -- Cohort B","Patients receive oral sunitinib malate once daily on days 1-28. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity. ECOG Performance Status 2."
"9814",11525,"NCT00894504",298333,0.14084507,10,71,NA,NA,"Panitumumab/Gemcitabine/Carboplatin",NA
"9816",11528,"NCT00490139",449356,0.140655106,292,2076,"Serious adverse events (SAEs) and non-serious AEs were collected from randomization until 10 years post-study entry.","SAEs and non-serious AEs are reported for the Safety Population, comprised of all randomized participants who were administered at least one dose of investigational targeted treatment, as recorded on the “administration of study drug” Case Report Form pages, but excluding any post-event treatments and not considering compliance.","Trastuzumab","Participants received treatment per one of the following three designs. Design 1: tras 8 mg/kg IV LD, followed by 6 mg/kg IV every 3 weeks for 52 weeks. Design 2: weekly tras (4 mg/kg IV LD, followed by 2 mg/kg IV weekly) concomitantly with weekly paclitaxel 80 mg/m^2 IV or docetaxel 75 mg/m^2 IV every 3 weeks, for 12 weeks. After completion of paclitaxel or docetaxel, participants received tras (6 mg/kg without a LD every 3 weeks for 40 weeks. Design 2B: weekly tras (4 mg/kg IV LD, followed by 2 mg/kg IV weekly) concomitantly with docetaxel 75 mg/m^2 every 3 weeks and carboplatin AUC6 IV, for 18 weeks. After completion of docetaxel and carboplatin, participants received tras every 3 weeks (6 mg/kg without a LD) for 34 weeks. Participants also received adjuvant radiotherapy and adjuvant anti-estrogen therapy when clinically indicated."
"9839",11560,"NCT01121939",223064,0.139534884,6,43,"18 months","Includes adverse events of all grades, regardless of their relationship to study treatment","All Patients","Bevacizumab: 15 mg/kg IV Day 1. The first dose should be administered over
90 minutes. If no adverse reactions occur after the initial dose, the second dose should
be administered over a minimum of 60 minutes. If no adverse reactions occur after the
second dose, all subsequent doses should be administered over a minimum of 30
minutes. Bevacizumab will be infused prior to pertuzumab.
Pertuzumab: 840 mg IV loading dose infused over 60 minutes. The loading dose is given on Cycle 1, Day 1 or as below. Subsequent doses of pertuzumab are 420 mg IV. If the patient tolerates the initial infusion over 60 minutes, the patient may receive subsequent infusions over 30 minutes.
Sandostatin LAR® Depot: 30 mg will be given every 28 days by IM injection."
"9842",11564,"NCT00161213",544999,0.139534884,6,43,"5 years","All patients who received one dose of protocol therapy were evaluated for toxicity.","Gemcitabine and Imatinib","imatinib mesylate: 400 mg/day, given orally Day 1-5 and 8-12 every 21 days.
gemcitabine hydrochloride: fixed dose rate infuration at 1200 mg/m2/120 minutes on Days 3 and 10 every 21 days."
"9875",11599,"NCT01469000",126375,0.138461538,9,65,NA,"All participants who received at least 1 dose of study drug.","250 mg Gefitinib","250 mg Gefitinib taken orally once QD"
"9888",11612,"NCT01871805",53180,0.137931034,12,87,"From baseline to up to 28 days after the last dose of alectinib (up to Week 105; data cut-off date 24 October 2014)",NA,"Alectinib 600 mg (Fed): Phase II","Participants received 600 mg alectinib capsules orally BID from Cycle 1 Day 1 for 3-weekly cycles until disease progression, death or withdrawal for any other reasons."
"9895",11619,"NCT00022672",576481,0.137931034,8,58,NA,NA,"Anastrozole (After Start of Trastuzumab)","1 mg oral dose of anastrozole every day for 24 Months in the Main phase. In the Extension Phase participants could cross-over to also receive trastuzumab 4 mg/kg initial loading dose intravenous (iv) over 90 minutes, followed by weekly doses of 2 mg/kg iv over 30 minutes."
"9896",11620,"NCT01634555",93270,0.137931034,4,29,NA,NA,"Ramucirumab (IMC-1121B) and FOLFIRI","Treatment is sequential. Ramucirumab (IMC-1121B) was administered before FOLFIRI (Irinotecan + Folinic acid + 5-Fluorouracil) during Cycles 2+
Ramucirumab (IMC-1121B): 8 mg/kg, administered as IV infusion on Day 1 of each 2-week cycle (except Cycle 1)
Irinotecan: 180 mg/m² administered IV on Day 1 of each 2-week cycle
Folinic acid: 400 mg/m² administered IV on Day 1 of each 2-week cycle
5-Fluorouracil: 400 mg/m² bolus over 2 to 4 minutes administered IV on Day 1 of each 2-week cycle, followed by 2400 mg/m² administered IV over 46 to 48 hours on Days 1 and 2 of each cycle"
"9906",11630,"NCT00574171",417053,0.137931034,4,29,NA,NA,"Arm 1","Capecitabine : 2000mg/m2 of body surface area (BSA), by mouth, divided into twice daily dosing. Capecitabine will be given for days 1 through 14 of a 21 day cycle.
lapatinib : 1250mg by mouth daily one hour before or after breakfast on a continuous basis."
"9913",11639,"NCT00513292",442307,0.137681159,19,138,NA,NA,"Arm A","Patients receive FEC comprising fluorouracil IV, epirubicin hydrochloride IV, and cyclophosphamide IV on day 1. Treatment repeats every 21 days for 4 courses. Beginning 21 days after completion of FEC, patients receive paclitaxel IV once weekly and trastuzumab (Herceptin) IV once weekly for 12 weeks. Within 6 weeks after completion of paclitaxel and trastuzumab, patients undergo surgery. Beginning 3-4 weeks after surgery, patients receive trastuzumab IV once every 3 weeks for up to 52 weeks. epirubicin hydrochloride: Given IV, cyclophosphamide: Given IV, paclitaxel: Given IV, trastuzumab: Given IV, therapeutic conventional surgery: Undergo surgery, laboratory biomarker analysis: Correlative studies"
"9937",11666,"NCT00347919",502199,0.136986301,10,73,"Study Entry until 28 days after the last dose.",NA,"Cohort 1: Lapatinib 1500 mg","Lapatinib 1500 milligrams (mg) administered orally once a day"
"9943",11672,"NCT00049543",573526,0.136546185,34,249,NA,NA,"Arm I (Gefitinib)","Patients receive gefitinib PO QD for 2 years in the absence of disease progression or unacceptable toxicity.
gefitinib: Given PO
laboratory biomarker analysis: Correlative studies"
"9947",11677,"NCT01243944",184169,0.136363636,15,110,"The duration of the study up to Week 32. This time frame defines the comparative phase of the study where the majority of patients remained on their original randomized assignment and exposure between ruxolitinib and best available therapy was similar.","Safety population: All subjects who were enrolled and took at least 1 dose of study medication.","Ruxolitinib","Starting dose of 10 mg BID with individualized dose titration ranging from 5 mg QD to 25 mg BID based on safety and efficacy"
"9967",11699,"NCT00865098",306964,0.136363636,3,22,"Time from first dose up to 60 days after the last dose of study treatment. Adverse Events (AEs) are summarized using the MedDRA version 13.0.","Treatment emergent Adverse Events (TEAEs) were defined as AEs that emerge or worsen on or after the first dosing day of trial treatment until 60 days after the last trial treatment administration.","Cetuximab With Radiotherapy","Subjects received cetuximab at an initial dose of 400 mg/m² infused 6 or 7 days before starting radiotherapy (RT). This was followed by subsequent weekly infusions of 250 mg/m² cetuximab administered in combination with radiotherapy (5 days/week) for 6 weeks. Subjects will receive cetuximab until radiographically documented progressive disease or unacceptable toxicity occurs or consent is withdrawn. If RT is delayed, administration of cetuximab every 7 days is continued. If RT is discontinued for any reason, treatment with cetuximab monotherapy every 7 days is continued."
"9989",11724,"NCT00529763",435198,0.13559322,8,59,NA,NA,"Chronic Phase","Participants with chronic phase (CP) CML who have received prior treatment with imatinib mesylate and can no longer be treated with this drug due to primary or acquired resistance or intolerance. Dasatinib was administered orally at a dose of 100 mg QD in patients with chronic phase CML. Participants were treated until progression of disease or intolerable toxicity as determined by the treating physician."
"10001",11738,"NCT00566995",419346,0.135135135,5,37,NA,NA,"Vandetanib in Participants With Kidney Cancer","300 mg/day (starting dose) oral dose of vandetanib once a day for 28 days"
"10067",11812,"NCT00270894",525995,0.133333333,4,30,"Adverse events were collected beginning on day 1 of study treatment until one month after the end of study treatment, up to 25 weeks.","Systematic Assessment - subjects were assessed for adverse events every other week by either the research coordinator, treating physician, or other appropriate sub-investigator.","Neoadjuvant Therapy","Neoadjuvant therapy will consist of epirubicin (100 mg/m^2) + cyclophosphamide (600 mg/m^2) every 2 weeks for 4 cycles; followed by a 3-week break; followed by docetaxel (75 mg/m^2) every 2 weeks for 4 cycles + trastuzumab (6 mg/kg [loading dose] once then 4 mg/kg [maintenance dose]) every 2 weeks for 4 treatments."
"10156",11910,"NCT00265798",527385,0.131578947,5,38,"Adverse events were monitored over the course of treatment","Adverse events of grade 3 or higher at least possibly related to treatment are reported","Sorafenib","Patients receive oral Sorafenib 400mg twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
"10167",11921,"NCT01393899",143198,0.131147541,8,61,"SAEs were assessed from informed consent through and including 28 calendar days after last administration of study treatment (30 weeks). Non-SAEs were recorded from time of first dose of study treatment through last participant visit (30 weeks).","The same event may appear as both an adverse event (AE) and an SAE. However, what is presented are distinct events. An event may be categorized as serious in 1 participant and as nonserious in another participant, or 1 participant may have experienced both a serious and nonserious event during the study.","Tofacitinib 10 mg BID","Tofacitinib 10 mg (two tofacitinib tablets) for oral administration at a dose of 10 mg BID for 26 weeks."
"10182",11937,"NCT00770809",344808,0.130434783,15,115,NA,"Adverse Event data is available on 295 participants (Arm I: 115. Arm II: 115, Arm III: 65)","Arm I (THL)","Patients receive trastuzumab 2 mg/kg IV over 30-90 minutes and paclitaxel 80 mg/m^2 IV over 1 hour once weekly and lapatinib ditosylate 750 mg PO once daily for 16 weeks in the absence of disease progression or unacceptable toxicity."
"10196",11953,"NCT00824746",322132,0.130434783,3,23,"2 years",NA,"Single Arm","Gefitinib retreatment"
"10243",12007,"NCT01233869",186858,0.129032258,4,31,"Baseline up to 30 days after last study drug administration","The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another participant, or one participant may have experienced both a serious and non-serious event during the study.","Bosutinib 400 mg/Day","Participants received bosutinib 400 mg tablet orally QD in the morning with food for 24 months in the ITP. All participants were dose-reduced during the ITP based on a protocol amendment. Those who remained active in the study at the time of the amendment are represented in the bosutinib 400/200 mg/day group."
"10248",12013,"NCT00454805",462363,0.129032258,4,31,NA,NA,"Placebo","Placebo+Fulvestrant 250 mg
Patients randomised to the control arm (fulvestrant + placebo) received treatment according to the following schedule:
Day 1: fulvestrant 500 mg im
Day 15: fulvestrant 250 mg im
Day 29, and every 28 days thereafter: fulvestrant 250 mg im
and daily: placebo to match cediranib (administered orally)"
"10261",12026,"NCT01404260",140972,0.128440367,14,109,"4years","Safety analysis included all patients who received at least one dose of the study drug and had at least one follow-up safety assessment. Safety assessments were analyzed mainly using descriptive statistics.","Arm A","Arm A: gemcitabine 1250mg/m2+Carboplatin AUC=5, every 4 weeks, maximum 4 cycles, gefitinib 250mg/d every cycle d15-25, and gefitinib 250mg/d from d15 of last cycle until disease progression
gefitinib: gefitinib 250mg/d every cycle d15-25,and gefitinib 250mg/d from d15 of last cycle until disease progression"
"10269",12034,"NCT00709826",367828,0.128205128,5,39,"First dose of study drug to 30 days after last dose of study drug","Only drug-related serious adverse events are listed.","Placebo/Gemcitabine/Erlotinib","Patients randomized to receive placebo + gemcitabine + erlotinib."
"10317",12090,"NCT00820222",323703,0.126394052,34,269,"Participants were analyzed from the first dose of study medication until 30 days after the last dose of study medication (average of 10 months).","Serious adverse events (SAEs) and non-serious AEs were collected in the Safety Population, comprised of all randomized participants who received at least one dose of study medication, according to the actual treatment received.","Lapatinib Plus Capecitabine","Participants received a daily dose of 5 tablets of lapatinib (1250 mg) at approximately the same time every day, either 1 hour (or more) before breakfast or 1 hour (or more) after breakfast. Participants also received capecitabine 2000 mg/m^2) per day (divided and administered orally twice daily, 12 hours apart), for 14 days, every 21 days. Capecitabine was taken with food or within 30 minutes after food. Participants received study medication until disease progression, unacceptable toxicity, or participant withdrawal."
"10363",12142,"NCT00567190",419229,0.125,6,48,"First treatment dose (12 February 2008) through final data analysis cut-off (11 February 2014) for a total safety analysis time frame of 6 years. The AE data derived from a snapshot taken on 24 March 2014 of the final analysis dataset (11 February 2014).","Of those who started the study (pertuzumab [Ptz]=402, placebo[Pla]=406), 2 patients in each group received no treatment (total of 4), 9 Pla patients received at least 1 dose of Ptz, 1 Ptz patient received Pla at every cycle; resulting in Ptz=408 (402-2+9-1) and Pla=396 (406-2-9+1)","Crossover From Placebo to Pertuzumab","Forty-eight of 406 patients (11.8%) randomized to the placebo treatment group whose disease had not progressed crossed over to an open-label pertuzumab treatment group between July 2012 and November 2012. Patients received pertuzumab administered as an IV loading dose of 840 mg at cycle 1 then 420 mg IV every q3w until investigator-assessed radiographic or clinical evidence of PD, unacceptable toxicity, or withdrawal of consent. Trastuzumab and docetaxel doses continued in accordance with the pre-crossover placebo treatment regimens and according to dosing specifications indicated in the study protocol."
"10380",12163,"NCT00500292",446434,0.125,4,32,NA,NA,"Vandetanib 100 mg Plus FOLFOX","vandetanib 100 mg plus FOLFOX"
"10381",12164,"NCT00447226",464751,0.125,4,32,"All adverse events (AEs) and serious adverse events (SAEs), regardless of relationship to lapatinib, were collected from the first dose until 5 days after the last dose of study medications (up to 84.1 weeks).","The AEs and SAEs presented below represent data collected from all participants, whether taking open-label lapatinib or whether randomized to lapatinib/placebo. The SAE of cerebral hemorrhage was reported 2 days after the last dose of study drug was taken and was thus not an on-treatment event.","All Participants","All participants treated in the open-label phase (1500 mg lapatinib, orally once a day), including those subsequently randomized to lapatinib (1500 mg, orally once a day) or matching placebo"
"10394",12177,"NCT00252187",531262,0.125,3,24,"Adverse events were collected over the 8 week study period",NA,"BPN Group","BNP (nesiritide) administered subcutaneously twice daily for 8 weeks at 10 mcg/kg."
"10438",12226,"NCT00076024",569711,0.125,2,16,NA,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.","Axitinib (Phase 2, Open-label)","Axitinib (AG-013736) 5 mg tablet orally BID continuously in cycles of 4 weeks."
"10480",12273,"NCT01035658",249755,0.125,1,8,NA,NA,"Dose Level -1","Systemic therapy with pazopanib and liposomal doxorubicin (Doxil). Single-agent pazopanib will be given for a 7 day run-in period, followed by a combination of pazopanib (400mg) and liposomal doxorubicin (30mg) administered in 28-day treatment cycles. Cycles will continue until disease progression, unacceptable toxicity or withdrawal.
Pazopanib: All patients will begin treatment with a 7-day run in period of single-agent pazopanib. Patients will receive pazopanib orally days 1-28 of a 28 day cycle.
Doxil: Liposomal doxorubicin (Doxil) will be administered IV on day 1 of a 28-day treatment cycle"
"10495",12289,"NCT00815295",325785,0.125,1,8,NA,"The adverse events for this study were collected using Common Terminology Criteria for Adverse Events (CTCAE) version 3.0, and have been converted to CTCAE version 4.0 for entry into ClinicalTrials.gov.","Phase 1 - Dose Level 1","Cetuximab was administered at the standard approved dose: 400 mg/m2 loading dose followed by 250 mg/m2 weekly. Sorafenib 200 mg/m2 was administered orally twice daily."
"10496",12290,"NCT00815295",325784,0.125,1,8,NA,"The adverse events for this study were collected using Common Terminology Criteria for Adverse Events (CTCAE) version 3.0, and have been converted to CTCAE version 4.0 for entry into ClinicalTrials.gov.","Phase 1 - Dose Level 2","Cetuximab was administered at the standard approved dose: 400 mg/m2 loading dose followed by 250 mg/m2 weekly. Sorafenib 400 mg/m2 was administered orally twice daily."
"10498",12292,"NCT00788775",337313,0.125,1,8,"AE assessment was ongoing from the start of study drug and up to day 30 post-treatment. Mean treatment duration was 5.5 months (range 0-45; no/with CNS mets 7.4m/ 3m).","Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3.","CNS Metastatic Cohort","Nilotinib was given at a dose of 400 mg orally daily (200 mg pills twice per day). Patients received treatment up to 12 months as long as they were receiving clinical benefit. Patients were classified into two cohorts based upon presence or absence of measurable brain metastases."
"10502",12296,"NCT00727506",361355,0.125,1,8,"Between first intake through 28 days after last drug intake.",NA,"Phase I - Afatinib 40 mg Plus Temozolomide 75mg/m^2","Patients receiving Afatinib 40mg once daily (q.d.) plus Temozolomide 75 mg/m^2 for 21 days followed by 7 days off - Phase I part"
"10503",12297,"NCT00726232",361711,0.125,1,8,NA,NA,"ET: Ruxolitinib 10 mg BID","Participants with Essential Thrombocythemia received 10 mg Ruxolitinib orally twice a day (BID) for 56 days (two 28-day cycles) during the dose-ranging phase. After patients completed 2 cycles of treatment at the randomized dose, Investigators were permitted to adjust the dose/regimen on an individual basis to achieve an optimal balance of efficacy and safety. Treatment continued until a patient met a withdrawal criterion, had intolerable toxicity, progression of disease, or withdrew consent."
"10507",12302,"NCT00686036",377214,0.125,1,8,NA,NA,"Placebo","Placebo to match vandetanib 300 mg tablet"
"10514",12310,"NCT00430027",472050,0.125,1,8,"Participants were monitored for approximately 2 years.","Patients were assessed weekly at their clinic visits.","Capecitabine, Oxaliplatin, Cetuximab, and Radiation Therapy","Patients enrolled on the trial received neoadjuvant combined capecitabine, oxaliplatin, cetuximab, and radiation therapy. This was followed by surgical resection and adjuvant capecitabine, oxaliplatin, and cetuximab"
"10543",12341,"NCT00706706",369279,0.123809524,13,105,"AEs/SAEs: From signing of informed consent form up to 28 days after last dose","The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.","Sunitinib","Sunitinib 50 mg capsule orally once daily for 4 weeks followed by 2 weeks off-treatment period in cycles of 6 weeks until disease progression, unacceptable sunitinib-associated toxicity or withdrawal."
"10718",12545,"NCT01393899",143200,0.118644068,7,59,"SAEs were assessed from informed consent through and including 28 calendar days after last administration of study treatment (30 weeks). Non-SAEs were recorded from time of first dose of study treatment through last participant visit (30 weeks).","The same event may appear as both an adverse event (AE) and an SAE. However, what is presented are distinct events. An event may be categorized as serious in 1 participant and as nonserious in another participant, or 1 participant may have experienced both a serious and nonserious event during the study.","Placebo","Placebo (two placebo tablets) to match tofacitinib for oral administration BID for 26 weeks."
"10765",12598,"NCT01011075",257923,0.117647059,4,34,"1 year",NA,"Imatinib Mesylate and Paclitaxel","Experimental: Treatment (enzyme inhibitor, chemotherapy) Patients receive paclitaxel IV on days 3, 10, and 17 and imatinib mesylate PO QD on days 1-4, 8-11, and 15-18. Treatment repeats every 28 days for 4-6 courses in the absence of disease progression or unacceptable toxicity."
"10780",12614,"NCT01207492",195369,0.117647059,2,17,NA,NA,"Nilotinib","Nilotinib 200 mg taken as 400 mg twice daily, continuously
nilotinib: Taken orally twice daily"
"10793",12628,"NCT00112671",558015,0.117647059,2,17,NA,NA,"Treatment (Sorafenib Tosylate)","Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
sorafenib tosylate: Given orally
laboratory biomarker analysis: Correlative studies"
"10809",12644,"NCT00434161",470359,0.117117117,13,111,"Adverse Events were collected for a period of up to 222 days.",NA,"Palifermin Before Only","Subjects to receive palifermin before-high dose chemotherapy (total 3 doses) and matched placebo after-high dose chemotherapy (total 3 doses). A total of 109 subjects were randomized to treatment and 107 received at least one dose of study treatment. Due to protocol deviations 4 patients randomized to Palifermin Before and After group were included Palifermin Before Only group and therefore a total of 111 subjects were included in this safety analysis set."
"10822",12657,"NCT00439608",468176,0.116666667,7,60,NA,NA,"Treatment","Cetuximab, Paclitaxel, Carboplatin and Radiation for Esophageal, Gastroesophageal Junction and Gastric Cancer"
"10844",12680,"NCT00391586",487360,0.11627907,5,43,"Patients are assessed for toxicity/adverse events for 28 days after completion of the last course of any on-study therapy.",NA,"Erlotinib Followed by Chemotherapy","Erlotinib at 150 mg orally per day for at least 2 cycles (6 weeks) and for a maximum of 8 months. Upon progression or drug intolerance, this is followed by standard of care platinum-based chemotherapy selected by the treating physician, every 3 weeks for at least 2 cycles"
"10905",12752,"NCT00802841",331480,0.114583333,11,96,NA,NA,"Nilotinib","Participants received 400 mg nilotinib twice daily (BID)."
"10942",12794,"NCT00079274",568948,0.113636364,5,44,"6 months or during treatment","All patients that received protocol treatment and completed at least one adverse event assessment are included in this analysis. Adverse event data was not collected for Arm G patients.","Arm F (Combination Chemotherapy, Monoclonal Antibody)","Patients receive cetuximab as in arm D and chemotherapy as in arm C.
irinotecan hydrochloride: Given IV
oxaliplatin: Given IV
leucovorin calcium: Given IV
fluorouracil: Given IV
cetuximab: Given IV"
"10962",12814,"NCT00556712",423757,0.113163972,49,433,"Adverse events (AEs) were recorded from Day 1 (after randomization) through the end of study, up to 27 months. Serious adverse events (SAEs) were recorded from Day 1 (after randomization) through the second data cut-off, up to 71 months.","All participants who received at least 1 dose of investigational treatment and had at least 1 safety follow-up, whether prematurely withdrawn or not, were included in the safety analysis.","Erlotinib, 150 mg/Day","Participants completed 4 cycles (3 or 4 week cycles) of a standard platinum based non-investigational chemotherapy according to local practice and in concordance with the local labeling instructions (chemotherapy run-in period). Participants who completed all 4 cycles of chemotherapy run-in without PD according to RECIST were randomized to receive erlotinib, 150 mg/day, PO as tablets from randomization until PD, death, unacceptable toxicity, or end of study, up to 27 months."
"10963",12815,"NCT00079274",568950,0.113122172,150,1326,"6 months or during treatment","All patients that received protocol treatment and completed at least one adverse event assessment are included in this analysis. Adverse event data was not collected for Arm G patients.","Arm D (Combination Chemotherapy, Monoclonal Antibody)","Patients receive cetuximab IV over 1 hour on days 1 and 8 and oxaliplatin, leucovorin calcium, and fluorouracil as in arm A. Treatment repeats every 14 days for up to 12 courses in the absence of unacceptable toxicity or recurrent disease.
oxaliplatin: Given IV
leucovorin calcium: Given IV
fluorouracil: Given IV
cetuximab: Given IV"
"10999",12856,"NCT01328951",159340,0.111801242,36,322,"Up to approximately 4.5 years (visits at Baseline and Weeks 6, 12, and 18 and every 12 weeks until disease progression, death, or unacceptable toxicity during BP; per local standards and 28 days after last visit during OLP)","Safety Population: All participants who received at least one dose of study treatment, according to drug actually received. Non-serious adverse events (NSAEs) were not collected in the OLP. Hence, 0 participants would be affected and at risk in Other (Not Including Serious) Adverse Events. However, an NSAE in 1 participant was reported to Roche outside protocol (see Rash). Other NSAEs that may have occurred during the OLP are not included in the table because they were not reported to Roche.","Erlotinib (Early Erlotinib)","Participants received blinded erlotinib tablets, 150 mg PO once daily during the BP in the maintenance setting until disease progression, death, or unacceptable toxicity."
"11097",12967,"NCT00243191",533179,0.111111111,2,18,"3 years, 6 months",NA,"Imatinib",NA
"11137",13012,"NCT00715403",365699,0.111111111,1,9,"From the first intake of trial medication until 28 days after last intake of medication, up to 1119 days",NA,"150mg BID","Patients were treated with 150 mg Nintedanib twice daily."
"11139",13014,"NCT00686036",377215,0.111111111,1,9,NA,NA,"Vandetanib","Vandetanib 300 mg tablet"
"11149",13024,"NCT00506831",444534,0.111111111,1,9,NA,NA,"Imatinib Mesylate",NA
"11155",13031,"NCT00411788",479262,0.111111111,1,9,"Adverse events were collected in aggregate through the end of the study (up to 58 weeks).",NA,"Sirolimus and Trastuzumab","Patients received oral sirolimus 6 mg daily in combination with weekly trastuzumab administered intravenously with a loading dose of 4 mg/kg followed by 2 mg/kg weekly in a 28-day cycle. A subsequent amendment allowed trastuzumab to be administered every 3 weeks for patient convenience, with a loading dose of 8 mg/kg followed by a 6 mg/kg in a 21-day cycle. Sirolimus was administered at a 6 mg oral daily dose. Cycles were repeated on an every 21 or 28-day schedule until disease progression, unacceptable toxicity, or the development of any of the criteria for study removal. Doses were reduced or discontinued based on tolerability."
"11160",13036,"NCT00339144",503752,0.111111111,1,9,NA,NA,"Dasatinib 100 mg","Participants were administered an oral dose of 100 mg dasatinib tablet once daily for a period of 4 weeks. Initially, 3 participants were treated at one dose level. If no dose limiting toxicity (DLT) was observed, the dose was escalated to next higher level. If a DLT was observed among 1 of 3 treated participants in the first course at a dose level, 3 participants were additionally enrolled and treated at the same dose level. If no further DLT was observed during the first course in these additional participants, the dose was escalated to next higher dose level. Dose was not escalated above 200 mg daily."
"11249",13132,"NCT01013740",257281,0.108108108,4,37,"In the RP, serious adverse events (SAEs) and non-serious AEs were collected from Screening until PD/treatment withdrawal (average of 27 study weeks). In the CP, SAEs and non-serious AEs were collected from the time of crossover until tre","Serious and non-serious adverse events were collected in members of the Safety Population, comprised of all participants who received at least one dose of study medication.","Lapatinib Plus Capecitabine in the RP","Participants received a daily dose of 5 tablets of lapatinib (1250 milligrams [mg]) continuously at approximately the same time every day, either 1 hour (or more) before food or 1 hour (or more) after food. Participants also received capecitabine 2000 mg per meters squared (mg/m^2) per day, divided and administered orally twice daily, 12 hours apart, for 14 days, every 21 days. Capecitabine was taken with food or within 30 minutes after food with approximately 200 milliliters (mL) of water. After disease progression in the Randomized Phase (in which participants received lapatinib plus vinorelbine), participants were given the option of crossing over to the alternative treatment arm (lapatinib plus capecitabine), and continuing in a post-progression Cross-over Phase."
"11268",13153,"NCT00588445",412252,0.107692308,7,65,NA,NA,"Treatment","Gefitinib: Patients will receive gefitinib 250 mg po daily for at least 21 days preoperatively (depending on the timing of the surgery). Treatment with gefitinib will be stopped 2 days before the date of surgery.
Patients who have had at least a minor response to gefitinib therapy preoperatively (> 25% reduction in tumor measured bidimensionally) and / or have mutations in the protein-tyrosine kinase domain of the EGF receptor gene identified will continue on the study and will resume gefitinib treatment after at least 7 days from surgery providing adequate wound healing has occurred.
Patients who are determined to be candidates for adjuvant chemotherapy and/or radiation therapy by their treating physician may receive treatment with adjuvant chemotherapy and/or radiation therapy. The post-operative gefitinib will be started after completion of the chemotherapy and/or radiation therapy."
"11308",13200,"NCT00674973",380811,0.106796117,11,103,"Adverse events were assessed from baseline up to 28 days after discontinuation of study drug (up to 30 months)",NA,"Placebo","Participants with advanced pancreatic carcinoma with Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0 to 2, who had failed 1 prior regimen of chemotherapy or who were considered unsuitable for chemotherapy, received placebo matching to erlotinib 150 mg tablet orally once daily until disease progression (PD), unacceptable toxicity, withdrawal, or death."
"11389",13294,"NCT00726232",361714,0.105263158,2,19,NA,NA,"PV: Ruxolitinib 10 mg BID","Participants with Polycythemia Vera received 10 mg Ruxolitinib orally twice a day (BID) for 56 days (two 28-day cycles) during the dose-ranging phase. After patients completed 2 cycles of treatment at the randomized dose, Investigators were permitted to adjust the dose/regimen on an individual basis to achieve an optimal balance of efficacy and safety. Treatment continued until a patient met a withdrawal criterion, had intolerable toxicity, progression of disease, or withdrew consent."
"11401",13309,"NCT00088907",567166,0.105263158,2,19,"Assessed every cycle (1 cycle = 4 weeks) while on treatment and for the 30 days following the last dose of protocol drug (which was included in the form for the last cycle).","Prior to diagnosis of progression / relapse or after start of non-protocol therapy, severe (Grade ≥ 3) long term toxicity that has not been previously reported was included in the report as well.","Step 2: ZD1839","ZD1839 (Iressa, gefitinib) 250 mg/daily orally starting on day 1. Treatment to continue from days 1-28 of each cycle."
"11430",13342,"NCT00770809",344807,0.104347826,12,115,NA,"Adverse Event data is available on 295 participants (Arm I: 115. Arm II: 115, Arm III: 65)","Arm II (TH)","Patients receive trastuzumab 2 mg/kg IV over 30-90 minutes and paclitaxel 80 mg/m^2 IV over 1 hour once weekly for 16 weeks in the absence of disease progression or unacceptable toxicity."
"11473",13393,"NCT01013740",257279,0.103448276,3,29,"In the RP, serious adverse events (SAEs) and non-serious AEs were collected from Screening until PD/treatment withdrawal (average of 27 study weeks). In the CP, SAEs and non-serious AEs were collected from the time of crossover until tre","Serious and non-serious adverse events were collected in members of the Safety Population, comprised of all participants who received at least one dose of study medication.","Lapatinib Plus Capecitabine in the CP","Participants received a daily dose of 5 tablets of lapatinib (1250 milligrams [mg]) continuously at approximately the same time every day, either 1 hour (or more) before food or 1 hour (or more) after food. Participants also received capecitabine 2000 mg per meters squared (mg/m^2) per day, divided and administered orally twice daily, 12 hours apart, for 14 days, every 21 days. Capecitabine was taken with food or within 30 minutes after food with approximately 200 milliliters (mL) of water. After disease progression in the Randomized Phase (in which participants received lapatinib plus vinorelbine), participants were given the option of crossing over to the alternative treatment arm (lapatinib plus capecitabine), and continuing in a post-progression Cross-over Phase."
"11531",13459,"NCT00556322",423971,0.102040816,20,196,"All adverse events (related and unrelated) occurring during the study and for up to 28 days after the last dose of study medication were reported.","All participants who received at least one dose of the trial medication and had at least one safety follow-up, whether withdrawn prematurely or not, were included in the safety analysis population (SAP).","Erlotinib","Participants received a single oral dose of erlotinib 150 mg/day until disease progression, unacceptable toxicity or death."
"11559",13494,"NCT01196052",198583,0.101351351,15,148,NA,"Safety-evaluable population: All participants who received at least 1 dose of trastuzumab emtansine.
All adverse events that occurred while participants were receiving trastuzumab emtansine are reported.","Trastuzumab Emtansine","Trastuzumab emtansine 3.6 mg/kg was administered intravenously on Day 1 of each 3-week treatment cycle up to a maximum of 17 cycles."
"11621",13568,"NCT01393899",143199,0.1,6,60,"SAEs were assessed from informed consent through and including 28 calendar days after last administration of study treatment (30 weeks). Non-SAEs were recorded from time of first dose of study treatment through last participant visit (30 weeks).","The same event may appear as both an adverse event (AE) and an SAE. However, what is presented are distinct events. An event may be categorized as serious in 1 participant and as nonserious in another participant, or 1 participant may have experienced both a serious and nonserious event during the study.","Tofacitinib 5 mg BID","Tofacitinib 5 mg (one placebo tablet and one tofacitinib tablet) for oral administration at a dose of 5 mg BID for 26 weeks."
"11641",13590,"NCT01037127",249417,0.1,4,40,"Serious AEs and non-serious AEs are presented from the date of the first dose of study medication until the last participant's last visit (up to 1130 days).",NA,"Trametinib 2 mg: Prior BRAF Inhibitors","Participants who were previously treated (before the start of this study) with BRAF (v-Raf murine sarcoma viral oncogene homolog B1) inhibitors received trametinib 2 milligram (mg) tablets orally once daily (qd) until treatment discontinuation criteria were met. Per the pre-specified study design, enrollment could have been stopped if objective response was observed in fewer than 3 participants among the first 30 participants enrolled. Per this criterion, enrollment in this cohort was stopped because, after enrollment of the first 30 participants, no objective responses were observed. Eligible participants who had been consented at the time the 30th participant was dosed were allowed to enroll, leading to overenrollment of 10 participants (total of 40 participants in this cohort). An interim analysis was performed after 30 participants had completed the first target post-dose disease assessment at 8 weeks."
"11649",13598,"NCT00268346",526393,0.1,4,40,"From study start to 30 days after final treatment",NA,"Prior Chemotherapy","Patients may not have received more than one previous systemic treatment regimen. Systemic treatment may have been given as part of definitive (adjuvant, neoadjuvant, concurrent, or sequential) management or for metastatic or recurrent disease. Patients receive oral gefitinib once daily for at least 8 weeks in the absence of disease progression or unacceptable toxicity."
"11659",13612,"NCT00780676",340263,0.1,3,30,"Adverse event data collected with each cycle of therapy i.e. every 28 days. Overall collection period June 2009 to July 2012.","Selumetinib pathway predictor groups (both MEK pathway activity predictor positive and MEK pathway predictor negative) had no patients assigned to treatment, only treated participants (30) included in analysis and adverse event reporting. Adverse event reporting was by treatment population rather than predictive groups.","Dasatinib 100 mg","Participants with one of 3 predictive gene signatures (dasatinib sensitivity signature, SRC pathway activity signature and dasatinib target index) received Dasatinib 100 mg orally daily."
"11682",13643,"NCT01283334",172219,0.1,2,20,"Up to 25 months",NA,"Carboplatin, Cetuximab and Everolimus","Carboplatin, cetuximab and RAD001 (everolimus)
Carboplatin, cetuximab and RAD001: For phase I, dose escalation will be 2.5mg, 5mg, 7.5mg or 10mg given orally on a daily basis"
"11807",13778,"NCT00453310",462830,0.1,1,10,NA,NA,"Sunitinib Malate","The dose of sunitinib malate will be a continuous daily dose of 37.5 mg administered orally for 6 weeks. The cycle of therapy is 42 days (or 6 weeks)
sunitinib malate"
"11821",13792,"NCT00267085",526770,0.1,1,10,"2 years 3 months",NA,"CML Vaccine","Imatinib mesylate subcutaneously every 2 weeks x 4 weeks, then every three weeks x 1 week, followed by monthly for 10 months"
"11829",13802,"NCT00109031",559514,0.1,1,10,"40 days from first dose of palifermin","Seven participants received the wrong sequence of placebo and palifermin as follows (# participants [from assigned arm to actual treatment arm]): 2 participants (A to C), 2 participants (D to B), 1 participant (C to A), 1 participant (B to D), 1 participant (C to D). Adverse event data are summarized by actual treatment group.","Palifermin 60 µg/kg for 3 Days (A)","Palifermin 60 µg/kg on the 3 days prior to fractionated total body irradiation (fTBI) and palifermin 60 µg/kg on Days 0, 1 and 2 after peripheral blood progenitor cell transplantation (PBPC)."
"11874",13852,"NCT01275196",174307,0.098484848,13,132,NA,"The safety set consisted of all patients who received at least one dose of study medication. Two patients (1 in each arm) who were randomized but never treated were excluded from the safety set.","Imatinib 400 mg qd","Patients received 400 mg qd (400 mg/day; may be increased to 600 mg/day)."
"11938",13930,"NCT01227928",188553,0.097222222,7,72,NA,"Serious adverse events (SAEs) and non-serious AEs were collected in members of the All Treated Population, comprised of all randomized participants who received at least one dose of investigational product. Treatment assignments in the All Treated Population were based on the actual treatment received, if different from the randomized treatment.","Pazopanib 800 Milligrams","Participants received pazopanib 800 milligrams administered orally once daily for up to 24 months."
"11957",13953,"NCT00802841",331479,0.096774194,9,93,NA,NA,"Imatinib","Participants receievd 600 mg imatinib once daily (QD)."
"12049",14052,"NCT00652340",389224,0.095238095,4,42,"First dose of study drug to 30 days after last dose of study drug.","Only drug related serious adverse events are listed.","Placebo/Erlotinib","Patients randomized to receive placebo and erlotinib."
"12053",14056,"NCT00079274",568949,0.095238095,4,42,"6 months or during treatment","All patients that received protocol treatment and completed at least one adverse event assessment are included in this analysis. Adverse event data was not collected for Arm G patients.","Arm E (Combination Chemotherapy, Monoclonal Antibody)","Patients receive cetuximab as in arm D and irinotecan, leucovorin calcium, and fluorouracil as in arm B. Treatment repeats every 14 days for up to 12 courses in the absence of unacceptable toxicity or recurrent disease.
irinotecan hydrochloride: Given IV
leucovorin calcium: Given IV
fluorouracil: Given IV
cetuximab: Given IV"
"12142",14157,"NCT00616122",401970,0.09375,3,32,NA,NA,"Sunitinib, Cyclophosphamide, and Methotrexate","Phase I patients received escalating doses of sunitinib in a 3x3 design (12.5, 25, 37.5 mg). Phase I and II patients received sunitinib for 2 weeks, followed by the addition of metronomic cyclophosphamide (50mg/day) and methotrexate (2.5mg BID 2 days/week). Phase II patients received 37.5mg sunitinib during the 2-week lead-in period followed by either 37.5mg sunitinib and metronomic CM or 25mg sunitinib and metronomic CM (dose reduction due to a protocol amendment)."
"12181",14202,"NCT01328951",159339,0.092741935,23,248,"Up to approximately 4.5 years (visits at Baseline and Weeks 6, 12, and 18 and every 12 weeks until disease progression, death, or unacceptable toxicity during BP; per local standards and 28 days after last visit during OLP)","Safety Population: All participants who received at least one dose of study treatment, according to drug actually received. Non-serious adverse events (NSAEs) were not collected in the OLP. Hence, 0 participants would be affected and at risk in Other (Not Including Serious) Adverse Events. However, an NSAE in 1 participant was reported to Roche outside protocol (see Rash). Other NSAEs that may have occurred during the OLP are not included in the table because they were not reported to Roche.","Second-Line Erlotinib (Late Erlotinib)","Participants who received blinded placebo and who demonstrated disease progression were unblinded and could receive second-line erlotinib as 150-mg tablets PO once daily, provided by the Sponsor. This treatment continued during the OLP until disease progression, death, or unacceptable toxicity."
"12186",14207,"NCT01632904",93681,0.092592593,5,54,"The duration of the study up to Week 16. This time frame defines the blinded, comparative phase of the study where the majority of patients remained on their original randomized assignment and exposure between ruxolitinib and hydroxyurea was similar.",NA,"Ruxolitinib","Ruxolitinib Ruxolitinib will be orally self-administered at a starting dose of 10 mg (two 5 mg tablets) twice a day. Dose increases of 5 mg (1 tablet) in twice-daily increments are permitted after 4 weeks and again after 8 weeks of therapy for subjects who meet prespecified criteria for inadequate efficacy.
HU-placebo All placebo will be self-administered, and dosing will be the same as with the blinded dose.
When adjustments are made to the ruxolitinib dose, the dose of HU-placebo will be adjusted concurrently."
"12195",14218,"NCT00494299",447841,0.092511013,21,227,NA,"Acronyms in Adverse Event section: - Absolute Neutrophil Count (ANC) - Alanine Transaminase (ALT) - Aspartate Transaminase (AST) - Atrioventricular (AV) - Central Nervous System (CNS) - Gastrointestinal (GI) - International Normalized Ratio (INR) - Not Otherwise Specified (NOS)","Placebo","Sorafenib (Nexavar, BAY43-9006) matching placebo (2 placebo tablets) orally administered bid (twice daily)."
"12204",14228,"NCT00770809",344806,0.092307692,6,65,NA,"Adverse Event data is available on 295 participants (Arm I: 115. Arm II: 115, Arm III: 65)","Arm III (TL)","Patients receive paclitaxel 80 mg/m^2 IV over 1 hour once weekly and lapatinib ditosylate 15000 mg PO once daily for 16 weeks in the absence of disease progression or unacceptable toxicity. (Discontinued as of 6-15-11)"
"12348",14388,"NCT01347788",154112,0.090909091,1,11,"Over the entire study period",NA,"Cohort 1","Dose level 0: cabozantinib 40 mg daily"
"12369",14412,"NCT00754923",351330,0.090909091,1,11,NA,NA,"Treatment: Sorafenib","Sorafenib will be administered at a dose of 400 mg taken twice daily, continuously on a 28 day cycle.
sorafenib: administered orally at 400 mg taken twice daily , continuously on a 28 day cycle as an outpatient."
"12370",14413,"NCT00752986",352505,0.090909091,1,11,NA,NA,"Placebo to Match Vandetanib 100 mg and 300 mg","placebo to match vandetanib 100 mg orally once-daily plus placebo to match vandetanib 300 mg orally once-daily plus fulvestrant LD (500 mg im. at day 1 and 250 mg at day 14, 28 and thereafter every 28th day +/- 3)."
"12389",14434,"NCT00424515",473852,0.090909091,1,11,"AE assessment occurred every other month from the start of study drug and up to day 30 post-treatment.","Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3.","Amplified KIT","Imatinib was given at a dose of 400 mg orally daily (4 100 mg pills). Patients received treatment up to 12 months as long as they were receiving clinical benefit. Dosage may have been increased to twice daily if disease worsened and patient was in otherwise good clinical condition. Patients were classified into two cohorts based upon KIT molecular status."
"12391",14436,"NCT00373425",493298,0.090909091,1,11,"From the first dose of study drug until 30 days after the last dose. Maximum time on treatment for the Randomized Cohort was 24 months; maximum time on treatment for the BPC was 13 months on blinded study drug and 26 months on open-label erlotinib.","One participant in the Randomized Cohort assigned to the erlotinib arm received placebo instead due to a dispensing error and is included in the placebo group for safety analyses. For the Breached Protocol Cohort safety analyses are based on the total no open-label and open-label populations.
Safety data are based on the 11 June 2014 cut-off date.","BPC-NOLC: Placebo Only","The BPC no open-label cohort (BPC-NOLC) includes participants randomized prior to 07 November 2007 who did not participate in the open-label erlotinib period and who were previously randomized to receive either erlotinib or placebo in the blinded period, and did not receive any erlotinib."
"12450",14504,"NCT01233869",186856,0.089285714,5,56,"Baseline up to 30 days after last study drug administration","The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another participant, or one participant may have experienced both a serious and non-serious event during the study.","Placebo","Participants received placebo tablet orally QD in the morning with food for 24 months in the ITP. After a 30-day washout period, participants who entered the ETP continued to receive placebo matched bosutinib QD for up to 46 months."
"12572",14633,"NCT00412217",479147,0.086956522,4,46,"From Baseline until end of treatment (up to 1 year)","ITT Population. Adverse events (AEs) are organized by Medical Dictionary for Regulatory Activities (MedDRA) System Organ Class (SOC), but the AE terms included below are same as they were originally registered and saved.","Erlotinib","Participants with histologically confirmed advanced SCC of the head and neck, treated with surgical resection and chemoradiotherapy or radiotherapy alone, received erlotinib tablets as 150 mg once daily for 1 year until disease progression or intolerable toxicity."
"12590",14657,"NCT00656669",387982,0.086956522,2,23,"Cycles 1 through 9 of treatment",NA,"Paclitaxel/Sunitinib","4 cycles (16 weeks) of neoadjuvant treatment with the combination of sunitinib and paclitaxel."
"12662",14740,"NCT01650805",89888,0.085526316,13,152,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",NA,"Imatinib 400 mg","imatinib (Gleevec/ Glivec): 400 mg tablet, taken orally once daily"
"12682",14767,"NCT00390455",487874,0.085106383,12,141,NA,"Adverse event was available on 278 participants (Arm I: 141, Arm II: 137)","Arm I (Lapatinib)","Patients receive 1500 mg lapatinib ditosylate PO QD on days 1-28 and fulvestrant IM on days 1 (500 mg) and 15 (250 mg) of course 1 and on day 1 (250 mg)of each subsequent course."
"12692",14779,"NCT00866320",306758,0.085106383,4,47,"Adverse events collected from the start of treatment to the end of the study for a period of 3 years and 8 months.",NA,"Sorafenib","Patients receive Sorafenib 400 mg BID until disease progression or toxicity. Dose may be escalated to 600mg and 800 mg BID after the 8 week disease reassessment."
"12715",14803,"NCT01328951",159341,0.084639498,27,319,"Up to approximately 4.5 years (visits at Baseline and Weeks 6, 12, and 18 and every 12 weeks until disease progression, death, or unacceptable toxicity during BP; per local standards and 28 days after last visit during OLP)","Safety Population: All participants who received at least one dose of study treatment, according to drug actually received. Non-serious adverse events (NSAEs) were not collected in the OLP. Hence, 0 participants would be affected and at risk in Other (Not Including Serious) Adverse Events. However, an NSAE in 1 participant was reported to Roche outside protocol (see Rash). Other NSAEs that may have occurred during the OLP are not included in the table because they were not reported to Roche.","Placebo (Late Erlotinib)","Participants received blinded placebo tablets PO once daily during the BP in the maintenance setting until disease progression, death, or unacceptable toxicity."
"12840",14937,"NCT00329641",505722,0.083333333,2,24,"While the patient is on treatment until resolution of acute toxicities with maximum grade reported","Regular investigator assessments are reported after each cycle of protocol treatment","Intervention","Sorafenib, Carboplatin, Paclitaxel"
"12855",14953,"NCT01682135",83475,0.083333333,1,12,NA,NA,"Cohort 3 - 8mg/kg/2w Ramucirumab","8mg/kg ramucirumab administered IV every 2 weeks for 6 weeks (one cycle)."
"12921",15026,"NCT00109031",559511,0.083333333,1,12,"40 days from first dose of palifermin","Seven participants received the wrong sequence of placebo and palifermin as follows (# participants [from assigned arm to actual treatment arm]): 2 participants (A to C), 2 participants (D to B), 1 participant (C to A), 1 participant (B to D), 1 participant (C to D). Adverse event data are summarized by actual treatment group.","Palifermin 180 μg/kg on Day −3 (D)","Palifermin 180 μg/kg on Day −3 and placebo on Days −1 and −2 prior to fTBI, and palifermin 60 μg/kg on Days 0, 1, and 2 after PBPC."
"12942",15048,"NCT01275196",174306,0.082706767,11,133,NA,"The safety set consisted of all patients who received at least one dose of study medication. Two patients (1 in each arm) who were randomized but never treated were excluded from the safety set.","Nilotinib 300 mg Bid","Patients received 300 mg bid (600 mg/day)"
"12989",15104,"NCT00103844",561801,0.081632653,4,49,NA,NA,"IMATINIB","Imatinib 400 mg BID"
"12990",15105,"NCT00103194",561941,0.081632653,4,49,"Assessed every 4 weeks while on treatment and for 30 days after the end of treatment.",NA,"GW572016 (Lapatinib)","GW572016 was administered at a dose of 1500 mg orally daily on an outpatient basis. Patients were advised to take GW572016 on an empty stomach (either 1 hour before or 1 hour after meals). GW572016 was administered continuously until disease progression or unacceptable toxicities. For the purposes of protocol evaluations, a cycle was defined as 28 days."
"13061",15181,"NCT01458951",128968,0.080357143,9,112,"Baseline up to Day 98","The same event may appear as both an adverse event (AE) and an serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another participant, or one participant may have experienced both a serious and non serious event during the study.","Placebo BID","Participants received tofacitinib-matched placebo tablets, orally, BID for 9 weeks of double blind treatment period."
"13115",15242,"NCT00353301",500514,0.08,2,25,"Adverse events were collected throughout the period of active therapy up to 4 weeks.","Monitoring included patient interview, physical exam, routine laboratory tests (even in absence of symptoms) and appropriate work-up of any new symptoms or laboratorial abnormalities.","Erlotinib and Sirolimus","Erlotinib (Tarceva) therapy was started at 150 mg by mouth daily from day 1 to be taken at least 1 hour before or 2 hours after a meal. Sirolimus was initiated on day 8 (D8) with a loading dose of 6mg by mouth, followed by a daily dose of 2mg by mouth, on the basis of the product prescribing information for low-to-moderate immunologic risk renal transplant patients."
"13160",15295,"NCT00825734",321947,0.078947368,6,76,NA,NA,"Dose Level 1a","Includes patients treated at the Phase II dose - Sorafenib PO BID (400mg), Ixabepilone IV every 21 days (32mg/m^2)"
"13183",15323,"NCT01230710",188000,0.078431373,4,51,NA,"Safety population: All participants who had received at least 1 dose of erlotinib and had at least 1 safety follow-up, whether withdrawn prematurely or not.","Erlotinib","Participants received erlotinib 150 mg orally once a day for 48 weeks."
"13186",15326,"NCT00943670",282878,0.078431373,4,51,"1 year",NA,"Single-Agent T-DM1 Treatment","Trastuzumab emtansine (T-DM1) was administered to participants by intravenous (IV) infusion on Day 1 of every 3 week cycle at a dose of 3.6 mg/kg."
"13294",15450,"NCT00434109",470417,0.076923077,3,39,"4 years",NA,"Sunitinib Malate and Hepatic Artery Embolizations","Sunitinib Malate and Selective Hepatic Artery Embolizations: Sunitinib malate (Sutent) at a dose of 37.5mg. 1-3 selective hepatic artery embolizations."
"13335",15492,"NCT01871805",53181,0.076923077,1,13,"From baseline to up to 28 days after the last dose of alectinib (up to Week 105; data cut-off date 24 October 2014)",NA,"Alectinib 900 mg (Fed): Phase I","Participants received single dose of 20 or 40 or 150 mg alectinib capsules orally to make a dose of 900 mg on Cycle 1 Day -3 and then received 900 mg BID dose for 3-weekly cycles until disease progression, death or withdrawal for any other reasons."
"13349",15506,"NCT01347788",154110,0.076923077,1,13,"Over the entire study period",NA,"Cohort 3","Dose level 0: cabozantinib 40 mg daily"
"13380",15538,"NCT00802841",331477,0.076923077,1,13,NA,NA,"Cross-over to Imatinib","600 mg QD"
"13404",15562,"NCT00320190",511283,0.076923077,1,13,"Baseline to Month 12 and Month 12 to Month 24",NA,"Imatinib, 800 mg","Imatinib, 400 mg, administered orally twice daily"
"13446",15608,"NCT00436332",469547,0.075949367,6,79,"From date of registration to maximum of 3 years.","Only adverse events and serious adverse events that are possibly, probably or definitely related to study drug are reported.","Erlotinib and Bevacizumab","Patients receive oral erlotinib hydrochloride once daily on days 1-21 and bevacizumab IV over 30-90 minutes on day 1."
"13457",15620,"NCT01012258",257489,0.075757576,5,66,"Up to Day 60 after last trial treatment administration and before EOT","An adverse event (AE) was defined as any untoward medical occurrence in the form of signs, symptoms, abnormal laboratory findings, or diseases that emerges or worsens relative to baseline during a clinical study with an IMP, regardless of causal relationship and even if no IMP has been administered.","Cetuximab: Treatment Emergent Phase","Participants received cetuximab 400 milligram/square meter (mg/m^2) intravenous (IV) infusion over 120 minutes for 1 week, subsequently followed by 250 mg/m^2 IV infusion over 60 minutes, from week 2 to 7 along with concomitant boost radiotherapy: 72.0 Gray (Gy) total for 42 fractions in 6 weeks, initially, once-daily fractions: 32.4 Gy in 18 fractions of 1.8 Gy for 3.6 weeks (5 fractions/week), followed by twice-daily fractions 39.6 Gy in 24 fractions for 2.4 weeks: morning dose 1.8 Gy/fraction for a total of 12 fractions 5 fractions/week; evening dose 1.5 Gy/fraction for a total of 12 fractions 5 fractions/week. Doses were separated by at least a 6-hour interval. Treatment emergent phase, i.e. treatment-emergent adverse events (TEAEs, adverse events which occur or worsen on the first dosing day of trial treatment and until 60 days after the last trial treatment administration (cetuximab or radiotherapy)."
"13479",15644,"NCT01040780",248352,0.075376884,15,199,NA,"Events were collected by systematic assessment","Gefitinib","Gefitinib 250 mg every 24 hours by mouth"
"13629",15820,"NCT00887575",300110,0.073170732,3,41,NA,NA,"Dose Level I","Neoadjuvant - Paclitaxel IV (70 mg/m^2) days 1, 8 and 15 of each cycle, Carboplatin IV (AUC = 5) day 1 of every cycle and Sunitinib PO (25mg) daily.
Maintenance - Sunitinib PO (25mg) daily"
"13710",15914,"NCT01831466",58204,0.071428571,5,70,"SAEs were assessed from informed consent through and including 28 calendar days after last administration of study treatment. Non-SAEs were recorded from time of first dose of study treatment through last participant visit.","The same event may appear as both an AE and an SAE. However, what is presented are distinct events. An event may be categorized as serious in 1 participant and as nonserious in another participant, or 1 participant may have experienced both a serious and nonserious event during the study. All AEs (including treatment area AEs) are presented.","Mild/Moderate: Tofacitinib 10 mg/g BID","Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 10 mg/g, BID for 12 weeks."
"13719",15924,"NCT01632904",93680,0.071428571,4,56,"The duration of the study up to Week 16. This time frame defines the blinded, comparative phase of the study where the majority of patients remained on their original randomized assignment and exposure between ruxolitinib and hydroxyurea was similar.",NA,"Hydroxyurea","Hydroxyurea (HU) Hydroxyurea (500 mg capsules) will be orally self-administered at the dose that the subject was receiving previously. The dose may be increased after 4 weeks and again after 8 weeks of therapy to optimize efficacy for subjects meeting prespecified criteria.
Ruxolitinib-placebo All placebo will be self-administered, and dosing will be the same as with the blinded dose.
When adjustments are made to the HU dose, the dose of ruxolitinib-placebo will be adjusted concurrently."
"13720",15925,"NCT00802841",331478,0.071428571,4,56,NA,NA,"Cross-over to Nilotinib","Nilotinib 400 mg BID"
"13799",16015,"NCT00549328",427414,0.071428571,1,14,NA,NA,"Pazopanib 800 mg","Pazopanib 800 milligrams (mg) monotherapy given orally once daily"
"13929",16158,"NCT00343083",503390,0.069767442,3,43,NA,NA,"Cetuximab (ERBITUX) and Concurrent Carboplatin",NA
"13975",16211,"NCT01328054",159644,0.068965517,4,58,"Serious adverse events (SAEs) and non-serious adverse events (AEs) were collected from Day 1 until the follow-up visit (up to 28 days after the last dose of lapatinib [up to end of Study Week 4]).","The number of participants in 1st Period - placebo (57) is different from 2nd Period - lapatinib (58) because one participant was double dosed with lapatinib (i.e., received lapatinib during both the 1st period and 2nd period) due to dosing error.","Lapatinib 2000 mg","Participants received three doses of lapatinib 2000 mg (250 mg x 8 tablets/dose) in the morning and evening on Day 3 and in the morning on Day 4."
"13978",16214,"NCT01765569",67448,0.068965517,2,29,"From Screening to 28 days after the last dose of study treatment or until initiation of another anticancer therapy, whichever occurred first.",NA,"Period B","Vemurafenib 960 mg orally BID from Day 8 to Day 28."
"14019",16261,"NCT01125566",221880,0.068493151,5,73,"From first administration of treatment within the trial until 28 days after last administration of treatment within the trial, up to 869 days.","For the AV group, in the participant flow Total participants (Started) are 339 and for Adverse events Total # participants affected at risk are 337, this is because out of 339 subjects from the AV group, 2 subjects were not treated with the treatment.","AV Switched to TV","This group describes patients who crossed over from AV to TV following DMC recommendation to terminate recruitment on 26Apr2013. Patients discontinued AV and switched to TV if they were without disease progression on Afatinib+ Vinorelbine treatment on 26Apr2013."
"14047",16293,"NCT00770588",344946,0.068027211,10,147,NA,NA,"Gefitinib","Gefitinib (Iressa® 250 mg) 1 tablet daily"
"14178",16437,"NCT00090987",566174,0.066666667,2,30,NA,NA,"Imatinib Mesylate (Gleevec)","Imatinib mesylate (Gleevec) is administered 400 mg orally once a day"
"14226",16488,"NCT00754494",351541,0.066666667,1,15,"The onset date of adverse event is between the randomization date and the date of off-study, up to 95 days.",NA,"Arm I (25 mg)","Patients receive 25mg of erlotinib hydrochloride PO and one 100 mg of placebo and one 25 mg of placebo PO QD.
erlotinib hydrochloride: Given PO
placebo: Given PO
laboratory biomarker analysis: Correlative studies"
"14486",16773,"NCT01764022",67737,0.063492063,4,63,"Day 127","Population for safety analysis included patients who received at least one injection of study drug (n=124).","BCD-022 (CJSC BIOCAD)","BCD-022 is a product code for trastuzumab biosimilar manufactured by CJSC BIOCAD, Russia. In this arm patients will receive 6 courses of treatment with BCD-022 in combination with paclitaxel. Patients will receive BCD-022 at a loading dose of 8 mg/kg (once), followed by maintenance dose of 6 mg/kg every 3 weeks (5 administrations), + paclitaxel 175 mg/m2 every 3 weeks as 3 hour intravenous infusion (6 administrations)."
"14489",16776,"NCT00629499",396866,0.063492063,4,63,NA,NA,"Intervention","100 mg/m2 of intravenous (IV) nab paclitaxel weekly (i.e., on Days 1, 8, and 15 of each 3 week treatment cycle) in combination with 600 mg/m2 of IV cyclophosphamide once every 3 weeks for 4 cycles (i.e., a total treatment period of 12 weeks [84 days]). Patients with fluorescence in situ hybridization (FISH) HER2+ or IHC3+ breast cancer will also receive treatment with trastuzumab in addition to the nab paclitaxel / cyclophosphamide combination therapy. Maintenance therapy with trastuzumab will continue (for the HER2+ patients who are receiving trastuzumab) after the 12-week treatment period with combination nab paclitaxel/cyclophosphamide/trastuzumab. The total treatment time for trastuzumab will be 52 weeks rather than only 12 weeks."
"14518",16807,"NCT00374322",493023,0.062937063,99,1573,"Non-serious adverse events (AEs): collected from start of treatment until up to 5 days after the last dose of study treatment (up to 12 months). SAEs: collected up to any time during the follow-up period post discontinuation of study drug (up to 6 years).","Non-serious AEs and SAEs were collected in members of the Safety Population, comprised of all randomized participants who received at least one dose of randomized treatment. Two participants were randomized to placebo but received lapatinib; therefore, they are included in the lapatinib treatment arm.","Lapatinib 1500 mg","Participants received lapatinib 1500 milligrams (mg) orally once daily. Treatment was continued for a maximum of 12 months or until disease recurrence or development of a second primary cancer, withdrawal from study treatment due to unacceptable toxicity, or consent withdrawal."
"14556",16849,"NCT00098371",563156,0.0625,4,64,NA,"NCI Common Toxicity Criteria of Adverse Events (version 3) and modified NCI Common Toxicity Criteria guidelines for evaluating hematologic toxicity for leukemia was used to grade adverse events for patients. Adverse events are reported across all grades.","Treatment (Alvocidib)","Patients receive flavopiridol IV over 30 minutes followed by a 4-hour infusion on days 1, 8, 15, and 22. Treatment repeats every 42 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients achieving at least a partial remission (PR) and whose PR lasts for > 6 months after completion of treatment may receive 6 additional courses of flavopiridol."
"14607",16905,"NCT01449513",132011,0.0625,1,16,NA,NA,"Ingenol Mebutate Gel (PEP005 Gel)","Ingenol mebutate gel (PEP005 gel)
Ingenol mebutate gel (0.05%) once daily on two consecutive days to an 25cm2 area"
"14627",16926,"NCT01017653",255848,0.0625,1,16,"16 months","The adverse events were gathered in Common Terminology Criteria for Adverse Events v.3.0, and have been converted to v.4.0 for entry into ClinicalTrials.gov","Panitumumab and Irinotecan","Panitumumab in Combination with Irinotecan : Panitumumab, 6mg/kg, as an intravenous infusion every other week in combination with Irinotecan (dose dependent upon whether the patient is taking an enzyme-inducing anti-epileptic drug [EIAED]). On an enzyme-inducing anti-epileptic drug (EIAED), irinotecan will be dosed at 340 mg/m2 every other week. Not on an EIAED, irinotecan will be dosed at 125 mg/m2. Treatment will continue until tumor progression or unacceptable toxicity."
"14822",17141,"NCT00553358",425330,0.060402685,9,149,NA,"Only events, assessments, and treatments with a start date on or before the end date of the neoadjuvant phase have been summarized. One non-serious event was reported as an uncoded event. A non-serious event of dental care was actually coded to Surgical and medical procedures.","Trastuzumab 2 mg/kg","Trastuzumab (4 mg/kilograms [kg] IV load followed by 2 mg/kg IV weekly) for 6 weeks, followed by trastuzumab plus weekly paclitaxel (80 mg/m^2 IV) for an additional 12 weeks"
"14946",17276,"NCT02222207",16614,0.058823529,3,51,"From the start of study treatment until 30 days after last dose of study drug treatment (up to Week 16).",NA,"Part A Regorafenib","Participants self-administered 30 mg/mL, 25 mcL, 1 drop of regorafenib eye drops, topically thrice daily (TID) to the study eye for 12 weeks."
"15282",17642,"NCT00070499",570830,0.055555556,4,72,"While the patient is on treatment until resolution of acute toxicities with maximum grade reported","Regular investigator assessments are reported after each cycle of protocol treatment","Standard Dose Imatinib A","Randomization occurred between standard dose imatinib A and high dose imatinib/ patients received 400 mg imatinib daily"
"15298",17661,"NCT01164579",209839,0.055555556,2,36,"Adverse events were collected up to 28 calendar days after the last administration of investigational product.","The same event may appear as both an adverse event (AE) and a serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in 1 participant and as nonserious in another participant, or 1 participant may have experienced both a serious and nonserious event during the study.","Tofacitinib (CP-690,550) Plus MTX","Participants received CP-690,550 10 mg, tablets, PO, BID, and MTX 10 mg/week to 20 mg/week, capsules, PO, for a maximum of 12 months. MTX dose was titrated as follows: 10 mg once weekly for 4 weeks; if well tolerated, then at Month 1 titrate up to 15 mg once weekly for 4 weeks; if well tolerated, then at Month 2 titrate up to 20 mg once weekly for the duration of the study. A single dose reduction of MTX 5 mg was allowed because of lack of tolerance, as long as the participant remained on a dose of at least MTX 10 mg weekly. Participants also received folate supplementation according to local MTX label guidelines and standard of care."
"15748",18166,"NCT00124618",554505,0.051724138,3,58,NA,NA,"Cetuximab/Radiation","Cetuximab (C225) and Radiation therapy"
"16070",18515,"NCT01328951",159338,0.049382716,8,162,"Up to approximately 4.5 years (visits at Baseline and Weeks 6, 12, and 18 and every 12 weeks until disease progression, death, or unacceptable toxicity during BP; per local standards and 28 days after last visit during OLP)","Safety Population: All participants who received at least one dose of study treatment, according to drug actually received. Non-serious adverse events (NSAEs) were not collected in the OLP. Hence, 0 participants would be affected and at risk in Other (Not Including Serious) Adverse Events. However, an NSAE in 1 participant was reported to Roche outside protocol (see Rash). Other NSAEs that may have occurred during the OLP are not included in the table because they were not reported to Roche.","Second-Line Chemotherapy (Early Erlotinib)","Participants who received blinded erlotinib and who demonstrated disease progression were unblinded and could receive an approved second-line therapy (but not EGFR targeted therapies) or BSC as chosen by the investigator. This treatment continued during the OLP until disease progression, death, or unacceptable toxicity."
"16198",18662,"NCT02595450",2301,0.048109966,14,291,"Up to 6 years","Analysis population included participants who received at least 1 documented treatment cycle.","Erlotinib","Participants with locally advanced or metastatic non-small cell lung cancer were treated with erlotinib according to the product label. This non-interventional study did not affect by any means the treatment, medical care or monitoring of the participant, since it reported retrospective data, which already existed in the participants' medical files."
"16335",18815,"NCT00509587",443605,0.047619048,1,21,NA,NA,"Treatment (Pazopanib Hydrochloride)","Patients receive oral pazopanib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
pazopanib hydrochloride: Given orally
pharmacological study: Correlative studies
laboratory biomarker analysis: Correlative studies"
"16375",18862,"NCT00281658",522986,0.046979866,7,149,NA,"Serious adverse events and adverse events were collected in the Safety Population, comprised of all randomized participants who received at least one dose of investigational product.","Lapatinib 1500 mg","Lapatinib 1500 mg administered once daily. This is not a comparative treatment arm."
"16557",19068,"NCT01946529",43457,0.045454545,1,22,"Adverse events were collected from the on-study date through 05/03/2016.",NA,"Group B (High Risk) - Total","All Group B High Risk participants with ESFT or DSRCT.
Participants received vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide. Patients with measurable disease were eligible to receive irinotecan, temozolomide, and temsirolimus. Additionally, all patients were eligible to receive a maintenance therapy at the end of treatment including bevacizumab and sorafenib. Depending on the size and location of the participant's tumor, they had surgery alone, radiation alone, or surgery followed by radiation."
"16596",19109,"NCT00817531",325225,0.045454545,1,22,"3-4 weeks","Following the patient's written consent to participate in the study, then to the end of 3-4 week treatment","Dasatinib","Patients took Dasatinib 100mg daily"
"16605",19118,"NCT00726232",361710,0.045454545,1,22,NA,NA,"ET: Ruxolitinib 25 mg BID","Participants with Essential Thrombocythemia received 25 mg Ruxolitinib orally twice a day (BID) for 56 days (two 28-day cycles) during the dose-ranging phase. After patients completed 2 cycles of treatment at the randomized dose, Investigators were permitted to adjust the dose/regimen on an individual basis to achieve an optimal balance of efficacy and safety. Treatment continued until a patient met a withdrawal criterion, had intolerable toxicity, progression of disease, or withdrew consent."
"16654",19175,"NCT01480674",123163,0.044776119,6,134,"Up to 1 year","An AE is defined as any unfavourable and unintended sign, symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug .The data was reported for prospective period. Participants with available data in the prospective period were analysed.","Trastuzumab","Eligible participants with HER2-positive metastatic or locally advanced breast cancer, who were treated with trastuzumab as a first-line therapy and were progression-free for at least 3 years after treatment initiation, were included and were followed for one year."
"16684",19206,"NCT01445769",132596,0.044444444,2,45,"From the first dose of study medication through the Follow-Up Visit.","Safety population: All participants who took at least 1 dose of study drug.","Ruxolitinib","Participants initially received ruxolitinib 10 mg twice a day (bid). Dose increases of 5 mg bid were permitted at Weeks 12 and 18 for subjects who did not meet criteria for or have a dose hold over the prior 6 weeks, had a platelet count ≥100 x 10^9/L at week 12 or ≥150 x 10^9/L at week 18, and had a self-reported PGIC score of 3 (minimally improved) to 7 (very much worse) OR the subject's palpable spleen length had been reduced by less than 40% at that visit relative to Baseline. The maximum dose was 15 mg BID at Week 12 and 20 mg bid at Week 18. There were also protocol-required dose decreases for protocol-defined anemia and thrombocytopenia."
"16789",19322,"NCT01910181",48625,0.043478261,2,46,"Baseline until up to 28 days of last dose (up to 16 months as of data cutoff 15-Dec-2014)","Safety Population.","Vemurafenib: All Participants","Participants were entered into the study into one of two cohorts. Vemurafenib was administered orally as 960 mg twice daily until progression, unacceptable toxicity, consent withdrawal, decision by the investigator or Sponsor, or protocol/eligibility violation. The PK Cohort received treatment on Days 1 to 21 (morning dose only on Day 21), with a drug holiday from Days 22 to 27, and resumed treatment on Day 28. The Expansion Cohort received the same regimen from Day 1 onward, without a drug holiday."
"16974",19521,"NCT01458951",128970,0.041958042,18,429,"Baseline up to Day 98","The same event may appear as both an adverse event (AE) and an serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another participant, or one participant may have experienced both a serious and non serious event during the study.","Tofacitinib 10 mg BID","Participants received tofacitinib 10 mg tablets, orally, BID for 9 weeks of double blind treatment period."
"17033",19582,"NCT00412217",479146,0.041666667,2,48,"From Baseline until end of treatment (up to 1 year)","ITT Population. Adverse events (AEs) are organized by Medical Dictionary for Regulatory Activities (MedDRA) System Organ Class (SOC), but the AE terms included below are same as they were originally registered and saved.","Placebo","Participants with histologically confirmed advanced SCC of the head and neck, treated with surgical resection and chemoradiotherapy or radiotherapy alone, received placebo tablets (matched to erlotinib) once daily for 1 year until disease progression or intolerable toxicity."
"17037",19588,"NCT02000531",36360,0.041666667,1,24,"start of second-line treatment to data cut-off in December 2014 (within 12 months)",NA,"Chemotherapy-Erlotinib","Chemotherapy in first-line treatment, followed by erlotinib in the second-line treatment"
"17131",19690,"NCT01465763",127406,0.040983607,5,122,"Baseline up to Day 98","The same event may appear as both an adverse event (AE) and an serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another participant, or one participant may have experienced both a serious and non-serious event during the study.","Placebo BID","Participants received tofacitinib-matched placebo tablets, orally, BID for 9 weeks of double blind treatment period."
"17157",19717,"NCT01787383",63797,0.040816327,4,98,NA,NA,"Ingenol Mebutate Gel Sequential Treatment","Ingenol mebutate gel in 2 doses (0.015% and 0.05%) were applied sequentially: ingenol mebutate gel 0.015% (Picato®) was applied once daily for 3 consecutive days on on face/scalp and ingenol mebutate gel 0.05% (Picato®) was applied once daily for 2 consecutive days on trunk/extremities."
"17360",19943,"NCT00573144",417476,0.04,1,25,NA,NA,"Nesiritide","Infusion of 72 hours of IV nesiritide at 0.006 mcg/kg/min."
"17367",19950,"NCT00376935",492506,0.04,1,25,NA,NA,"Palifermin (20 Mcg/kg)","Participants will receive 1 palifermin 20 mcg/kg (0.004) mL/kg IV bolus injection, two placebo for palifermin IV bolus injections on each of 3 consecutive days: day 1 (entry), day 2 and day 3."
"17368",19951,"NCT00376935",492505,0.04,1,25,NA,NA,"Palifermin (40 Mcg/kg)","Participants will receive 1 palifermin 40 mcg/kg (0.008) mL/kg IV bolus injection, two placebo for palifermin IV bolus injections on each of 3 consecutive days: day 1 (entry), day 2 and day 3."
"17595",20204,"NCT00661193",386515,0.038461538,1,26,"From date of registration to 3 years or death, whichever comes first.","Only adverse events and serious adverse events that are possibly, probably or definitely related to study drug are reported.","Arm II","Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1 and oral erlotinib hydrochloride once daily on days 2-16. Treatment repeats every 21 days for 4 courses. Beginning in course 5 and for all subsequent courses, patients receive oral erlotinib hydrochloride alone on days 1-21. Courses with erlotinib hydrochloride repeat every 21 days in the absence of disease progression or unacceptable toxicity."
"17886",20514,"NCT00815308",325770,0.036363636,2,55,NA,NA,"Cetuximab, Concurrent Chemo-radiotherapy","Cetuximab, injection, loading dose400 mg/m^2,(Day1 in Week1) followed by 250 mg/m^2(Day1, every week for Weeks 2-8) Paclitaxel, injection,45 mg/m^2 (Day 1, every week for Weeks 2-8) Cisplatin, injection,20 mg/m^2 (Day 1, every week for Weeks 2-8) radiation therapy, 59.4 Gy, 1.8 Gy/33 fractions,1 fraction daily, Days 1-5 every week for Weeks 2-7, and Days 1-3 for Week 8"
"17984",20625,"NCT01765569",67447,0.035714286,1,28,"From Screening to 28 days after the last dose of study treatment or until initiation of another anticancer therapy, whichever occurred first.",NA,"Period C","Single oral dose of digoxin 0.25 mg on Day 29, and vemurafenib 960 mg orally BID from Day 29 to Day 35."
"18024",20669,"NCT00230126",535295,0.035714286,1,28,"1 year",NA,"Arm A: 150 mg/Day Cycles 1 - 3","150 mg/day cycles 1 - 3
erlotinib: Arm A: 150 mg/day cycles 1 - 3. Arm B: Cycle 1 - 175 or 200 mg/day depending on body weight; Cycle 2 - if rash developed, then 150 mg/day; if no rash, then 175 mg/day; Cycle 3 - if rash developed, then 175 mg/day; if no rash, then 200 mg/day."
"18052",20701,"NCT00999804",261503,0.035294118,3,85,"7 months","Adverse events experienced by participants will be collected and reported from initiation of study medication, throughout the study, and within 30 days of the last dose of study medication.","24-week Arm","Participants will receive 24-weeks of lapatinib plus trastuzumab. Participants who are estrogen receptor (ER) and/or progesterone receptor (PR) positive will also receive endocrine therapy.
Lapatinib: 1000 mg by mouth daily
Letrozole: 2.5 mg by mouth daily (for hormone receptor positive participants only)
Trastuzumab: 6 mg/kg intravenously, every 3 weeks"
"18213",20876,"NCT00447122",464755,0.034482759,1,29,NA,NA,"Treatment","lapatinib, 1,500 mg/day, and Gemcitabine, 1 gm/m2/week for 3 weeks followed by 1 week off, until disease progression"
"18245",20909,"NCT00765882",346326,0.034146341,7,205,"Adverse Event reporting occurred from October 2008 through August 2009.",NA,"Linaclotide 290µg","Linaclotide, 290µg dose, oral administration, once per day"
"18299",20966,"NCT00112736",557981,0.033898305,2,59,"Adverse Events were collected weekly for the first cycle and then at the start of each cycle while on treatment and at time of off study.",NA,"Phase II (Erlotinib & Erlotinib)","Oral erlotinib 1 daily days 1-28 (150mg), temsirolimus IV 30 minutes days 1, 8, 15, 22 at MTD phse I. Every 28 days until disease progression or unacceptable toxicity.
PHASE II (preoperative component): Patients who are surgical candidates may opt to undergo surgical resection of the tumor. Beginning 5-7 days before surgery, these patients receive oral erlotinib once daily until surgery. Patients also receive temsirolimus IV over 30 minutes at the MTD and then undergo surgical resection of the tumor 3-24 hours later. Beginning 2-4 weeks after surgery, patients receive temsirolimus at the MTD and erlotinib as in phase I.
therapeutic conventional surgery: Undergo surgical resection
laboratory biomarker analysis: Correlative studies"
"18324",20995,"NCT01465763",127408,0.033613445,16,476,"Baseline up to Day 98","The same event may appear as both an adverse event (AE) and an serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another participant, or one participant may have experienced both a serious and non-serious event during the study.","Tofacitinib 10 mg BID","Participants received tofacitinib 10 mg, tablets, orally, BID for 9 weeks of double blind treatment period."
"18833",21548,"NCT00661193",386516,0.03125,1,32,"From date of registration to 3 years or death, whichever comes first.","Only adverse events and serious adverse events that are possibly, probably or definitely related to study drug are reported.","Arm I","Patients receive oral erlotinib hydrochloride once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity."
"19075",21825,"NCT01787383",63798,0.02970297,3,101,NA,NA,"Ingenol Mebutate Gel Simultaneous Treatment","Ingenol mebutate gel in 2 doses (0.015% and 0.05%) were applied simultaneously: ingenol mebutate gel 0.015% (Picato®) was applied once daily for 3 consecutive days on on face/scalp and ingenol mebutate gel 0.05% (Picato®) was applied once daily for 2 consecutive days on trunk/extremities."
"19403",22172,"NCT02075073",29176,0.027777778,1,36,NA,NA,"SB3 (Proposed Trastuzumab Biosimilar)","SB3, single dose of 6 mg/kg via intravenous infusion (study drug)
SB3"
"19414",22184,"NCT01164579",209838,0.027777778,1,36,"Adverse events were collected up to 28 calendar days after the last administration of investigational product.","The same event may appear as both an adverse event (AE) and a serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in 1 participant and as nonserious in another participant, or 1 participant may have experienced both a serious and nonserious event during the study.","Tofacitinib (CP-690,550)","Participants received CP-690,550 10 mg tablets, PO, BID and matching placebo MTX capsules, PO, once weekly for a maximum of 12 months. To maintain the blind, matching placebo MTX was titrated as follows: 4 capsules once weekly for 4 weeks; if well tolerated, at Month 1 titrate up to 6 capsules once weekly for 4 weeks; if well tolerated, then at Month 2 titrate up to 8 capsules once weekly for the duration of the study. A single dose reduction of MTX placebo to 2 capsules was allowed because of lack of tolerance, as long as the participant remained on a dose of at least 4 MTX placebo capsules weekly. Participants also received folate supplementation according to local MTX label guidelines and standard of care."
"19527",22305,"NCT01831466",58201,0.027027027,2,74,"SAEs were assessed from informed consent through and including 28 calendar days after last administration of study treatment. Non-SAEs were recorded from time of first dose of study treatment through last participant visit.","The same event may appear as both an AE and an SAE. However, what is presented are distinct events. An event may be categorized as serious in 1 participant and as nonserious in another participant, or 1 participant may have experienced both a serious and nonserious event during the study. All AEs (including treatment area AEs) are presented.","Mild/Moderate: Tofacitinib 10 mg/g QD","Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment 10 mg/g, QD for 12 weeks."
"19618",22409,"NCT01401166",141469,0.026548673,6,226,NA,"Safety population: All participants who received at least 1 dose of trastuzumab.
Not all participants in the safety population received trastuzumab both subcutaneously and intravenously due to participants discontinuing from the study before they crossed-over to the other route of administration.","Trastuzumab IV – Cohort 1 – Continuation Period","Participants received trastuzumab 6 mg/kg intravenous Participants received trastuzumab 6 mg/kg intravenously on Day 1 of each 3-week cycle for up to 10 remaining cycles."
"19704",22501,"NCT01642914",91585,0.026143791,4,153,"Adverse event reporting occurred over a 10 month period from August of 2012 to June of 2013 at 141 study sites in the United States and Canada",NA,"Linaclotide 145 Micrograms","Linaclotide 145 micrograms
Linaclotide 145 micrograms: oral capsule, taken once daily each morning at least 30 minutes before breakfast"
"20013",22840,"NCT01151852",213859,0.024390244,1,41,NA,NA,"Imatinib","Patients will be randomly assigned to receive imatinib at a dose of 400mg/day, taken once daily with food, in the form of 100-mg tablets. The study medication will be administered until disease progression, unacceptable toxicity, or withdrawal of consent."
"20127",22961,"NCT01401166",141468,0.023809524,1,42,NA,"Safety population: All participants who received at least 1 dose of trastuzumab.
Not all participants in the safety population received trastuzumab both subcutaneously and intravenously due to participants discontinuing from the study before they crossed-over to the other route of administration.","Trastuzumab Self-administered SC – Cohort 1 – Cont","Participants in Cohort 1, who had at least 2 treatment cycles remaining of their 18-cycle treatment course, were offered the opportunity to self-administer trastuzumab 600 mg subcutaneously using the single-injection device on Day 1 of each 3-week cycle under the direction of a trained health care practitioner."
"20253",23092,"NCT00999804",261502,0.023255814,1,43,"7 months","Adverse events experienced by participants will be collected and reported from initiation of study medication, throughout the study, and within 30 days of the last dose of study medication.","12-week Arm","Participants will receive 12-weeks of lapatinib plus trastuzumab. Participants who are estrogen receptor (ER) and/or progesterone receptor (PR) positive will also receive endocrine therapy.
Lapatinib: 1000 mg by mouth daily
Letrozole: 2.5 mg by mouth daily (for hormone receptor positive participants only)
Trastuzumab: 6 mg/kg intravenously, every 3 weeks"
"20363",23211,"NCT00398398",484102,0.022727273,1,44,"1 year after completion of study treatment. If patients received another treatment, toxicity assessment was not done further.",NA,"Xelox Plus Cetuximab","Capecitabine, oxaliplatin and cetuximab"
"20662",23533,"NCT00730015",360367,0.021052632,2,95,"Adverse Event data were collected from October 2008 through October 2009. The Treatment Period lasted 12 weeks and the Randomized Withdrawal (RW) Period started after the Treamtent Period and lasted 4 weeks.",NA,"Linaclotide 145μg to Placebo RW Period","Linaclotide 145μg, oral administration, once per day to Dose-matched placebo, oral administration, once per day"
"20885",23774,"NCT00942604",283530,0.02,2,100,"57 days",NA,"PEP005 (Ingenol Mebutate) Gel","PEP005 (ingenol mebutate) Gel 0.05% once daily for 2 consecutive days"
"21055",23953,"NCT01401166",141466,0.019417476,4,206,NA,"Safety population: All participants who received at least 1 dose of trastuzumab.
Not all participants in the safety population received trastuzumab both subcutaneously and intravenously due to participants discontinuing from the study before they crossed-over to the other route of administration.","Trastuzumab SC – Cohort 2 – Continuation Period","Participants received trastuzumab 600 mg/kg subcutaneously on Day 1 of each 3-week cycle for up to 10 remaining cycles."
"21098",24002,"NCT01786668",64042,0.019230769,1,52,"From informed consent through and including 28 calendar days after the last administration of the investigational product.","The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in 1 participant and as nonserious in another participant, or 1 participant may have experienced both a serious and nonserious event during the study.","Tofacitinib 5 mg BID","Participants were administered 4 tablets (one 5 mg tablet of tofacitinib, one 5 mg and two 1 mg matching placebo tablets) orally BID (in the AM and PM) for a total of 12 weeks."
"21099",24003,"NCT01786668",64041,0.019230769,1,52,"From informed consent through and including 28 calendar days after the last administration of the investigational product.","The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in 1 participant and as nonserious in another participant, or 1 participant may have experienced both a serious and nonserious event during the study.","Tofacitinib 10 mg BID","Participants were administered 4 tablets (two 5 mg tablets of tofacitinib and two 1 mg matching placebo tablets) orally twice a day (in the AM and PM) for a total of 12 weeks."
"21285",24204,"NCT00730015",360370,0.01843318,4,217,"Adverse Event data were collected from October 2008 through October 2009. The Treatment Period lasted 12 weeks and the Randomized Withdrawal (RW) Period started after the Treamtent Period and lasted 4 weeks.",NA,"Linaclotide 290μg","Linaclotide, 290μg dose, oral administration, once per day"
"21360",24291,"NCT00096031",563821,0.018181818,1,55,"After every 28 days while on treatment","Standard AE form","Cetuximab",NA
"21559",24506,"NCT00387621",488497,0.017241379,1,58,"Participants were followed for adverse events from the time of randomization until the completion of the second visit, approximately two months.",NA,"Nesiritide","The first 10 subjects in each group received a dose of 5 ug/kg and the next 10 subjects received a dose of 10 ug/kg. As this was a cross over study, all participants received placebo and nesiritide."
"21969",24953,"NCT01600014",99489,0.015555556,7,450,"8-week treatment periods (1st or 2nd cycle)",NA,"Ingenol Mebutate 0.015% Gel (1. Cycle)","Open label topical field treatment once daily for 3 consecutive days with ingenol mebutate 0.015% gel within a 25 cm2 treatment area on the face or scalp"
"22056",25052,"NCT00916006",291867,0.015151515,2,132,"57 days","For the safety population, the total sample size was 132 patients who received PEP005 Gel (2 patients never received study medication and one patient actually received vehicle gel) and 135 patients who received vehicle gel.","PEP005 (Ingenol Mebutate) Gel, 0.015%","PEP005 (ingenol mebutate) Gel 0.05% once daily for 3 consecutive days"
"22278",25292,"NCT00765882",346327,0.014084507,3,213,"Adverse Event reporting occurred from October 2008 through August 2009.",NA,"Linaclotide 145µg","Linaclotide, 145µg dose, oral administration, once per day"
"22364",25384,"NCT00730015",360371,0.013824885,3,217,"Adverse Event data were collected from October 2008 through October 2009. The Treatment Period lasted 12 weeks and the Randomized Withdrawal (RW) Period started after the Treamtent Period and lasted 4 weeks.",NA,"Linaclotide 145μg","Linaclotide, 145μg dose, oral administration, once per day"
"22440",25470,"NCT00686166",376980,0.013513514,1,74,"Up to 4 years","Eligible patients who received any treatment and were assessed for adverse events are included in the adverse event summaries.","Chemotherapy","Patients receive oxaliplatin 50 mg/m^2 IV (Days 1, 8, 15, 22, 29), cetuximab 400 mg/m^2 IV (Day 1), cetuximab 250 mg/m^2 IV (Days 8, 15, 22, 29), capecitabine 1650 mg/m^2 PO (Monday-Friday, Day 1-35). Cycle is 35 days, followed by a 14-day break."
"22683",25731,"NCT01642914",91584,0.0125,2,160,"Adverse event reporting occurred over a 10 month period from August of 2012 to June of 2013 at 141 study sites in the United States and Canada",NA,"Linaclotide 290 Micrograms","Linaclotide 290 micrograms
Linaclotide 290 micrograms: oral capsule, taken once daily each morning at least 30 minutes before breakfast"
"22888",25956,"NCT00460811",460426,0.011764706,1,85,"Adverse event data were collected from March of 2007 to April 2008.",NA,"290 µg Linaclotide Acetate","Linaclotide, 290μg dose, oral administration, once per day"
"23302",26407,"NCT00938717",284669,0.009950249,4,402,"Adverse event data were collected from July of 2009 to September of 2010 (26 weeks of safety data were collected)",NA,"Linaclotide","Linaclotide 290μg, oral administration, once per day."
"23390",26504,"NCT01880424",52096,0.009615385,4,416,"Adverse event data were collected from July 2013 to May 2015 (12 weeks of safety data were collected). Includes serious adverse events that occurred on or after the date of the first dose of study drug and within 30 days of the last dose of study drug.","Of the 839 randomized patients, a total of 835 patients received at least one dose of double-blind study drug and were included in the Safety Population.","Linaclotide Arm","Linaclotide 290 ug capsules, oral, once daily"
"23470",26587,"NCT00667251",383512,0.00931677,3,322,"Median follow-up of 21.5 months","Serious Adverse Events that were reported to Health Canada","Lapatinib","Plus taxane based chemotherapy"
"23682",26812,"NCT01401166",141471,0.008350731,4,479,NA,"Safety population: All participants who received at least 1 dose of trastuzumab.
Not all participants in the safety population received trastuzumab both subcutaneously and intravenously due to participants discontinuing from the study before they crossed-over to the other route of administration.","Trastuzumab SC – Crossover Period","Participants received trastuzumab 600 mg subcutaneously (SC) on Day 1 of each 3-week cycle for 4 cycles."
"23787",26923,"NCT00742391",355325,0.008,1,125,"57 days","One patient in the PEP005 Gel, 0.05% group discontinued study medication (Day 2 dose not applied) due to an AE (application site pain)","PEP005 (Ingenol Mebutate) Gel","PEP005 (ingenol mebutate) Gel 0.05% once daily for 2 consecutive days"
"23900",27051,"NCT01600014",99488,0.007462687,1,134,"8-week treatment periods (1st or 2nd cycle)",NA,"Ingenol Mebutate 0.015% Gel (2. Cycle)","Repeat use once daily for 3 consecutive days with ingenol mebutate 0.015% gel of the same treatment area (25 cm2 treatment area on the face or scalp) in a randomised, controlled, double-blind setting, at Week 8 (field recalcitrant subgroup) or Week 26 or Week 44 (field recurrent subgroup)"
"23988",27148,"NCT00915551",292007,0.007042254,1,142,"57 days",NA,"PEP005 (Ingenol Mebutate) Gel, 0.015%","PEP005 (ingenol mebutate) Gel 0.05% once daily for 3 consecutive days"
"24506",27699,"NCT00948818",280984,0.004926108,2,406,"Adverse event data for the treatment period was collected from July of 2009 to July of 2010","803 patients were randomized to treatment. A total of 802 patients received double-blind study drug and were included in the Safety Population.","Linaclotide - Treatment Period","Linaclotide 290µg, oral administration, once per day."
"24635",27839,"NCT01401166",141470,0.0041841,2,478,NA,"Safety population: All participants who received at least 1 dose of trastuzumab.
Not all participants in the safety population received trastuzumab both subcutaneously and intravenously due to participants discontinuing from the study before they crossed-over to the other route of administration.","Trastuzumab IV – Crossover Period","Participants received trastuzumab 6 mg/kg intravenously (IV) on Day 1 of each 3-week cycle for 4 cycles. In case Cycle 1 of the crossover period was the first cycle of trastuzumab treatment, a loading dose of trastuzumab 8 mg/kg IV was administered."
"24973",28197,"NCT00475852",454449,0.001429388,5,3498,NA,NA,"Nesiritide","0.01 mcg/kg/min IV infusion (with or without 2 mcg/kg bolus) for 24 to 168 hrs"
"25349",28614,"NCT00344773",503008,NA,4,NA,NA,NA,"Gefitinib","Gefitinib 250mg tablet"
"25439",28719,"NCT00264498",527829,NA,4,NA,NA,NA,"Experimental","Gefitinib"
"25490",28776,"NCT00229723",535440,NA,9,NA,NA,NA,"250mg/Placebo","Concomitant gefitinib 250 mg (plus cisplatin and radiotherapy) followed by placebo as maintenance therapy"
"25491",28777,"NCT00229723",535439,NA,21,NA,NA,NA,"500mg/Placebo","Concomitant gefitinib 500 mg (plus cisplatin and radiotherapy) followed by placebo as maintenance therapy"
"25492",28778,"NCT00229723",535438,NA,15,NA,NA,NA,"250mg/250mg","Concomitant gefitinib 250 mg (plus cisplatin and radiotherapy) followed by gefitinib 250 mg as maintenance therapy"
"25493",28779,"NCT00229723",535437,NA,14,NA,NA,NA,"500mg/500mg","Concomitant gefitinib 500 mg (plus cisplatin and radiotherapy) followed by gefitinib 500 mg as maintenance therapy"
"25494",28780,"NCT00229723",535436,NA,16,NA,NA,NA,"Placebo/250mg","Concomitant placebo (plus cisplatin and radiotherapy) followed by gefitinib 250 mg as maintenance therapy"
"25495",28781,"NCT00229723",535435,NA,11,NA,NA,NA,"Placebo/500mg","Concomitant placebo (plus cisplatin and radiotherapy) followed by gefitinib 500 mg as maintenance therapy"
"25572",28871,"NCT00137449",550591,NA,13,NA,NA,NA,"AM Dose Sunitinib Malate","Subjects received sunitinib malate at a starting dose of 37.5 mg/day in repeated 4-week cycles and cycles could be repeated for up to 1 year in the absence of any withdrawal criteria. Subjects were randomized to receive either morning (AM) or afternoon (PM) dose. Doses could be increased to 50 mg daily."
"25573",28872,"NCT00137449",550590,NA,12,NA,NA,NA,"PM Dose Sunitinib Malate","Subjects received sunitinib malate at a starting dose of 37.5 mg/day in repeated 4-week cycles and cycles could be repeated for up to 1 year in the absence of any withdrawal criteria. Subjects were randomized to receive either morning (AM) or afternoon (PM) dose. Doses could be increased to 50 mg daily."
"25574",28873,"NCT00137423",550631,NA,21,NA,NA,NA,"AM Dose Sunitinib Malate (SU011248)","Patients received a starting dose of 37.5 mg/day of sunitinib malate in the morning repeated 4-week cycles continuing for up to 1 year in absence of any withdrawal criteria."
"25575",28874,"NCT00137423",550630,NA,20,NA,NA,NA,"PM Dose Sunitinib Malate (SU011248)","Patients received a starting dose of 37.5 mg/day of sunitinib malate in the evening repeated 4-week cycles continuing for up to 1 year in absence of any withdrawal criteria."
"25621",28923,"NCT00075218",570059,NA,83,NA,NA,NA,"Sunitinib Double-Blind Treatment","Starting dose: 50 mg orally once daily as a single agent for 4 consecutive weeks followed by a 2-week off-treatment period to form a complete cycle of 6 weeks. (Schedule 4/2). Subjects received best supportive care in addition to the study treatment."
"25622",28924,"NCT00075218",570058,NA,27,NA,NA,NA,"Placebo Double-Blind Treatment","Starting daily dose of 1 capsule, size- and color-matched to the sunitinib 50-mg capsule for 4 consecutive weeks followed by a 2-week off-treatment period to form a complete cycle of 6 weeks (Schedule 4/2). Subjects received best supportive care in addition to the study treatment. Subjects were provided the opportunity to receive open-label sunitinib at the time of confirmed disease progression or study unblinding."
"25623",28925,"NCT00075218",570057,NA,122,NA,NA,NA,"Sunitinib Open-Label Treatment","Subjects experiencing disease progression could have their treatment assignment unblinded, and subjects who had been receiving placebo could crossover to open-label treatment with sunitinib; subjects who had been receiving sunitinib during double-blind treatment of the study could continue to do so after unblinding if, in the opinion of the investigator, there was sufficient evidence of clinical benefit."
